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Quantitative ultrasound (QUS) measurements of broadband ultrasound attenuation (BUA) 
and speed of sound (SOS) at the calcaneus have been introduced as a novel non- 
invasive technique for assessing skeletal status in individuals at risk of osteoporosis. The 
objective of this thesis was to evaluate the use of QUS measurements as a first line 
method of assessing skeletal status and to compare them with bone mineral density 
(BMD) measurements by dual energy x-ray absorptiometry (DXA), the currently accepted 
'gold standard' for bone densitometry. I examine the hypothesis that QUS technology 
has developed to the point where for most clinical purposes it could be substituted for 
DXA. To investigate this hypothesis a study was designed to address some of the issues 
that are currently perceived as obstacles to the wider clinical application of QUS. The 
long-term stability and precision of QUS equipment was examined, reference data 
established, and the application of QUS in clinical practice investigated. Three calcaneal 
QUS devices were examined; the Hologic UBA575+, Hologic Sahara and Osteometer 
DTUone. 
The long-term stability was poor with all three devices showing drifts and abrupt 
calibration changes and temperature dependence of the SOS measurements. The short- 
term standardised precision of QUS was twice as large as that found for DXA, while mid- 
and long-term standardised precision were twice that observed in the short-term. QUS 
imaging improved standardised precision in the short-term but not the long-term. 
QUS and DXA reference data were derived using a single study population, allowing T- 
and Z-scores to be calculated for each individual. Annual decreases, standardised and 
expressed in T-score units, decreased with age and years since menopause at a similar 
rate to that observed for lumbar spine BIVID measured by DXA. Although measurements 
of BUA or SOS on the three devices were highly correlated, there were large variations in 
both mean values and clinical ranges and therefore results from one device cannot be 
directly compared to those obtained on the others 
correlated with BIVID at the spine, hip and calcaneus 
BUA and SOS were significantly 
However, these correlations were 
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modest and a large proportion of the variation in BUA and SOS was left unexplained by 
BMD. 
Revised diagnostic criteria were derived for QUS using DXA-equivalent prevalence rates. 
A T-score threshold of -1.80 was proposed for identifying postmenopausal women at risk 
of osteoporosis and a T-score threshold of -0.50 for classifying postmenopausal women 
as normal or osteopenic. Clinical risk factors, commonly used by General Practitioners to 
identify women who would benefit from bone densitometry assessment, affected QUS Z- 
scores to the same extent as axial BMD. QUS measurements were able to discriminate 
between women with and without a history of fragility fracture at the spine, hip or forearm 
as well as axial BIVID measurements. The combination of QUS and BIVID measurements 
did not enhance vertebral fracture discrimination compared to either method alone. 
Although one of the QUS devices demonstrated a significant response to treatment after 
one year of antiresorptive therapy, once long-term precision was taken into account, BIVID 
measurements of the spine remained the optimum way of monitoring response to 
treatment. 
In conclusion, QUS measurements were shown to be equivalent to DXA in many 
applications such as the diagnosis of osteoporosis, the investigation of patients with 
clinical risk factors for osteoporosis, and the identification of patients at risk of fracture. 
The principle limitations to the wider use of QUS measurements remain: (1) poor long- 
term stability combined with temperature dependence of some devices; (2) poor precision 
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1.1 BONE BIOLOGY 
1.1.1 Bone Structure and Function 
Bone is an essential, dynamic connective tissue that has three major functions- the 
provision of mechanical integrity for locomotion and protection, the maintenance of 
mineral homeostasis and the primary site of haemopoiesis. Mature bones consist of a 
central fatty or haematopoietic marrow that is supported and surrounded by bone 
tissue and the periosteum [1]. Over 90% of the volume of bone tissue consists of bone 
matrix, while the remaining 10% consists of bone cells, cell processes and blood 
vessels [1]. 
The skeleton consists of two types of bone tissue: cortical and trabecular. Each has 
the same composition and structure but variations in the distribution and arrangement 
of the bone tissue account for differences in the mechanical properties of specific 
bones [1]. The volume of cortical bone is greater and consists of collagen fibers 
arranged concentrically around vascular channels. Cortical bone accounts for 80% of 
skeletal mass and surrounds the marrow and the trabecular bone plates. Trabecular 
bone is found chiefly at the end of long bones and in cuboid bones such as the 
vertebrae and consists of rod-like plates that form a three-dimensional lattice structure 
orientated along lines of mechanical stress. 
Bone tissue consists of an organic and inorganic phase. The inorganic phase accounts 
for 65% of the wet weight of bone and acts as an ion reservoir and gives bone the 
majority of its stiffness and strength [1]. It consists largely of the plate-like crystal 
hydro)cyapatite (Ca, O[PO41[OH2]21). Although recent evidence suggests that the crystals 
contain both carbonate ions and acid phosphate groups (HP04 -2 ) and in addition, do 
not contain OH groups [1]. 
The organic phase consists primarily of Collagen and a small proportion consists of 
non-collagenous glycoproteins and bone-specific proteoglycans [1,2]. The Collagen 
fibrils are densely packed to form lamella, and these fibrils interconnect both within 
lamella and between individual lamellae, therefore increasing bone strength. The non- 
collagenous proteins include osteocalcin, osteonectin and bone phosphoproteins. The 
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role of these proteins is unclear but it is thought that they influence mineralisation and 
the behaviour of bone cells [1]. Bone matrix also contains growth factors such as 
insulin-like growth factor-1 , intedeukin-1 and transforming growth factor-P and it is 
believed that these play a role in controlling bone cell function. Bone is a well- 
organised tissue in which the mineral phase impregnates collagen fibril arrays in such a 
way that its mechanical properties are optimised. The tensile strength of bone is nearly 
equal to that of cast iron, however, bone is three times lighter and ten times more 
flexible [1]. 
1.1.2 Bone Remodelling 
Bone is a dynamic tissue that is continuously being broken down and rebuilt throughout 
life. The process by which old bone is removed and subsequently replaced by new 
bone is termed bone remodelling [3]. Bone remodelling allows bone to adapt to 
mechanical stresses placed upon it as well as preventing the accumulation of fatigue 
damage. Even though trabecular bone accounts for just 20% of skeletal mass, bone 
remodelling is a surface based phenomenon and subsequently the rate of bone 
remodelling is five to tens times higher in trabecular bone than in cortical bone. 
Research over the past two decades indicate that bone resorption and bone formation 
are finely regulated processes, controlled by local and systemic factors and is carried 
out by a family of different interacting cells [4]. Bone metabolism is regulated by bone 
cells, namely osteoblasts, osteocytes and osteoclasts. Osteoblasts line the surface of 
bone and are the so-called bone-forming cell. The primary role of osteoblasts is the 
synthesis and secretion of the organic matrix of bone. Evidence also suggests that 
osteoblasts may play a role in mineral homeostasis, mineralisation and the activation of 
osteoclasts [1]. When the osteoblasts become embedded in the lucuna of the bone 
matrix it becomes an osteocyte. Approximately ninety percent of bone cells in the adult 
skeleton are osteocytes, however, their role in bone remodelling remains unclear. 
Osteoclasts are the active agents in bone resorption and they are characterised by a 
ruffled border, which plays a critical role in the resorption of the bone matrix. 
Bone remodelling takes place in bone structural units (BSU) and the normal 
remodelling sequence consists of 5 stages: quiescence, activation, resorption, reversal 
and formation [3]. At any one time 80% of trabecular bone and 95% of cortical bone is 
inactive and this inactive bone is covered by a thin layer of lining cells. A thin layer of 
unmineralized osteoid is found between these lining cells and bone and when this layer 
is exposed by the removal of the lining cells it is thought that the activation sequence is 
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then initiated. Osteoclasts are attracted to the bone surface during the activation stage 
but it is unclear by which mechanism they are attracted or how the osteoclasts are 
regulated [5]. The osteoclasts will then begin the process of bone resorption, creating 
tunnels in cortical bone and thin crescents in trabecular bone. The reversal stage of 
bone remodelling consists of the time interval between the completion of bone 
resorption and the initiation of bone formation and takes between 1 and 2 weeks. The 
osteoblasts are then attracted to the resorption cavity and begin the process of bone 
formation. Initially, osteoid is synthesised and laid down in the resorption cavity and 
then 5 to 10 days later the osteoblasts mineralise the protein matrix. The time of 
completion for each BSU ranges from 3-6 months and most of this time is occupied by 
the bone formation stage [3]. 
1.1.3 Mineral homeostasis 
Bone plays an important role in calcium homeostasis. The skeleton contains 99% of 
the total calcium found in an adult human in the form of hydroxyapatite [6]. The 
remaining 1% of calcium is found in the extracellular fluid (ECF) and soft tissue. Figure 
1.1 displays the major fluxes of calcium in a healthy adult. The exchange of calcium in 
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Figure 1.1: Major fluxes of calcium [mmol/day] in healthy adults. B, bone. Ca, calcium. K, 
kidney. PTH, parathyroid hormone. Adapted from Kanis [7]. 
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Calcium normally enters the body only by absorption across the intestinal mucosa. 
The amount of calcium absorbed depends upon dietary factors such as the presence of 
phosphate and on vitamin D which increases intestinal absorption M. Approximately 
1% of the skeletal content of calcium is freely exchangeable with the ECF. Although 
small, this amount of calcium is roughly equal to the total content of calcium in the ECF 
and soft tissues and is important in plasma calcium homeostasis so important 
biochemical processes can be controlled and maintained. 
This process of mineral homeostasis has to be distinguished from the movements of 
calcium that occur in bone due to bone formation and resorption. Healthy young adults 
neither gain nor lose bone so the amount of bone resorbed exactly matches the 
amount of bone formed. If serum calcium is stable, the total excretion of calcium 
reflects the net input of calcium to the ECF largely from the intestine and skeletal 
sources. The kidney is the major site of excretion of calcium from the body. A large 
amount is filtered, although most is reabsorbed leaving between 1-3% excreted into the 
urine [7]. 
These fluxes of calcium across bone, intestine and kidney are affected by many factors 
including direct influences from parathyroid hormone (PTH), calcitonin and vitamin D 
metabolites as well as indirectly by thyroid, growth, adrenal and gonadal hormones [7]. 
1.2 OSTEOPOROSIS 
The word 'osteoporosis' is derived from Classical Greek with 'osteon' meaning bone 
and 'poros' meaning pore. Thus, the term osteoporosis simply means 'porous bone'. 
Osteoporosis began to capture the attention of the medical community in the 1940's 
due to the work of Albright and colleagues [8]. However, it was over a century before 
these pioneering works that osteoporosis was first recognised as a disease of the aged 
[9] and the term osteoporosis was first used by pathologists [10]. It is almost certain 
that osteoporosis existed before these times and recent reports in the literature have 
revealed that osteoporosis could even date to 460 B. C. when Hippocrates stated the 
low back pain was an affliction of the elderly [11,12]. Perhaps more convincing 
evidence comes from the discovery of a skeleton dated to the XIIth Dynasty (1990- 
1786 B. C. ) which displayed osteoporosis with associated fractures of the femoral neck 
and compression fractures in the spine [13]. 
Over the years many definitions of osteoporosis have been offered reflecting the state 
of knowledge of the phenomenon itself [10]. Osteoporosis is commonly defined in 
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terms of the amount of bone present. However, other factors contribute to skeletal 
fragility and fracture risk. Definitions will variously emphasise bone mass or other 
determinants of skeletal fragility such as the degree of trauma [14]. There are many 
different approaches to defining osteoporosis due to the multifactorial nature of the 
disease, however, in 1993 a Consensus Development Conference was held and the 
currently accepted definition of osteoporosis was devised [15]: 
"Osteoporosis is a systemic disease characterised by low bone mass and 
microarchitectural deterioration of bone tissue, with a consequent increase in 
bone fragility and susceptibility to fracture. " 
As well as having a definition of osteoporosis it is equally important to define what level 
of low bone mass constitutes osteoporosis so that it can be diagnosed readily in a 
clinical setting. At the present time, bone mass is the best and easiest variable related 
to fracture risk to measure non-invasively in vivo and therefore there is a widely 
accepted convention to define osteoporosis in terms of bone mineral density (BMD) as 
recommended by a World Health Organisation Working Party [16]: 
9 Normal. A BIVID greater than or equal to a value one SID below the young adult 
reference mean. 
Low bone mass (osteopenia). A value for BIVID between 1 SID and 2.5 SID 
below the young adult mean. 
Osteoporosis. A BIVID than or equal to a value 2.5 SID below the young 
adult mean. 
Established osteoporosis. A value for BIVID more than 2.5 SID below the 
young adult mean in the presence of one or more fragility fractures. 
1.3 DETERMINANTS OF BONE MASS AND FRACTURE RISK 
Osteoporosis is characterised by low bone mass and a subsequent increase in fracture 
risk. Bone mass accounts for approximately 70% of bone strength and bone mass as 
well as age are the two most important determinants of fracture risk. Fracture risk 
increases with increasing age and declining bone mass [17]. For each SID decrease in 
bone mass there is an approximate doubling in fracture risk [18]. Figure 1.2 displays 
the changes in bone mass and fracture risk with age. The amount of bone present in 
skeleton is a function of the amount of bone gained during childhood and adolescence 
and that which is lost during adulthood. 
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1.3.1 Changes in Bone Mass during Childhood and Adolescence 
At birth the skeleton weighs just 25g (excluding marrow) and this increases to between 
1000-1200g at maturity by the process of bone modelling. During growth and 
development bone modelling primarily consists of longitudinal growth at growth plates 
and bone remodelling processes at the periosteal and endosteal envelopes. A phase 
of rapid linear and appositional growth occurs during childhood and adolescence, with 
an estimated 40% of peak bone mass acquired during adolescence. Linear growth 
reaches a maximum near the end of the second decade of life, however, bone mass 
may continue to increase by appositional growth in a phase termed consolidation. It is 
unclear at which age peak bone mass is attained but it is thought that it occurs at some 
time during the third decade of life [19-22]. At this time, bone mass in males is 
approximately 15-50% higher than in females depending on the skeletal site measured 
[21]. 
1.3.2 Peak Bone Mass 
Peak bone mass is a major determinant of subsequent bone mass and ultimate 
fracture risk. Therefore, maximal bone mass at maturity could be considered as 
important as risk factors that influence bone mass in later life. Peak bone mass is 
influenced largely by genetic factors. Heritability estimates for peak bone mass range 
from 0.42 to 0.98 and are higher at the spine than at cortical-rich appendicular sites 
[479]. Genetic factors also influence bone density during adulthood and this genetic 
influence persists into old age [23,24]. However, heritibility estimates for 
postmenopausal women are often lower than those seen for premenopausal women as 
other influences have effected bone mass at this stage of life [25]. 
Gonadal hormones also influence peak bone mass as shown in studies that 
demonstrate that bone density is significantly lower in amenorrheic adolescents or in 
children in whom puberty is delayed [21,26,27]. Gonadal status is also an important 
determinant of bone mass in premenopausal women when oestrogen deficiency 
reduces bone mass even in the presence of adequate nutrition and exercise [28-30]. 
A failure to reach the genetic potential of bone mass can result from inadequate 
nutrition or exercise. Inadequate skeletal loading due to a lack of exercise can affect 
bone mass due to suboptimal stimulation of bone deposition and therefore lower 
overall bone mass [30-32]. Calcium has two roles during life; to increase bone 
accretion during development and to maintain bone mass during adulthood. Evidence 
suggests that an increase in calcium intake will lead to an increase in peak bone mass 
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[21,32,33]. When two communities in Yugoslavia with a low and high intake of calcium 
were compared it was found that bone mass was higher in the community considered 
to have a high intake of calcium. This difference in bone mass could be observed in 
people as young as 30, indicating that a high intake of dietary calcium has a positive 
influence on peak bone mass as well as subsequent bone mass [20]. There is 
evidence that calcium has a greater influence on the skeleton when bone is being lost 
in later life [34]. An increase in calcium intake has been shown to slow bone loss at the 
spine in perimenopausal women [35] and postmenopausal women [36]. The latter 
study indicated that an increase in dietary calcium was most effective in maintaining 
bone mass when baseline calcium intake was low [36]. 
1.3.3 Age and Menopause Related Bone Loss 
As shown in Figure 1.2, after peak bone mass has been achieved bone mass begins to 
decrease. There is much controversy surrounding the age at which this occurs. In 
women, there is some evidence that there is a decrease in bone mass before the age 
of menopause [37,38]. However, the decreases observed in these studies were small 
and other studies have shown no decrease in bone mass during the premenopausal 
period [39]. Bone mass begins to decrease in both men and women during the fifth 
decade of life and men and women show similar rates of this slow bone loss. 
However, women undergo a transient accelerated period of bone loss during the early 
postmenopausal period which contributes further to the discrepancy in bone mass 
between men and women [40]. 
The early works of Albright and colleagues directed attention to oestrogen deficiency 
as a cause of postmenopausal osteoporosis. In the 42 cases of osteoporosis 
described in these pioneering works, 40 of these cases were in postmenopausal 
women with no secondary causes for low bone mass. Albright distinguished this 
postmenopausal bone loss from "senile osteoporosis" which was due to atrophy of 
bone due to ageing [8]. In 1986 this theory was modified by Riggs et al who suggested 
that osteoporosis could be subdivided into type I (postmenopausal) and type 11 (senile) 
osteoporosis. Type I osteoporosis occurred primarily in women and was related to a 
lack of oestrogen at menopause while type 11 was related to ageing factors that cause 
bone loss [41]. 
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Figure 1.2: Lifetime changes in bone mass. Adapted from Compston 
The theory by Riggs et al in 1986 [41] has since been updated in 1998 when Riggs and 
colleagues proposed a unitary model for involutional osteoporosis. In this model both 
menopausal and age-related bone loss are said to be caused by oestrogen deficiency 
and this lack of oestrogen causes bone loss in both men and women [42]. Oestrogen 
deficiency at menopause is associated with an increase in bone remodelling [43]. A 
45% increase in activation frequency and 39% increase in bone resorption has been 
observed at the time of menopause [44]. A study on changes in bone remodelling at 
menopause revealed that bone formation markers increased by 45% while bone 
resorption makers increased by 90% which induced a net increase in bone resorption 
[45]. This imbalance in bone remodelling results in a net decrease in bone mass. As 
this increase in bone resorption and impaired compensatory bone formation occurs 
concurrently at menopause, Riggs et al proposed that it is almost certainly caused by 
oestrogen deficiency [42]. 
Oestrogen deficiency has also been proposed as a mechanism of bone loss in men in 
this unitary model. The pattern of the continuous phase of bone loss and associated 
increases in serum PTH and bone resorption markers in ageing men is superimposable 
on those occurring in women which suggests a common causal method [42]. In 
addition free serum oestrogen rather than testosterone has been shown to be the most 
significant predictor of bone mass in men (46]. 
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With advancing age there is a decrease in calcium absorption and an increase in 
serum PTH levels and these factors are associated with the age-related decline in 
bone mass. In one model which examined the relative contribution of menopause and 
ageing on bone loss in females found that ageing explained more of the bone loss 
observed than years since menopause [47]. Bone density at the spine and hip has 
been shown to be inversely related to serum intact parathyroid hormone concentrations 
in postmenopausal women [48]. Calcium absorption efficiency declines at menopause 
and with ageing as oestrogen enhances calcium absorption indirectly by enhancing 
1,25 [OH12D production in the kidney [49]. Serum 25(OH) D declines with age because 
of less efficient skin synthesis of vitamin D, less intestinal absorption, and possibly also 
reduced sun exposure and dietary intake of the vitamin. This in turn reduces calcium 
absorption and increases PTH, which in turn increases bone resorption [49]. 
Regardless of the primary mechanism involved in bone loss during adult life, over a 
lifetime women can expect to lose 35% of their cortical bone and 50% of their 
trabecular bone and men can expect to lose two-thirds of these amounts [41]. 
1.3.4 Bone Mass and Biomechanical Factors 
Biomechanical factors are also important in determining bone mass and bone loss 
during life. Frost [50,51] has proposed a biomechanical explanation for bone loss. It 
was suggested that bones adapt to the loads placed upon them by muscles and that as 
muscle bulk decrease after the age of 30, bones are subjected to decreasing loads and 
subsequently bone remodelling processes will act to reduce bone mass [50]. There is 
a clear relationship between mechanical loading and bone mass. This relationship is 
curvilinear with a much steeper slope observed at low levels of loading [52]. 
Consequently, the most easily demonstrable effects of bone loading on bone mass is 
that seen during immobilisation. Immobilisation is associated with a substantial loss of 
bone, up to 40% per annum for complete bed rest [52,53]. The importance of bone 
loading has been emphasised by bone loss observed during space flight with 
particularly large losses seen in trabecular-rich appendicular sites [54]. 
The amount of bone gained by active people is rather limited by comparison. Studies 
on the effects of exercise are difficult due to problems in quantifying past and present 
exercise and problems with compliance and blinding in prospective studies. Studies on 
elite athletes have shown that they have significantly higher bone mass compared to 
inactive controls [55]. However, excessive exercise can lead to amenorrhoea or 
oligomenorrhoea, which can partially or entirely override the beneficial effects of 
exercise on BIVID [27,29,56-58]. Exercise in both premenopausal and postmenopausal 
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women have shown that it is associated with small increases in bone density [59]. 
Even though the increase in bone density associated with exercise is small it has been 
shown that it can reduce fracture risk [60] and furthermore, the increase in muscle 
mass is likely to increase neuromuscular co-ordination which will reduce the propensity 
to fall in elderly people. 
1.3.5 Bone Mass and Secondary Causes of Osteoporosis 
Bone loss is also associated with lifestyle factors such as smoking [61,62], alcohol 
intake [22], caffeine intake [60,63] and parity and lactation [64,65]. In a large study of 
1600 perimenopausal women anthropometric and lifestyle factors explained 19-25% of 
the variability in bone mass [66]. 
There are also a variety of secondary causes of osteoporosis which are associated 
with increased bone resorption, bone loss and low bone mass. An estimated 20% of 
women and 40% of men presenting with vertebral or hip fracture have a secondary 
cause of osteoporosis [41]. Diseases associated with low bone mass include primary 
hyperparathyroidism, thyrotoxicosis, liver and gastro-intestinal diseases, rheumatoid 
arthritis and poorly controlled insulin-dependent diabetes [34]. Medications taken in 
excess such as thyroxine [67], corticosteroids [68], anticonvulsants, heparin and 
cytotoxic drugs are also associated with reduced bone mass. 
1.3.6 Other Factors Related to Fracture Risk 
While bone mass is the most important determinant of fracture risk, other factors will 
also contribute to overall fracture risk. It has been demonstrated that even if bone 
mass is maintained at a constant level, fracture risk will continue to increase with age 
[17]. Age is not only associated with a decrease in bone mass but also an increase in 
the likelihood of falling [69,70]. This increase in falling is also accentuated by a 
decrease in neuromuscular function with ageing and a decrease in soft tissue 
protection, making it more likely that an individual will fall on more vulnerable bony 
sites. Ageing is also associated with an accumulation of fatigue damage and a loss of 
trabecular connectivity that decrease bone strength [52,71-73]. Bone geometry, such 
as hip axis length, has also been shown to be an independent predictor of fracture risk 
[74]. 
1.4 CONSEQUENCES OF OSTEOPOROSIS 
Osteoporosis is the most common generalised disease of the skeleton. It has been 
estimated that 30% of all white postmenopausal women have osteoporosis in the USA 
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[75]. However, there is no evidence to suggest that bone loss itself causes any 
symptoms and progressive bone loss has been called the 'silent thief' [76]. The 
morbidity associated with osteoporosis arises from the fractures sustained due to the 
increased fragilitY of the skeleton. 
1.4.1 Epidemiology of Osteoporotic Fractures 
The three most common fracture sites associated with reduced bone mass are the 
spine, hip and distal forearm. It has been estimated that 90% of all hip and spine 
fractures can be attributed to osteoporosis [77]. However, evidence suggests that 
fractures at other skeletal sites such as the humerus or rib could also be associated 
with osteoporosis [78]. A combination of increasing frequency and severity of trauma 
from failing and also the increase in skeletal fragility with ageing causes the incidence 
of fractures at the spine, hip and forearm to rise with age in both men and women [791. 
There aro limited data for the incidence of osteoporosis-related fractures in the UK. 
However, a large epidemiology study has been carried out in the Trent region of the 
UK, which serves approximately 9% of the population of England and Wales. Age and 
sex-specific rates were obtained for hospital inpatient admissions for all fractures for 
the year 1989-1990 [80]. The incidence of fractures was similar among men and 
women, but large differences were observed in the age at which fractures occur. In 
men three quarters of fractures occurred before the age of 45, while in women three 
quarters of fractures occurred after this age. The age- and sex-specific rates were 
bimodal with the first peak observed in childhood and adolescents. Rates were low in 
middle life and increased again after age 45. Rates in men exceeded those in women 
until age 55 and then rates increased exponentially in both sexes but were consistently 
greater in women. The site of fracture between ages and sexes also differed. Colles' 
fractures of the distal forearm were common in women immediately following the 
menopause. However hip fractures assumed a greater importance with age and by 
age 85, hospital admissions were largely attributable to hip fractures. The incidence of 
age-related fractures for women and men after the age of 45 were 62,965 and 9,867 
respectively. 
The lifetime risk of sustaining a hip or Colles fracture for a 50 year old white woman 
has been estimated to be 15%, while the lifetime risk of sustaining an atraumatic 
vertebral fracture was 32%. The lifetime risks of hip fracture for black women or men 
are lower at 5.6% and 5.2% respectively [81]. Osteoporotic fractures are associated 
with an increase in both morbidity and mortality. The lifetime risk of death due to hip 
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fracture for a 50-year old white woman is 2.8% which is significantly lower than the 
31% lifetime risk of dying from coronary heart disease but comparable to the lifetime 
risk of dying from breast cancer [81]. 
1.4.2 Fractures of the Hip 
Hip fractures are considered the most severe type of osteoporotic fracture as they are 
associated with more deaths, disability and, medical costs than all the other fractures 
combined [82]. Hip fractures usually require hospitalisation and therefore the estimates 
of the incidence, costs and consequences are better documented. It was estimated 
that there were 1.66 million hip fractures worldwide in 1990, and with the increasing 
ageing of the World's population this figure is expected to rise to 6.26 million by the 
year 2050 [83]. The lifetime risk of hip fractures varies between countries and these 
differences among different populations may be attributed to differences in bone mass, 
risk of falling, lifestyle or genetic factors, but there is still uncertainty regarding the 
precise mechanism that underlie the differences in hip fracture incidence [84]. There is 
also evidence that incidence rates of hip fracture are rising over time in excess of that 
which can be accounted for by demographic changes [80,85]. However, there is great 
variation in the results obtained for studies examining secular trends [86]. It is 
interesting to note, however, that there does seem to be a rise in the incidence of hip 
fractures associated with moderate trauma with are usually attributed to osteoporosis 
[86]. 
There were 46,000 hip fractures in England and Wales in 1985 and this was associated 
with an average length of hospital stay of 30 days and bed use of 3500 beds per day. 
A total of one-fifth of all orthopaedic beds are occupied by hip fracture patients [87]. 
Hip fractures are associated with significant increases in both morbidity and mortality. 
As many as 50% of hip fracture patients will be unable to walk independently after hip 
fracture and they will have an increased likelihood of being institutionalised [88]. 
Various surveys indicate that between 12-40% of all hip fracture patients will die within 
the first 6 months of fracture [80,82]. The financial costs associated with hip fracture 
are immense and was estimated to be E160 million per annum in 1988 for England and 
Wales, which accounts for approximately 88% of inpatient hospital costs for fractures in 
men and women aged 45 and over [87]. 
1.4.3 Fractures of the Spine 
Since the earliest description of the disease in 1941, vertebral fractures have been 
synonymous with osteoporosis [8]. The epidemiology of vertebral fractures is difficult 
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to establish and quantify. Vertebral fractures are rarely associated with an episode of 
external trauma and instead are commonly due to loading of the vertebral column 
during normal daily activity [89]. Consequently, many vertebral fractures do not come 
to hospital attention and may in fact be asymptomatic. In addition, there is no 
universally accepted definition for vertebral fracture and so possible vertebral fractures 
are often referred to as vertebral deformities to account for this. 
Prevalence rates of vertebral fractures obtained from an age-stratified sample of 
women from Rochester, USA revealed that 18% of white women aged over 50 had one 
or more vertebral fractures and this rose to 27% for women aged over 65 [89]. The 
European Vertebral Osteoporosis Study (EVOS), a population based study of 15,570 
people, revealed that 12% of both males and females were considered to have at least 
one vertebral deformity. This data was extrapolated to the UK population and a total of 
900,000 males and 1 million women aged 50-79 years were estimated to have a 
vertebral deformity. It was estimated that approximately 350,000 of these women would 
come to medical attention [90]. Prevalence rates for the USA have been estimated to 
be 25.3 per 100 women aged 50 years and over and the incidence of vertebral fracture 
was 17.8 per 1000-person-years. If this data is projected nationally in the USA then 
500,000 of Caucasian women will develop vertebral fractures each year and over 
seven million will be affected at any given time [91]. 
Vertebral fractures are also associated with increased morbidity and a slight increase in 
mortality. Health consequences such as pain, reduced functional capacity and 
psychological morbidity are all associated with vertebral fracture [92,93]. Results from 
the European Prospective Osteoporosis Study (EPOS) revealed that there is a modest 
excess mortality associated with vertebral fracture, especially in women [94]. 
1.4.4 Fractures of the Distal Forearm 
Distal forearm fractures nearly always follow a fall on an outstretched arm. The most 
common fracture of the forearm is a Colles fracture. The incidence of forearm fractures 
is different to that observed for the hip or vertebrae. Incidence rates increase linearly 
from age 40 with rapid increases following the first five years after menopause and 
reach a peak at age 65 before stabilising. In men the incidence of forearm fractures 
remain relatively constant between the ages of 20-80 years [76,95]. A possible reason 
for the plateau observed in the incidence of forearm fractures after age 65 may relate 
to a change in the pattern of failing with advancing age. In women, there is an increase 
in the risk of falling from age 45, with 19% falling once during the preceding year at age 
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45-49 and rising to 48% for women aged 85 and over [69]. It has been suggested that 
the slower gait and impaired neuromuscular function associated with advancing age 
makes elderly women more likely to fall on their hip rather than an outstretched arm 
[70]. However, it must be noted that only a very small number of falls result in fracture. 
The lifetime risk of sustaining a forearm fracture for a 50-year old white woman is 
appro)dmately 15% [81]. There are approximately 10,000 hospital admissions in the 
UK associated with distal forearm fractures [80]. Fractures of the distal forearm cause 
less morbidity than hip fractures and are not associated with an increase in mortality. 
Nevertheless, forearm fractures are painful, may require one or more reductions and 
30% of people with Colles fracture will suffer from algodystrophy [80]. 
1.4.5 The Financial Costs of Osteoporosis 
The costs associated with osteoporosis are immense including acute hospital care, 
care in the home or nursing home, outpatient services etc. The annual cost of 
fractures occurring in women aged 50 years and over in the UK has been estimated to 
be E727 million, of which E629 million can be attributed to hip fracture [95a]. A report 
from the National Osteoporosis Foundation revealed that an estimated $13.8 billion 
was spent on the treatment of osteoporotic fractures in the USA in 1995 [96]. Major 
emphasis is often placed on the financial costs of hip fracture but 37% of the $13.8 
billion was spent on fractures other than the hip. These values are likely to be 
underestimates as they do not take into account all factors associated with 
osteoporosis such as expenditure on research or the development of new technologies 
[96]. Moreover, fractures other than at the spine, hip and forearm or high trauma 
fractures may also be associated with osteoporosis and this may result in an 
underestimation of the true financial costs of osteoporosis [78,97]. 
1.5 PREVENTION AND TREATMENT OF OSTEOPOROSIS 
1.5.1 Hormone Replacement Therapy 
Oestrogen status is an important determinant of skeletal status in women throughout 
life. Studies on both premenopausal [98,99] and postmenopausal women [100] have 
revealed that oestrogens have a primary role in determining both bone mass and bone 
loss. Hormone replacement therapy (HRT) is an antiresorptive therapy that mediates 
its effects on bone mass by reducing bone resorption and the activation frequency of 
new remodelling cycles [101]. 
Hormone replacement therapy for two years has been shown to increase bone mineral 
density in postmenopausal women by between 5-10% and the filling in of bone 
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remodelling sites accounts for the majority of the observed increase in BIVID [102]. 
One study noted a 13.1% increase in lumbar spine BIVID in postmenopausal women 
who had received HIRT for 10 years, while women who had received no treatment over 
the study period showed a 4.7% decrease in spine BIVID [103]. In another study, an 8- 
9% increase in spine BIVID and a 2.3% increase in femoral neck BIVID was observed in 
postmenopausal women after 3 years of HIRT use [104]. Other investigators have 
found similar results [105] and the route of administration does not appear to influence 
the effects of HIRT on BIVID [106]. 
There is controversy whether the beneficial effects of HIRT remain after HRT- 
withdrawal and whether bone loss is actually accelerated when HIRT is discontinued. A 
study which compared BIVID in women who had taken HIRT previously compared to 
never-users found that only women who had taken HIRT for more than 7 years had 
significantly higher BMD. Furthermore, this difference amounted to just 3.2% in women 
aged over 75 [107]. BIVID is not the only factor associated with fracture risk and it has 
been suggested that bone turnover itself may also be an independent determinant of 
fracture risk and therefore HIRT may mediate its effects on fracture risk in this way 
[45,108]. The efficacy of HIRT in reducing fracture risk is certainly greater than that 
expected by changes in BIVID alone and this may relate to architectural and structural 
changes in BIVID as well as changes in bone turnover [109,110]. Women who take 
HIRT have a relative risk of hip fracture of 0.55 compared to women who have never 
received treatment (111 ]. There is little evidence to suggest that withdrawal of H RT 
leads to accelerated bone loss either as bone loss after HRT-use appears to be at the 
same rate as normal postmenopausal bone loss [1121. 
As well as alleviating menopausal symptoms HIRT is associated with a 50% decrease 
in the risk of cardiovascular disease which, in part, can be explained by changes to a 
more favourable serum lipid profile [113]. Women on HIRT have been estimated to 
have an increase in life expectancy by 2 years, primarily due to the decreased risk in 
cardiovascular disease [114]. Although HIRT has also been shown to reduce the risk of 
developing dementia, findings have been heterogeneous so far and further trials are 
required [115]. However, HIRT use is also associated with an increase in the risk of 
breast cancer [116]. Women who have been on HIRT for more than five years have 
been shown to have a relative risk of breast cancer of 1.35. Nevertheless 5 years or 
more after cessation of HIRT there is no excess risk of breast cancer [116]. One of the 
major disadvantages of HRT-use in postmenopausal women is the return of menstrual 
bleeding, which will undoubtedly affect compliance. In recent years, non-bleed HIRT 
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therapies, such as the synthetic compound tibol. n. e, have been introduced which does 
not stimulate the endometrium and consequently there is no need for a progestogen- 
induced withdrawal bleed. A study on tibolone found that although it has relative weak 
hormonal properties, BIVID increased at both the spine and hip after 2 years of use 
[117]. 
1.5.2 Bisphosphonates 
Bisphosphonates had an unlikely start as a potential treatment of osteoporosis as they 
were initially developed as water softeners in washing powders [118]. The fact that 
bisphosphonates also had bone antiresorptive properties was first described in the late 
1960's [119]. Bisphosphonates are synthetic analogues of the naturally-occurring 
pyrophosphate and are characterised by a PCP bond. This structure allows a 
considerable number of variations and different compounds have considerable 
differences in potency and pharmacological profiles. The bisphosphonates decrease 
bone resorption and hence bone turnover [120] and so are widely used in conditions 
that are characterised by excessive bone resorption such as Paget's disease. 
Although the exact mechanisms that brings about these effects are unclear, it is now 
accepted that they interfere with the biochemical processes of osteoclasts when they 
solubilize bisphosphonate-containing bone, which leads to a loss of resorptive function 
[121]. Three of the compounds have been shown to cause a 4- to 24-fold increase in 
osteoclast apoptosis [122]. There is also evidence that bisphosphonates also act by 
inhibition of osteoclast formation from precursor cells [121] as well as decreasing the 
secretion of osteoclast-stimulating activity by osteoblasts [118]. 
The intestinal absorption of bisphosphonates is low ranging from one percent to a few 
percent [118,123] and this is decreased further in the presence of calcium or iron. 
Approximately 30 to 50% of that absorbed is taken up by bone where it may remain for 
a long time and only released when the bone is resorbed. Bisphosphonate use is 
associated with relatively few side effects. The PaFeRt GQFRPQWAd Etidronate at doses 
higher than routinely used can inhibit bone mineralisation but this is not a problem in 
clinical practice as it is given as a cyclic intermittent therapy [118]. There is a 
theoretical risk with the more potent bisposphonates that they may decrease bone 
turnover to such low levels that there may in turn be an increased risk of fragility 
fractures due to impaired microdamage repair. However, if bisphosphonates are given 
at the correct dosage and regimen, the only common occurring side-effects are gastro- 
intestinal disturbances such as diarrhoea or oesophageal stricture. 
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Currently 6 bisphosphonate compounds have been evaluated including etidronate, 
alendronate, pamidronate, tiludrDnate, clodronate and risedronate and two are currently 
approved for the treatment of osteoporosis. Studies on the paFeAt eempeund 
etidronate given as a low-dose intermittent therapy have shown that it can increase 
BMD at the lumbar spine by approximately 5% [124,125] and approximately 2% at the 
proximal femur [124,125] after 2 to 3 years of use. Vertebral fracture rate is also 
reduced by about 50% with etidronate therapy [124,126]. Three years of alendronate 
therapy increase IBIVID by between 8-10% at the spine and 5-8% at the hip [126]. Data 
from the large Fracture Intervention Trial showed that two years of alendronate therapy 
decreased vertebral fracture rate by 47% compared to those on placebo [102,127]. An 
increase in total body BIVID of 2.5% has also been observed after 3 years of 
alendronate therapy [126]. The relative risk of sustaining a vertebral, hip or wrist 
fracture while on alendronate therapy is about 0.50 [126]. Continuous pamidronate 
and ibandronate therapy have also been shown to produce increases in BIVID 
[128,129], reduce vertebral fracture rates [tx56`] and reduce both bone resorption and 
bone formation [129]. 
1.5.3 Calcium and Vitamin D 
An adequate intake of calcium is necessary for both skeletal growth and skeletal 
maintenance. The lack of oestrogen at menopause results in a fall in calcium 
absorption efficiency and an increase in calcium urinary losses and therefore there is a 
need for increased calcium to offset these losses and prevent calcium from being taken 
from the skeletal reservoir [49]. Calcium has two therapeutic roles; to prevent against 
further deterioration of bone mass and secondly to support therapies that increase 
bone mass [130,131]. There is little risk of adverse effects with calcium 
supplementation though they can interfere with the absorption of iron, zinc and other 
trace minerals. 
Calcium supplementation in postmenopausal women can prevent bone loss at the 
spine, hip and forearm [35,36,132] and can sometimes produce small increments in 
BIVID after 1 to 2 years of use [133]. A meta-analysis of calcium supplementation in 
postmenopausal women revealed that calcium has a consistent prevention effect on 
the rate of bone loss and the effects were greatest when baseline dietary calcium was 
low [1341. 
Calcium therapy can also decrease the incidence of vertebral [135] and nonvertebral 
fractures [132,133,136]. The Mediterranean Osteoporosis Study of over 5000 women 
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revealed that the relative risk of hip fracture was 0.75 for women on calcium 
supplements [111 ]. 
Vitamin D serum levels decline with increasing age due to impaired renal function, 
diminished activity of la. -hydroxylase enzyme and decreased cutaneous production of 
vitamin D. This in tern will lead to a decrease in intestinal calcium absorption and 
increase serum PTH [137]. The active vitamin D metabolite calcitriol and the synthetic 
compound alfacalcidol have been shown to reduce vertebral fracture rates in 
postmenopausal women [138,139]. Vitamin D supplementation has also been shown 
to reduce bone loss during wintertime in northern latitudes [140]. 
1.5.4 Calcitonin 
Calcitonin is a 32 amino acid peptide that is produced by the C cells of the thyroid. 
Calcitonin can lower plasma calcium levels and decrease bone resorption [102]. 
Calcitonin reduces bone resorption by inhibiting the action of osteoclasts by flattening 
the brush border of the osteoclast and altering their cytoplasm [102,141]. Calcitonin 
may also interfere with the differentiation of precurser osteoclasts [141]. Salmon or 
human calcitonin can be given by subcutaneous or intramuscular injection, however 
this may induce nausea, flushing or diarrhoea and is expensive [102]. Evidence also 
suggests that the effect of calcitonin therapy may wane over time due to antibody 
formation and thus bring about resistance [102,141]. Although, the development of 
intranasal salmon calcitonin is associated with fewer adverse effects, transient flushing, 
nausea and nasal discomfort are sometimes reported. 
Calcitonin can retard BIVID loss or produce small increases in BIVID compared to 
women on no treatment or on calcium alone [142-144]. A two year study on 72 
postmenopausal women with at least two atraumatic vertebral fractures demonstrated 
a 60% decrease in incident vertebral fractures in women taking 100 IU/day salmon 
calcitonin, while women on calcium only showed a 45% decrease in incident vertebral 
fractures [1421. A similar effect on incident vertebral fractures was also observed in 
another study of salmon calcitonin [144]. The relative risk of sustaining a hip fracture 
while on calcitonin therapy was 0.69 in the MEDOS study [111]. Calcitonin appears to 
be most effective when baseline BIVID is low [143] or when baseline bone turnover is 
high [141]. A potential benefit of calcitonin therapy in the treatment of osteoporosis is 
that it appears to have analgesic properties, decreasing back pain in women with 
recent osteoporotic-related vertebral fractures [145]. 
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1.5.5 Fluoride 
Both sodium fluoride and sodium monofluorophosphate are used for the treatment of 
osteoporosis. Unlike the more traditional therapies used for the treatment of 
osteoporosis, fluoride stimulates bone formation. Biochemical markers used to 
examine the effects of fluoride therapy have shown that bone formation is increased 
while the rate of bone resorption is unaffected [102]. Fluoride increases bone 
formation by increasing osteoblastic cell populations, but the exact mechanism of 
action is unclear. Fluorides also increase intracellular calcium levels which itself is 
associated with bone cell proliferation [146], and fluoride may replace the hydroxyl ion 
in hydroxyapatite, which makes it more resistant to osteoclastic resorption [141]. 
Fluoride therapy can significantly increase BIVID [147] that may amount to as much as 
8% per annum [148]. However, it is unclear whether the new bone is as mechanically 
strong as normal bone. It remains if this increase in BIVID is associated with 
a decrease in fracture risk. A5 year study on 110 women treated with cyclic sodium 
fluoride reported a decrease in the number of patients with new vertebral fractures 
[147]. However, several other studies have demonstrated that fluoride therapy did not 
affect incident vertebral fracture rates [148,149] and fluoride therapy may in fact 
increase fracture risk [111 ]. Fluorides can cause gastric irritation, though this can be 
reduced by taking fluorides with calcium supplementation [102] or using low-dosage, 
sustained release preparations [141]. Lower extremity pain syndrome is reported in 
15-20% of patients, most likely related to an increase in microfractures [141,148]. 
1.5.6 Parathyroid Hormone 
Parathyroid hormone (PTH) given in intermittent low doses stimulates bone formation. 
This may be mediated by an increase in insulin-like growth factor-1 and transforming 
growth factor-P which are both mitogenic for osteoblasts [141]. Studies have reported 
an increase in cancellous bone mass but this may also be associated with an increase 
in cortical porosity [141,150]. The incidence of vertebral deformities was reduced in 
women taking 400 U/day of PTH for 3 years [151 ]. 
1.5.7 Other New and Potential Treatments 
A relatively new treatment for osteoporosis is the so-called selective estrogen- receptor 
modulators (SERMS) such as raloxifene, droloxifene and idoxifene. SERMs have 
oestrogen-agonist effects on the skeleton and cardiovascular systems and oestrogen- 
antagonist effects on the breast and endometrium. Raloxifene has been the most 
investigated so far and studies have revealed that it can reduce bone turnover [152- 
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154] and increase BIVID [153,154]. In addition to this, raloxifene also decreases serum 
cholesterol by 4-8%, reduces low-density lipoprotein cholesterol levels and does not 
stimulate either the breast or endometrium [152,153]. 
Other potential treatments include anabolic steroids that decrease bone turnover, 
ipriflavone that has weak oestrogenic properties [155] and strontium salts. A number of 
cytokines and growth factors such as insulin-like growth factor have potent effects on 
osteoblasts and may provide additional approaches for prevention and treating 
osteoporosis in the future. 
1.6 MEASUREMENT OF BONE MASS 
The clinical value of bone densitometry depends on its ability to predict fracture risk. 
Many cross-sectional and prospective studies have revealed a strong inverse 
relationship between bone density and fracture risk. The largest study to date of 8134 
women aged 65 and over demonstrated a 2.6 fold increase in risk of hip fracture for 
each standard deviation decrease in femoral neck BMD [156]. A meta-analysis of 
prospective studies between 1985 and 1994 revealed a remarkable consistency 
between studies and that there is an approximate doubling in fracture risk for each SID 
decrease in BMD [18]. The predictive abilities of bone density is similar to that seen for 
blood pressure and stroke and better than serum cholesterol and cardiovascular 
disease [18]. 
Even though osteoporosis is a systemic disease the correlation in BIVID between 
skeletal sites is less than perfect, especially in older people as different skeletal sites 
show different rates and patterns of bone loss. The correlation coefficient between 
sites is approximately 0.6 to 0.7 [157,158]. Because of this BIVID measurements at one 
site cannot predict BIVID accurately at another site. Studies examining the relationship 
between bone mass and fracture risk have shown hip BIVID is the best predictor of hip 
fracture risk and spine BIVID the best predictor of spinal fracture risk [18,156], although, 
other studies have not found a difference in predictive capabilities between sites [159]. 
The calcaneus seems to have the best predictive abilities out of all the peripheral 
skeletal sites, perhaps due to the large amount of trabecular bone found at this site 
[156,159,160]. 
Bone densitometry techniques provide an accurate assessment of BMD so they can be 
used not only as prognostic tools for predicting fracture risk but also as diagnostic tools 
for defining osteoporosis. Values for BMD and fracture are continuously distributed in 
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the population so no absolute criterion can identify those people who will fracture from 
those who will not. However, the WHO Working Party recommended that a value of 
greater than 2.5 SID below the young adult mean should be used to define osteoporosis 
[16]. Results of BIVID scans are often presented as T- and Z-scores so BIVID values 
can be readily interpreted. T- and Z-scores are based on comparison with a young 
adult or age-matched population respectively and these are matched for sex and race. 
This means that accurate reference data are crucial for the reliable interpretation of 
BIVID scans. Problems have been identified with manufacturer-based reference data 
where discrepancies have occurred between skeletal sites and different densitometry 
devices [161,162]. An International Committee for Standards in Bone Measurement 
has been established to address these issues and recommend methods for 
standardising BIVID measurements [163]. As well as defining osteoporosis and 
estimating fracture risk, bone density measurements can also be used to aid decisions 
regarding treatment as well as monitoring disease progression or the efficacy of 
treatment. 
There are many ways in which to assess skeletal status. Those methods which 
quantify bone mass have become the most widely used techniques in clinical practice. 
Although bone strength depends on bone quality, bone architecture and bone mass, 
bone mass is currently the easiest of these variables to measure in vivo and it accounts 
for up to 80% of the variance in bone strength [164]. Techniques which quantify bone 
mass include radiographic absorptiometry, single and dual energy photon 
absorptiometry, single and dual energy x-ray absorptiometry, quantitative computed 
tomography, quantitative magnetic resonance and quantitative ultrasound. Other 
techniques are also utilised to assess skeletal status. Subjective evaluation of 
radiographs can be used, although this method is not particularly sensitive and a large 
amount of bone has to be lost before it is detected. Nevertheless radiographs are 
useful for identifying vertebral deformity. Techniques that involve the evaluation of 
trabecular texture can also be used such as the Singh Index in the proximal femur or 
calcaneus [165,166]. Other techniques which were once popular but have since been 
superseded include the Compton scattering technique used for the estimation of bone 
mineral density in peripheral sites [167] and neutron activation analysis which can 
assess bone mass in the entire skeleton. 
Bone densitometry techniques which utilise X- and y-radiation are based on recording 
the decreased transmission of photons from the incident photon beam as it passes 
through bone and soft tissue. Low energy photon levels are used so the predominant 
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modes of interaction is photoelectric absorption and Compton scattering. The amount 
transmission factor depends on the energy of the incident beam and the nature of the 
material through which it travels: If 1. is the incident beam intensity and 1,, is the 
transmitted intensity then: 
Ix = 10 exp - ýtmpx Equation 1.1 
Where g. is the mass attenuation coefficient, p the physical density and x the thickness 
of the material. When a measurement is made the transmission factor (lx/lo) can be 
calculated and along with the knowledge of mass attenuation coefficient, the areal 
density (px) can be calculated [158,164]. Areal density (px) is the product of the 
physical density (p) and the thickness of the attenuating material (x). In physical terms, 
px is the total mass in the column of unit cross-sectional area centred on the x-ray 
beam and has units of grams per square centimeter. 
1.6.1 Radiographic Absorptiometry 
Radiographic absorptiometry (RA) is the oldest method for quantifying bone mineral 
[168]. It involves measuring the optical density of bone on radiographs calibrated with 
a wedge of aluminium or hydroxyapatite [158]. RA is usually performed on the 
phalanges or metacarpals to avoid problems associated with variable soft tissue 
thickness. 
In the past, the calibration and evaluation of each radiograph was performed manually 
which meant that this technique was highly operator dependent and labour intensive. 
Radiographs can now be sent to central evaluation facilities where microdensitometers 
scan radiographs with a light beam and compute optical density, which has enhanced 
precision and made it more widely available for primary care physicians [169]. 
Recently, small systems have become available that perform high-resolution digital 
radiographic images of the hand so radiographic films are no longer needed. The in 
vivo precision of RA is approximately 2% [158,170] and studies have revealed that RA 
can predict vertebral deformity [171] and shows moderate correlations with axial 
measurements of the spine and hip [169]. 
1.6.3 Single Photon Absorptiometry 
Single photon absorptiometry (SPA) was introduced in 1963 as a radiological technique 
for quantifying bone mass at the distal radius and this lead to the rapid evolution of new 
bone densitometry techniques [172]. The original SPA devices used a sealed 
44 
Chapter 1- Introduction 
radioactive isotope source and a detector consisting of a sodium iodide crystal coupled 
to a photomultiplier tube [164]. The radionuclide source used was 1251 for the forearm 
and fingers or 24'Am for the upper arm or thigh. SPA devices became commercially 
available in the early 1970's. SPA measurements need to be performed on bone 
surrounded by soft tissue of constant thickness and this is usually achieved by 
submerging the limb into a water-bath. For this reason, this technique is limited to 
peripheral skeletal sites. The technique presumes that soft tissue can be closely 
simulated by water, yet periosteal, subcutaneous and intraosseous fat can affect the 
appearance of the baseline. Accuracy errors range from 3-6% and the precision of 
SPA is between 3-5% [158,164]. Measurements were usually performed at the radius 
that is both easily accessible and convenient for the patient. However, the need for 
source replacement and subsequent recalibration meant that this technology has been 
replaced by others. 
1.6.4 Single X-ray Absorptiometry 
Due to the problems associated with source replacement, the radionuclide source 1251 
in SPA devices was replaced with a low-voltage x-ray tube. Single x-ray 
absorptiometry (SXA) devices are small, simple to use and expose the patient to a very 
low dose of radiation and yield in vivo precision errors of approximately 1% [173,174]. 
Although, SXA image quality and spatial resolution are superior to SPA, there is still a 
need for a waterbath. SXA devices have become less popular with the introduction of 
peripheral dual energy x-ray absorptiometry devices which do not need a water-bath 
and have faster examination times. 
1.6.5 Dual Photon absorptiometry 
Dual photon absorptiometry (DPA) was first developed in the 1960's and 1970's [175] 
but commercial devices did not become available until the early 1980's. DPA devices 
use the radionuclide 153 Gd that emits photons at two discrete energies of 
44 and 
1 00keV [158]. This substitution of a dual- instead of a single-energy source meant that 
axial sites could be measured as well as the assessment of body composition 
[176]. 
Although DPA was an important development in bone densitometry, it was soon 
superseded as scanning times were long and there was still a need for the costly and 
complicated process of source replacement. 
1.6.6 Dual Energy X-ray Absorptiometry 
Dual energy x-ray absorptiometry is the most widely used technique to assess skeletal 
status and some consider this to be the "gold standard" in the 
field of bone 
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densitometry. The first commercial DXA device was introduced in 1987 by Hologic 
(Bedford, MA, USA). The introduction of a x-ray tube which has a higher photon flux 
and a smaller diameter source led to enhanced image definition, increased precision 
and shorter examination time [158]. However, the use of an x-ray tube instead of a 
radionuclide source can produce a phenomenon known as beam hardening. X-ray 
tubes generate polyenergetic spectra and lower energy photons will be preferentially 
removed from the radiation beam compared to higher-energy photons, which will lead 
to a progressive shift in spectral distribution towards higher effective photon energies 
with increasing body thickness. This means that the mass attenuation coefficients for 
bone and soft tissue will change with body thickness and consequently will vary 
between patients and different sites within the body [177]. The Hologic commercial 
DXA device compensates for this effect by simultaneous calibration, achieved by 
continuously interposing known amounts of bone and soft tissue equivalents mounted 
on a wheel or rotating drum which rotates synchronously with the x-ray pulses. The 
dual energy x-rays can be generated in two ways, either by an energy-switching 
system or by rare-earth filtered x-ray sources. 
The original DXA devices used a pinhole collimator to produce a pencil beam that was 
coupled to a scanning arm with a single detector. This meant that scanning times were 
relatively long as a raster scan had to be performed to cover a particular area. New- 
generation scanners utilise a slit collimator to produce a fan-beam so the scanning arm 
performs a single sweep across the patient which has reduced scanning time from 5-10 
minutes to just 10-30 seconds. The replacement of pencil beam to fan-beam 
technology had little effect on BIVID estimates [178] but is associated with an increase 
in radiation dose to both the patient and operator [179,180]. However, radiation doses 
are still low. 
The body is considered a two-compartment system consisting of soft tissue and bone. 
The attenuation coefficients of bone and soft tissue depend on photon energy and so a 
measurement of the transmission factor at two different energy levels enable two areal 
densities of two types of tissue to be inferred [158]. An edge-detection algorithm is 
used to delineate bone edges and BIVID is calculated and averaged over all the pixels 
within the bone edges. Bone mineral content (BMC) can also be calculated by 
multiplying the BIVID by the projected area, although BIVID is the more precise 
measurement [181]. The precision of DXA is just 1% at the spine and 1-2.4% for the 
different hip regions [182]. Due to its high hydrogen content, fat has a slightly different 
attenuation coefficient to lean tissue. Furthermore, when assessing the soft tissue 
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regions adjacent to bone to obtain a baseline this technique assumes that the soft 
tissue above and below the bone is equal to that on both sides of bone. These errors 
due to the non-uniform distribution of fat can lead to accuracy errors of 5-10% at the 
spine [164,183] and approximately 7% at the femoral neck or trochanter (184]. 
As lean and fat tissues have different attenuation coefficient characteristics, especially 
at low energy photon levels, body composition measurements can be performed on 
DXA devices. When the x-ray beam does not intersect bone, the ratio of the 
attenuation values for high and low energy beams are dependent on the soft tissue 
composition so lean and fat tissue can be evaluated separately [158]. Body 
composition studies may be useful in clinical trials so the effects of treatments on body 
tissues can be determined. 
The use of a rotating C arm means that lateral scans of the spine can be performed 
without the patient moving from a supine position. DXA scans of the spine in the 
posteroanterior (PA) direction include the posterior elements as well as the vertebral 
body. The vertebral body consists of 60% trabecular bone while the posterior elements 
consist of 90% cortical bone. Trabecular bone is metabolically more active than 
cortical bone so lateral scans of the vertebral body may be more sensitive to losses in 
bone mass. In addition, osteoarthritis is common in elderly people [185] and along with 
aortic calcification can artificially increase BIVID in the PA direction. Although lateral 
spine BIVID has been shown to display better discrimination between young adults and 
elderly people, precision is over twice that seen in the PA direction [186]. DXA is a 
projectional technique and for a given volumetric BIVID larger vertebrae yield higher 
areal BIVID results. Volumetric estimates can be derived by using paired PA and lateral 
scans and this has been shown to enhance fracture discrimination [187]. 
The fan-beam coupled to a solid-state detector constructed in the form of multi-element 
linear array has increased image resolution so that anatomic details can are depicted 
clearly. This has lead to the development of morphometric x-ray absorptiometry where 
vertebral dimensions can be estimated and pre-existing vertebral fractures identified 
[188,189]. This technique may become useful in monitoring efficacy of treatment or 
predicting future fractures. Peripheral sites such as the forearm and calcaneus can 
also be measured which may be useful in clinical trials or in patients where axial 
measurements are not possible. 
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1.6.7 Quantitative Computed Tomography 
Quantitative computed tomography (QCT) is the only absorption method available for 
assessing trabecular and cortical bone separately and unlike the other absorption 
methods, QCT provides a measurement of the physical (volumetric) density. Instead of 
a measurement being taken along a fixed line through an object, a series of 
measurements are performed along a line by rotating the source and the detector. 
This produces a 2-dimensional map of x-ray attenuation coefficients in a particular 
cross-section of the body and these attenuation coefficients can be used to determine 
tissue density at any point in the image [190]. QCT scans can be performed in single- 
or dual-energy modes, however the single-energy modes is usually used in clinical 
practice as it displays higher precision and gives a lower radiation dose. QCT is most 
often performed on commercial CT scanners. A specially designed calibration 
phantom is used to convert the CT Hounsfield units into bone mineral equivalents. 
QCT is primarily used to determine bone density in the vertebral body that has a high 
trabecular content. It has been shown that the age-related loss observed using QCT is 
3-4 times higher than that measured by areal DXA and displays the highest diagnostic 
sensitivity to disease [157,164]. The precision of spinal QCT is between 2-4% [158]. 
Lately, there has been interest in developing volumetric or 3-D QCT [191] and high 
resolution or microcomputed tomography, which allow examination of trabecular 
microstructure. QCT scanners have improved recently with the introduction of 
automated scanning and analysis, yet scanning time is still several minutes and 
compared to other methods, QCT is relatively expensive and entails a higher radiation 
dose. 
Peripheral QCT (pQCT) is an alternative to spinal QCT, it offers several advantages 
such as a lower radiation dose, and pQCT devices are smaller and cheaper. The most 
common measurement site used in pQCT is the forearm and these devices have 
precision errors of less than 1% [158,164,192]. These devices have the potential to 
provide additional information on the structural properties of trabecular bone [318, i5S ]. 
1.6.8 Quantitative Magnetic Resonance 
The technique of quantitative magnetic resonance (QMR) is a development of the 
traditional MR technique that was introduced in the 1970's. QMR does not involve 
photon or x-ray absorptiometry but instead a radiofrequency wave is used to excite 
hydrogen nuclei in a strong magnetic field and the relaxation time of the processing 
electrons is used to generate an image [158]. This non-invasive modality allows 
the 
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quantitative study of trabecular bone structure and correlates well with traditional bone 
histology studies [193]. Magnetic resonance microscopy ([tMR) has also been 
developed to quantify trabecular microarchitecture and texture tools such as fractal 
analysis can be used to quantify trabecular structure [170,194]. Both QMR and [tMR 
are relatively expensive and time consuming, but it has been suggested that this 
technique could be employed when examining high-risk individuals or monitoring the 
more aggressive therapies [170]. 
1.7 QUANTITATIVE ULTRASOUND 
Previously, the diagnosis of osteoporosis has focused on the assessment of BMD 
using DXA. However, the introduction of new drugs for the prevention of bone loss and 
increased public awareness of osteoporosis over the past decade has increased the 
demand for bone densitometry services. The cost and availability of DXA has led to an 
increase in research and commercial development of other non-invasive screening 
tools for assessing skeletal status. 
Ultrasound testing of materials in engineering is established and well accepted. Early 
studies on bone demonstrated that sound waves are modified in a manner that 
depends on the mechanical and structural properties of bone as well as bone volume 
and density [195-198]. One of the early attractions of using ultrasound to assess the 
properties of bone was that it might provide information on bone strength that is 
independent of BMD. This additional information could be useful as BIVID alone fails to 
explain all the variance in fracture risk The other obvious attraction is the lack of 
ionising radiation. 
It was not until the pioneering work of Langton and colleagues in 1984 that the 
ultrasound assessment of bone became recognised as a potential clinical tool for the 
assessment of fracture risk [199]. The acronym quantitative ultrasound [QUS] was 
used to describe this technique [200]. Preliminary clinical results demonstrated that 
QUS measurements were able to discriminate between subjects with fracture and 
those without and this encouraged further investigation and commercial development. 
This technology has focused on measuring frequency-dependent attenuation and the 
velocity of sound at the calcaneus. However, the utility of other skeletal sites including 
the phalanxes [201], tibia [202,203] and patella [204,205] have also been assessed. 
Recently a device has been developed that has the potential to assess previously 
inaccessible sites such as the proximal femur and posterior processes of the lumbar 
spine [206]. A large number of studies have been published over the past two decades 
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on QUS and these promising results has lead to a widespread consensus that QUS 
has a role in the field of osteoporosis. 
1.7.1 The Calcaneus 
The calcaneus has been the most popular skeletal site for performing QUS 
measurements. The calcaneus was chosen as it is easily accessible and the medio- 
lateral surfaces are reasonably flat and parallel. The calcaneus is a weight-bearing 
bone that is over 90% trabecular bone [54]. Calcaneal BIVID is significantly correlated 
with BIVID at the spine [207] and displays similar age-associated losses to other 
skeletal sites [208-210]. Several large prospective fracture studies have demonstrated 
that calcaneal BIVID can predict the risk of sustaining spinal or non-spinal fractures 
[156,159,211,212]. A meta-analysis of prospective studies showed that measurements 
at the calcaneus have similar predictive capabilities to spine, hip and forearm BIVID 
measurements [18]. As well as BIVID, calcaneal structural variables such as trabecular 
thickness or separation are also significantly different in subjects with osteoporotic 
fracture compared to healthy controls [194]. 
A potential drawback of performing QUS at the calcaneus is that it is heterogeneous in 
terms of both external geometry and internal structure and density. Most of the 
commercially available QUS devices measure BUA and SOS at a fixed point of the 
calcaneus relative to a footplate. Consequently, variations in the size and shape of the 
calcaneus and the thickness of the surrounding soft tissue may result in different areas 
of bone being measured in different individuals. 
Several studies examining ultrasound attenuation at different sites of the calcaneus 
reported that variability between sites may be as high as 30% [213-215]. To address 
this problem, ultrasound transmission imaging at the calcaneus has been developed 
over recent years [115,213,216-219]. BUA images of the calcaneus allows the precise 
location of a specific ROI so the same anatomical area of bone can be assessed in 
different individuals and the same area of bone selected for repeat measurements. In 
principle this technical advance should improve the precision of calcaneal 
measurements and possibly improve discriminatory ability. 
1.7.2 Ultrasound Velocity 
Ultrasound is a mechanical wave consisting of frequencies above the range of human 
hearing (20 kHz). When an ultrasound signal passes through bone both the velocity 
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and intensity of the signal is altered. Therefore, bone tissue can be characterised in 
terms of ultrasound velocity and ultrasound attenuation. 
When an ultrasound signal is passed through a homogeneous and nondispersive 
media with a radius that is small compared to the wavelength then the relationship 
between the velocity of longitudinal waves c and the mechanical properties of the 
medium is given by the equation: 
(E/p) Equation 1.2 
where p is the density of bone and E is the Young's modulus. This equation does not 
apply to heterogeneous, anisotropic or dispersive media. The equation is often used to 
provide a first-order estimate for the relationship between bone properties and velocity 
[220]. Complex materials like bone can also support other propagation modes and 
conversion of one mode to another may occur. 
The equation for velocity identifies a direct relationship between the biomechanical 
properties of bone and the velocity of sound. This has been proven experimentally 
where ultrasound velocity has been shown to be related to the material properties and 
structural properties of bone [195,196,198,221]. 
In the clinical application of ultrasound velocity, measurements on bone are usually 
carried out in transmission mode where two transducers are used; one serves as a 
transmitter and the other a receiver. A measurement device using a typical U shaped 
frame with a transmitting and receiving transducer was developed as early as 1966 and 
was used to estimate the velocity of sound through bone and other tissues [197]. 
However. The first publications on the clinical application of ultrasound velocity were 
not until the late 1980s and early 1990s [222]. 
There are three different methods for calculating speed of sound (SOS) at the 
calcaneus (Figure 1.3). QUS devices that utilise a water bath (Figure 1.3a) generally 
take a so-called time-of-flight velocity (VTOF)measurement that is the average velocity 
through water, soft tissue and bone. It is calculated using a substitution method where 
the transit time is calculated with and without the sample in place. If x is the distance 
between the transducers, Vw is the SOS in water and At is the difference in transit time 
with and without the sample, then: 
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x- [At Vw] 
Equation 1.3 
The TOF method assumes a constant heel thickness. To determine SOS through 
bone only (Vbone) an estimate of bone width (xb) is required. A pulse-echo technique 
can be utilised in which each transducer emits a pulse and the transit time of the 
reflected signal from the soft tissue and bone interface is recorded. If s, andS2are the 
soft tissue thickness', tj andt2 the transit times through them and Tb is the transit time 
through bone only then: 
Vbone )& 7- 
-X--"-LS1 
+ SZ1 
Tb tx - [tl + t2l 
Equation 1.4 
TheVbone method assumes that the velocity of sound in soft tissue is equal to the 
velocity of sound in water. Furthermore, the surface of the medial face of the 
calcaneus is curved which may make the detection of the reflected signal difficult. 
The third method of calculating velocity is that used by contact QUS systems where the 
SOS is the average velocity through soft tissue and bone (Figure 1.3b). The 
transducers come into direct contact with the heel and so the width of the heel (X-h) can 
be directly measured. If t is the transit time through the heel thenVheel is given by: 
Vheel :- &h 
t 
Equation 1.5 
A study which compared the three methods for calculating SOS found that they were 
highly correlated with each other (r--0.83-0.98), although the three methods did yield 
different values and biological ranges [223]. It was also shown that each method 
showed comparable standardised precision [223]. 
At present, only one device (no longer commercially available) provides a velocity 
measurement through bone only. Other devices assume a constant heel or bone 
thickness. However, the effect of sample thickness appears to be small and Miller et al 
concluded that additional measurement errors associated with estimating bone width 
may affect standardised precision and therefore clinical utility [223]. 
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Figure 1.3: Measurements of SOS using (a) a water-based QUS system and (b) a contact QUS 
system. 
In commercial devices, the SOS through bone is measured simultaneously with a 
measurement of frequency-dependent attenuation. This means that a broadband 
signal is used and therefore the velocity of the signal is a group velocity consisting of a 
finite number of frequencies. There are also a number of different criteria used to 
define signal arrival time such as the first deviation from zero or first zero crossing. 
This has implications when measuring the transit time of the broadband signal. 
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Commercial QUS devices which utilise broadband pulses assume that the pulse shape 
is unchanged during its passage through bone. It has been shown that frequency- 
dependent attenuation causes errors in the calculation of transit time in both soft tissue 
[224] and bone [225,226]. The extent of which SOS is affected by frequency- 
dependent attenuation depends upon which criteria are used to define the transit time 
of the pulse as well as the resonant frequency of the transducer. Although it has been 
demonstrated that this may only cause deviation in SOS measurements of up to 1% 
[226], this may become important when attempting to standardise SOS measurements 
using different commercial devices. 
Bone is also a dispersive medium and therefore each frequency component 
propagates at its own velocity. Dispersion has been shown to effect transit time 
measurements in trabecular bone [227]. In addition to frequency-dependent 
attenuation and dispersion, it has been revealed that the different criteria used to define 
the transit time of a pulse can produce differences in SOS estimates of up to 257m/s 
[227]. 
At present, there is no convention for the use of terms or the calculation protocol for 
ultrasound velocity. It has been recognised that this is one of the challenges for 
standardising QUS measurements and the further development of QUS devices [228]. 
As well as measuring SOS in transmission mode at the calcaneus, other QUS devices 
have been developed that perform SOS measurements at other skeletal sites. These 
so-called semi-reflection techniques take velocity measurements along a fixed 
longitudinal section of bone and remove some of the measurement errors associated 
with soft tissue and bone shape and thickness. QUS devices using this semi-reflection 
technique have been developed for the tibia [202] and more recently at multiple 
skeletal sites such as the radius, ulna, phalanxes and metacarpals [206]. 
1.7.3 Broadband Ultrasound Attenuation 
The attenuation of an ultrasound signal occurs by a reduction in its amplitude and 
results in a loss of acoustic energy. The signal amplitude A(f) at frequency 
f 
decreases with distance according to the relationship: 
A. (f) = A. (f) exp-ýL (ý x Equation 1.6 
where Ao(f) is the incident amplitude, ýi(f) the frequency-dependent attenuation 
coefficient and Ax(f) the amplitude after traversing thickness x. 
In bone, attenuation of 
54 
Chapter 1- Introduction 
the ultrasound beam occurs primadly through the processes of scattering and 
absorption [220]. Other factors that contribute to attenuation include diffraction, 
reflection, refraction and mode conversion. 
Ultrasound attenuation is a function of frequency and for bone, attenuation is 
approximately linearly proportional to frequency over the frequency range 0.1 -1 MHz: 
ýL(f) = Equation 1.7 
where cc is the slope of attenuation as a function of frequency and is expressed in 
dB/MHz. This has been termed broadband ultrasound attenuation (BUA). 
Figure 1.4 displays the principles for measuring BUA. The measurement of BUA was 
first described by Langton et al in 1984 and the majority of commercial devices adopt 
this method [199]. The increase in attenuation as a function of frequency between 0.2- 
0.6 MHz is obtained by comparing the amplitude spectrum for a reference material 
(degassed water and a surfactant) with the amplitude spectrum for the signal 
transmitted through bone (Figure 1.4a). When the attenuation due to the patients heel 
is plotted against frequency a linear relationship is found. The slope of this regression 
line is referred to as BUA (Figure 1.4b). The early work of Langton et al [199] revealed 
that BUA was significantly lower for patients with hip fracture compared to healthy 
controls (Figure 1.4c). 
At the present time, no commercial devices normalise BUA to heel or bone width, and 
so the devices measure ax rather than a. Several in vitro studies have revealed that 
BUA depends on calcaneal thickness [229-231]. It has been shown that normalising 
for bone width can enhance discriminatory ability [2-321 and the correlation between 
BUA and BIVID [233], although these effects were small. In vivo studies have shown 
that the in vivo SID in calcaneal width for adult populations is only 3mm [231]. Wu et al 
concluded that in a clinical environment, the impact of bone width on BUA is small 
[231]. 
A potential error of measuring BUA is that of phase cancellation. The majority of 
commercial QUS devices use large aperture transducers with diameters significantly 
larger than the wavelength of sound. This limits the loss of ultrasound energy by the 





















Figure 1.4 Description of BUA. (A) The power spectrum of the sound transmitted through the 
patients heel is compared with the reference signal through water only. The difference between 
the bone and reference trace is the attenuation due to the patients heel. (B) Attenuation as a 
function of frequency is plotted and BUA is the slope of the regression line. (C) Measurement of 
BUA in women with hip fracture and healthy controls. Adapted from Blake [234] and Njeh [235]. 
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process of diffraction. When an ultrasound signal propagates through the calcaneus, 
variations in the internal composition may lead to various components of the wavefront 
arriving at the transducer out of phase with one another. This leads to an apparent 
decrease in intensity and subsequently attenuation will be overestimated. It has been 
demonstrated that BUA can be overestimated by between 15-57 dB/MHz when using 
large aperture transducers [236]. The effect of phase cancellation is frequency- 
dependent and therefore may cause scatter in the linear plot of attenuation versus 
frequency. It has been suggested that a form of signal analysis could be performed to 
detect any phase cancellation effects [237]. However, phase cancellation effects are 
greater in subjects with high BUA and therefore may actually enhance the differences 
between osteoporotic subjects and healthy controls [234]. Phase cancellation may 
also therefore effect SID values used in the calculation of T-scores. 
1.7.4 Determinants of QUS 
1.7.4.1 Age and menopause 
There has been a number of studies which have examined the relationship between 
QUS variables and risk factors associated with low bone density such as age, 
menopause, genetics and anthropometric factors, exercise and factors that can cause 
secondary osteoporosis. It has been shown that QUS variables are negatively 
associated with age [238-245]. It has demonstrated that calcaneal BUA declines by 
0.2-1 dB/MHz per annum which corresponds to approximately 0.5-1% [238- 
240,242,243,245]. The rate of decline per year for calcaneal velocity measurements is 
approximately 1-2m/s per annum which, if reported as a percentage, is 0.07-0.15% per 
annum [240,243-245]. Velocity measurements performed at other skeletal sites such 
as the proximal phalanxes [201,246], tibia [202] and patella [247] have also shown a 
negative relationship with age. There have been relatively few studies examining QUS 
variables in men, although those that have been published have shown that QUS 
variables also decrease with age [238,244,248]. The standardised age-associated 
decline in BUA and SOS are comparable to those observed for BMID measurements 
using DXA [242,244,249]. It would appear that BUA displays a faster rate of decline 
with age than SOS but if the smaller biological variation of SOS measurements is taken 
into account, the rates of decline for BUA and SOS are similar. 
As with BMD, there is considerable variation regarding the age at which QUS variables 
start to decline. Several studies have shown that QUS variables decrease from age 
20-30 years [238,242,248] although another study showed no significant decline in 
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BUA until after the age of 50 [243]. Longitudinal studies in premenopausal women are 
required to determine if QUS variables decrease with age before menopause. 
To date only two studies have examined longitudinal changes in QUS variables and 
both of these used calcaneal QUS devices [250,251]. It was revealed that the age- 
related decreases in BUA and SOS assessed longitudinally were considerably different 
to those obtained cross-sectionally [251]. Furthermore, only 22% of women for SOS 
measurements and 39% of women for BUA measurements displayed changes that 
were larger than the measurement error during follow-up [251]. Additional studies are 
required to fully assess the effect of age on QUS and whether QUS can be used to 
monitor individuals over time. 
The menopause in women also influences QUS variables. Many studies have shown 
that BLIA and SOS are significantly lower in postmenopausal women compared to 
premenopausal women [242,245,252]. A study which examined changes in QUS 
measurements and biochemical markers with menopause found that both BUA and 
SOS were lower in postmenopausal women and this was associated with an increase 
in bone markers for bone resorption [253]. A study on 842 healthy Japanese women 
showed that BUA decreased with age from age 20, but 75% of this decrease was 
observed in the 10 years following menopause [245]. Many studies have revealed a 
negative relationship between QUS measurements and years since menopause 
[201,238,243]. Herd and colleagues found that BUA decreased by 2.5% in the first five 
years following menopause and this fell to 0.5% for the next 5 years after menopause 
[241]. A similar finding was reported in another study by the same authors [240]. 
Thus, it would appear that the accelerated period of bone loss associated with 
menopause can be detected using QUS- 
1.7.4.2 QUS and HRT 
It has been indicated that QUS variables are influenced by HIRT use in 
postmenopausal women [244,247,249,254,255]. A study on 110 women revealed that 
the annual decrease in SOS measured at the patella was significantly lower for women 
on HIRT compared to non-users (-7.82 vs. -4.11 m/s respectively). Furthermore, the 
longer the duration of HRT-use the greater the mean Z-score for patella SOS [247]. It 
has also been reported that QUS variables at the calcaneus were 12% higher on 
women using HIRT compared to non-users [254]. Salmon calcitonin therapy has also 




1.7.4.3 QUS and Genetic Factors 
Genetic factors play an important role in determining bone mass. Twin and family 
studies have revealed that QUS variables have a major genetic component that is 
independent of BMD, with heritability estimates of 53-82% [25,257,258]. The 
polymorphism Of a2HS-Glycoprotein has been shown to contdbute in part to the genetic 
influence on BUA [259]. Polymorphisms in the vitamin D receptor gene have been 
associated with variations in bone density, although a twin study did not detect any 
associations between VDR polymorphisms and calcaneal QUS measurements [260]. 
A recent study examining the racial differences in QUS measurements demonstrated 
that BUA was significantly higher in Black postmenopausal women compared to 
Caucasian women, but there were no significant differences in SOS (261]. Further 
studies are required to assess whether there are any racial differences in BUA or SOS 
and whether these differences are independent of BIVID. 
1.7.4.4 QUS and Anthropometric Factors 
It has been demonstrated that anthropometric variables are associated with QUS 
measurements. Body weight, height and body mass index are positively associated 
with both BUA and SOS [202,244,248,262-265]. It has also been demonstrated that 
handedness influences QUS variables, particularly in men and young women where 
BUA is significantly higher on the dominant side [266]. 
1.7.4.5 QUS and Exercise 
There have been very few studies examining the effect of exercise on QUS variables. 
As is seen for BIVID, immobilisation and severe disability is associated with significantly 
reduced QUS variables [244,267]. A study of Japanese female golf caddies found that 
these women had higher QUS measurements compared to age-mat&ed controls and 
that they did not show a significant decline in QUS variables with years since 
menopause [268]. A study that examined the effect of brisk walking over a 1-year 
period found that walking caused BUA to increase by 13 dB/MHz, while the controls 
displayed a decrease of 4 dB/MHz [269]. 
1.7.4.6 QUS and Clinical Risk factors for Osteoporosis 
Clinical risk factors such as diseases or treatments known to affect bone metabolism 
can reduce bone mass and increase the risk of osteoporosis. To date, there have 
been relatively few investigations into the effects of clinical risk factors on QUS 
variables. It has been shown that women with risk factors for osteoporosis have 
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significantly lower BUA values compared to healthy controls [270]. Both primary and 
secondary hyperparathyroidism is negatively associated with QUS variables [271,272]. 
Hyperthyroidism is also associated with reduced BUA and SOS values [273]. Ovarian 
status has been shown to effect SOS measurements at the phalanxes, with SOS being 
higher in premenopausal women with regular menses compared to women with 
irregular cycles [201]. Corticosteroid use is negatively associated with BUA and SOS 
[244,274]. Renal failure also leads to significantly lower BUA values (275]. The 
majority of these studies have been performed on relatively small numbers of people 
and the International QUS Consensus Group recommends that further research is 
undertaken in this area and determine how clinical risk factors influence QUS variables 
[228]. 
1.7.5. Precision of QUS Measurements 
Knowledge of the precision error of any quantitative technique is required to discern the 
ability of the technique to stratify individuals relative to normal values and the ability to 
monitor the changes in measurement variables over time. The precision error is often 
expressed as the coefficient of variation. As the normal changes in bone density are 
slow, a high reproducibility is required so that changes of such small magnitudes can 
be detected. 
Daily measurements of phantoms are carried out to monitor machine stability and to 
assess in vitro precision. The in vitro precision of QUS devices has been reported to 
be approximately 1% for BUA and 0.1-0.3% for SOS measurements [243,276,277]. 
Manufacturer provided QUS phantoms are suitable for monitoring equipment but there 
are no validated data on their acoustic properties. Furthermore, QUS devices are often 
set in a different mode to that used for patient scanning because the acoustic 
properties of the phantom differ significantly from those of the calcaneus [278]. 
Recently, there has been an attempt to develop phantoms that simulate heel 
architecture and that are not device specific [278]. 
The in vivo reproducibility of the "gold-standard" DXA is high, short term precision 
errors for spinal BIVID are just 1%, and for the hip measurement regions precision 
errors are 1-2.5%. [181,182,279]. The in vivo precision errors for QUS measurement 
has been shown to be approximately 1-7% for BUA [239-241,243,276,277,280,281] 
and 0.2-1% for SOS [201,240,243,276,277]. To date, there have been very few 
studies that have examined the long-term precision of QUS measurements and the few 
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studies that have been reported have taken measurements over a relatively short time 
period. 
At first glance, it would appear that the reproducibility of SOS is superior to both BUA 
and BMD measurements. Miller and colleagues suggested that precision errors should 
be standardised to eliminate the favourable bias on instruments that offer a small range 
of clinical values or have large mean values [223]. There are a number of ways in 
which precision errors can be standardised including dividing by the biological range, 
the young adult standard deviation or the expected change per annum for 
postmenopausal women. The standardised precision errors for QUS measurements 
have been shown to be approximately double that observed for DXA techniques 
[244,280]. 
There is a large variation in the reported precision errors obtained for QUS 
measurements. The precision errors will vary depending on the QUS device used and 
the size and characteristics of the study population. A comprehensive study that 
compared four calcaneal QUS devices showed that the precision errors varied 
depending on the device used [280]. The majority of the reproducibility estimates are 
based on young healthy women and therefore these estimates may be different for 
other populations such as men or patients with osteoporotic fracture. One study found 
that the precision errors, for BUA and SOS measurements, were actually lower in 
osteoporotic patients compared to healthy controls [277]. 
The precision in vivo will be inferior to that observed in vitro due to the uncertainties 
that arise when measuring the calcaneus in vivo, such as variable bone shapes and 
sizes [229,276,282], soft tissue thickness [282], oedema [283] and water-temperature 
[276]. An extensive study on the factors, which affected the precision of BUA, found 
that variations in the positioning of the heel produced errors as high as 9.2% [284]. 
The majority of commercial calcaneal QUS devices take measurements at a fixed 
location relative to a footplate and therefore it is important that the heel is placed in the 
same position between the transducers each time a measurement is performed. The 
advent of QUS imaging has allowed the same area of bone to be selected for repeated 
measurements. An improvement in precision has been reported when a variable 
region of interest was used instead of a fixed location relative to a footplate [285,286]. 
Precision errors of 1.2-2.2% for BUA and 0.2-0.32% for SOS have been reported for 
measurements performed on QUS imaging devices [216,218,285]. 
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1.7.6 Correlation between QUS and BMD 
Since QUS has been introduced as a method for assessing skeletal status, there have 
been a large number of studies examining the relationship between QUS variables and 
BMID measured by the more traditional techniques, typically DXA. It was hypothesised 
that BLIA and SOS measured at the calcaneus should correlate with BIVID at the 
femoral neck and vertebral bodies as they are all sites rich in trabecular bone, which 
responds more rapidly to osteoporotic change compared to predominantly cortical- 
sites. 
The relationships between QUS measurements and BIVID reported in the literature 
have shown barely significant correlations to highly significant relationships 
[157,213,214,240,242-244,248,249,266,268,277,281,287-305]. In-vitro studies tend to 
report a more significant relationship which is most likely due to the more ideal 
experimental conditions obtained in in-vitro studies compare to those found in a clinical 
environment [203,297,299,301]. The size of the study group used to examine the 
relationship between QUS and BIVID varies considerably as well as the study group 
characteristics such as gender, age and age-range and menopausal and disease 
status. The more homogeneous populations, which have been subdivided, often 
display a less significant relationship. 
There could be a number of reasons why the relationship between QUS and BIVID is 
relatively weak. QUS measurements taken at the calcaneus are often compared to 
BIVID at other skeletal sites, primarily the spine and hip. Even if the same technique is 
used to measure different skeletal sites, the relationship between them will be modest 
[157,265,287,306]. A comprehensive study which examined the relationship between 
five of the currently available bone assessment techniques found that the correlation 
between x-ray based methods and QUS was only marginally lower than those obtained 
between x-ray based methods alone [157]. 
The correlation between QUS and BIVID measurements is often higher when both 
measurements are performed at the same site [249,281,293,303]. The reproducibility 
and accuracy errors inherent in both QUS and BIVID techniques may also preclude a 
close relationship. Ultrasound imaging allows the acoustical properties of the calcaneus 
to be mapped and therefore anatomically identical sites can be chosen when 
performing QUS and BIVID measurements. Higher correlations between QUS variables 
and BMID have been found in studies using QUS imaging devices [213,286,302]. In 
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one in vitro study that utilised QUS imaging, the correlation coefficient between 
calcaneal BIVID and QUS variables was approximately 0.90 [302]. 
The relationship between QUS and BIVID is often more significant in studies with 
populations that have low bone density [287]. This could be explained by two recent 
studies that found that the relationship between BUA and density is not linear, except 
where the apparent density is less than approximately 0.6 g/CM2 [307,308]. A recent 
twin study found that only 35% of the variance in BUA was attributable to genes 
specific to hip BIVID [258]. 
One of the most frequent explanations given to account for the relatively poor 
relationship between QUS and BIVID is that QUS provides information about bone that 
is independent of bone density. Bone strength depends not only on BIVID but also on 
bone mechanical and structural properties. Absorptiometry techniques measure bone 
density only and therefore a proportion of the variance in bone strength cannot be 
accounted for. Many studies have been undertaken to elucidate the nature of the 
information derived from QUS. 
1.7.7 Relationship between QUS and the Structural and Mechanical 
Properties of Bone 
The overlap of BIVID values observed between fracture and non-fracture groups 
suggests that factors other than bone quantity are important in determining bone 
fragility. Ultrasound velocity can be modelled theoretically using bar wave theory which 
states that velocity is related to the density and elasticity of bone by E=pV2 . Therefore, 
bone elasticity can be determined once density and velocity are known. In trabecular 
bone, bone elasticity is also related to yield strength (i. e. the stress level where bone 
undergoes permanent deformation). 
Scattering is the principle mechanism of attenuation in trabecular bone and this is 
largely governed by the large number of trabeculae. Therefore, it is thought that BUA 
may reflect bone architectural properties, such as porosity and trabecular thickness, 
separation and connectivity. 
Studies have been undertaken to examine the variation in QUS variables along three 
orthogonal axes. As the density of a cube of bone is independent of the axis studied, 
any variation in QUS variables with orientation would suggest a structural component. 
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Several studies have shown that BUA and SOS measurements vary according to 
which direction through bone the measurements were taken [298,309-312]. 
Measurements of BUA in both bovine and human bone have been shown to be related 
to bone structural variables such as porosity [313] and trabecular separation, thickness 
and connectivity [310,312,314]. A 2-dimensional histomorphometric study on 17 
human calcanei found that the correlation between QUS measurements and structural 
variables was no longer significant when bone volume was taken into account. The 
authors concluded that QUS measurements reflect bone quantity rather than bone 
microarchitecture [314]. An in vitro study on 70 human vertebral bodies found 
significant but poor to moderate correlations between bone structural properties and 
QUS, but when the correlations were adjusted for density, very few remained 
significant. In fact, no correlations between QUS and structural variables remained 
significant in the medio-lateral direction, which is the direction used to perform clinical 
measurements of the calcaneus [312]. 
It has been demonstrated that QUS measurements are related to bone mechanical 
properties such as elasticity, yield strength, ultimate strength and energy-absorption 
capacity [296-300,315-319]. An in vitro study of 20 human calcanei, found that BUA 
explained 72% and 69% of the variance in bone elasticity and yield strength 
respectively [300]. Both BUA and SOS have been shown to explain between 40% and 
64% of the variance in bone elasticity and the ultimate strength of human calcanei 
[297]. It would appear that QUS variables are related to the mechanical properties of 
bone. However, the majority of studies report no significant improvement in the 
prediction of bone strength when a combination of BIVID and QUS is used compared to 
using BIVID alone [296,299,300,316]. 
As yet, there is no comprehensive theory on which properties of bone QUS is actually 
measudng and it remains unclear whether QUS is merely a surrogate for density or 
whether QUS variables reflect non-mass properties of bone as well. A recent 
in vitro 
study, which used parametric imaging at the calcaneus to examine the relationship 
between QUS and BIVID and controlled for potential sources of error in QUS 
measurements, revealed that BIVID explained approximately 90% of the variance 
in 
QUS measurements. Therefore, it was concluded that QUS reflects other bone 
properties only to a small extent [302]. Further research is required to validate what 
QUS variables are actually measuring and whether QUS could augment current 
techniques which measure bone density only. 
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1.7.8 QUS and Fracture Risk 
Examining the relationship between QUS and BIVID is useful for determining whether 
QUS provides any additional information on bone strength but determining whether 
QUS can identify individuals at risk of fracture is of primary importance. The early 
detection of bone fragility before fractures occur is essential if therapeutic intervention 
is to reduce the risk of fracture 
There has been an abundance of cross-sectional studies that have shown that QUS 
variables are significantly lower in individuals with fragility fracture compared to healthy 
controls [205,222,240,241,252,320-326]. A study of 50 women with hip fracture 
demonstrated that BUA values were 27% lower for the hip fracture group compared to 
controls [327]. Another study revealed that BUA values were 1.09 SID lower in patients 
with hip fracture [328]. Odds ratios obtained for QUS variables are similar to those 
obtained for BIVID measurements performed using DXA [171,329,330]. One study on 
women with vertebral fracture found that BUA yielded an odds ratio of 1.8 which was 
superior to femoral neck BIVID and almost as high as the odds ratio obtained using 
lumbar spine BIVID [331]. Receiver-operator characteristic curve analysis has revealed 
that QUS has equivalent sensitivity and specificity to BIVID [327,332]. A study which 
compared the ability of a number of bone densitometry techniques to discriminate 
between women with vertebral fracture and healthy controls found that the area under 
the curve for QUS was not significantly different than that obtained for QCT or DXA. 
However, an interesting point was that the diagnostic agreement between the methods 
was poor, yielding kappa scores of only approximately 0.4 [157]. 
It has been demonstrated that QUS variables are still able to discriminate between 
fracture patients and controls even after adjustment for BIVID [333]. Therefore, this 
may imply that QUS measures properties independent of BIVID and these properties 
contribute to fracture risk. It has also been revealed that combining BIVID and QUS 
measurements increases the sensitivity of identifying those at risk of fracture [330,333]. 
It remains unclear whether a combination of BIVID and QUS measurements increases 
sensitivity enough to warrant the increased cost and time of additional examinations. 
Combining QUS results from multiple skeletal sites, made possible by the development 
of a new multi-site QUS device, has been shown to moderately improve fracture 
discrimination [206]. 
Despite the strong and persistent relationship between QUS variables and fracture risk, 
cross-sectional studies have a major disadvantage in that they cannot separate cause 
from effect [335]. The initial prospective studies using QUS were small but showed 
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that QUS variables can identify individuals at risk of sustaining an osteoporotic fracture. 
Although the number of individuals that sustained a fracture during follow-up was small 
and this may affect the results obtained [336,337]. A prospective study of 3180 
postmenopausal women aged 45 to 75 years, followed up for three years, reported a 
relative risk of fracture of 1.4 and 1.3 for BUA and SOS respectively [338]. A 
prospective study by Pluijm et al of 710 men and women aged 70 years and over in 
residential care, reported that a one SID decrease in BUA and SOS was associated 
with a relative risk of hip fracture of 2.3 and 1.6 respectively [339]. 
The first large prospective study on QUS examined 1414 elderly women in residential 
care [169]. During a mean follow-up of two years, 73 women suffered a hip fracture. 
These women had significantly lower BUA values compared to women who did not 
sustain a fracture [51 vs. 40 dB/MHz]. However, IBIVID was not measured in this study. 
There have been two large population-based prospective studies to date, the main 
findings of which are displayed in Figure 1.5 [341,342]. During the two-year follow up 
in the study of 5662 elderly women in the USA, 54 women suffered a hip fracture. The 
relative risk for each standard deviation in BUA and SOS was 2.0 and 1.7 respectively, 
which was comparable to the relative risk of 1.9 obtained for hip BIVID. BUA and SOS 
remained significant predictors after controlling for hip BIVID [341]. The largest 
prospective study to date is the EPIDOS study on 6189 women aged over 65. During 
the two-year follow-up, 115 women sustained a hip fracture. It was shown that there 
was a doubling of risk of hip fracture associated with each SD decrease in BUA. The 
relative risk remained significant at 1.5 after adjustment for femoral neck BIVID. 
However, a combination of BIVID and BUA did not significantly improve the fracture risk 
prediction [342]. 
These prospective studies have been carried out on water-based, non-imaging 
calcaneal QUS systems. Therefore, there is a need for further studies on other 
calcaneal devices, as well as systems that perform measurements at other skeletal 
sites, so these promising findings can be confirmed. 
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Figure 1.5: The ability of QUS to predict the risk of hip fracture. Results are expressed as the 
relative risk associated with each SD decrease in each measurement variable. Error bars 
represent the 95% confidence intervals. Results from the [a] EPIDOS Study [342] and [b] the 
Study of Osteoporotic Fracture Study [341]. 
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Chapter 2 
Study Objectives and Methodology 
2.1 STUDY OBJECTIVES AND SUMMARY OF STUDY DESIGN 
2.1.1 Study Objectives 
The objective of this thesis was to evaluate the use of calcaneal QUS as a first line 
method of assessing skeletal status in patients at risk of osteoporosis. The hypothesis 
that I set out to investigate is: 
"That technology for performing quantitative ultrasound measurements of the 
calcaneus has evolved to the point where such equipment could substitute for dual 
energy x-ray absorptiometry as the primary method of assessing skeletal status in 
patients referred for a bone density investigation because they are thought to be at risk 
of osteoporosis. " 
To examine this hypothesis a study was designed to investigate and address some of 
the issues that are currently perceived as obstacles to the wider application of 
calcaneal QUS in clinical practice. The study was set in a busy Outpatient Unit in 
which a wide spectrum of patients referred for assessment of their skeletal status by 
hospital consultants and general practitioners are currently investigated using DXA 
measurements of BMD. 
2.1.2 Summary of Study Design 
There are three main parts to this study: 
I The long-term stability and precision of QUS 
The long-term stability of QUS equipment has been examined and in vivo short-, mid- 
and long-term in vivo precision investigated based on intensive measurements of 
phantoms and volunteers (Chapter 3). 
2 Determination of reference data for QUS 
Reference ranges for both QUS and BMD measurement variables were constructed, 
using a single study population, so any differences between different manufacturers' 
QUS devices or QUS and BMD are due to differences in technology rather than 
discrepancies in manufacturer reference data (Chapter 4). 
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These reference ranges were used to determine whether QUS variables are influenced 
by age- and menopause-related factors to the same extent as BIVID (Chapter 4). In 
addition the correlation between the three calcaneal QUS devices and between QUS 
and BIVID was assessed (Chapter 5). 
3 The clinical application of QUS 
The four main ways of utilising non-invasive measurements of skeletal status in clinical 
practice have been examined for QUS: (i) the diagnosis of osteopenia and 
osteoporosis; (ii) the evaluation of individuals with clinical risk factors for osteoporosis-, 
(iii) the identification of individuals at risk of fracture (iv) the monitoring of skeletal 
responses to treatment. 
The applicability of the WHO criteria for diagnosing osteopenia and osteoporosis using 
QUS has been assessed and revised diagnostic criteria derived for QUS (Chapter 6). 
QUS and DXA measurements of women with clinical risk factors for osteoporosis have 
been compared to establish whether QUS measurements are affected to the same 
extent as BIVID measurements (Chapter 7). The ability of QUS to discriminate between 
women with fragility fracture and those without has been investigated and whether the 
combined use of QUS and DXA improves fracture discrimination has been assessed 
(Chapter 8). The suitability of QUS for longitudinal studies has been assessed by 
investigating whether QUS can monitor skeletal response to treatment in 
postmenopausal women (Chapter 9) and whether QUS can monitor skeletal changes 
during adolescence (Chapter 10). This latter study also allowed an evaluation of the 
suitability of QUS in the assessment of skeletal development during adolescence. 
2.2 STUDY POPULATION 
The study population consisted of 1217 female subjects aged 11-82 years. These 
subjects were recruited from five main sources: 
(i) women referred by their General Practitioner or Hospital Consultant for routine 
bone density screening by DXA; 
(ii) women from the Guy's Hospital metabolic bone clinic; 
(iii) hospital staff and volunteers from the general population who contacted the 
Guy's Hospital Osteoporosis Unit to volunteer for clinical research; 
(iv) women enrolled on a two-year study examining the seasonal variations of BMD 
and the effect of vitamin D supplementation (referred to as the Seasonal Study). 
At the end of the study, analysis of the data revealed that neither season nor 
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vitamin D supplementation had any effect on BMD. Therefore, QUS and BIVID 
data for these women were included at various stages of the study. 
(v) adolescents enrolled on a three-year study examining the effect of intensive 
ballet training on development and BIVID, consisting of 50 girls from two 
performing arts schools who underwent varying amounts of ballet training and 
37 control girls from a normal school (referred to as the Dance Study). 
The obtain a population of women that was a close representation of the general 
population, the exclusion criteria used by Ryan et al [343] for the construction of BMD 
reference ranges was applied to all adult subjects (Table 2.1). 
Table 2.1: Exclusion criteria used to construct reference data for QUS and BMD 
measurement variables 
Non-Caucasian 
History of atraurnatic fracture 
Menopause before the age of 40 years 
History of amenorrhoea of longer than 6 months duration 
The use of any treatments or history of any diseases known to affect bone metabolism 
As the exclusion criteria described in Table 2.1 were not applicable to adolescents, the 
group of 37 girls from the control arm of the Dance Study from a normal school was 
used to construct reference values for adolescents. 
A group of women from the metabolic bone clinic with known vertebral fractures was 
recruited and used at various stages of the study. Radiographs to confirm vertebral 
fracture were generally not available, but confirmation of fracture was obtained from 
examination of patient hospital notes or the General Practitioner referral letter. These 
women constituted a group with severe osteoporosis and were therefore used to 
represent women with confirmed osteoporosis (rather than rely on using T-score of :! ý- 
2.5 as recommended by the WHO study group). A recent study by Rea et al, on a 
selection of the women described above, reported that only 4 out of 42 subjects that 
had vertebral fractures noted on their referrals, were classified as normal using a semi- 
quantitative method of defining vertebral fracture [344]. 
The source of the study population and the number of subjects in each subgroup are 
shown in Table 2.2. Also shown in this table are the Chapter numbers in which the 
different groups of women were used. 
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The height and weight of every subject was measured to the nearest mm and 0.1 kg 
respectively, using a Harpingden stadiometer and electronic scales. 
This study along with the Seasonal study was approved by the Guy's Hospital 
Research Ethics Committee and all subjects gave written informed consent. The 
Dance study was approved by the Lambeth, Southwark and Lewisham Health 
Commission Ethics committee and written informed consent was obtained from all 
subjects and parents (Appendix 1). 




GP/Hospital Consultant referral 280 
Guy's Metabolic Bone Clinic 118 
Volunteers 664 
Seasonal Study 68 
Dance Study 87 




Data' Fracture Adolescents 
76 20 0 
4 76 0 
422 8 0 
28 0 0 
37 0 87 
530 104 na 










' the group of subjects who did not meet any of the exclusion criteria described in Table 2.1 
b excluding adolescents. 
2.3 EQUIPMENT 
Study subjects were measured on a DXA machine (Hologic QDR4500A) and three 
calcaneal QUS devices: Hologic UBA575+ (UBA), Hologic Sahara (SAH) and 
Osteometer DTLlone (DTU). Not all women were measured on the DXA and all three 
QUS devices and Table 2.3 shows the number of subjects in both the total population 
and the subgroups measured on each device. The study began in June 1996 using the 
UBA device. The SAH was received in September 1996 and the DTU in January 1997. 
Therefore, rather fewer subjects were measured on the SAH and DTU (Table 2.3) 
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Table 2.3: Number of subjects measured by DXA and the three QUS devices. 
QUS 
Tota I DXA UBA SAH DTU 
All Subjects 1217 968 1140 1016 722 
Reference data 567 465 517 498 379 
Vertebral fracture 104 104 99 102 90 
Adolescents 87 87 87 87 85 
2.3.1 Hollogic QDR4500A DXA Scanner 
BIVID was measured using a Hologic QDR4500A DXA scanner (Figure 2.1). The 
QDR4500A consists of a x-ray tube that is coupled, using a rotating C-arm, to a linear 
array of 216 solid state detector. X-rays of two different photon energies (100 and 140 
kVp) are transmitted through the body, via a slit collimator to generate a fan-beam, and 
the intensity of the transmitted signal is registered by the multidetector array. The dual 
energy beam is generated by switching the HV generator between 100 and 140 kVp 
during alternative half cycles of the mains supply [345]. Simultaneous calibration is 
achieved by continuously interposing known amounts of bone- and soft tissue- 
equivalent material into the beam using a rotating calibration drum. A typical Hologic 
DXA scan report of the lumbar spine is shown in Figure 2.2. The scan report provides 
values for projected area, bone mineral content (BMC) and BIVID for each vertebra from 
L1-L4 and averaged to give a BIVID for the lumbar spine, with units of gram per square 
centimetre. Also included on the scan report are T- and Z-scores which allow the 
physician to compare the BIVID results to a young adult and age- and sex-matched 
population (section 2.4.1). 
Figure 2.1: An outline of a Hologic QDR4500A DXA scanner. 
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Figure 2.2: A typical DXA lumbar spine BMD scan report using a Hologic QDR4500A. 
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All subjects who underwent DXA assessment had a scan of the lumbar spine and left 
hip, and a subgroup of 94 pre- and postmenopausal women had additional DXA scans 
of the calcaneus. The adolescents also had DXA scans of the lateral spine and total 
body but these data are not described here. 
The effective radiation doses for the DXA assessment at the spine and hip are shown 
in Table 2.4. Effective dose, rather than entrance skin dose, was used as it quantifies 
the total radiation risk to the patient and the risk of genetic injury of their offspring for 
patients of reproductive age. 
The ICRP (international Commission on Radiation Protection) Publication 60 (1990) 
defines effective dose as the sum of the absorbed dose to each irradiated organ 
weighted for the radiation type and radiosensitivity of that organ [346]. 




PA Spine Ll-L4 
Hip including ovaries 
excluding ovarieS 
Fast Array Array 
2.0ý6v 4.0 ýLSv 
5.4 ýLSv 10.8 ýtSv 
0.6 ýLSv 1.2 ýtSv 
a data from three sources [347-349]. 
b applies to postmenopausal women. 
The majority of DXA scans were performed in the fast array mode (30 seconds), with 
the exception of subjects weighing over 100 kg when the array mode (60 seconds) was 
used. Follow-up scans were analysed using the compare function on the QDR4500A 
software, where scans are directly compared to the baseline scan. All subjects of 
reproductive age were questioned for the possibility of pregnancy prior to scanning. 
2.3.1.1 DXA of the lumbar spine 
BIVID of the lumbar spine (LS BMD) was obtained with the subject in the supine 
position on the QDR4500A positioning table and the scan performed in the 
posteroanterior (PA) projection. A large foam block is placed under the subject's lower 
leg that flexes the hips and knees and flattens the natural lorditic curve of the lumbar 
spine. A pillow is placed under the subjects' head and arm's placed by their sides. 
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BIVID of the lumbar spine was assessed over 1-1-1-4 and averaged to give the total 
lumbar spine BMD. Vertebrae showing evidence of degenerative change or fracture 
were excluded from the analysis. 
2.3,1.2 DXA of the hip 
This was performed immediately after the PA spine scan with the subject supine on the 
positioning table. The left hip was scanned unless the subject had had a total hip 
replacement, osteoarthritis or a previous fracture of the left hip, in which case the right 
hip was scanned. The leg to be scanned was placed on a foot holder and rotated 
medially by turning the leg and foot, by approximately 250. A strap placed across the 
foot and attached to the foot holder ensured this position was maintained throughout 
the scan. The fast array scan takes approximately 30 seconds and includes the entire 
femoral head, the greater trochanter and the proximal end of the femoral shaft below 
the lesser trochanter. As shown in Figure 2.3, there are several measurement regions 
of interest (ROI) in the femur. However, in this study only BMD data for the femoral 
neck (FN BMD) and total hip (THIP BMD) were used. The femoral neck ROI is located 
between the femoral head and trochanter, lies perpendicular to the central axis of the 
femoral neck, and contains roughly equal amounts of trabecular and cortical bone. The 
total hip ROI includes the femoral neck, inter-trochanteric and trochanteric region of the 
hip and THIP BIVID is an area weighted mean of these three sites. Due to the large 
BIVIC contributed by the inter-trochanteric region, THIP BIVID consists largely of cortical 
bone. 








Figure 2.3: Measurement regions of interest in the femur. 
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2.3.1,3 DXA of the calcaneus 
The subject was positioned in the left lateral decubitus position on the positioning table. 
The right knee is flexed and the lower leg positioned on a foam block positioning aid, 
with the sole of the foot placed against the back edge of the aid. A pillow was placed 
under the subject's right knee. As this was a research scan only, the right forearm 
scan of the Hologic software was used to scan the right lateral calcaneus. 
The scanning arm was positioned just below and anterior to the lateral malleolus. The 
scan takes approximately 25 seconds and includes the calcaneus and at least 3-4cm of 
air above the upper edge of the heel to ensure proper software analysis. Figure 2.4 
shows a typical DXA scan of the right calcaneus. Two BIVID measurements are 
obtained, total calcaneal BIVID and a circular ROI positioned (by the operator) in the 
region of apparent lowest density located in the posterior tuberosity of the calcaneus. 
Only the ROI BIVID was used as recommended by the manufacturer. The right lateral 
calcaneus was scanned as this side was measured using QUS. 
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Figure 2.4: A typical DXA heel scan report using a Hologic QDR4500A. The circular ROI BIVID 
was used for analysis as recommended by the manufacturer. 
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2.3.2 Calcaneal QUS Devices 
Three calcaneal QUS devices were used in this study: (i) Hologic UBA575+; (ii) Hologic 
Sahara; (iii) Osteometer DTUone. These devices were located in the same study 
room, along with the device-specific manufacturer-provided phantoms. The water used 
in the two water based devices (Hologic UBA575+ and Osteometer DTUone) was 
prepared at least twenty-four hours in advance of scanning to degas and reach 
equilibrium with ambient temperature. Following the initial experience, from May 1997, 
room and water temperature were measured every day prior to phantom and patient 
scanning, using a mercu ry-i n-g lass thermometer with an accuracy of 0.50C. The 
manufacturer-supplied phantoms were scanned daily prior to patient scanning. 
The right calcaneus was routinely scanned unless the right leg had recently been 
immobilised, fractured or if the subject had severe oedema. Subject's were first 
scanned on the Sahara, then the UBA575+ and finally the DTUone. Figure 1.3 
displays the general set-up of water-based and contact calcaneal QUS devices and 
sections 1.7.2 and 1.7.3 of Chapter 1 describes the measurement of SOS and BUA at 
the calcaneus. 
2.3.2.1 Hologic UBA575+ 
The UBA575+ was chosen, as it was a validated device, against which the new QUS 
devices could be compared. The Hologic UBA575+ (UBA) is a water-based, fixed 
point device (Figure 2.5). The water-bath is stabilised to room temperature. This 
system consists of two unfocused transducers, 18mm in diameter and resonant 
frequency of 600 kHz, mounted coaxially in a waterbath containing 30ml of surfactant 
(Star Drops). A reference trace, without the heel in the water-bath, is first performed 
and then the heel positioned in the water bath, ensuring the lower leg was parallel to 
the sides of the UBA and the heel resting against the back of the scanner. The foot 
was immobilised using a pneumatic foot restraint. The subject's heel is immersed and 
allowed to stabilise for approximately three minutes. A rectilinear scan of the heel is 
performed with measurements averaged over 9-points in a3x3 grid, 5x 5mm in size. 
BLIA (UBA BUA) is measured over the frequency range 200 and 600 kHz and is 
calculated using a fast Fourier Transform method (FFT). SOS (UBA SOS) is the 
average velocity of sound through water, soft tissue and bone as descdbed in section 
1.7.2. A pulse echo technique is utilised to provide an estimate of bone thickness and 
this allows a measurement of the velocity of sound through bone only (UBA BV). UBA 
specifications are shown in Table 2.5. The total scanning time is approximately 4 
minutes. 
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Figure 2.5: The Hologic UBA575+. 
The UBA is supplied with two phantoms consisting of beads encased in rubber, one 
representing 'low' BUA and the other representing 'normal' BUA. These phantoms do 
not provide a SOS measurement. 
2.3.2.2 Hologic Sahara 
The Hologic Sahara (SAH) is a dry system designed to emulate the UBA and consists 
of two unfocused transducers mounted coaxially on a motorised calliper. 
The 
transducers, 19mm in size and resonant frequency of 600 kHz, are acoustically 
coupled to the subject's heel using soft rubber pads and an oil-based coupling gel 
supplied by the manufacturer (Figure 2.6). Before patient scanning, a measurement of 
the velocity of sound is taken with the pads touching and no heel interposed, 
this 
allows corrections to be made for the time delay incurred as the acoustic signal passes 
through the rubber pads. To determine the attenuation of the heel alone, a reference 
measurement is made during calibration at the factory of the manufacturer-supplied 
phantom. The subject's heel is thoroughly wiped using a wet-wipe and 
dried before 
scanning. A rigid foot-positioning device ensures proper positioning of 
the foot and 
immobilisation of the lower leg during scanning. BUA and SOS are measured at a 
fixed location of the calcaneus. Encoders on the motorised callipers measure the width 
of the heel during QUS assessment and therefore SOS represents the average velocity 
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of sound through soft tissue and bone over the measured heel width. BUA and SOS 
are combined, with equal weighting, to provide a parameter called the Quantitative 
Ultrasound Index (QUI). The QUI was found to be highly correlated with heel BIVID in 
studies by the manufacturer and so QUI is converted into an estimate of heel BIVID 
(SAH BIVID), by linear rescaling. SAH BIVID is expressed in units of grams per square 
centimetre by BUA and SOS using the following equation: 
SAH BMD = 0.00259 * (BUA + SOS) - 3.687 (g/CM2) Equation 2.1 
It is important to note that SAH BMD is inferred from a linear combination of BUA and 
SOS and is not an actual measurement of calcaneal BMD. SAH BMD rather than QUI 
results are described in this study, as SAH BMD is linearly related to QUI. Scanning 
time is appro)dmately 10 seconds. The specifications of the SAH are shown in Table 
2.5. 
Figure 2.6: The Hologic Sahara. 
The SAH is supplied with two phantoms; a rubber phantom with expected values Of 
27.9 dB/MHz and 1520.2 m/s for BUA and SOS respectively, and a temperature 
independent phantom with an expected SOS value of 1626.1 m/s. The temperature 
independent phantom consists of a mixture of alcohol and water encased in an outer 
casing. Alcohol and water have opposite temperature coefficients, which means that 
measurements of this phantom should be independent of ambient temperature. 
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During the study period, examination of the quality control data of the phantoms 
revealed that the SAH showed evidence of a drift in both BIJA and SOS (Chapter 3). 
On discussions with the manufacturer, it was realised that this drift was due to a 
change in the shape and stiffness of the rubber transducer pads. It then became 
practice to replace these rubber pads annually to avoid this problem. Specific details of 
the long-term stability of the SAH and other QUS devices are examined in Chapter 3. 
2.3.2.3 Osteometer DTUone 
The DTU consists of two focused transducers, 20mm in diameter with a resonant 
frequency of 500 kHz, mounted coaxially in a water bath (Figure 2.7). 
Figure 2.7: The Osteometer DTUone. 
The waterbath is stabilised at room temperature and contains 23ml of surfactant 
(Osteometer DTUone Solution). A reference trace through the water is obtained 
without the heel interposed. The subject's heel is then placed in the waterbath 
supported by a plastic fixabon ring located at the bottom of the waterbath to ensure the 
heel is posifioned at the correct height and in the same position at follow-up. A 
rectilinear scan of the calcaneus is performed producing a high-resolution image 
approximately 60 by 80 mm in size, with a pixel size of 0.6mm. Both BUA and SOS 
are calculated at each pixel and an automatic search algorithm places an automatic 
ROI (4.8mm in diameter) in an area with a local minimum of attenuation in the posterior 
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tuberosity of the calcaneus. The SOS measurement is the average velocity of sound 
through water, soft tissue and bone. The DTU specifications are shown in Table 2.5. 
The DTU was supplied with one phantom with values of 41.98 dB/MHz and 1628.1 m/s 
for BUA and SOS respectively. However, this was replaced in March 1999 by the 
manufacturer as it was found that the original phantom might not have been stable over 
time. The new phantom expected values were 61.7 and 1425.2 for BUA and SOS 
measurements respectively. It was recommended that the phantom measurements be 
performed in a waterbath between 20 and 250C in temperature. In practice, this was 
not always possible because, despite being located in an air-conditioned building 
ambient temperature was sometimes outside these limits. However, measurements 
were still taken to check device performance. 
Table 2.5: Specifications of the UBA575+, Sahara and DTUone QUS devices. 
UBA575+ Sahara DTUone 
Measurements BUA dB/MHz BUA dB/MHz BUA dB/MHz 
SOS m/s SOS m/s SOS m/s 
BV m/s BMD g/cm2 
Measurement time 4 minutes 10 seconds 3 minutes 
Transducers Unfocused Unfocused Focused 
Diameter 18 mm 19 mm 20 mm 
Centre frequency 600 kHz 600 kHz 500 kHz 
Frequency used to calculate BUA 200-600 kHz 200-600 kHz 300-650 kHz 
Coupling medium water bath at oil-based water bath at 
room temperature coupling gel room temperature 
surfactant 30 ml Stardrops na 23 ml DTU solution 
Dimensions 
Height 38 cm 30 cm 44 cm 
Width 29 cm 36 cm 28 cm 
Depth 50 cm 43 cm 53 cm 
Weight 11.3 kg 8.2 kg 22 kg 
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2.4 DATA ANALYSIS 
Data analysis was performed using Excel version 6.0 and Stata version 5.0. For all 
analyses p values of <0.05 were considered statistically significant. 
2.4.1 Summary Statistics 
Data are expressed as the mean and standard deviation (SD), unless otherwise stated. 
Ninety-five percent confidence intervals (Cl) were used to describe the variation of the 
data. Data were tested for normality and non-parametric statistics applied to data that 
deviated from normality. 
As BIVID and QUS measurement variables have different physical units, data were 
often converted into T- and Z-scores, as is conventional in bone densitometry, so 
results could be better compared. The Z-score for an individual is defined as the 
deviation from the average value for an age matched population divided by the SID of 
the age-matched population: 
Z-score = measurement value - aqe-matched mean Equation 2.2 
age-matched population SID 
The T-score for an individual is defined as the deviation from the average value for a 
young adult population divided by the SID of the young adult population: 
T-score = measurement value - young-adult mean 
Young adult population SID 
Equation 2.3 
The age range of the young adult population used in the present study was 20-40 
years. 
2.4.2 Comparing means and standard deviations 
Student's Mest was used to compare the means of two groups. The variance of the 
two groups was compared using the Bartlett's test, and a Mest assuming equal or 
unequal variances used accordingly. If data for the same individuals were compared a 
paired Student Mest was used. One-way analysis of variance (ANOVA) was used to 
compare the means of more than two groups. 
For non-parametric data, the Wilcoxon rank sum test or Wilcoxon matched-pairs 
signed-rank test was used to compare the means of unpaired and paired data 
respectively. 
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The F-test was used to compare two population variances. 
2.4.3 Precision errors 
Precision errors characterise the reproducibility of a diagnostic technique. The 
precision error of a technique is defined as the variability occurring with repeated 
measurements on the same subject [350]. Precision errors were expressed in both 
absolute units and as a percentage, termed the coefficient of variation, defined as the 
standard deviation divided by the mean. Precision errors in individual subjects were 
combined using the root-mean-square (RMS) average of individual SID values rather 
than the arithmetic mean of the individual SID values as suggested by GlOer et al [351]: 
m 
RMS SD (Y- SD 12 /M 
j=l 
Equation 2.4 
where m is the number of subjects. This equation only applies when each subject has 
the same number of measurements as was the case in the present study. 
The RMS standard errors of the estimate (SEE), derived from linear regression 
analysis, was used to calculate long-term precision errors as the SEE allows for the 
true changes in BIVID or QUS that occur, provided they are linear with time (351]: 
m 
RMS SEE 1, SEEj2 
j=l 
Equation 2.5 
So the precision errors for BMD, BUA and SOS could be directly compared, absolute 
precision errors were converted into T-score units by dividing by the young adult 
population SID giving standardised precision (SP): 
SID =- precision error 
young adult population SID 
Equation 2.6 
The precision of the different measurement variables was compared using the F-test. 
Equations used for the calculating of precision errors for the different precision studies 
performed in this study are given in Chapter 3. 
2.4.4 Relationship between two variables 
The Pearson's product moment correlation coefficient (r) was used to describe how 
closely two variables were related. Ninety-five percent confidence intervals of the 
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correlation coefficient were obtained using Fisher's z transformation. The correlation 
coefficient squared (r) was used to describe the proportion of variability of one variable 
explained by the other variable. For non-parametric data, Spearman's rank correlation 
coefficient (p) was calculated. 
Linear regression analysis was used to quantify the relationship between two variables: 
Y=a+bx+E Equation 2.7 
where Y is the outcome or dependent variable, x the predictor or independent variable, 
a the constant, b the regression coefficient and E the random error around the 
regression line. 
Where indicated by the scatter plots, different regression models (i. e. linear, 
polynomial, power, logarithmic) were applied to data and the model that yielded the 
highest coefficient of determination was used to describe the relationship between two 
variables. 
As the correlation coefficient only describes the strength of the relationship between 
two variables, Bland and Altman plots were used to assess the agreement between 
two variables [352]. The method described by Bland and Altman involves plotting the 
difference between two variables against the their mean [352]. Bland-Altman plots give 
a more accurate indication of the relationship between two variables than linear 
regression, which gives a biased result if both variables have random errors. 
To assess the level of diagnostic agreement between different measurement 
techniques or measurement variables, the index of positive agreement was used. This 
index was proposed by Cicchetti and Feinstein [353,354] to estimate the proportion of 
agreement between two techniques or two measurement variables when neither is 
regarded as the 'gold standard'. This index was originally proposed to assess the level 
of agreement between two observers for the reading of radiographs, however, in this 
study, Ppos represents the proportion of subjects classified by both techniques as 
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where a is the number of subjects identified as osteoporotic by both techniques and b 
and c are the number of subjects identified as osteoporotic by technique 1 and 
technique 2 respectively. 
2.4.5 Relationship between multiple variables 
Multivariate regression analysis was used to assess the relationship between more 
than two variables. Multivariate regression analysis provides a regression model in 
which the dependent variable is expressed as a combination of the independent 
variables: 
b, x4 Equation 2.9 
where Y is the dependent variable, b. the constant, b, the regression coefficient for the 
ith independent variable (x4). 
Forward stepwise multivariate regression analysis was used to establish which 
variables contributed independently to the dependent variable. A p-value of 0.2 was 
chosen for inclusion in the forward stepwise multivariate regression model. 
2.4.6 Discriminatory ability of a technique 
To examine the fracture discriminatory ability of a technique, logistic regression 
analysis was used. As the dependent variable is a binary quantity (the presence or 
absence of a fracture), multivariate regression is not suitable. Logistic regression is 
based on the logit transformation (logit (p)) where p represents the proportion of 
individuals with a history of fracture. Therefore 1-p represents the proportion of 
individuals without a history of fracture, which allows the calculation of the log odds: 
Logit (p) = log,. (p /1-p) Equation 2.10 
So the different techniques could be compared, each measurement variable was 
standardised by dividing by the population SID of the normal population. Therefore, 
reported odds ratios represented the odds ratio per standard deviation of each 
measurement variable. In addition, the logistic regression model was adjusted for age. 
An example of an age-adjusted logistic regression equation, for a one SID decrease in 
BUA for example, is shown below: 
Logit (p) = b. + bi . age + 
b2 
. BUA Equation 2.11 
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which can be wriften: 
p exp (b, 
-tbl. 
aqe + b2. BUA) 
1+ exp (bo + bi. age + b2. BUA) 
Equation 2.12 
where b, is the constant and b, and b2are the regression coefficients for age and BUA 
respectively. 
Forward stepwise logistic regression was performed to assess whether different 
measurement variables contributed independently to fracture discrimination. 
Receiver operating characteristic (ROC) analysis was performed to further assess the 
discriminatory ability of the different measurement variables [355]. ROC curves plot 
sensitivity over the false positive rate (one minus specificity) and so removes the effect 
of using different choices of cut-off values. The area under the curve (AUC), in the 
context of comparing techniques in bone densitometry, represents the probability that a 
subject with fracture is rated at greater risk than a subject without fracture [355]. The 
larger the AUC the greater the ability of that measurement technique to discriminate 
between those subjects with fracture and those without. To assess whether two AUC 
values were significantly different, the method described by Hanley and Mcneil was 
used [356]. 
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Chapter 3 
The Long-term Stability and 
Precision of QUS 
3.1 STUDY DESIGN 
3.1.1 Aims 
The aim of this section of the study was to examine the long-term stability of QUS 
equipment and both the short- and long-term precision of QUS measurements based on 
intensive phantom and in vivo studies. 
3.1.2 Introduction 
The long-term stability and reproducibility of any measurement technique are important 
factors in determining its utility. These factors are particularly important in the field of 
bone densitometry, as the changes in BIVID associated with ageing [38,357], disease or 
treatment are relatively small [102]. The long-term stability of a device is usually 
assessed by scanning quality control phantoms on a regular basis. This allows the 
operator to monitor the stability of the device and identify, and correct for, any shifts in 
calibration. This monitoring of machine performance is essential so results at both 
baseline and follow-up can be interpreted with confidence [358]. 
The precision error of a technique is described as the variability occurring with repeated 
measurements on the same subject [350]. Precision is most often expressed as the 
percentage of the mean termed the coefficient of variation (CV). Knowledge of the 
precision error is used to characterise the ability of a technique to monitor significant 
changes in BIVID [354]. The smaller the precision error, the shorter the time it takes to 
detect a significant change in BIVID in an individual and in research studies, an 
improvement in precision will decrease the number of subjects required as well as 
decrease the length of time to detect a significant change in BIVID [350]. 
Both the stability and the excellent precision of DXA has meant that DXA is currently the 
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accepted 'gold standard' in the field of bone densitometry and has been utilised in large 
epidemiological studies of osteoporosis [17] as well as large clinical trails assessing the 
efficacy of treatments for osteoporosis [127,359]. In contrast, the precision of QUS has 
been reported to be relatively poor in comparison, ranging from 1.2 to 6.7% for BUA 
[214,239-241,243,248,250,251,262,276,277,280,291,327,336,341,360] and 0.1 to 1.1% 
for SOS [223,240,243,248,250,251,262,276,277,280,291,360]. At first glance, it would 
appear that the precision of calcaneal velocity variables is excellent. However, precision 
errors need to be standardised relative to the clinical range of values found in clinical 
studies so different QUS variables and different techniques for assessing skeletal status 
can be properly compared [223,354]. In addition, the majority of the above QUS studies 
have investigated precision over a relatively short time (often on the same day) and 
therefore there is little information concerning the long-term precision of QUS in vivo. 
The calcaneus has been the most extensively studied skeletal site using QUS to date as 
it is rich in trabecular bone and easily accessible. However, the calcaneus is 
heterogeneous in terms of both its external geometry and internal structure and density 
[165,167,193,194]. The majority of the commercially available QUS devices measure 
BUA and SOS at a fixed point of the calcaneus relative to a foot plate. Consequently, 
variations in the shape and size of the calcaneus and the thickness of the surrounding 
soft tissue result in different area of bone being measured in different individuals and 
possibly different areas of bone being assessed during repeat measurements on the 
same individual. To overcome this problem, ultrasound transmission imaging at the 
calcaneus has been developed over recent years [213,216,218,225,361]. In principle, 
this technical advance should improve the precision of calcaneal QUS measurements. 
To date there has been only one study examining the long-term stability of QUS [276]. In 
addition to this lack of published data, QC measurements are performed on manufacturer 
provided phantoms, which are homogeneous in terms of structure, are not representative 
of trabecular bone and are device specific [278,362]. This limited experience with quality 
assurance for QUS and lack of information regarding the long-term precision of QUS in 
vivo has been identified as an area that requires further attention, before QUS can be 
fully accepted in the clinical community [228]. 
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3.1.3 Methods 
3.1.3.1 The long-term stability of QUS 
The long-term stability of QUS was assessed by performing daily measurements of the 
UBA, SAH and DTU man ufactu rer- provided phantoms prior to patient scanning. The 
UBA device uses two quality control phantoms, one representing 'low' BUA and the other 
C normal' BUA (these UBA phantoms did not provide a SOS result so we were unable to 
perform a quality control check on UBA SOS). These phantoms were stored at room 
temperature in the same room as the three QUS devices. The water used in the UBA 
and DTU was stabilised to room temperature for 24 hours prior to scanning and the 
temperature of both the room and water-baths was taken at the time measurements were 
made on the phantoms. 
As a comparison, results of the DXA quality control checks were obtained for the 
QDR4500 used in the Guy's Osteoporosis Unit. The man ufactu rer-provided Hologic 
anthropometric spine phantom was scanned daily on the QDR4500 prior to patient 
scanning as described in the Hologic QDR4500 User's Guide. 
During the study period, the Sahara device displayed evidence of a downward drift in 
both BUA and SOS (see section 3.2.1). After discussions with the manufacturer, it was 
realised that this drift was caused by a change in both the shape and size of the rubber 
pads that couple the transducer to the patients heel. After replacement of these pads, 
there was no further evidence of a drift in either BUA or SOS. The manufacturer then 
recommended that these rubber pads be replaced annually to prevent this problem 
recurring. During the remaining study period, these rubber pads were replaced on one 
other occasion and the machine recalibrated using the manufacturer-provided phantoms. 
The DTUone device was upgraded during the study period. However, due to an error in 
the upgraded DTU computer program the phantom and in vivo SOS data was not 
calculated correctly. Approximately two months later the DTU system was upgraded 
again and the in vivo SOS data collected during the preceding two months recalculated. 
Unfortunately, the phantom data collected during this time could not be recalculated and 
therefore velocity phantom results are unavailable for this part of the study. The DTUone 
phantom was also changed 6 months before the end of the study, with the new phantom 
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having different BUA and SOS values. All analyses have been adjusted to take into 
account the change of phantom. 
As an additional instrumental quality control check and assessment of the long-term 
stability, two young healthy volunteers had QUS measurements performed approximately 
weekly during the study period. 
3.1.3.2 Short-, mid- and long-term Precision 
Short-term precision: a selection of women from the premenopausal, postmenopausal 
and vertebral fracture groups had QUS measurements performed in duplicate with 
repositioning between each measurement. To obtain more detailed information on 
precision a group of 10 healthy volunteers had 10 repeated measurements performed on 
the same day, with repositioning between each scan. 
Mid-term precision: The 10 healthy subjects also had monthly QUS scans over 10 
months to examine mid-term precision. 
Long-term precision: Data for the 43 women enrolled on the 2-year study of seasonal 
variations in BIVID (see Chapter 2) were used to estimate long-term precision. These 
women were measured every three months for two years giving nine measurements per 
subject. As the SAH and DTU were not available at the beginning of this study, only 8 
measurements per subject over 21 months and 7 measurements per subject over 18 
months were performed on the SAH and DTU respectively. BIVID of the spine and hip 
was also measured in this study and allowed long-term precision to be estimated for DXA 
measurements of BIVID so QUS and DXA could be compared. 
Results for the two volunteers measured weekly to determine the long-term stability of 
QUS devices were also used to provide an additional estimate of long-term precision. 
3.1.3.3 Data analysis 
To estimate the long-term stability of each of the three QUS devices, the standard 
deviation and coefficient of variation was calculated for the daily measurements of the 
phantoms: 
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CV = SD. 100% Equation 3.1 
x 
Short-term precision assessed by performing scans in duplicate was expressed as the 
coefficient of variation defined as the root mean square SD (RMS SD) divided by the 
mean, calculated as follows: 




where d is the difference between the first and second result and n the number of 
subjects. Short-term precision for the 10 volunteers measured 10 times on the same day 
was expressed as the coefficient of variation after calculating the RMS SID: 
CV = ý(JSD 
2 /n). 100% 
I x/n 
Equation 3.3 
As no significant changes in QUS variables were expected for either the 10 subjects 
measured over 10 months or the 2 subjects measured weekly (all young healthy 
subjects), mid- and long-term precision was calculated using the same formula as that 
used to calculate short-term precision (Equation 3.3). 
For long-term precision estimated for the 43 subjects measured every three months, The 
RMS SEE was used rather than the RMS SID to estimate long-term precision: 
CV = 4(Y-SEE/n). 100% 
Y, )(/n 
Equation 3.4 
The in vivo precision estimates were standardised so the precision of the different 
devices and different measurement variables could be better compared in relation to their 
clinical range. Standardised precision (SP) was defined as the RMS SID divided by the 
young adult population SID and was expressed in T-score units: 
SP RMS SD 
Young adult SID 
Equation 3.5 
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The precision of the different devices was compared using the F-test. 
Multivariate analysis was used to examine the effect of machine recalibration and 
temperature on the QUS variables for the daily phantom measurements and the two 
subjects measured weekly. To correct for temperature, QUS measurements were 
normalised to that expected at 200C using the coefficients from multivariate regression 
3.2 RESULTS 
3.2.1 The Long-term stability of QUS devices 
3.2.1.1 Instrumental QC 
The daily QC measurements of the phantoms are shown in Figures 3.1 a-f for the 3 QUS 
devices and the corresponding CV results are shown in Table 3.1. 
Table 3.1: The long-term stability of QUS devices, estimated using in vitro (phantom) and in 
vivo measurements. 
in vitro in vivo 
n SD CV% n SD CV% 
UBA BUA dB/MHz 453 2.69 3.80 137 3.14 3.80 
UBA SOS m/s na na na 137 2.34 0.16 
UBA BV m/s na na na 137 15.54 0.95 
SAH BUA dB/MHz 431 2.00 7.15 146 3.36 4.49 
SAH SOS m/s 431 12.96 0.86 146 8.65 0.56 
SAH tS0Sa nl/S 293 2.91 0.18 na na na 
DTU BUA dB/MHz 326 1.23 2.93 119 1.89 3.67 
DTU SOS m/s 288 2.46 0.15 119 4.64 0.30 
DXA LS BMD 730 0.005 0.5 na na na 
na, not applicable. 
a temperature independent phantom 
Only data for the UBA 'normal' phantom is shown (Figure 3.1a) as the 'low' phantom 
gave similar results (both BUA phantoms were used to calculate the CV using 
multivariate regression). During the study period there appeared to be a small upward 
drift in BUA on the UBA device (p<0.0001). On further examination, it was found that 
there was a jump in calibration in December 1996 that coincided with a recalibration 
performed by a manufacturer representative due to a loose connection between the UBA 
system and the computer. 
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Figure V: Quality control plots of phantom measurements for (a) UBA BUA, (b) SAH BUA, (c) 
SAH SOS. The red dashed line represents the actual phantom values and the arrows represent 
the date of machine recalibration. 
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The mean BUA values before and after this recalibration were significantly different 
(Table 3.2). The long-term reproducibility of the UBA over the entire study period was 
3.80% (Table 3.1). 
Table 3.2: The effect of recalibration on in vitro and in vivo measurements 
in vitro in vivo 
calibration libration 
Recalibration No. factoro SE p factora SE p 
UBA BUA dB/MHz 
1 3.39 0.14 <0.0001 na na na 
SAH BUA dB/MHz 
1 -2.41 0.52 <0.001 -2.18* 0.54 0.003 
2 -0.79 0.09 <0.001 0.39** 0.61 ns 
SAH SOS m/s 
1 -18.39 3.07 <0.001 -8.55** 1.28 <0.001 
2 -3.56 0.43 <0.001 3.38** 1.41 0.02 
DTU BUA dB/Mhz 
1 -0.54 0.18 0.003 1.79** 0.70 0.01 
2 -1.88 0.27 <0.001 -0.10** 1.05 ns 
3 -1.70 0.14 <0.001 0.26** 0.5 ns 
DTU SOS m/s 
1 0.63 0.35 ns 0.69 0.93 ns 
2 -0.58 0.53 ns -1.29* 1.41 ns 
3 1.11 0.30 <0.001 2.06** 0.66 0.003 
a derived from multivariate regression analysis (corrected for temperature) 
na, not applicable. ns, not significant. 
p <0.05 versus in vitro calibration factor. 
p <0.001 versus in vitro calibration factor. 
As mentioned in section 3.1.2.1 and displayed in Figures 3.1b and 3.1c, the SAH showed 
a significant downward drift in both BLIA (-0.039 dB/MHz per day, p<0.0001) and SOS (- 
0.117 m/s per day, p<0.0001). BLIA started to show evidence of a drift from April 1996 
onwards while SOS appeared to drift from the beginning of the study period. The SAH 
device does not report a QC failure until BUA or SOS has deviated by 10% or 1% 
respectively, from the actual phantom values. Therefore, it was only approximately half 
way through this period of machine drift that the SAH device reported that the QC had 
failed. As Figures 3.1b and 3.1c show once the transducer pads were replaced in 
September 1996 and the machine recalibrated the phantom BLIA and SOS returned to 
within accepted limits. The transducer pads were replaced again approximately 12 
months later and the machine recalibrated. 
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Multivariate analysis was used to examine the effect of machine drift and recalibration on 
the SAH phantom BUA and SOS results (Table 3.2). As BUA and SOS were dependent 
on temperature (section 3.2.1.3), this was corrected for in multivariate regression 
analysis. The calibration shift after the first recalibration was large due to the significant 
drift in BUA and SOS. When the transducer pads were replaced for a second time and 
the machine recalibrated both BUA and SOS showed a significant calibration shift (BUA: 
-0.79 dB/MHz, SOS: -3.56 m/s). The long-term reproducibility of the Sahara device was 
7.15% for BUA and 0.86% for SOS (Table 3.1). 
The DTU device showed a significant downward drift in BUA (-1.46 dB/MHz per annum, 
p<0.0001) and upward drift in SOS (0.892 m/s per annum, p<0.0001) during the study 
period (Figures 3.1 e and 3.1 f). Only results for the original DTU phantom are shown as 
the replacement phantom had significantly different BUA and SOS values. The DTU was 
recalibrated on three occasions due to technical problems and system upgrades. 
Multivariate analysis (correcting for temperature) revealed that BUA measurements on 
the DTU phantom showed small but significant changes due to machine recalibration 
(Table 3.2). BUA measurements differed by -0.54 (p<0.003, -1.88 (p<0.001) and -1.70 
(p<0.001) dB/MHz for the three recalibrations respectively, compared to the mean BUA 
before the first recalibration. The third recalibration caused a significant shift in DTU SOS 
of 1.11 m/s (p<0.001). The long-term reproducibility of the DTU was 2.93% for BUA and 
0.15% for SOS (Table 3.1). 
As a comparison, Figure 3.2 shows the daily QC measurements of the Hologic spine 
phantom measured on the QDR4500 in the Guy's Osteoporosis Unit during the same 
study period. Due to a long-term drift, the QDR4500 was reset when it underwent a 
repair for an oil leak. The mean lumbar spine BMD averaged 1.021 g/CM2 before the 
recalibration and mean lumbar spine BMD increased to an average of 1.027 g/CM2 after 
the recalibration. The long-term reproducibility of the QDR4500 BIVID measurements 
using the spine phantom was 0.50% (Table 3.1). 
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Figure 3.2: Quality control plot of the Hologic spine phantom on the Hologic QDR4500 DXA 
scanner. 
3.2.1.2 In vivo Quality Control 
Two volunteers were measured approximately weekly as a further assessment of 
instrumental quality control and the results are displayed in Figures 3.3 a-i. The long- 
term reproducibility measured in vivo for each device is shown in Table 3.1. The in vivo 
results in Table 3.1 were not corrected for any calibration drifts or changes. The long- 
term reproducibility of LIBA BUA was 3.80% for the two volunteers, which is identical to 
that obtained in vitro. Neither of the volunteers showed a significant drift in BUA on the 
UBA during the study period (Figures 3.3a-c). It was not possible to determine the effect 
of recalibration of the UBA in vivo measurements, as there were too few measurements 
on the two volunteers prior to the recalibration. The long-term reproducibility in vivo of 
UBA SOS was 0.16% and 0.95% for UBA VB. These figures could not be compared to 
the in vitro phantom measurements as the UBA phantom provides a BUA measurement 
only. 
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Figure 3.3: Scatter plots for the two volunteers measured weekly for (a) UBA BUA, (b) UBA SOS, 
(c) UBA BV. The arrows represent the date of machine recalibration. 
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Figure 3.3 cont.: (d) SAH BUA (uncorrected for machine drift), (e) SAH BUA (corrected for 
machine drift), (0 SAH SOS (uncorrected for machine drift). 
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Figures 3d-g show the long-term reproducibility of the in vivo measurements on the SAH 
device before and after correction for instrumental drift. The in-vivo data collected during 
the period of instrumental drift was corrected using a time-dependent correction factor 
obtained from the slope of the regression line using the phantom data. Both BUA and 
SOS measurements were effected by the period of machine drift and SAH BUA was also 
effected by the second recalibration (Table 3.2). When the calibration shifts for the 
phantom and in vivo SAH measurements were compared (Table 3.2), the drift in BUA 
and SOS observed using the SAH phantom was significantly larger than the drift seen for 
the two volunteers (BUA: -2.41 vs. -2.18 dB/MHz, SOS: -18.39 m/s vs. -8.55 m/s, 
respectively). In addition, the second calibration shifts were in opposite directions for the 
phantom and in vivo measurements (-3.56 m/s vs. 3.38 m/s, respectively). 
The long-term in-vivo reproducibility of the DTU was 3.67% for BUA and 0.30% for SOS 
(Table 3.1 and Figures 3.3 h and i). Multivariate regression analysis revealed that 
recalibration of the DTU resulted in small changes in the BUA and SOS measurements 
performed on the two subjects, although these changes were only significant for BUA 
after the first recalibration and for SOS after the third recalibration (Table 3.2). The 
calibration shift in BLIA after the first recalibration was positive for the in vivo 
measurements but negative for the phantom measurements (1.79 dB/MHz vs. -0.54 
dB/MHz, respectively). 
3.2.1.3 The effect of temperature on in vitro and in vivo measurements 
From May 1997, it became practice to take the temperature of the room or water bath 
prior to scanning. Multivariate regression analysis showed that, with the exception of 
IDTU BUA, QUS variables were significantly affected by the temperature of the room or 
water-bath for both phantom and in vivo measurements (Table 3.3). The temperature 
coefficients obtained for in vivo measurements were in the same direction as those found 
for measurements on phantoms. However, with the exception of UBA BUA, the 
temperature coefficients obtained using in vivo measurements were significantly larger 
than those obtained using phantom measurements. It is interesting to note that the SAH 
temperature independent phantom was dependent on room temperature. Furthermore, 
the temperature coefficient for SAH tSOS was as large as that seen for SAH SOS but 
was positive rather than negative (0.55 ms-1 OC-1 vs. -0.59 ms-1 OC-1, respectively). 
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Table 3.3: The effect of temperature on in vitro and in vivo measurements. 
in vitro in vivo 
Measurement coeff icient' SE p coeff icienta SE p 
UBA BUA dB/MHz 0.41 0.02 <0.001 0.34** 0.13 0.01 
UBA SOS m/s na na na -0.76 0.07 <0.001 
UBA BV m/s na na na -4.03 0.55 <0.001 
SAH BUA dB/MHz -0.19 0.02 <0.001 -0.21 ' 0.10 0.05 
SAH SOS m/s -0.59 0.08 <0.001 -0.85' 0.24 <0.001 
SAH tSOS m/s M5 0.02 <0.001 na na na 
SAH BMD g/CM2 na na na -0.003 0.001 <0.001 
DTU BUA dB/MHz 0.03 0.07 ns 0.04 0.09 ns 
DTU SOS m/s -0.37 0.06 <0.001 -1.74** 0.11 <0.001 
a coefficients derived from multivariate regression analysis (corrected for recalibration) 
na, not applicable. 
** p <0.001 versus in vitro temperature coefficient. 
To examine the size of this effect of temperature on in vivo measurements, the expected 
change in each measurement variable was calculated for a temperature variation of 50C 
(e. g. between 20-250C) and divided by the young adult and so expressed in T-score units 
(Figure 3.4). As Figure 3.4 shows, the velocity measurements were effected to a greater 
extent than BUA. The water-based devices show a larger temperature effect than the dry 
SAH device, with the DTU SOS varying by one T-score unit for a typical temperature 







Figure 3.4: QUS changes for a 
50C change in temperature 
divided by the young adult SID 
(Table 4.6) and expressed in 
T-score units. 
3.2.1.4 The long-term stability of QUS after correction for calibration changes and 
temperature 
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The long-term reproducibility of all of the QUS measurement variables measured using 
the phantoms were significantly improved when corrected for calibration changes and the 
temperature of the room or water-bath (Table 3.4). The long-term reproducibility of in 
vivo SOS measurements and SAH BUA were also significantly improved when corrected 
for temperature and calibration changes (Table 3.4). The long-term reproducibility of 
UBA BUA DTU BUA was not significantly improved by these corrections. 
Table 3.4: The long-term stability of QUS devices corrected for temperature, calibration 
changes and drifts. 
Uncorrected Corrected 
in vitro in vivo in vitro in vivo 
CV% CV% CV% CV% 
UBA BUA dB/MHz 3.80 3.80 2.50** 3.76 
UBA SOS m/s na 0.16 na 0.10** 
UBA BV m/s na 0.95 na 0.79** 
SAH BUA dB/MHz 7.15 4.49 2.07** 3.59** 
SAH SOS m/s 0.86 0.56 0.19** 0.40** 
SAH tSOS m/s 0.18 na 0.04** na 
DTU BUA dB/MHz 2.93 3.67 2.21 ** 3.60 
DTU SOS m/s 0.15 0.30 0.11** 0.17** 
na, not applicable. 
** P<0.001 versus CV before corrections. 
3.2.2 In vivo Precision 
3.2.2.1 Short-term Precision 
The short-term precision estimates for the UBA, SAH and DTU are shown in Table 3.5. 
When the coefficient of variation was used as a measure of precision, the DTU imaging 
device was significantly better than the UBA and SAH devices for BUA measurements 
and significantly better than the SAH for measurements of SOS (Table 3.5). The UBA 
BV showed significantly poorer precision than the UBA SOS measurement when scans 
were performed in duplicate (CV: UBA BV 0.48% vs UBA SOS 0.08%, p<0.0001) and 
when performed 10 times (CV: UBA BV 1.06% vs. UBA SOS 0.16%, p<0.0001). 
When the CV values were standardised by dividing the precision error by the young adult 
SID (Table 4-6), the SP of DTU BUA measurements remained significantly better than 
UBA and SAH BUA when measured in the short-term (Table 3.5). The SID of duplicate 
scans was significantly better on the UBA and DTU than the SAH, while both SAH SOS 
and DTU SOS SP was significantly better than that for UBA SOS when assessed in the 
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10 individuals measured 10 times. Once the UBA BV variable was standardised, the SP 
of the UBA BV variable was not significantly different from the SP for UBA SOS. 
3.2.2.2 Mid- and long-term precision 
The mid- and long-term precision estimates for all QUS variables were generally larger 
than that observed in the short-term (Table 3.6). The SAH data were corrected for the 
period of significant machine drift occuning at the beginning of the study. When the CV 
was used to express precision, the DTU displayed the best precision for BUA when 
assessed over 10 months (mid-term) and when measured in the 43 subjects over 18 
months (long-term), however when assessed in the two subjects measured weekly, all 
three devices gave comparable precision values. 
The CV for UBA SOS was significantly better than that for SAH and DTU SOS for the 
mid-term and two long-term precision studies. The CV for DTU SOS was also 
significantly better than that observed for SAH SOS when estimated over the mid- and 
along-term. 
For BUA measurements, the mid-term SP was significantly better on the UBA and IDTU 
compared to the SAH. The SP estimated using the weekly measurements of two 
subjects was significantly poorer for IDTU BUA compared to that for UBA and SAH BUA. 
In contrast, the SP for DTU BUA measured every three months was significantly better 
than the SP of UBA and SAH BUA. 
For both the mid- and long-term precision studies, the SID of UBA and SAH SOS was 
significantly better than that for DTU SOS. The SAH SOS SID was also significantly 
better than that for UBA SOS. The SID of UBA BV was similar to or smaller than that 
obtained for UBA SOS when estimated over the mid- and long-term. 
The SP results obtained in the short- and mid-term on the 10 volunteers and in the long- 
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Figure 3.5: The short-, mid- and long-term standardised precision of QUS. The red dashed line 
represents the long-term standardised precision of LS BMD. 
As a comparison, the dashed line on Figure 3.5 represents the long-term SP for LS BMD. 
This figure shows that, with the exception of the two UBA velocity measurements, short- 
term SP is generally half that observed in the mid- and long-term. UBA SOS and BV 
yielded similar SP values when estimated in the short-, mid- and long-term. SOS 
measurements tended to show poorer precision than BUA measurements, particularly 
when measured over mid- and longer-time periods. DTU SOS measurements displayed 
the poorest SID for mid- and long-term precision studies with SP of 0.60 and 0.71 
respectively. Mid- and long-term SID ranged from 0.27 to 0.71 but was generally around 
0.35 T-score units. As a comparison, the long-term SID for DXA measurements of BIVID 
was 0.11,0.19 and 0.11 for LS, FN and TH IP BIVID measurements respectively. 
3.2.2.3 Differences in SP between study groups 
Duplicate scans were performed on a subgroup of females taken from the adolescent, 
premenopausal, postmenopausal and vertebral fracture groups, to examine whether any 
differences in precision exist between groups. Duplicate scans were not performed on 
the vertebral fracture group using the UBA or the adolescent group using the DTU. Table 
3.7 shows the SP for QUS measurement variables for the four groups. The SP of BLIA 
measurements performed on the SAH and DTU was significantly better in the vertebral 
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fracture group, with a SP of just 0.09 for DTU BUA. The SAH SOS and DTU SOS 
variables also displayed significantly better SP when assessed in the vertebral fracture 
group compared to the other groups. The SP of UBA BV was significantly poorer for the 
adolescent group compared to the premenopausal and postmenopausal groups. The 
postmenopausal group tended to yield poorer SP estimates on the SAH device while the 
premenopausal group displayed poorer SID on the DTU. 
3.3 DISCUSSION 
3.3.1 The long-term Stability of QUS 
With the increasing acceptance of QUS technology worldwide, it is important that QUS 
devices are stable over time. At present there is little information regarding the long-term 
stability of QUS equipment, although it has recently been recognised that this area needs 
attention and more practical experience is required (228]. 
Many studies on QUS devices have reported that phantom measurements performed 
daily yielded reproducibility estimates for BUA ranging from 0.8% to 6% 
[243,250,277,363-365] and 0.1% to 3% for SOS [243,250,277,363,365]. As a 
comparison the long-term reproducibility for phantom measurements using DXA are less 
than 1% [279] and in the present study, a CV of 0.50% was obtained. The reproducibility 
of the three devices used in the present study ranged from 2.9% to 7.1% for BUA and 
0.15% to 0.86% for SOS (Table 3.1). The majority of the reproducibility estimates 
reported in the literature have been estimated over relatively short time periods, from just 
days up to 6 months and very few have evaluated instrument performance during this 
time. 
To date, there has been very few studies examining the long-term stability of QUS 
devices [251,276]. A study by Hans et al evaluated five Lunar Achilles devices over 12- 
months that were being used in the large prospective EPIDOS study. It was shown that 
this longer than typical evaluation time of 12 months allowed for the detection of 
alterations in performance that would not have otherwise been apparent, such as abrupt 
variations in precision and small shifts in the slope, suggesting that the performance of 
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A study by van Daele et al on the Lunar Achilles device found that daily phantom 
measurements over a two-year study period showed evidence of increasing BUA and 
decreasing SOS [251]. This shift in calibration was found to be due to a slight narrowing 
of distance between the transducers. 
In the present study, the SAH showed a downward drift in both BUA and SOS that 
eventually caused the QC procedures to fail. The UBA device also displayed a small 
upward drift in BUA during the study period. Although, the drift in SAH measurement 
variables was large, it only became apparent after a couple of months when the SAH 
variables dropped below a certain level. A study examining longitudinal QC for DXA 
found that visual inspection of the phantom data meant that problems were detected 
quickly and only one failure in performance was not detected out of a possible eight 
[358]. It is important that QUS phantom data be continuously monitored, perhaps using 
methods such as Cusum charts, so any changes in calibration can be identified as 
quickly as possible. 
During the study period, the UBA underwent one recalibration due to a loose connection, 
the SAH was recalibrated on two occasions after replacement of the transducer rubber 
pads and the DTU was recalibrated on three occasions due to system upgrades and 
technical problems. In the majority these occasions, machine recalibration led to 
calibration shifts to new baselines values, a problem also observed with DXA [169,366]. 
However, if phantom data is available, in vivo data can be corrected based on the mean 
values of the two time intervals in order to offset the effect of recalibration [353,358,366]. 
When examining phantom data it is usually assumed that the phantom data will track the 
in vivo data sufficiently closely if equipment performance errors occur [366]. However, a 
recent study reported that a change in calibration of a DXA scanner was not predicted or 
explained by the phantom data but significantly affected in vivo measurements at the 
femur [367]. In the present study, in vivo data collected on the two subjects was effected 
by recalibration of the QUS devices. However, with the exception of DTU BUA, the in 
vitro and in vivo data did not always display similar size calibration shifts and in addition, 
were sometimes in the opposite direction (Table 3.2). This is probably because the 
phantoms do not represent the situation encountered in vivo. 
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At present, there is no universal calibration standard for QUS [368] and the device- 
specific phantoms that are available do not reflect the architecture of the heel [278]. The 
manufacturer-supplied phantoms are homogeneous in terms and structure and shape 
and therefore it is not surprising that they may not fully reflect changes in calibration that 
may occur in vivo. There has been an attempt to develop phantoms that mimic the heel 
more closely, such as the Leeds Phantoms [278,362] and the Vancouver Quality 
Assurance Phantoms. The International QUS consensus Group recommended that QUS 
reference phantoms be developed that mimic bone with regards to both velocity and 
frequency-dependent attenuation [228]. These phantoms would allow intercomparisons 
to be made between QUS devices from different manufacturers and provide the 
necessary calibration for longitudinal studies. It was reported by Hans et al that QUS 
devices from the same manufacturer show a degree of interunit variability [276]. QUS 
reference phantoms could be used to assess whether any differences do exist between 
devices and differences could then be corrected for so QUS could be used more 
effectively in multicentre studies where data are pooled. 
Both the phantom and in vivo QUS measurements were dependent on the temperature of 
either the room or water-bath (Table 3.3). Unlike other commercial devices that use a 
tem peratu re-control led water-bath, the UBA and IDTU use water stabilised to room 
temperature. It is known that the velocity of sound is dependent on temperature [369] 
and it has been reported that both in vitro and in vivo QUS SOS measurements are also 
affected by temperature [276,282,370,371]. A cadaver study by Nicholson et al revealed 
that velocity decreases linearly with increasing temperature, while BUA increases, with 
temperature coefficients of -1.8 to -2.8 m/s/OC and +0.2 to 0.7 dB/MHZ/OC respectively. 
It was suggested that BUA increases with increasing temperature due to a greater 
acoustic impedance mismatch between the trabeculae and fatty marrow at higher 
temperature causing larger interface losses, and this was confirmed theoretically [371]. 
BUA measurements performed on the UBA and SAH were dependent on temperature, 
although to a lesser extent than the velocity measurements. BUA measured on the UBA 
was positively associated with temperature while BUA measured on the SAH yielded 
negative temperature coefficients (Table 3.3). It is unclear why BUA measured on these 
two devices have opposite temperature coefficients. 
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The temperature coefficients were in the same direction for phantom and in vivo 
measurements, although with the exception of UBA BUA, the temperature coefficients 
obtained in vivo were significantly larger than that for phantom measurements (Table 
3.3). If one assumes that the room temperature will vary between 20-250C in a clinical 
setting then SOS measurements may vary up to 20 m/s in the case of the UBA BV 
variable. If the expected variation in SOS due to temperature is examined in relation to 
the young adult SID then the extent of the problem becomes apparent (Figure 3.4). BUA 
and SOS measurements should be performed in a tem peratu re-control led water-bath or 
QUS devices should use an algorithm that corrects for heel or water-temperature at the 
time of QUS assessment. 
It has been suggested that combined variables, such as SAH BIVID on the SAH or the 
Stiffness Index provided by the Lunar Achilles, will improve precision as BUA and SOS 
have opposite temperature coefficients [372]. However, as SAH BUA and SOS were 
both negatively associated with temperature, there was no improvement in precision 
using the BUA and SOS combined SAH BIVID variable (Tables 3.5 and 3.6). 
A surprising finding was that the SAH temperature independent phantom was actually 
dependent on ambient temperature. This phantom is filled with a mixture of alcohol and 
water, which have opposite temperature coefficients and therefore this phantom should 
be independent of temperature. On discussion with the manufacturer, it was suggested 
that the water/alcohol solution might have reacted with the inside casing of the phantom. 
Other researchers have reported significant improvements in precision using this 
phantom compared to the other manufacturer-supplied SAH phantom [373]. However, it 
appears the phantom used in this study was not stable over time. 
3.3.2 The long-term stability of QUS after correction for calibration changes 
and temperature 
Correction of the phantom and in vivo data for calibration changes and temperature 
significantly improved the long-term reproducibility in vitro for all measurements variables 
and in vivo for SOS measurements and SAH BUA (Table 3.4). This indicates that 
advances in QUS technology and correction for temperature could improve the long-term 
stability of QUS in the future, which is critical if QUS is to be used effectively in clinical 
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practice. 
3.3.3 Short-, mid- and Long-term in vivo precision 
The short-term precision errors observed in this study are comparable to those reported 
in the literature [214,223,239-241,243,248,250,251,262,277,280,291,327,342,360,374- 
376]. The precision of BUA measurements appears poorer than SOS measurements and 
the latter appears superior to that reported for DXA [279]. However, when comparing 
different QUS variables, different QUS devices and different techniques it is important 
that they are standardised to take into account the different units and different clinical 
ranges observed. Different approaches have been adopted to standardise precision 
error, including standardising the precision errors to the clinical range [223,251,280,291], 
the population SD [248,376], the annual rate of loss [248] and the difference between 
young normals and osteoporotics [201,375]. Therefore, the SP results from different 
studies using different QUS devices may not be directly comparable. 
The precision errors in this study have been standardised by dividing them by the young 
adult SID and therefore SP was expressed in T-score units. As T-scores are now the 
accepted method of diagnosing osteoporosis using axial DXA, precision errors expressed 
in this way can be readily interpreted as it provides a direct indication of how accurately 
the QUS measurements can categorise patents in the context of the WHO criteria for 
diagnosing osteoporosis [15,354]. The short-term standardised precision of QUS 
measurements has been shown to be approximately double that observed for DXA 
techniques [244,280]). The short-term SP estimates for the two non-imaging devices 
(UBA and SAH) of between 0.16 and 0.36 seem to confirm this if one assumes a SP of 
0.10 for DXA at the spine (0.01 gCM2 / 0.1 gCM2). Rather better SP errors that 
approached the precision error estimated for DXA were obtained on the DTU in the short- 
term (Table 3.5). 
The short-term precision errors observed for the DTU are comparable to those reported in 
the literature for other imaging QUS devices and were significantly better than the two 
non-imaging devices used in this study [126,161,286]. In addition, BLIA measured on the 
DTU displayed significantly better long-term SP than the UBA and SAH when estimated 
in the 43 subjects measured every three months (Table 3.6). It seems that at least in the 
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short-term and possibly for DTU BUA in the long-term, QUS imaging overcomes some of 
the limitations of the precision of measurements taken at a fixed location relative to a 
footplate. A comprehensive study, which examined factors that could lead to imprecision, 
found that foot movement in the heel-toe direction could change BUA by up to 9% [384]. 
Therefore, it is important that the spatial inhomogeneity of bone density and structure in 
the calcaneus can be visualised and an appropriate measurement ROI selected 
accordingly. Several studies have reported an improvement in precision when an 
anatomically chosen ROI was used instead of a fixed ROI relative to a footplate, when 
measurements were performed on the same device [286,377]. An automatic ROI can be 
selected by using anatomical landmarks utilising image segmentation or by using 
acoustical features such as the region of minimum attenuation. The DTU uses an 
algorithm that automatically selects a ROI in an area of minimum attenuation, thus 
avoiding additional inter-operator errors that may occur using manual analysis. It has 
been shown that this area of minimum attenuation can be found in all individuals [377]. 
The mid- and long-term SP of DTU SOS measurement was significantly poorer than that 
observed on the other two devices (Table 3.6). The DTU SOS measurement was highly 
dependent on the temperature of the water-bath (Table 3.3) and the temperature 
coefficient obtained for this device was large when expressed in T-score units (Figure 
3.4). Other possible problems that may have effected the precision of DTU SOS include 
the electronic stability of the DTU or a problem with the algorithm selected to measure 
SOS. QUS imaging has the potential to improve the monitoring ability of QUS as it 
removes one of the largest sources of uncertainty associated with repeat measurements. 
However, the DTU used here was in the early stages of commercial development and 
several upgrades and technical problems affected the stability of this device, especially 
for SOS measurements. Further studies are required on imaging devices to fully assess 
their potential. 
Precision estimates based on measurements taken in the short-term represent optimal 
conditions. Long-term precision estimates are expected to be larger than those obtained 
in the short-term as they reflect other sources of imprecision, such as small changes in 
instrument calibration, change in patients weight' or soft tissue thickness, variations in 
patient positioning and operator influences [276,354]. Information on the long-term 
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precision of QUS is essential for the interpretation of follow-up scans as the precision 
error can be used to estimate whether any changes in QUS variables measured in an 
individual over time are significant or not. The mid- and long-term precision results for 
QUS were between one and half times and three times as those seen in the short-term 
(Table 3.6). The long-term SP was 0.11 for BIVID measurements at both the LS and 
THIP, which is between 2.5 and 6.5 times smaller than that observed for QUS 
measurements (Figure 3.5). This indicates further advances are required in QUS before 
it can show comparable performance to DXA assessment of BMD. A more relevant way 
to interpret these results is to express results as the ratio of the treatment effect over 
precision, which provides a more clinically relevant index for comparing different QUS 
devices and different techniques [354]. A discussion of this is given in Chapter 9. 
3.3.4 Sources of error associated with QUS 
As mentioned previously, the inhomogeneous nature of the calcaneus and temperature 
can affect the precision of in vivo QUS measurements. Other factors may also affect the 
precision of QUS measurements. Anthropometric factors such as soft tissue thickness 
and composition [229,282,283] and heel and bone width [229-231,262] may effect the 
precision of QUS variables. Immersion time can also affect the reproducibility of QUS. It 
has been demonstrated that BUA and SOS varies with immersion time and eventually 
reaches a plateau, after approximately three and six scans for BLIA and SOS respectively 
[378]. Air bubbles at the surface of the skin can also affect BUA and SOS measurements 
[370]. 
Another possible source of imprecision is that different commercial QUS devices use 
different methods of defining the pulse arrival time for SOS measurements such as the 
earliest detectable deviation from zero or the first zero crossing [226] and as yet it is not 
clear which method yields the most reproducible results. Although QUS is being 
developed for use in older women, many QUS precision studies are carried out on young 
healthy subjects. Therefore, other factors such as ankle oedema and mobility will lead to 
imprecision [283]. Ankle oedema is a common problem in the elderly, the severity of 
which will vary from day to day. It has been shown that ankle oedema affects both SOS 
and BUA measurements [283]. 
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The dry SAH device was developed to replace the UBA, which uses a water-bath. The 
use of a water-bath can be inconvenient for both the operator and patient and in addition, 
factors such as detergent concentration, water depth, air bubbles and immersion time 
may influence precision. The SAH device is one of the few truly portable devices, 
particularly because it can operate independently of a PC. The SAH and LIBA yielded 
essentially equivalent precision errors both in the short- and long-term (Table 3.5 and 3.6) 
and it has been reported that contact and water-based systems provide the same 
information in terms of discrimination etc. [379]. With contact systems, skin preparation is 
as important as the wetting agents used in water-based devices. It has been 
demonstrated that if the time between applying ultrasound gel and QUS scanning is 
increased, the precision of QUS measurement variables can be improved by 50% [380]. 
Other factors that may affect precision include electronic stability and operator influences. 
It is important that operators undergo adequate training to reduce the errors associated 
with positioning. 
The majority of commercial QUS devices use the 'time of flight' method to estimate 
ultrasound velocity and therefore the measurement averages the velocity of sound 
through water and soft tissue as well as bone. A pulse-echo technique is utilised by the 
UBA to estimate bone width and the UBA is the only commercial device that provides a 
measurement of the velocity of sound through bone only. It has been shown that 
measuring bone width cannot improve SP but only lead to an additional source of 
imprecision [223]. In the present study, the UBA BV results displayed similar SP to the 
UBA SOS variable both in the short- and long-term (Table 3.5 and 3.6). Therefore, if BV 
measurements yield essentially equivalent SP errors to SOS, it would only be useful to 
measure BV if it enhanced discrimination. Studies have shown that BV provides similar 
information to SOS [223]. Therefore, SOS seems a reliable surrogate for measurement 
of the true velocity of sound in bone at the calcaneus. Nevertheless, pulse-echo 
techniques may be useful to ensure a constant foot angle at follow-up measurements by 
using echoes from the cortices to match the distance between each side of the calcaneus 
and the transducer. 
Precision errors of BMD measurements using DXA are poorer when assessed in patients 
with osteoporosis compared to normals due to edge detection and positioning problems. 
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In contrast, precision errors are no worse in osteoporotic patients than 'normals' using 
QUS [365]. The SID observed in the vertebral fracture patients was significantly less for 
the SAH and DTU measurement variables than the SID observed in pre- and 
postmenopausal women (Table 3.7). It has been shown that both apparent density and 
structural parameters such as trabecular number and separation are significantly reduced 
in women with osteoporosis [194]. Therefore, the ultrasound signal will undergo less 
modification as it passes through the calcaneus in women with osteoporosis and 
subsequently will be less susceptible to problems such as phase cancellation, reflection 
and refraction, which will all adversely affect precision. 
The precision of QUS measurements in the group of adolescents was comparable to that 
of the other study groups, although precision of the UBA measurements tended to be 
poorer (Table 3.7). Neither the UBA or SAH was adapted for this study population but it 
would appear that the SP was at an acceptable level so that QUS assessment was 
possible in this population (Chapter 10). 
3.4. Conclusions and Further Work 
The long-term stability and precision of the three QUS devices has been assessed based 
on intensive phantom and in vivo measurements. The long-term stability of QUS was 
poor and all three devices displayed drifts or calibration changes. The stability of the 
devices was adversely effected by temperature, especially for SOS measurements 
performed in the two water-based devices. Both the in vitro and in vivo precision of the 
majority of the measurement variables was significantly improved when these factors 
were corrected for. Further development of QUS technology is required to ensure that 
QUS devices remain stable over time, an important requirement if QUS is to be used 
effectively in clinical practice. As with DXA, measurements of manufacturer- provided 
phantoms should be performed on a daily basis, before patient scanning. Visual 
inspections of the phantom data identified small shifts in calibration and therefore regular 
inspections should be incorporated in the daily quality control procedures so changes in 
calibration can be both detected and corrected for. There is a need to develop phantoms 
that mimic the acoustic properties of the heel so changes in phantom data reflects 
changes occurring in vivo. These phantoms would also allow the many commercially 
available QUS devices to be compared and provide the necessary calibration for 
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longitudinal studies. 
Precision errors should be standardised and ideally expressed in T-units so they can be 
readily interpreted. The short-term precision of QUS was twice as large as that expected 
for DXA and was device-specific, although the precision errors were smaller than the 
reported differences between 'normals' and patients with osteoporosis. QUS imaging 
yielded significantly better short-term precision errors and precision approached that 
expected for DXA. Mid- and long-term precision errors were approximately twice that 
seen in the short-term and were over two and half times larger than that observed for 
DXA. QUS measurements should be performed in a tem peratu re-control led water-bath 
or in the case of contact devices, measurements should be corrected for skin 
temperature. Additional longitudinal studies are required to establish long-term precision 
estimates for other QUS devices and to establish if further advances in QUS technology 
will improve the short- and long-term precision of QUS. 
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Chapter 4 
Reference Data for QUS and 
Age- and Menopause-Related Changes 
4.1 Study Design 
4.1.1 Aims 
The aim of this chapter is to establish reference ranges for the three calcaneal QUS 
devices and to examine the age- and m enopause- related changes in QUS 
measurement variables. 
4.1.2 Introduction 
Due to the widely accepted convention to express bone densitometry results as T- and 
Z-scores, appropriate reference ranges are essential so QUS results can be interpreted 
with confidence. To date, reference data for commercial devices are limited [228] and 
the number of subjects used to construct man ufactu rer- provided reference ranges is 
often relatively small or not fully specified. Therefore, it is likely, as seen for DXA [161], 
that there are inconsistencies in reference data provided by manufacturers of different 
QUS devices. It is important therefore, both in this study and other similar studies, that 
consistent reference ranges are constructed for both QUS and BIVID measurement 
variables based on a single study population, so any differences between techniques 
or different QUS devices are due to differences in technology rather than discrepancies 
in manufacturer reference ranges. Changes in QUS measurement variables with age 
and menopause have also been examined and compared to changes in axial BIVID to 
determine whether QUS variables are influenced to the same extent as BIVID by age- 
and menopause related factors. 
4.1.3 Methods 
4.1.3.1 Subjects 
The exclusion criteria described in Table 2.1 were applied to the 1130 study subjects 
(excluding adolescents). A total of 600 women were subsequently excluded leaving 
530 "healthy" pre- and postmenopausal women, used to construct reference ranges for 
BIVID and QUS measurement variables. The adolescent girls aged 12-17 years, who 
were the control arm of the longitudinal study on adolescents (Table 2.2), were also 
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included in analysis. Women used to construct reference ranges were also used to 
examine the age- and menopause related changes. 
4.1.3.2 Data Analysis 
Different age groups of women and the pre- and postmenopausal women were 
compared statistically using a two-sample Student t-test. Measurement SlDs for 
different age groups were compared using the F-test. 
Linear regression analysis was used to: (i) obtain expected BIVID and QUS values at 
each age for the purpose of calculating Z-scores, (ii) determine the relationship 
between each BIVID and QUS measurement variable and both age and years since 
menopause. Forward stepwise linear regression analysis was performed to examine 
the independent influence of height and weight on BIVID and QUS measurement 
variables. As a comparison, data for the 94 pre- and postmenopausal women who had 
additional DXA heel scans, were used to examine the influence of height and weight on 
calcaneal BMD. Different regression models were applied to the reference data and 
the model that yielded the highest coefficient of determination was used to describe the 
changes in BIVID and QUS with age. 
The regression coefficients (annual changes) in BMD and QUS measurement variables 
with age and years since menopause were expressed as absolute changes and as 
fractional changes relative to the SID of the young adult group so a direct comparison 
between techniques could be made. 
4.2 Results 
4.2.1 Reference Data 
A total of 530 pre- and postmenopausal women were considered normal using the 
exclusion criteria described in Table 2.1. These women were used to construct 
reference ranges for BIVID and QUS measurement variables. Table 4.1 gives the 
heights, weights and BMI for these normal women in 5-year age bands. Women in the 
third decade of life were taller than the other age groups and the mean height of 
women decreased in the later age groups. Mean height for women in the eighth 
decade of life was 5.1 % lower compared to women in the third decade of life. The 
mean height for women aged 75-79 years was slightly higher than the mean for women 
in the preceding age groups, however, this is probably due to the small number of 
subjects included in this age group. Both weight and BMI were similar 
for the different 
age groups although women aged 55-64 years were slightly heavier. 
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Table 4.11: Anthropornetric characteristics of the reference population 
Height (cm) Weight (kg) BMI kg/M2 
Age mean SD mean SD mean SD 
20-24 166.7 7.8 64.5 11.2 23.2 3.5 
25-29 167.1 6.1 65.4 10.3 23.5 3.9 
30-34 164.9 5.4 63.9 12.4 23.5 4.2 
35-39 163.1 5.2 67.2 12.9 25.3 5.0 
40-44 163.9 7.4 65.1 10.8 24.2 3.9 
45-49 164.1 5.5 64.9 9.7 24.1 3.5 
50-54 163.2 5.9 64.1 9.6 24.0 3.3 
55-59 162.6 5.9 66.7 9.6 24.8 5.4 
60-64 161.0 5.6 67.7 9.0 26.1 3.2 
65-69 158.5 5.8 63.2 10.5 25.2 4.2 
70-74 156.7 6.8 65.5 10.9 26.7 3.9 
75-80 160.0 3.8 63.1 8.2 24.6 2.7 
Reference data for BIVID and QUS measurements are shown in Table 4.2. All the BIVID 
and BUA measurements were significantly lower in the adolescent girls compared to 
women aged 20-24 years. Velocity measurements obtained on the adolescent girls 
were not significantly lower than those obtained for women in the third decade of life. 
Lumbar spine BMD remained stable between ages 20-44 years and decreased 
thereafter until age 70 years when LS BMD appeared to increase. Both the hip BMD 
measurements peaked in the 20-24 year age group and declined thereafter, with FN 
BMD decreasing by 28% and THIP BMD decreasing by 21 % between the second and 
eight decade of life. The hip BMD measurements increased slightly (2-3%) between 
ages 65-69 and 70-74 years. BUA measurements on the UBA and SAH peaked at 
ages 30-34 years, remained stable until age 50 and declined thereafter. UBA and SAH 
BUA decreased by 22% and 15% respectively, between the third and eight decade of 
life. DTU BUA peaked at ages 30-39 years and started to decline at age 55 years and 
over, decreasing by 11% between the third and eighth decade of life. UBA and SAH 
SOS measurements remained stable until age 45-49 years and decreased thereafter, 
while DTU SOS started to decrease later at ages 50-54 years. SOS on the three 
devices decreased by 0.60%, 1.57% and 0.71 % between the third and eighth decade 
of life respectively. UBA BV started to decrease earlier than UBA SOS at age 35 
onwards and decreased by 3.79% between the third and eight decade of life. 
SAH 
BIVID peaked in the fourth decade of life, decreased from age 50 years and decreased 
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The SID of the BIVID and QUS measurements for each age group was examined to 
determine whether the SID changed with increasing age (Table 4.2). If the SID for the 
20-24 and 75-80 year age groups were ignored, the SID for hip BIVID measurements 
remained relatively stable from ages 25-75 years. The SID for LS BIVID appeared to 
increase slightly for women aged over 50 years of age, however the mean SID for 
women more than 50 years (0.152) was not significantly greater than the mean SID for 
women less than 50 years (0.120). The SID for SAH and DTU BUA measurements 
remained stable for all age groups, with the exception of the SID for women aged 20-24 
and 25-29 years. The SID for UBA BUA appeared to decrease with age, although the 
mean SID did not differ between women younger or older than 50 years of age (SID: 
15.4 vs. 13.6 respectively). With the exception of the 20-24 and 75-80 years age 
groups, the SID for velocity measurements was similar for all age groups. As the SID for 
both BIVID and QUS measurements appeared not to decrease or increase with age, the 
mean SID for all age groups (excluding adolescent girls) was calculated for the purpose 
of calculating Z-scores (Table 4.3). 
Measurement SDa 
LS BMD g/CM2 0.137 
FN BMD g/CM2 0.119 
THIP BMD g/CM2 0.111 
UBA BUA dB/MHz 14.5 
UBA SOS m/s 7.2 
UBA BV m/s 47.1 
Table 4.3: BIVID and QUS measurement 
standard deviations for the calculation of 
Z-scores. 
SAH BUA dB/MHz 13.6 
SAH SOS m/s 29.3 
SAHBMD g/CM2 0.106 
DTU BUA dB/MHz 6.3 
DTU SOS m/s 10.3 
estimated by calculating the root mean square mean of the individual SID for each age group. 
To obtain the BIVID and QUS value expected at each age for the purpose of calculating 
Z-scores, linear regression analysis was performed for women aged less than 50 years 
and for women aged 50 years and over (Table 4.4). Only FN BIVID, THIP BIVID and 
UBA SOS and BV displayed significant decreases with age in women less than 50 
years. Therefore, data for the other measurement variables, for all women aged 
less 
than 50 years, were combined to estimate the mean for this age group (Table 4.5). 
The significant regression coefficients (Table 4.4) or the mean values for women less 
than 50 years (Table 4.5) were then used to estimate the expected BIVID and QUS 
measurement for each age (in years) and this along with a knowledge of the 
SID (Table 
4.3), allowed Z-scores to be calculated for each individual. 
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Table 4.4: Regression equations for the calculation of Z-scores, for women aged 
<49 years and women >50 years. 
Measurement Regression equation a 
a+bx SEE p 
aged <49 years 
LS BMD g/CM2 1.089 -0.0009 Age 0.114 ns 
FN BMD g/CM2 0.998 -0.003 Age 0.112 0.01 
THIP BMD g/CM2 1.069 -0.003 Age 0.104 0.001 
UBA BUA dB/MHz 86.1 -0.205 Age 15.2 ns 
UBA SOS m/s 1511.1 -0.117 Age 7.0 0.05 
UBA BV m/s 1670.0 -1.013 Age 46.0 0.01 
SAH BUA dB/MHz 73.3 + 0.097 Age 14.1 ns 
SAH SOS m/s 1562.2 -0.073 Age 28.9 ns 
SAH BMD g/CM2 0.553 + 0.0001 Age 0.107 ns 
DTU BUA dB/MHz 54.0 -0.009 Age 6.1 ns 
DTU SOS m/s 1559.1 -0.196 Age 9.9 ns 
aged >50 years 
- LS BMD b g/CM2 1.376 -0.008 Age 0.145 0.04 
FN BMD g/CM2 1.115 -0.006 Age 0.113 0.002 
THIP BMD g/CM2 1.189 -0.005 Age 0.117 0.01 
UBA BUA dB/MHz 97.9 -0.485 Age 14.3 0.02 
UBA SOS m/s 1519.2 -0.277 Age 7.4 0.01 
UBA BV m/s 1691.1 -1.461 Age 46.3 0.01 
SAH BUA dB/MHz 100.4 -0.494 Age 13.6 0.01 
SAH SOS m/s 1590.2 -0.757 Age 29.2 0.02 
SAH BMD g/CM2 0.698 -0.003 Age 0.106 0.02 
DTU BUA dB/MHz 67.8 -0.262 Age 6.1 0.01 
DTU SOS m/s 1567.4 -0.333 Aqe 10.4 0.004 
a these equations were used to estimate the expected measurement value at 
each age (in years) and combined with a knowledge of the SID, allowed the 
calculation of Z-scores for each individual. 
b only women less than 70 years were included due to the increase in LS BIVID 
in women over 70 years. 
Table 4.5: Mean BMID and QUS measurements in women less than 50 years used for the 
calculation of Z-scores. 
Measurement 
Variablea Mean 
LS BMD g/cm 
2 1.046 
BUA UBA 78.3 
_ SAH BUA 77.1 
SAH-SOS m/s 1559.0 
SAH BMD gjCM2 0.555 
DTU BUA 53.7 
DTU SOS m/s 1551.2 
a only the measurement variables that 
not decrease signficantly (Table 4.4) 
In women less than 50 years are shown. 
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A subgroup of normal women aged 20-40 years was used to estimate the young adult 
mean and SID for each measurement variable for the purpose of calculating T-scores 
(Table 4.6). 
Table 4.6: The young adulf mean and SID for QUS and BIVID variables used for the calculation of T- 
scores 
Measurement 






LS BMD g/CM2 1.068 0.118 1.047 0.11 
FN BMD g/CM2 0.892 0.104 0.895 0.1 
THIP BMD g/CM2 0.988 0.098 0.975 0.12 
UBA BUA dB/MHz 80.2 15.5 na na 
UBA SOS m/s 1507.5 6.6 na na 
UBA BV m/s 1639.0 46.4 na na 
SAH BUA dB/MHz 77.7 13.5 na na 
SAH SOS m/s 1560.7 25.1 na na 
SAHBMD g/CM2 0.561 0.096 0.537 0.08 
DTU BUA dB/MHz 54.0 6.0 51.3 6.4 
DTU SOS m/s 1553.5 8.4 1557.8 10.2 
NHANES values: FN BIVID g/CM 2 0.849 (0.111), THIP BIVID g/CM2 0.942 (0.122) [162] 
a healthy women aged 20-40 years. 
na not available. 
Also shown in Table 4.6 are the corresponding manufacturer values for the young adult 
mean and SID, where available. Although all three QUS devices measure BUA and 
SOS in the mid-calcaneus there was a wide variation in both the mean and SID values. 
The young adult mean for DTU BUA was approximately 30% lower than that seen for 
the other two QUS devices. The DTU BUA SID was also significantly lower. The UBA 
BV measurement displayed a larger young adult mean and SID compared to the other 
velocity measurements. The mean and SID using this reference population for each 
measurement variable were similar to those used by the manufacturer, although the 
manufacturer young adult mean tended to be lower (except for DTU SOS). The 
manufacturer SID was higher than that obtained for this reference population for DTU 
BUA, DTU SOS and THIP BIVID but lower for LS BIVID, FN BIVID and SAH BMD. The 
reference data used for this study for the hip BIVID measurements was closer to the 
Hologic manufacturers' reference data than reference data from the NHANES study 
[162]. 
The influence of height and weight on BIVID and QUS variables is shown in Table 4.7. 
Also included is the influence of these anthropometric parameters on heel BIVID 
measured by DXA. Height was positively associated with spine and 
hip BIVID and UBA 
and DTU BUA measurements. BIVID increased by 0.006 g/CM2 
for every cm increase in 
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height, while UBA and DTU BUA increased by 0.386 dB/MHz and 0.159 per cm 
increase in height respectively. Weight was positively associated with all BIVID 
variables and SAH BUA, DTU BUA and UBA SOS. BIVID increased by approximately 
0.003 g/CM2 per kg increase in weight, UBA SOS increased by 0.127 m/s and SAH and 
DTU BUA increased by approximately 0.155 dB/MHz. A one unit increase in height 
and weight was associated with a BIVID increase of approximately 0.05 and 0.03 T- 
score units respectively, while QUS measurements increased by approximately 0.02 T- 
scores units (Table 4.7). BIVID measurements appeared to be affected by these 
anthropometric variables to a greater extent than QUS measurements. 
4.2.2 Age- and Menopause-related changes in BMD and QUS 
measurement variables 
The 530 women used to construct reference ranges for BIVID and QUS measurements 
were also used to examine age- and menopause-associated changes. Figures 4-la-k 
show scatter plots of BIVID and QUS measurements against age. Also shown in these 
figures are the data for adolescent girls aged 12-17 years. Both BIVID and QUS 
measurements show a large scatter of values at all ages. As noted earlier, the 
adolescent group had BIVID and BUA values that were significantly lower than those 
observed for premenopausal women but SOS values were essentially similar for these 
two groups. 
Due to the inclusion of adolescent girls, second and third order polynomial regression 
models were applied to these data as these described the data best (i. e. the highest 
coefficient of determination). The regression equations are shown in Figures 4.1a-k. 
With the exception of DTU SOS and UBA BV, third order polynomial regression models 
described the changes in BIVID and QUS measurement variables best. Second order 
polynomial models described the changes in DTU SOS and UBA BV best. Between 
19-26% of the variance in BIVID was attributable to age. Approximately 10% of the 
variance in UBA and SAH BUA was attributable to age, while the corresponding figure 
for DTU BUA was 19%. Between 7-14% of the variance in velocity measurements was 
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Figure 4.11: Scatter plots showing the correlation between age and (a) LS BIVID, (b) FN BIVID, (c) 
THIP BMD. 
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Figure 4.1 cont.: (d) UBA BUA, (e) UBA SOS, (D UBA BV. 
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Figure 4.1 cont.: (g) SAH BUA, (h) SAH SOS, (i) SAH BMD. 
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Figure 4.1 cont.: 0) DTU BUA and (k) DTU SOS. 
To examine the age- and menopause related changes further, women were separated 
into pre- and postmenopausal groups (further analysis of the adolescent data is 
discussed in Chapter 10). Figures 4.2a-c show the mean BIVID and QUS 
measurements for pre- and postmenopausal women. Corresponding figures for UBA 
BV were 1631.5 and 1602.5 for pre- and postmenopausal women respectively. All 
measurement variables were significantly lower in postmenopausal women. 
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Figure 4.2: Mean BMD and OUS measurements in pre- and postmenopausal women 
During the premenopausal period, only FN BIVID, THIP BIVID, UBA BV and DTU SOS 
displayed a significant decrease with age (Table 4.8). All BMD and OUS measurement 
variables showed a significant decrease with age for postmenopausal women (Table 
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4-8). In postmenopausal women BIVID measurements decreased by approyjmately - 
0.005 g/CM2 per annum. BUA annual decreases ranged from -0.21 to -0.55 dB/MHz 
and annual decreases in SOS ranged from -0.23 to -0.59 m/s. When the annual losses 
were expressed in T-score units, the hip BMD measurements showed a greater rate of 
decline than LS BIVID and QUS measurement variables in postmenopausal women 
(Table 4.8). The decrease in QUS measurements was more consistent once 
expressed in T-score units, although DTU BUA showed a slightly higher annual 
decrease than both SAH and UBA BUA. 
Table 4.8: Age-related changes in BIVID and QUS measurement variables in pre- and 
postmenopausal women 
Premenopausal 
Correlation Annual Annual 
Coefficient Loss Loss/SD" 
Postmenopausal 
Correlation Annual Annual 
Coefficient Loss Loss/SDa 
UBA BUA dB/MHz 0.09 ns ns 0.23** -0.403 -0.025 
SAH BUA dB/MHz 0.01 ns ns 0.22** -0.362 -0.027 
DTU BUA dB/MHz 0.01 ns ns 0.27** -0.206 -0.034 
UBA SOS m/s 0.12 ns ns 0.25** -0.228 -0.035 
SAH SOS m/s 0.07 ns ns 0.17* -0.593 -0.024 
DTU SOS m/s 0.16* -0.190 -0.023 0.24* -0.297 -0.035 
UBA BV m/s 0.17* -0.884 -0.019 0.25** -1.379 -0.029 
Sah BMD g/CM2 0.05 ns ns 0.27** -0.002 -0.021 
LS BMD g/CM2 0.06 ns ns 0.17* -0.003 -0.025 
FN BMD g/CM2 0.24** -0.003 -0.029 0.41 ** -0.006 -0.057 
THIP BMD g/CM2 0.20* -0.002 -0.02 0.33** -0.005 -0.051 
a annual losses were divided by the young adult SID so the change per annum is expressed 
in T-score units. 
* P<0.05 ** P<0.001 
ns, not significant. 
The decrease in BIVID and QUS measurement variables with years since menopause is 
shown in Table 4.9. The correlation coefficient between measurement variables and 
YSM were greater than those with age, with the exception of SAH BMD. The annual 
decreases associated with years since menopause were also greater than those 
associated with age. Spine BIVID decreased by -0.004 g/CM2 with each advancing year 
since menopause, while the two hip BIVID measurements decreased by approximately 
-0.006 g/CM2 . BUA and 
SOS decreases with YSM ranged from -0.26 to -0.55 dB/MHz 
and -0.25 to -0.81 m/s respectively. When the annual decreases associated with YSM 
were expressed in T-score units, the LS BIVID and QUS measurement variables 
decreased by approximately -0.035, while hip measurements decreased by 
approximately -0.065. 
133 
ChaDter 4- Reference data 
Years Since Meno pause 
Correlation Annual Annual 
Coefficient Loss Loss/SD a 
UBA BUA dB/MHz 0.30** -0.551 -0.035 SAH BUA dB/MHz 0.27** -0.481 -0.036 
DTU BUA dB/MHz 0.32** -0.26 -0.043 
UBA SOS m/s 0.27** -0.254 -0.039 SAH SOS m/s 0.22* -0.807 -0.032 DTU SOS m/s 0.28** -0.357 -0.042 
UBA BV m/s 0.26** -1.534 -0.032 
Sah BMD g/CM2 0.25** -0.003 -0.031 
LS BMD g/CM2 0.21* -0.004 -0.034 
FN BMD g/CM2 0.46** -0.007 -0.067 
THIP BMD g/CM2 0.39** -0.006 -0.061 a annual losses were divided by the young adult SID so the 
change per annum is expressed in T-score units 
* p<0.05 ** p<0.001 
Table 4.9: Changes in 
BIVID and QUS 
measurement variables 
with years since 
menopause. 
The DTU measurement variables tended to show slightly greater decreases with YSM. 
When examining the relationship between measurement variables and YSM, linear 
regression models were more appropriate than other regression models, indicating that 
an accelerated rate of loss during the early postmenopausal period was not evident in 
the data. 
4.3 DISCUSSION 
4.3.1 Reference Data 
It has been reported that inconsistencies in reference data can lead to differences in 
the proportion of women classified as osteopenic or osteoporotic and this may lead to 
errors regarding the decision to treat an individual [161,381,382]. To date, these 
reports on inconsistencies in reference data have concentrated on BIVID measurements 
acquired using DXA. However, with the diversity of QUS technology and the relatively 
short time it has been available, it is almost certain that reports on the problems 
associated with QUS reference data will follow. There has been an attempt in recent 
years to standardise BIVID results from different manufacturers [163], however the 
diversity of QUS technology is far greater than that observed for DXA and this has 
been recognised by the International Ultrasound consensus Group as a challenge to 
overcome in the future [228]. However, the aim of this part of the study was not to 
highlight problems associated with manufacturers reference data, but rather to 
establish consistent reference values for both BIVID and QUS measurements that could 
be applied to the study population. This consistency is advantageous as any 
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differences that remain between DXA and QUS or between different QUS devices are 
due to differences in technology rather than differences in manufacturer reference data. 
The group of normal pre- and postmenopausal women was selected using the 
exclusion criteria described by Ryan et al for the construction of BIVID reference ranges 
[343], as described in Chapter 2. The use of such criteria allows a group of women to 
be selected that reflect the general population as closely as possible. Large 
population-based sampling studies, such as the United States NHANES study, do not 
exclude individuals due to disease or medication use for example [162]. However, 
women used in the present study were recruited from two sources: women referred by 
their General Practitioner for bone density screening by DXA and women who had 
volunteered for research. A large percentage of women referred by their GP had risk 
factors for low BIVID that led to be them being excluded and a small percentage of the 
volunteers were aware that they had a risk factor for low BIVID and wished to have their 
bone density assessed. Therefore, it was important to exclude these women, as 
inclusion would have lead to significantly lower BIVID and QUS reference values. The 
effect of risk factors on BIVID and QUS values is discussed further in Chapter 7. 
It was not possible to directly compare the reference data obtained here for QUS 
measurement variables with other studies reporting normal values for QUS as the 
actual values are often not reported for each age group. In addition, the actual study 
population characteristics can vary considerably between different studies. The 
number of subjects examined may vary, as well as the age and age-range of the 
subjects. Differences in study design affect the method in which subjects are recruited 
and the exclusion criteria applied. However, the young adult mean and SD values 
corresponded relatively closely to the manufacturers' values (Table 4.6). Studies on 
water-based QUS devices, such as the UBA or Lunar Achilles, have reported 
decreases in BUA of approximately 15-30% between the third and eight decade of life 
[242,243,248]. These results are similar to the 22% decrease observed for UBA BUA. 
SAH BUA decreased by 15%, which is similar to that reported by Langton et al [363] 
but lower than that reported by Herd et al [341] on the CUBA Clinical device. The SOS 
measurements appeared to decrease by a smaller amount (0.71-3.79%). However, to 
interpret these findings the smaller biological range of SOS must be taken into account. 
The percentage decrement observed in the present study for SOS measurements were 
slightly lower than that observed in other studies on both water-based 
[238,243,245,248) and contact QUS devices [240,363]. 
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Z-scores for all of the 1130 study subjects were calculated using one SD for all age 
groups (Table 4.3). It has been reported that the SD for LS BIVID increases with age, 
probably due to the effects of aortic calcification and degenerative changes in the spine 
associated with advancing age which affect the accuracy of LS BIVID results [381]. Due 
to differential rates of bone loss due to menopause or ageing one would expect the SD 
to increase slightly with age, particularly around the time of menopause [381]. Neither 
the spine nor hip BIVID SD increased significantly with age. The SD for QUS 
measurements was also relatively similar for different age groups. The UBA BLIA 
measurement SD appeared to actually decrease with age, although the SD for women 
greater than 50 years of age was not statistically different than that observed for 
measurements in women less than 50 years. It has been proposed that the process of 
phase cancellation may overestimate BUA by up to 35 dB/MHz [236], causing the SD 
to be artificially increased. The process of phase cancellation would be higher in young 
adults (as the ultrasound signal undergoes more modification due to higher bone mass) 
and this, combined with the fact that the UBA uses the largest diameter transducers, 
could explain the decreasing SD for BLIA measurements with increasing age. 
BIVID at the spine and hip was positively associated with height and weight (Table 4.6), 
which is in accordance with other studies [383]. The calcaneus is a weight-bearing 
bone and it has been reported that BIVID at the calcaneus is associated with height, 
weight and BMI [210]. A small group of women had DXA scans of the heel in the 
present study and these measurements were positively associated with weight and 
BMI only. Height was positively associated with BUA measurements on the UBA and 
DTU and UBA SOS and weight was positively associated with UBA SOS and SAH and 
DTU BUA. A study by Hans et al on the influence of such factors on calcaneal QUS 
measurements found that weight was the only significant predictor of BUA after 
adjustment for age and other anthropometric variables [262]. A study by Damilakis et 
al found no influence of weight or BMI on BLIA [239]. When the changes in QUS 
variables associated with one unit increase in height and weight were standardised and 
expressed in T-score units, the changes were relatively small and unlikely to be of 
clinical significance. Therefore, the QUS reference data were not corrected for 
variations in these anthropometric variables. In addition, BIVID measurements were 
influenced by anthropometric factors to a greater extent than QUS measurements, 
indicating that although the calcaneus is a weight bearing bone, QUS measurement 
variables are less dependent on weight than BIVID measurements. 
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4.3.2 Age- and 
measurement variables 
menopause-related changes in BMD and QUS 
The age-related changes in BMD and QUS measurement variables were assessed in 
females aged 12-80 years. With the exception of DTU SOS and UBA BV, third order 
polynomial regression models described the changes in BIVID and QUS measurement 
variables with age best and yielded the highest coefficients of determination than other 
regression models. This is consistent with the three distinct phases of changes with 
bone mass during life: (i) a rapid increase in skeletal size and BIVID during childhood 
and adolescence; (ii) BIVID is maintained or decreases slowly between the third and 
fifth decade of life; (ii) BIVID decreases and in females this may be associated with an 
accelerated period of bone loss in the first few years postmenopause. 
BIVID measurements at the lumbar spine and hip increased rapidly during adolescence 
and reached a peak at approximately age 30 (Figures 4.1a-c). BIVID decreased from 
this age onwards, although only the hip measurement showed a significant decrease 
with age in the premenopausal period (Table 4.8). This is in accordance with other 
studies that showed that LS BIVID is maintained in premenopausal women but hip BIVID 
decreases [39,357]. The longitudinal study by Hui et al of over 400 females aged 6-90 
years, found that the onset of bone loss began at 37 years at the femoral neck but age 
48 years at the lumbar spine [357]. 
Calcaneal BUA measurements displayed a similar pattern of changes with age to that 
seen at the lumbar spine. BUA increased during adolescence and early adulthood, 
peaked at age 30 and appeared to decrease from approximately age 40 onwards 
(Figures 4.1 d, g and j). There was no significant decrease in BUA measurements 
during the premenopausal period, which is consistent with other studies examining 
both calcaneal BUA [243,363,385,386] and calcaneal BIVID [207,387]. 
Velocity measurements displayed a different pattern to BMD and BUA measurement 
variables (Figures 4.1 e, f, h and k). UBA and SAH SOS increased, although not 
significantly, during adolescence, peaked at approximately age 20 years and declined 
thereafter. UBA BV and DTU SOS peaked earlier, during the second decade of life 
and declined thereafter. Other studies examining the age-related changes in velocity 
measurements have reported that SOS decreases from the third decade of life 
[243,248,385,386], although others have observed no significant decrease until after 
age 40 years [238,363]. 
137 
Chapter 4- Reference data 
A surprising finding was that SOS measurements did not significantly increase during 
adolescence and the mean values for girls aged 12-17 years were not significantly 
different to those of women aged 20-29 years. A similar finding was observed for a 
slightly older group of girls aged 15-19 years [385]. This is discussed further in 
Chapter 10. 
Both the BUA and SOS measurement variables readily differentiated between pre- and 
postmenopausal women (Figure 4.2). In postmenopausal women, an inverse 
relationship between QUS and years since menopause was observed (Table 4.9). 
There was no evidence of accelerated bone loss during the first few years after 
menopause as reported by others [240,241]. The annual losses in postmenopausal 
women were similar to those observed in other cross-sectional studies 
[157,243,244,248]. However, the annual decreases in SOS were somewhat lower than 
those reported in the literature [157,243,244,248]. 
To date, results from two longitudinal studies have been reported for calcaneal QUS 
[185,251]. A study of 113 healthy postmenopausal women reported annual decreases 
of -1.01 dB/MHz and -11.3 m/s for BUA and SOS respectively [185]. A total of 323 
postmenopausal women from the Rotterdam Study, measured at baseline and again 
after a median duration of 1.4 years, displayed decreases of -2.5 m/s for SOS but no 
significant change in BUA [251]. However, up to 27% of the changes observed could 
be accounted for by the measurement error [251]. Additional longitudinal studies are 
required over longer periods to determine the true rate of change of QUS 
measurements with advancing age. The DTUone and other QUS imaging devices use 
an acoustically selected measurement ROI (area of lowest attenuation). However as 
the calcaneus displays an inhomogeneous response to ageing and therapy, it is not 
clear whether the ROI may be located in the anatomically different region of the 
calcaneus at follow-up compared to baseline [54,216]. Longitudinal studies using 
imaging devices are required to see whether this is indeed the case. 
A larger proportion of the variance in BIVID measurements was aftdbutable to age than 
that observed for QUS measurement variables (Figures 4.1 a-k). There may be several 
reasons for this: (i) calcaneal BIVID is not influenced by age or menopause-related 
factors to the same extent as axial BMD; (ii) QUS measurement variables measure 
bone properties that are not influenced by age and menopause-related factors to the 
same extent as BMD; (iii) precision and accuracy errors inherent in QUS 
measurements preclude a closer association between QUS and age. The first 
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explanation is unlikely as studies comparing the age-related changes in calcaneal BIVID 
to axial BIVID have shown that calcaneal BIVID decreases with age by similar amounts 
to spine and hip BIVID [209,388]. A negative correlation between calcaneal BIVID and 
age has been observed in several studies [207,209,210] and this decrease with age 
continues even in very elderly populations [388]. 
Since the introduction of QUS, it has been suggested that QUS measurement variables 
are influenced by material and structural properties of bone as well as BMD. This 
relationship has been proven experimentally [195,300,313,389], although several 
studies have reported that QUS measurement variables reflect bone quantity not bone 
quality [213,312,390,391]. However, even if QUS variables are influenced by such 
properties, it has been shown that structural properties such as trabecular number, 
separation and thickness and mechanical properties of bone decrease with age to the 
same extent as BIVID [71,72,392,393]. Therefore, it is unlikely that this could explain 
the rather poorer correlation with age observed for QUS compared to BMD. 
QUS measurements are influenced by precision and accuracy errors that may preclude 
a closer association between QUS and age. To date, there is no comprehensive 
theory on how QUS interacts with bone and therefore the assessment of the accuracy 
of QUS is difficult to determine. However, potential sources of error have been 
investigated such as phase cancellation [236], frequency-dependent attenuation 
[226,303), diffraction and dispersion [394] and temperature effects [371,395]. Other 
sources of error associated with in vivo measurements include variations in bone width 
[229-231], soft tissue thickness and composition [229,282] and oedema [283]. The 
most influential determinant of precision relates to the inhomogeneity of the calcaneus. 
The development of QUS imaging allows for the accurate placement of a specific ROI 
[213,216,218,285,396] and it has been shown that the precision of QUS imaging 
devices approach that of DXA [218,286,377]. The short-term precision of DTU BUA 
was superior to that obtained on the fixed-point devices (Chapter 3). The standardised 
annual decreases were greater for DTU BUA than those observed on the UBA and 
SAH (Table 4.8) and a larger proportion of the variance in DTU BLIA was attributable to 
age (Figure 4.1j). This may indicate that the removal of certain error sources leads to a 
better correlation between QUS measurement variables and age. This finding was not 
supported by the DTU SOS measurement variable due to the adverse effects of 
temperature on the accuracy and precision on this variable (Chapter 3). 
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4.3.3 Study Limitations 
A potential bias of collecting reference data using volunteers is that of self-selection. A 
large majority (89%) of women over 70 years of age were volunteers who had 
contacted the Osteoporosis Unit to participate in clinical research. This may have lead 
to a selection-bias towards fitter and healthier individuals being included in the older 
age groups. It has been suggested that excluding individuals with a history of fracture 
in older age groups is misleading and less representative of the general population 
[397]. When fractures are not secondary to disease, they reflect only age or oestrogen 
deficiency and therefore exclusion of such individuals will underestimate bone loss 
[397]. This factor, along with the possibility of a selection-bias towards more healthy 
individuals in the older age groups, may explain the small increase observed in BIVID 
and QUS measurement variables after the age of 70 years and the slower rate of age- 
related decline seen for QUS measurements compared to other studies. A true 
population sample of women may have provided more accurate reference data, 
however, a study by Ryan et al that compared BIVID results from a population-based 
and a general practitioner referral-based population, reported no significant differences 
in spine BIVID between these two populations [398]. 
Longitudinal studies to assess the age-related changes in QUS variables are 
preferable as each subject acts as his or her own control and so any changes observed 
are adjusted for potential initial differences. 
4.4 Conclusions and Further Work 
A large group of women was used to construct reference ranges for BIVID and QUS 
measurement variables. This consistency in using local reference ranges removes the 
confounding effects of differences in manufacturer reference data and allows different 
technologies and different devices to be directly compared (Chapter 5). These data 
may also be used to provide reference values for QUS that could be applied to the 
local population if QUS is implemented into clinical practice. 
QUS measurements displayed similar changes with age to that observed for axial BIVID 
measurements, although velocity measurements did not significantly increase during 
adolescence (Chapter 10). When expressed in T-scores units, QUS measurement 
variables decreased by the same amount as LS BIVID with advancing age, however the 
two hip BIVID measurements tended to show greater decreases both during the pre- 
and postmenopausal periods. Longitudinal studies are required on a large age range 
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of subjects over a long period to fully determine the extent to which QUS 
measurements change with age. 
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Chapter 5 
The Correlation between Calcaneal QUS 
Devices and QUS and DXA 
5.1 STUDY DESIGN 
5.1.1 Aims 
The aim of this chapter was to compare the three calcaneal QUS devices and 
determine whether differences exist between the devices in the measured QUS 
variables. The correlation between QUS and BIVID, measured using DXA, has also 
been examined. 
5.1.2 Introduction 
Since the introduction of QUS in 1984, manufacturers have produced a great number 
of QUS devices. The diversity of QUS exceeds that of any other bone densitometry 
technology and this has been recognised as a challenge for the validation of QUS by 
the International QUS Consensus Group [228]. Even if one concentrates on calcaneal 
QUS devices, there are several different approaches to measuring BUA and SOS, 
including non-imaging fixed-point water-based devices, imaging water-based devices 
and contact 'dry' systems. Variations in SOS of up to 38 m/s and BUA variations up to 
33 dB/MHz have been found using three different commercial calcaneal QUS systems 
and a bench-top system [362] and the range of values observed on each device can 
vary by up to a factor of four [399]. Even devices from the same manufacturer have 
been shown to differ in terms of the measured variables [276,362]. In recent years, 
there have been discussions about the possibility of standardising DXA results to a 
universal reference range by using semi-anthropometric phantoms (400]. It is 
important to determine the extent of the differences between different QUS devices and 
this in turn could aid in the development of possible standardised methods for 
calibration and expression of measurement results using QUS [228]. The three QUS 
devices compared here represent the three types of methods available to measure 
BUA and SOS at the calcaneus; non-imaging water-based method, imaging water- 
based method and contact method. 
DXA is considered by many to be the 'gold standard' of bone densitometry due to its 
ability to measure BIVID both accurately and precisely. Therefore, since QUS became 
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available as an alternative technique for assessing skeletal status, there have been a 
great number of studies comparing QUS measurement variables with BIVID measured 
by DXA [157,214,215,249,265,275,277,280,281,287,289-291,293-295,301,306,364]. 
The correlation between calcaneal QUS measurement variables and both axial and 
calcaneal BMD has been assessed here. 
5.1.3 Methods 
5.1.3.1 Subjects 
The study population consisted of four groups: (i) 240 premenopausal women; (ii) 290 
postmenopausal women; (iii) 104 with vertebral fracture (osteoporotic); (iv) 37 
adolescents (Table 2.2). Women from groups (i) and (ii) fulfilled the criteria described 
in Table 2.1 and were those used to construct reference ranges in Chapter 4. 
5.1.3.2 Data Analysis 
Linear regression analysis was used to examine the correlation between QUS 
measurement variables measured on different devices, the correlation between BUA 
and SOS on the same device and the correlation between QUS measurement 
variables and BMD. Ninety-five percent confidence intervals were found for the 
correlation coefficient using Fisher's Z transformation. Different regression models 
were used to determine the most appropriate (i. e. highest coefficient of determination) 
regression equation that described the relationship between different variables best. 
To examine the level of agreement between BUA and velocity measurements 
measured on different devices, the difference between the values (in absolute units) 
was plotted against the mean of two measurements, as described by Bland and Altman 
[352]. Linear regression analysis was then applied to these data to assess whether the 
differences varied in a systematic way over the range of measurements. 
The mean and range of each QUS measurement variable was calculated using just the 
healthy pre- and postmenopausal groups. The range was defined as the 5th and 95th 
percentile values for the pre- and postmenopausal groups combined. 
5.2 RESULTS 
5.2.1 Correlation between calcaneal QUS devices 
The BLIA and velocity measurements obtained on the healthy pre- and 
postmenopausal women were used to examine the correlation between the three QUS 
devices. Table 5.1 gives the correlation coefficients for the BUA and SOS comparisons 
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on the different devices. When BUA measurements were compared, the highest 
correlation was observed between the UBA and SAH (r--0.77) and the lowest 
correlation was observed between the UBA and DTU device (r--0.65). For SOS 
measurements, the three comparisons yielded similar correlation coefficients of 
approximately 0.83. 
UBA SAH DTU Table 5.1: Correlation coefficients for BUA 
UBA 0.77 -06ý-. 66 -5 (upper-right half of table) and SOS (lower-half 
of table) comparisons on the three different SAH 0.83 0.74 devices. All correlations were significant at DTU 0.84 0.82 
-- p<0.0001. 
The correlations observed between QUS measurements performed on the different 
devices are shown in Figures 5.1 a-c for BUA and Figures 5.2 a-c for SOS. Also 
shown in each figure are the regression equations. When UBA BUA and SAH BUA 
measurements were compared, a linear regression model described the data best with 
59% of the variance in SAH BUA explained by UBA BUA. When both UBA BUA and 
SAH BUA were compared to DTU BUA (Figures 5.1b and c), a second order 
polynomial model was more appropriate than a linear model. The best fit lines in these 
scatter plots show that when UBA BUA or SAH BLIA exceed approximately 90 dB/MHz 
there was no further increase in IDTU BUA, while below 9OdB/MHz, DTU BLIA showed 
a linear increase with UBA and SAH BUA. To examine this further, Bland-Altman plots 
were drawn between DTU BUA and both LIBA and SAH BLIA (Figures 5.3 a and b). As 
a comparison, a Bland-Altman of UBA and SAH BLIA is also shown (Figure 5.3c). 
When UBA and SAH BUA measurements were compared, the difference between the 
two measurements does not change significantly with increasing BLIA and the mean 
difference between the two measurements was just 0.4 dB/MHz. However, there is 
evidence of increasing dispersion as BUA increases. In contrast, when IDTU BLIA was 
compared to UBA BUA (Figure 5.3a) and SAH BUA (Figure 5.3b) not only was DTLI 
BLIA consistently lower but also as the mean BLIA increased the difference between 
the two devices increased. For example, when the mean BUA of both measurements 
on the DTU and UBA increased from 40 dB/MHz to 80 dB/MHz, the difference in BLIA 
between the two devices increased from approximately zero to 36 dB/MHz. 
The mean and range (5" to 95h percentile) of BUA values also varied considerable 
between the different devices (Table 5.2 and Figure 5.4). The range of BUA values for 
pre- and postmenopausal women observed on the DTU was over two times smaller 
than the range of BUA values on the UBA and SAH. The mean and range of BLIA 
values observed on the UBA and SAH were similar. 
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Figure 5.1: Scatter plots showing the correlation between BUA measured on the (a) UBA and 
SAH, (b) UBA and DTU and (c) SAH and DTU. 
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Figure 5.2: Scatter plots showing the correlation between SOS measured on the (a) UBA and 
SAH, (b) UBA and DTU and (c) SAH and DTU. 
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Figure 5.3: Bland-Altman plots of the difference between BUA measurements against the mean 
of both measurements for (a) UBA and DTU, (b) SAH and DTU and (c) UBA and SAH. 
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Mean Range (5th-95th percentile) Table 5.2: The mean and 
BUA dB/MHz range of BUA and velocity 
UBA 73.8 52.0-103.0 measurements for pre- and 
SAH 73.9 52.7-99.9 postmenopausal women 
DTU 52.8 42.1 -61.6 
SOS M/S 
UBA 1504.7 1493.0 - 1519.0 
SAH 1551.9 1507.7 - 1606.3 
DTU 1549.2 1533.1 - 1566.4 
BV rn/s 
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Figure 5.4: The range (5 th and 
9ýth percentile) of BUA values 
observed in pre- and 
postmenopausal women. 
When the SOS measurements on the three different devices were compareka linear 
relationship was observed for all three comparisons (Figures 5.2 a-c). As SOS 
increased the dispersion about the regression line increased. Approximately 67% of 
the variance in one SOS measurement could be explained by the other SOS 
measurement. The slopes from the regression equations varied considerably, with 
SAH SOS increasing by 3.2 m/s for every 1m/s increase in UBA SOS. While DTU 
SOS increased by 1.2 m/s for every 1 m/s increase in UBA SOS, but only increased by 
0.3 m/s for every 1 m/s increase in SAH SOS. Figure 5.5a-c shows Bland-Altman plots 
comparing SOS measurements on the three devices. When UBA and SAH SOS were 
compared (Figure 5.5a), the difference in SOS increased with increasing SOS. For 
example, when the mean SOS increased from 1500 to 1560 m/s, the mean difference 
between UBA and SAH SOS increased from -11.6 to 86.3 m/s. UBA SOS was 
consistently lower than SAH SOS. A similar pattern was observed when comparing 
UBA and DTU SOS (Figure 5.5b), although the difference in SOS on the two devices 
did not increase as steeply as that observed when UBA and SAH SOS were compared. 
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Figure 5.5: Bland-Altman plots of the difference between SOS measurements against the mean 
of both measurements for (a) UBA and SAH, (b) UBA and DTU and (c) SAH and DTU. 
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The mean difference between UBA and DTU SOS was 44.7 m/s. Four outliers can 
also be seen on Figure 5.5b, due to SOS being unusually low on the DTU. When SOS 
on the SAH and DTU were compared (Figure 5.5c), the SAH yielded lower SOS values 
compared with the DTU at lower mean values of SOS but higher values when the 
mean SOS exceeded approximately 1550 m/s. The range of SOS values observed on 
each device also varied (Table 5.2 and Figure 5.6). The UBA SOS measurement 
yielded the lowest mean and the smallest range of just 26 m/s. The DTU SOS 
measurement yielded a higher mean value than UBA SOS and displayed a slightly 
larger range of values (33 m/s). The range of SOS values on the SAH was 
approximately three times larger than that observed on the UBA and DTU, ranging 
from 1508 m/s to 1606 m/s. 
UBA SOS 
SAH SOS 
DTU SOS ýM 
UBA BV 
1480 1530 1580 1630 1680 1730 
SOS M/s 
Figure 5.6: The range (5th to 95th 
percentile) of SOS values observed in 
pre- and postmenopausal women. 
The UBA BV measurement variable was significantly correlated with UBA SOS 
(r--0.94), SAH SOS (r--0.86) and DTU SOS (r--0.83). Scatter plots of UBA BV against 
the SOS measurements are shown in Figures 5.7a-c. As with the SOS comparisons, 
as BV and SOS increased the dispersion about the regression line increased. The 
UBA BV measurement variable yielded the highest mean value and the largest range 
(150 m/s) for the different velocity measurements (Table 5.2 and Figure 5.6). 
The correlation between BUA and SOS measurements on the different devices was 
assessed further by examining the correlation obtained for four different study groups; 
adolescents, healthy premenopausal, healthy postmenopausal and the osteoporotic 
group. Figure 5.8 shows the correlation between BUA measurements for the different 
study groups. BUA measurements on the osteoporotic group yielded the highest 
correlation coefficients for all three comparisons. When UBA BUA was compared to 
SAH BLIA and DTU BUA using measurements from the adolescent group, lower 
correlations were obtained. The slope obtained using linear regression analysis 
150 
orrelations 




C/) 1520 0 
CO 1510 
m Z) 1500 
1490 
1480 111 
1480 1530 1580 1630 1680 1730 1780 1830 1880 



















1480 1530 1580 1630 1680 1730 1780 1830 1880 
UBA BV m/s 






1480 1580 1680 1780 1880 











Figure 5.7. Scatter plots showing the correlation between BV and SOS measured on the (a) 
UBA, (b) UBA and SAH and (c) UBA and DTU. 
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Figure 5.8: The correlation between BUA measurements for dtfferent study groups (error bars 
represent the 95% confidence interval). 
between BUA measurements was greatest for the osteoporotic group for all 
comparisons, and for one comparison (UBA vs. DTU) was almost twice that observed 
for BUA comparisons in the adolescent and premenopausal groups. The correlations 
between SOS measurements for the different study groups were relatively consistent 
for all comparisons, with correlation coefficients ranging from 0.80 to 0.92 (Figure 5.9). 
The correlation between SOS measurements was greatest (although not significantly) 
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Figure 5.9: The correlation between SOS measurements for different study groups (error bars 
represent the 95% confidence interval). 
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BUA and SOS measurements performed on the same device were compared (Figures 
5.10 a-c). The highest correlation was observed between SAH BUA and SAH SOS 
(r--0.82) while the lowest correlation was observed between BUA and SOS on the DTU 
(r=0.63). The correlation between BUA and SOS on the UBA and SAH was 
significantly greater than that between DTU BUA and DTU SOS. Between 40% and 
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Figure 5.10: Scatter plots showing the correlation between BUA and SOS measured on the (a) 
UBA, (b) SAH. 
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5.2.2 Correlation with DXA 
D-RJ BUA dB/MHz 
Figures 5.11 a-h show scatter plots of QUS measurement variables against THIP BMD. 
Only scatter plots between QUS measurements and THIP BIVID are shown as the 
scatter plots between QUS measurements and other BIVID measurements displayed 
similar patterns. There was a large spread of values around the best-fit line and in 
several cases, there is evidence of possible outliers. The relationships between QUS 
measurement variables and BIVID did not deviate from linearity. 
The correlation coefficients obtained between QUS measurement variables and DXA 
measurements at the lumbar spine, hip and heel are shown in Table 5.3. As a 
comparison, the correlation coefficients obtained between heel BIVID and both lumbar 
spine and hip BIVID are also shown. These results are displayed graphically in Figure 
5.12. 
LS BIVID FN BIVID THIP BIVID HEEL BIVID Table 5.3 Correlation 
UBA 
coefficients for QUS 
BUA dB/MHz 0.46 0.45 0.45 0.61 and BIVID 
SOS m/s 0.54 0.53 0.56 0.68 comparisons. All 
BV m/s 0.49 0.49 0.51 0.60 correlations were 
SAH significant at 
BUA dB/MHz 0.44 0.40 0.44 0.57 p<0.0001. 
SOS M/S 0.46 0.41 0.43 0.59 
BIVID g/CM2 0.47 0.42 0.45 0.61 
DTU 
BUA dB/MHz 0.47 0.45 0.49 0.68 
SOS M/S 0.43 0.42 0.46 0.58 
DXA 
HEEL BIVID 0.49 0.51 0.56 ------ 
S. 
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Figure 5.11: Scatter plots showing the relationship between QUS measurement variables and 
THIP BIVID for (a) UBA BUA, (b) UBA SOS and (c) UBA BV. 
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The correlation between QUS measurement variables and axial BIVID measurements 
ranged from 0.40 to 0.56. The highest correlations were observed between UBA SOS 
and BIVID measurements and the lowest correlations were observed between SAH 
BUA and BIVID measurements, although these differences were not significant due to 
the large 95% confidence intervals. Heel BIVID displayed similar correlations with axial 
BIVID measurements and these were not significantly higher than those obtained for 
QUS measurements. The QUS measurement variables displayed similar correlations 
when correlated with lumbar spine BIVID measurements compared to FN and THIP 
E3MD measurements. 
The highest correlations were observed between QUS measurements and heel BIVID, 
ranging from 0.57 for SAH BUA to 0.68 for both UBA SOS and DTU BUA. The 
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correlation between DTU BUA and Heel BMD was significantly greater than the 
correlation between DTU BUA and FN BMD. With the exception of OTU BUA, the 
correlation between QUS measurement variables and Heel BMD were not significantly 
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Figure 5.12: Correlation coefficients for QUS and BMD comparisons (error bars represent the 
95% coffidence interval). 
5.3 DISCUSSION 
5.3.1 Correlation between calcaneal OUS devices 
The diversity of QUS technology has been recognised as a challenge for the 
advancement of QUS into widespread clinical use [228]. A lack of correlation between 
different QUS devices and lack of consensus regarding the definition of QUS 
measurements variables may lead to both confusion for Physicians regarding the 
interpretation of results and lead to individuals being diagnosed differently according to 
which device they were measured upon. 
The correlation between BUA measurements ranged from r--0.65 to 0.77. The highest 
correlation was observed between the UBA and SAH, which is not surprising as the 
SAH was developed to match the performance of the UBA. Scatter plots revealed that 
the relationship between DTU BUA and both UBA and SAH BUA was not linear and 
DTU BUA did not appear to increase with increasing UBA and SAH BUA when these 
exceeded approximately 90 dB/MHz (Figures 5.1b and c). Figures 5.3 a and b show 
158 
UBA UBA UBA SAH SAH SAH DTU DTU HEEL 
BUA BV SOS BUA SOS BMO BUA SOS BMD 
Chapter 5- Correlations 
that as mean BUA increases the difference between both UBA and SAH BUA and DTU 
BUA increases. A similar finding was found by Strelitzki et al who compared BUA 
measurements on the SAH and DTU using phantoms of different porosities. They 
reported that as the porosity of the phantoms decreased (i. e. to mimic increased BMD) 
the difference between SAH and DTU BUA increased [399]. The range of BUA for 
healthy pre- and postmenopausal women was 2.6 times smaller on the DTU compared 
to the range of BUA values on the UBA and SAH (Figure 5.4). The study by Strelitzki 
et al, using different porosity phantoms, reported a similar finding with the SAH BUA 
range being 2.3 times larger than the DTU range of BUA values [399]. Manufacturers 
use different algorithms to estimate BUA and this will lead to different BUA values and 
differences in clinical ranges. 
A possible explanation why DTU BUA did not increase with increasing UBA and SAH 
BLIA is that of phase cancellation [236]. The LIBA and SAH devices utilise transducers 
18 and 19mm in size respectively, which are significantly greater than the size of one 
wavelength. Any variations in path length or velocity will cause the transmitted signal 
to arrive out of phase. The transducer responds to the mean pressure over the entire 
transducer surface, therefore if the signal is out of phase, mean pressure will be 
underestimated and subsequently attenuation will be overestimated. Theoretically, any 
phase cancellation effects will be reduced using the DTU as it utilises concave 
transducers to focus the ultrasound beam and therefore both the spatial extent of beam 
and the region of bone interrogated by the signal will be reduced. In addition, the 
accurate placement of the DTU measurement ROI in a relatively homogeneous portion 
of the calcaneus will further reduce any phase cancellation effects. The effects of 
phase cancellation have been shown to overestimate BUA by up to 31 dB/MHz [2361. 
In contrast, it has been reported that BUA was not significantly different using phase 
sensitive and phase insensitive approaches to calculate BUA, although this study was 
performed in vitro [401]. An in vitro study by Strelitzki et al, examining BUA 
measurements using five different sized receiving transducers found that the relative 
differences in BUA exceeded 40 dB/MHz. However, there was no clear trend of 
increasing BUA with increasing aperture size and it was concluded that a combination 
of phase cancellation, averaging, diffraction and scattering may cause such differences 
in BUA (402]. To date, the only other study to compare an imaging with a non-imaging 
QUS device was an in vitro study performed by Nicholson et al who reported that there 
was no significant differences in BUA measured on the two devices [303]. 
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Any phase cancellation effects should be reduced in the osteoporotic group as it has 
been shown that both apparent density and structural parameters, such as trabecular 
connectivity and number, are significantly reduced in women with osteoporosis [1941. 
Therefore, the ultrasound signal will undergo less modification when propagating 
through the calcaneus in these subjects. The short-term precision errors were also 
significantly lower in the osteoporotic group for SAH and DTU BUA (Table 3.7), which 
may indicate, at least indirectly, that the ultrasound signal undergoes less modification 
as it traverses the calcaneus and thus less susceptible to accuracy errors. The 
correlation between BUA measurements on the DTU and UBA was higher for the 
fracture group compared to the other study groups (ý = 0.63 vs. approximately 0.41, 
respectively). The effect of phase cancellation may at least partly explain the non- 
linearity between DTU BLIA and both UBA BLIA and SAH BUA and the reduced range 
observed on the DTU. 
The mean BUA value on the DTU was significantly lower compared to UBA and SAH 
BIJA (Table 5.2). A study comparing BUA measurements using focused and 
unfocused transducers reported that although there was a highly significant correlation 
between the two measurements (r--0.97), BUA was consistently lower when focused 
transducers were used [219]. It may not be surprising that DTU BUA values are lower 
as the DTU uses an algorithm that automatically places the measurement ROI in a 
region of lowest attenuation and therefore provides the lowest BUA value in the 
posterior tuberosity of the calcaneus. 
Although the SAH was developed from the UBA, the SAH is a contact device, so 
dispenses with the need for a water-bath, and instead uses gel and rubber pads to 
couple the patients heel to the transducers. The correlation between the two devices 
using BUA was high (r--0.77) and they yielded similar mean and ranges (Table 5.2), 
however, 41% of the variance in SAH BUA was not explained by UBA BUA. A study 
comparing water-based and contact methods of measuring QUS measurement 
variables, reported significant differences in BUA between the two methods, with BUA 
measured on the contact device being on average 3 dB/MHz lower [229]. Although a 
very high correlation (r--0.94) between the two methods was reported, the study was 
performed in vitro [229]. An error that may preclude a closer association between BUA 
measured using water-based or contact devices is that of diffraction. It has been 
shown that diffraction can cause errors in BUA exceeding 10 dB/MHz using the contact 
method of estimating BLIA [403]. 
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In addition to accuracy and precision errors such as phase cancellation, diffraction and 
scattering, that reduce the correlation between devices especially in vivo, 
manufacturers use different methods and algorithms to calculate BUA. The details of 
measurement hardware and the algorithms used for commercial devices are often not 
available or not fully specified. For example, differences in transducer separation can 
cause BUA to vary as well as transducer size [402]. The frequency range used to 
calculate BUA can also differ from one device to another. For example, both the UBA 
and SAH use the frequency range of 0.2-0.6 MHz to calculate BUA while the DTU uses 
0.3-0.65 MHz frequency range. An investigation into the use of different frequency 
ranges to calculate BUA found that BUA could vary by up to 30%. In addition, the use 
of frequencies less than 0.4MHz causes a combination of a poor signal to noise ratio 
and departure from linearity between attenuation and frequency [404]. Therefore it 
may not be surprising that differences in BUA values are observed using devices from 
different manufacturers. 
The SOS measurements on the three devices were highly correlated (r = 
approximately 0.83, Figures 5.2 a-c). The range of SOS varied considerably for each 
device. The SAH SOS range was three times larger than that observed on the DTU 
and 3.8 times larger than that observed on the UBA (Table 5.2 and Figure 5.6). A 
study comparing the SAH and DTU using phantoms also reported that the SAH SOS 
range was larger than that for DTU SOS by a factor of 3.3 [399]. The UBA BV 
measurement yielded the highest mean values and the largest range (Table 5.2 and 
Figure 5.6). The intervening water and soft tissue with water-based and contact QUS 
devices causes the mean velocity to be lower than the true value of the velocity of 
sound through bone and also compresses the clinical range [405]. If true bone velocity 
is low, then the difference between BV and SOS will also be low as BV approaches the 
velocity of sound of water and soft tissue [405]. This can be seen by examining the 
correlation between UBA SOS and UBA BV (Figure 5.6a). The scatter around the 
regression line converges at lower BV and SOS values where the velocity of sound 
in 
bone equals that of water and soft tissue. In addition, the difference between BV and 
SOS is also lower than that observed at higher BV values. This pattern was also 
observed by Miller et al who compared BV with heel velocity (contact 
device). They 
reported BV and heel velocity converged at 1540 m/s where BV and 
heel velocity 
equalled the SOS in soft tissue [223]. The true velocity of sound 
in bone has been 
shown to be almost 100 m/s greater than SOS using contact or water-based 
techniques [229]. Increasing transducer separation in water-based devices can also 
compress the clinical range of SOS values. 
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A measurement of the true velocity of sound in bone may enhance discdmination as 
any accuracy errors associated with the surrounding soft tissue are removed. 
However, to obtain BV, a measure of calcaneal width is required which may lead to 
additional error sources that may adversely affect standardised precision. The UBA 
measures BV and provides an estimate of calcaneal width. Figure 5.13 shows the 
distribution of bone widths for the first 387 women who had QUS measurements on the 
UBA. The bone widths were estimated using a pulse-echo technique and were used in 
the calculation of UBA BV. The distribution of bone widths followed a Gaussian 
distribution with a mean bone width of 30.2mm and a SD of 2.9mm. However, bone 
width was positively associated with BMI (r--0.36) which may indicate that the 
measured bone width are not an accurate estimate of calcaneal width and 
subsequently UBA BV may not be an accurate representation of true bone velocity. 
The UBA remains the only calcaneal system that provided a BV measurement variable 
and this device is no longer commercially available so it is unclear whether a 
measurement of the true velocity of sound through bone would be of clinical use. In 
addition, it has been shown that BV is closely correlated with SOS using both water- 
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Figure 5.13: Calcaneal widths in a selection of pre- and postmenopausal women, estimated on 
the UBA for the calculation of BV. 
As seen for BUA measurements, there is a lack of consensus regarding the methods 
and algorithms used to calculate ultrasound velocity. There has been no attempt by 
different manufacturers to standardise the cdteda used to measure BUA and SOS. 
Commercial calcaneal QUS devices use different methods of defining the pulse arrival 
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time such as the earliest detectable deviation from zero, thresholding or the first zero 
crossing. It has been demonstrated that the difference in SOS obtained using these 
three different methods can be as high as 257m/s [227]. The precision of these 
different methods can also vary. When a broadband ultrasound signal propagates 
through the calcaneus, distortion of the signal will occur due to frequency-dependent 
attenuation, dispersion, phase cancellation and others [227,394]. Methods for defining 
the pulse arrival time such as the first deviation from zero and thresholding rely on the 
rising edge of the received pulse and assume that the shape of the signal is 
unchanged. A small amount of noise will lead to errors in identifying where the pulse 
begins. The first zero crossing method for defining the transit time of the pulse has 
been shown to be the most precise of the methods [227]. The exact criteria utilised by 
the UBA, SAH and DTU is unknown and so it is not possible to examine these different 
methods further. Differences in centre-frequency and transducer width may also lead 
to differences in SOS [227,303,394]. 
The correlation between BLIA and SOS measured on the same device ranged from 
0.63 on the IDTU to 0.82 on the SAH (Figures 5.9a-c). These figures are similar to 
those reported in the literature [157,244,249,291]. Although the two measurement 
variables are highly correlated, 30-60% of the variance in SOS was not explained by 
BUA. It has been suggested that the somewhat moderate correlation between BUA 
and SOS is that they measure different skeletal properties or that precision or accuracy 
errors associated with both would dilute the correlation between the two variables. An 
in vitro study by Laugier et al, that controlled for potential error sources, reported a very 
close relationship between BUA and bone velocity (r--0.95) and concluded that BUA 
and velocity reflect the same bone property [302]. Whether this is indeed the case is 
perhaps less important than determining whether BUA and SOS have similar predictive 
capabilities (Chapter 8). 
5.3.2 Correlation between QUS and DXA 
Since QUS became a potential tool for the diagnosis of osteoporosis and the 
identification of individuals at risk of fracture there have been a prolific number of 
studies examining the correlation between QUS measurement variables and BIVID, 
measured by more traditional techniques, mainly DXA. It was hypothesised that BUA 
and SOS should correlate with BMID at the femoral neck and lumbar spine as they are 
all sites rich in trabecular bone. All the QUS measurements displayed significant 
correlations with all the BIVID measurements (Table 5.3). The correlations observed 
were comparable to those reported in the literature for both non-imaging [157,240,242- 
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244,248,249,265,275,277,281,288,289,291-293,295,4061 and imaging devices 
[213,218,285,286]. Studies using more homogeneous study populations often reported 
less significant relationships while in vitro and site-matched studies reported higher 
correlations. The relationship between QUS measurement variables and BIVID is 
usually more significant in studies using individuals with low BIVID [407]. This may be 
explained by a recent study that found that the relationship between BLIA and density 
was not linear, except when apparent density was less than 0.64 g/CM2 [307]. 
Although the correlations reported here and in the literature are significant, a large 
proportion of the variance in QUS measurement variables is not explained by BIVID. In 
the present study, only 16-46% of the variance in QUS measurement variables is 
explained by BMD. Consequently, QUS cannot be used to predict BIVID, for example, if 
an individual had a DTU BUA result of 50 dB/MHz, the predicted THIP BIVID result 
would be 0.71-1.07 g/CM2 (95% confidence intervals) or when expressed in T-score 
units; -2.84 to +0.84. Such a range covers both the ranges for healthy young adults 
and individual with osteoporosis and so is obviously not acceptable. 
In previous studies examining the relationship between QUS and BIVID, three reasons 
have usually been given for the moderate correlations observed. One reason is that 
the precision and accuracy errors inherent in both QUS and DXA techniques preclude 
a close association between the two techniques. Secondly, QUS measurements may 
provide information on bone status that is independent of BIVID, such as bone elasticity 
or bone structural parameters. The third reason is that QUS measurements are 
performed at different skeletal sites to the spine and hip most often measured by DXA. 
Both DXA and QUS are associated with accuracy and precision errors. These errors 
will bias results and increase the population variance and therefore limit the correlation 
between QUS measurement variables and BMD. The introduction of QUS imaging 
removes some of the errors associated with the heterogeneous nature of the 
calcaneus, by allowing a more accurate placement of the measurement ROI and 
possibly reducing error sources such as phase cancellation, as mentioned previously. 
Studies have demonstrated that the relationship between QUS and DXA is improved 
using QUS imaging versus fixed measurement point devices [285,286]. At least in the 
short-term, the DTU BUA measurement variable yielded the lowest precision errors 
(Table 3.5) and this measurement variable along with UBA SOS displayed the highest 
correlation with heel BIVID (Table 5.3). A study by Laugier et al, that compared QUS 
imaging measurement variables and BIVID measured using QCT and controlled for 
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potential error sources reported very high correlations (as high as r--0.94) between 
QUS and BIVID [302]. Due to the fact that many factors can influence the precision and 
accuracy of both DXA and QUS measurements, especially in vivo, it may not be 
surprising that only moderate correlations were observed and that the correlation 
between imaging QUS and BIVID measurements was not significantly greater. 
One of the most frequent explanations given to account for the relatively poor 
relationship between QUS and BIVID is that QUS provides information about bone that 
is independent of bone density. Certainly both the scattering characteristics and 
ultrasound velocity have been utilised in many engineering and industrial applications 
as a means of non-destructively testing a materials mechanical and structural 
competence. As a rule, it is thought that ultrasound velocity is mainly related to BIVID 
and bone elasticity [196] while BUA is thought to relate to BIVID and bone structural 
parameters [408]. Several studies have reported that ultrasound velocity is related to 
bone elasticity [299,300,316-318,391]. However, in some cases, once density was 
taken into account, the relationship between ultrasound velocity and elasticity was no 
longer significant [316,391]. A significant relationship between BUA and structural 
properties, such as trabecular thickness, number and connectivity, has been observed 
[300,313,389,390]. BUA also varies with structural anisotropy, when measured in three 
orthogonal directions [305,309]. Indirect evidence comes from genetic studies that 
determine whether QUS and BIVID measurements are affected by common genetic 
factors. It has been reported that although QUS measurement variables are equally 
heritable traits as BIVID, only about 30% of the genetic variance in BUA and SOS was 
attributable to genetic factors specific to femoral neck BIVID [258]. However, several 
studies have concluded that QUS measurement variables reflect bone quantity rather 
than bone quality [213,314,316,391]. A comprehensive study by Nicholson et al found 
that structural variables were correlated with BLIA and velocity, but when adjusted for 
density, few significant relationships remained and the additional variance explained by 
structural variables was relatively small. In fact, none of the structural variables 
correlated with BUA or SOS measured in the medio-lateral direction, once density was 
taken into account and this is the only direction in vivo calcaneal measurements can be 
performed [312]. Approximately 90% of the variance in QUS could be explained by 
BIVID in another study [302]. It remains uncertain whether QUS is merely a surrogate 
for density or whether QUS can provide additional information on bone properties. 
However, emerging evidence seems to point to the fact, at least for calcaneal QUS 
measurements, that QUS reflect primarily bone density and only to a small extent, 
bone architecture. 
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The third reason for the relatively poor correlation between QUS and BIVID is that QUS 
measurements are traditionally taken at different skeletal sites to those most often 
measured by DXA. Only modest correlations have been observed between BIVID 
measurements made at different skeletal sites, even when using the same technique 
[157,240,242,265,291,292]. The comprehensive study by Grampp et al that compared 
the commonly available techniques for measuring bone status, found that the 
correlation between x-ray based methods and QUS were only marginally lower than 
those between x-ray based methods alone [157]. In the present study, the correlation 
between heel BIVID and both spine and hip BIVID is similar to that between QUS 
measurement variables and both spine and hip BIVID (Figure 5.12). It was 
hypothesised that calcaneal QUS measurements should correlate with BIVID at the 
femoral neck and vertebral bodies as they are all sites rich in trabecular bone. 
However, different skeletal sites are subjected to different loading patterns, have 
different proportions of trabecular and cortical bone and subsequently have differential 
rates of decline in response to decreasing oestrogen levels. 
Studies comparing site-matched measurements of QUS and BIVID at the calcaneus, 
tend to report slightly higher correlations [159,214,215,249,409]. In the present study, 
the correlation between QUS and BIVID is improved (although not significantly) when 
comparing heel BIVID to QUS measurement variables (Figure 5.12). However, the 
manufacturer-provided specifications were used to place the measurement ROI on the 
DXA scans of the heel and so the measurement ROls were not exactly matched. 
Nevertheless, using the DTU, the principle behind the placement of the ROI was similar 
for both QUS and DXA (region of lowest attenuation and region of apparent lowest 
BIVID, respectively). When a small group of women, who had both heel DXA and IDTU 
measurements, were examined further, the DXA and IDTU ROls were within 3mm of 
each other. The fact that many factors may influence QUS measurements in vivo such 
as phase cancellation, refraction, dispersion and soft tissue, could explain why no 
significant improvements in the correlation with BIVID was observed using the imaging 
QUS device. 
5.3.3 Study limitations 
In vivo QUS and BIVID measurements were used to assess the relationship between 
each of the measurement variables. Due to precision and accuracy errors associated 
with taking in vivo measurements such as variable amounts of soft tissue, variable 
bone widths, daily differences in room and water-bath temperature and so on, it is 
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difficult to determine true differences between measurement variables. In vitro studies 
use more ideal experimental conditions and therefore may be better suited to assess 
for differences. Studies on bone standards would perhaps be the optimum way of 
comparing different devices but at present, there are no bone standards for QUS that 
fully reflect the shape, composition and architecture of bone encountered in vivo. 
The exact methods and algorithms used by the manufacturer to estimate BUA and 
SOS were not fully known and therefore it was not possible to comment in detail on all 
the differences observed. 
5.4 CONCLUSIONS AND FURTHER WORK 
Although the measurements on the different QUS devices correlated with one another, 
there was a large discrepancy in both mean values and clinical range among the 
different devices. Results from one QUS device cannot be directly compared to results 
obtained on another device. An attempt to standardise both the methods used to 
calculate QUS measurement variables and the expression of the measurement results 
would aid in the clinical introduction of QUS. 
QUS measurement variables showed moderate correlations with axial and calcaneal 
BIVID, although a large proportion of the variance in QUS was not explained by BIVID. 
Since the introduction of QUS, there have been a great number of studies comparing 
QUS with IBIVID, usually measured by DXA. However, QUS was not developed to 
provide a way of estimating axial BIVID. Nevertheless, It is useful to examine the 
correlation between BMD and QUS measurement variables to aid in the understanding 
of which bone properties QUS is actually measuring. More importantly, the 
discriminatory and predictive capabilities of QUS need to be compared to the more 
established techniques to determine whether QUS can be used effectively in clinical 
practice. 
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Chapter 6 
Diagnostic Criteria for Calcaneal QUS 
6.1 STUDY DESIGN 
6.1.1 Aims 
The aim of this chapter was to assess whether the current WHO criteria for diagnosing 
osteoporosis can be applied to calcaneal QUS. The age-dependence of T-scores and 
the prevalence of osteoporosis as defined by the WHO have been examined for QUS 
and compared with axial BMD. Revised diagnostic criteria for classifying individuals as 
normal, osteopenic or osteoporotic have been derived for calcaneal QUS and the level 
of diagnostic agreement between QUS and DXA assessed. 
6.1.2 Introduction 
With the FDA approval of a number of QUS devices and the relatively high cost and 
lack of availability of DXA devices it is almost inevitable that the number of QUS 
devices being used Worldwide will increase further. Due to the large public health cost 
[96] of osteoporotic fractures it is important that available resources are optimised. 
Therefore, appropriate diagnostic criteria for QUS and guidelines for its clinical 
application are required so it can be used cost-effectively in clinical practice. 
At present, there is a widely accepted convention to define osteoporosis in terms of T- 
scores as recommended by the World Health Organisation (WHO) Working Party [16]. 
The WHO definition of osteoporosis of a T-score value of less than -2.5 was developed 
for BIVID measurements at the spine, hip and forearm. This threshold value of BIVID 
greater than 2.5 SID below the mean for a young adult population identifies 
approximately 30% of all postmenopausal Caucasian women as having osteoporosis at 
either the spine, hip or forearm. This is similar to the lifetime risk of fracture at these 
sites [79]. It has been reported that this definition of osteoporosis may not be 
appropriate at other skeletal sites or for different technologies such as QUS [109,380]. 
These studies show that few patients have a QUS T-score value below -2.5 and 
suggest that it may be necessary to provide an equivalent T-score threshold specific to 
the measurement technology employed. In addition to this, there are many different 
QUS devices available Worldwide, using a variety of physical principles, which will 
further increase the heterogeneity between devices. 
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6.1.3 Methods 
6.1.3.1 Subjects 
The study population consisted of two groups: (i) 530 healthy premenopausal (n=240) 
and postmenopausal (n=290) Caucasian women; (ii) 104 postmenopausal women with 
vertebral fractures (Table 2.2). Women from group (i) were those used to construct 
reference ranges in Chapter 4. 
6.1.3.2 Data Analysis 
The subgroup of healthy women aged 20-40 years (Table 4.6) were selected to 
est. imate the young normal mean and SID for each QUS and DXA measurement 
variable for the purpose of calculating T-scores. Postmenopausal women aged 50+ 
(n=268) were then classified into three groups according to their T-scores as defined by 
the WHO [16]: 
Normal A T-score equal to or greater than -1. 
O, steopenia A T-score less than -1 but greater than -2.5. 
Osteoporosis A T-score equal to or less than -2.5. 
The proportion of postmenopausal women aged over 50 in each WHO diagnostic 
category were expressed as percentages. To examine the age-related decrease in T- 
scores for each measurement variable women were placed into 5-year age groups 
(age 20-24,25-29 etc. ) and the mean T-score was then calculated for each age group. 
To investigate the optimum threshold for diagnosing osteoporosis using QUS four 
different approaches were compared: 
Approach 1: simple linear regression was performed between the age-related decline 
in each of the QUS measurement T-scores and the age-related decline in total hip T- 
scores (forcing the line through the origin) for healthy women in Group 1. The 
regression coefficient was then multiplied by -2.5 to estimate the equivalent T-score 
threshold for QUS. 
Approach 2: a threshold for QUS was estimated by taking the T-score threshold that 
would diagnose 15% of the healthy postmenopausal women in Group 1 as 
osteoporotic. This figure of 15% was chosen as it was the average prevalence of 
osteoporosis in healthy postmenopausal women using the spine (17%), femoral neck 
(16%) and total hip (12%) BIVID data individually (Table 6.2). 
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Approach 3: the percentage of women with vertebral fractures in Group 2 with a total 
hip T-score equal to or less than -2.5 was calculated. The T-score threshold for QUS 
was chosen by finding the T-score required to detect the same percentage of women 
with vertebral fractures as identified by a total hip BIVID T-score of -2.5. This method 
was identical to that applied by Hans et al [Zoooj to the EPIDOS Study QUS data in hip 
fracture patents. 
Approach 4: this approach is the similar to that applied by Hans et al [380] (Approach 
3) but it was applied to the healthy postmenopausal women in Group 1 identified as 
osteoporotic on the basis of having a LS or THIP BMD T-score of <-2.5, rather than a 
report of fracture: 
4a: The T-score threshold for QUS was chosen by finding the T-score required 
to detect the same percentage of women with a lumbar spine T-score equal to or less 
than -2.5 as identified by a total hip BIVID T-score of -2.5. 
4b: this approach is the same as 4a but a T-score threshold was chosen by 
finding the T-score required to detect the same percentage of postmenopausal women 
with a total hip T-score equal to or less than -2.5 as identified by a lumbar spine BIVID 
T-score of -2.5. 
Approach 2 was the preferred approach as it was the most similar to that used by the 
WHO Working Party for deriving a threshold for diagnosing osteoporosis using BMD 
[16]. This approach was also used to estimate a T-score threshold for QUS, above 
which postmenopausal women would be classified as normal and below which women 
would be classified as osteopenic. 
The index of positive agreement (Pp. ) (Chapter 2) was calculated to assess the 
agreement between the different QUS devices and between QUS and DXA for 
identifying postmenopausal women with osteoporosis. This index was proposed by 
Cicchetti and Feinstein [354] to estimate the proportion of agreement between two 
techniques when neither is regarded as the 'gold standard'. In this context, PpO. 
represents the proportion of women that are classified by both devices as osteoporotic 
and is expressed as a fraction of the mean number identified by the two devices 
separately. 
6.2 RESULTS 
6.2.1 Calculation of T-scores 
The young adult mean and SID for each measurement variable used to calculate T- 
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scores are shown in Table 4.6 in Chapter 4. The young adult population used was 
aged 20-40 years. 
6.2.2 Age-related decline in T-scores 
The age-related decline in T-scores for both BIVID and QUS measurements is shown in 
Figure 6.1 a-c. The T-scores calculated for BIVID measurements begin to fall at 
approximately age 40 and decline thereafter (Figure 6.1a). By age 60-64 years the 
average lumbar spine and hip BIVID T-score was approximately -1.82 (Table 6.1). The 
mean T-scores for the lumbar spine display an apparent increase after the age of 65 
that probably reflects degenerative changes in the spine which is a problem when 
measuring elderly subjects. As a comparison, the estimated heel BIVID provided by the 
Sahara device has also been plotted with spine and hip BIVID (Figure 6.1a). T-scores 
for estimated heel BIVID fell at approximately half the rate of the spine and hip BIVID and 
by age 60-64 years the average T-score was -1.09 (Table 6.1). When the three BUA 
measurements were compared, the Sahara and UBA T-scores decline at a similar rate 
while the DTU displays a rather slower age-related decline in T-scores (Figure 6.1 b). 
The BUA T-scores decline to about -1 at age 60-64 years, which is significantly higher 
than the mean T-score seen for the BIVID measurements at the same age (Table 6.1). 
The age-related decline in T-score for the velocity measurements display a similar 
pattern to BUA (Figure 6.1c). All four velocity measurements follow a similar age- 
related decline in T-scores failing to approximately -1.15 by age 60-64 years (Table 
6.1). 






LS BMD g/CM2 -1.71 Osteopenic 
FN BMD g/CM2 -1.94 Osteopenic 
THIP BMD g/CM2 -1.80 Osteopenic 
UBA BUA dB/MHz -1.15 Osteopenic 
UBA SOS m/s -1.24 Osteopenic 
UBA BV m/s -1.16 Osteopenic 
SAH BUA dB/MHz -0.96 Normal 
SAH SOS m/s -1.08 Osteopenic 
SAH BMD g/CM2 -1.09 Osteopenic 
DTU BUA dB/MHz -0.50 Normal 
DTU SOS m/s -1.14 Osteopenic 
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Figure 6.1: The age-related decline in T-scores for (a) DXA measurements and SAH BIVID, (b) 
QUS, measurements of BUA and (c) QUS measurements of velocity. 
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6.2.3 Prevalence of osteoporosis using the WHO criteria for QUS 
Figure 6.2 displays the percentage of postmenopausal women aged 50+ classified as 
normal, osteopenic and osteoporotic according to the WHO criteria. These data are 
also shown in Table 6.2. The average proportion of women classified as normal 
ranged from 41 % for the BIVID measurements to almost 60% for the QUS 
measurements. The prevalence of osteopenia was appro)dmately 40% for all 
measurement variables. The prevalence of osteoporosis for the BMD measurements 
was 17% at the lumbar spine, 18% at the femoral neck and 12% for the total hip site 
(Table 6.2). The mean prevalence of osteoporosis for all three skeletal sites was 15%. 
When defined as a T-score :5 -2.5 the prevalence of osteoporosis for QUS 
measurements is significantly lower compared to the lumbar spine and hip, ranging 
from just 2% for the UBA bone velocity variable to 8% for the DTU SOS measurement, 
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Figure 6.2: The proportion of postmenopausal women aged 50+ classified as normal, 
osteopenic and osteoporotic according to the WHO criteria. 
To examine this further, the prevalence of osteoporosis according to the WHO criteria 
was calculated for each decade for postmenopausal women aged 50-80 years for both 
the BIVID and QUS variables (Figure 6.3). As expected, the prevalence of osteoporosis 
increases as the population gets older. By ages 70-79, the prevalence of osteoporosis 
for the BIVID measurements ranges from 22% at the spine to almost 40% at the femoral 
neck. The prevalence of osteoporosis at the spine is lower because of the increased 
occurrence of osteoarthritis seen in women of this age, which will artificially increase 
BIVID values, If we examine postmenopausal women aged 50 and over, the 
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Table 6.2: The proportion of postmenopausal women aged 50+ classified as normal, osteopenic 
and osteoporotic according to the WHO criteria. 
Normal Osteopenia Osteop2rosis 
2 LS BMD g/cm 41.2 41.6 17.2 
FN EIMD g/CM2 34.4 50.0 16.2 
T. HIP BMD g/CM2 46.3 41.7 12.0 
Avemge BMD 40.6 44.4 15.1 
UBA BUA dB/MHz 59.9 37.9 2.2 
UBA SOS m/s 58.6 36.6 4,9 
UBA BV m/s 55.5 42.7 1.8 
SAH BUA dB/MHz 64.6 32.8 2.6 
SAH SOS m/s 59.4 37.0 3.7 
SAH BMD g/CM2 55.7 41.2 3.1 
DTU BUA dB/MHz 55.4 41.0 3.6 
DTU SOS m/s 56.6 34.9 8.4 
Av ous 58.2 38.0 3.8 
prevalence varies considerably according to the measurement site and measurement 
technique. The prevalence of osteoporosis is significanfly higher Na BIVID 
measurement is taken, with the prevalence being on average 15%. In comparison, the 
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Figure 6.3: The prevalence of osteoporx)sis as defined by the WHO criteria in postmenopausal 
women aged 50-80 years for BIVID and QUS variables. 
6.2.4 Revised diagnostic criteria for the Interpretation of OUS results 
The four different approaches described in section 6.1.3.2 were used to estimate the 
optimum threshold for QUS measurements to diagnose postmenopausal women as 
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osteoporotic. The different approaches yielded a wide range of T-score thresholds, 
however, in all cases the calculated T-score threshold was significantly less negative 
than the -2.5 currently used for BIVID measurements (Table 6.3). If linear regression 
was performed (Approach 1) to estimate the difference in slopes between the age- 
related decline in total hip BIVID and the QUS variables, the average T-score threshold 
was -1.50 (range -1.05 to -1.73). As an example of approach 1, Figure 6.4 shows the 
age-related correlation between the age-related decline in SAH BIVID and THIP BIVID T- 
scores. The regression coefficient of 0.59 was multiplied by -2.5 to give a T-score 
threshold of -1.48 for SAH BMD. 
0.2 y=0.5908x +0R2=0.9504 
0 
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Figure 6.4: The correlation between the age-related decrease in SAH BIVID and THIP BIVID T- 
scores. Each point represents the mean T-score for each five year age-group from 20-80 years. 
The T-score thresholds that captured 15% of postmenopausal women as osteoporotic 
(Approach 2) had a mean of -1.80 (range -1.45 to -2.10). Fifty-one (55%) of the 
women with vertebral fractures had a total hip T-score equal to or less than -2.5. The 
T-score threshold that identified 55% of the vertebral fracture group (Approach 3) 
yielded the lowest T-score thresholds for the QUS variables, with a mean of -1-89 
(range -1.39 to -2.12). The sensitivity of total hip BIVID for identifying spinal 
osteoporosis was 41 % and the sensitivity of lumbar spine for identifying osteoporosis at 
the hip was 50%. These figures were used to estimate T-score thresholds for QUS in 
approach 4a and 4b. Approach 4 yielded T-score thresholds for QUS ranging from - 
1.32 to -2.19, averaging -1.79 and -1.59 for approach 4a and 4b respectively. 
Regardless of which approach was utilised, the BUA measurements tended to have 
slightly less negative T-score thresholds than the SOS measurement variables. The 
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Figure 6.5: The T-score thresholds obtained for OUS measurements using approaches 1-4 
described in section 6.1.3.2. 
Approach 2 yielded a mean T-score threshold of -1.80 for diagnosing osteoporosis 
using the three QUS devices and this approach was used to assess the agreement 
between the different OUS devices and between QUS and DXA in identifying 
postmenopausal women with osteoporosis, the index of positive agreement (Pp.. ) was 
calculated (Table 6.4). Postmenopausal women with a T-score threshold of : 5-1.80 for 
either BUA or SOS on each QUS device, or: 5-2.50 at either the lumbar spine or total 
hip were considered osteoporotic. When the three QUS devices were compared, P. 06 
ranged from 0.68 to 0.76, indicating that approximately 72% of women were classified 
similarly using different QUS devices. Pp. ranged from 0.43 to 0.46 when OUS and 
DXA were compared, indicating that approximately 45% of women were classified 
similarly as osteoporotic. Approximately 50% (Pp. =0.50) of women were classified 
similarly using either BUA or SOS on the same device. As a comparison, 45% 
(Pp,, =0.45) of women were classified similady using lumbar spine and total hip BIVID 
measurements. 
Table 6A The index of positive agreement (Ppor) between each of the 
QUS devices and between OUS and BMD for diagnosing osteoporosis. 
UBA SAH DTU 
SAH 0.76 
DTU 0.68 0.75 - 
BMD 0.44 0.46 0.43 
Women were classified as osteoporotic if they had a T-score 
<-2.5 at either the LS or THIP for DXA measurements or 
<-1.80 for either BUA or SOS for OUS measurements. 
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The same analysis descdbed for Approach 2, based on DXA-equivalent prevalence 
rates, was also used to estimate a T-score threshold, above which women would be 
classified as normal and below which women would be classified as osteopenic. This 
allows postmenopausal women to be placed into three diagnostic categories (normal, 
osteopenic or osteoporotic) using QUS, as is currently done for DXA measurements 
using the WHO criteria. Of the postmenopausal women, 43.9,35.5 and 43.5% were 
classified as normal using lumbar spine, femoral neck and total hip BIVID respectively 
(Figure 6.2 and Table 6.2). The mean prevalence of women classified as normal was 
41% using the three BIVID measurements. A T-score threshold for QUS was then 
estimated by taking the threshold that classified 41% of healthy postmenopausal 
women as normal. The T-score thresholds for QUS ranged from 0.01 for DTU BUA to - 
0.68 for UBA SOS (Table 6.5). The average T-score threshold was -0.47 (-0.53 if DTU 
BUA was excluded). A T-score threshold of -0.50 was chosen for reasons of simplicity. 
Table 6.5: T-score thresholds for classifying 41 %a of postmenopausal women 
as normal using QUS measurements. 
T-score Threshold 
UBA 575+ 
BUA dB/MHz -0.59 
BV m/s -0.65 
SOS M/s -0.68 
SAHARA 
BUA dB/MHz -0.37 





BUA dB/MHz 0.01 
SOS M/s -0.51 
Average T-score Threshold -0.47 
a the mean prevalence of postmenopausal women 
classified as normal using LS, FN and THIP BIVID 
measurements. 
T-score thresholds estimated using Approach 2 were used to construct revised 
diagnostic criteria for QUS- 
Table 6.6: Diagnostic criteria for calcaneal QUS. 
Normal A T-score equal to or greater than -0.50. 
osteopenia A T-sGore less than -0.50 but greater than -1.80. 
Osteoporosis A T-score equal to or less than -1.80. 
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The revised criteria were applied to healthy postmenopausal women to obtain the 
proportion of women classified as normal, osteopenic or osteoporotic using QUS 












LS FN THIP USA USA USA SAH SAH SAH DTU 07U 
BMD BMO SMD SUA BV SOS SUA SOS BMD BUA SOS 
orotic a Osteopenic 0 ýOrmal 
Figure 6.6: The proportion of postmenopausal women classified as normal, osteopenic and 
osteoporotic using the revised criteria for QUS and the WHO crderia for DXA. 
The percentage of women classified as normal was 41.2% (range 33-57%) compared 
to the 40.6% of women classified as normal using BMD measurements. On average, 
approximately 43.7% (range 35-54% of women were classified as osteopenic using 
QUS compared to 44.1 % using BMD measurements. Approximately 15.2% (range 7- 
24%) of postmenopausal women were classified as osteoporotic using a T-Score 
threshold of :! 0.80 for QUS, compared to 15.5% of women for spine and hip 
measurements. The DTU BUA variable classified a larger percentage of women as 
normal and fewer women as osteoporotic compared to other QUS variables if the 
revised criteria were applied. 
6.2.5 The level of diagnostic agreement between QUS and DXA 
Figure 6.7 examines the consistency in classifying postmenopausal women into the 
three diagnostic categories for the three QUS devices, using the revised criteria for 
QUS and the WHO criteria for DXA. As a comparison, the classification of 
postmenopausal women using lumbar spine BMD was compared to that for total hip 
BMD. Appro)dmately 55% of the women classified as normal using OUS were also 
classified as normal using lumbar spine and total hip BMD. Of these women classified 
as normal using QUS, between 7-13% were cAassified as osteoporotic at either the 
lumbar spine or total hip. As a comparison, approAmately 70% of women classified as 
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Table 6.7: The proportion of postmenopausal women classified as normal, osteopenic and 




LS BMD g/CM2 41.2 40.6 18.2 
FN BMD g/cm 34.4 50.0 16.2 
THIP BMD g/CM2 46.3 41.7 12.0 
Average BMD 40.6 44.1 15.5 
UBA BUA dB/MHz 36.4 51.5 12.1 
UBA SOS m/s 34.2 48.1 17.8 
UBA BV m/s 32.9 53.7 13.4 
SAH BUA dB/MHz 46.6 43.4 10.1 
SAH SOS m/s 42.9 37.9 19.2 
SAH BMD g/CM2 39.3 43.4 17.4 
DTU BUA dB/MHz 56.6 36.3 7.1 
DTU SOS m/s 40.5 35.1 24.4 
Average QUS 41.2 43.7 15.2 
normal using lumbar spine BIVID were classified similarly using total hip BIVID and only 
2% of women classified as normal using lumbar spine BIVID were osteoporotic at the 
hip. Approximately 55% of women classified as osteopenic using QUS were also 
osteopenic at either the lumbar spine or total hip, while 20% of women classified as 
osteopenic using QUS were classified as normal and 20% as osteoporotic using BIVID 
measurements. A similar pattern was observed when the lumbar spine was compared 
to the total hip. Approximately 43% of women were classified similarly as osteoporotic 
using QUS and BIVID measurements. Of these women classified as osteoporotic using 
QUS, around 45% were classified as osteopenic and 10% were normal according to 
their BIVID results. As a comparison, approximately 12% of postmenopausal women 
classified as osteoporotic at the lumbar spine were classified as normal using total hip 
BMD. The patterns of classification were similar for the three QUS devices. 
6.3 DISCUSSION 
As the use of QUS for clinical studies increases there is a need for guidelines on how 
to interpret the results obtained with these devices. At present, the most commonly 
accepted guidelines are those proposed by the WHO Study Group for the interpretation 
of BMD measurements at the lumbar spine, femoral neck and distal forearm [ 16 ]. 
However, it is becoming increasingly clear that these criteria cannot be applied to QUS 
measurements. The aim of this study was to examine the consequences of using the 
WHO criteria for the interpretation of QUS measurements and to derive an improved 
diagnostic criteria for QUS which will be of practical use in a clinical setting. 
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Figure 6.7: Heterogeneity in the classification of postmenopausal women into the three 
diagnostic categories, using the WHO criteria for DXA and the revised criteria for QUS. Each 
woman was classified as norrnal, osteopenic or osteoporotic for either BUA or SOS 
measurements and the pie sections represent the proportion of women classified into the three 
diagnostic categories for either LS or THIP BMD. As a comparison, classification according to 
LS BMD was compared to that for THIP BMD. 
6.3.1 The age-related decline in T-scores 
The age-related decline in T-scores for QUS measurements was almost half that seen 
for the BMD measurements performed by DXA (Figure 6.1). By age 75, the average T- 
score for the QUS measurements was just -1.25. Similar findings have been reported 
for another study, that examined the age-related decrease in T-scores, using 
manufacturer normative databases [109]. There could be two explanations for this: (i) 
the calcaneus displays a slower rate of age-related bone loss and therefore QUS T- 
scores would decrease at a slower rate, or (ii) QUS has a higher population SID 
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compared to DXA, which means that QUS T-scores would decrease at a slower rate as 
the population SID is used in the calculation of T-scores. The first explanation is 
unlikely, as studies have revealed that the calcaneus displays similar rates of bone loss 
to the spine and hip when standardised by using the population SID [54,388,209]. One 
study showed that the annual changes in QUS measurement variables were 
comparable to BIVID measurements of the spine and hip [157]. A study examining the 
clinical utility of calcaneal DXA measurements, reported that the age-related decline in 
T-scores for calcaneal BIVID were similar to that for lumbar spine BIVID, falling to -2.22 
and -2.00 by age 67.5 for calcaneal BIVID and lumbar spine BIVID respectively [209]. 
The second explanation seems to be the more plausible. Random accuracy errors 
inherent in the QUS measurement technique may increase the young adult SID over 
and above the true variation due to BIVID differences. The effects of accuracy errors for 
DXA of the lumbar spine caused by osteoarthritis, aortic calcification etc. have been 
well documented but these problems are common in the elderly and so do not effect 
the accuracy of the young adult measurements which are used to calculate T-scores. 
Error sources such as phase cancellation [236], as reflection, refraction, frequency- 
dependent attenuation [226,257,410], dispersion [227] and even the criteria chosen to 
define the transit time of the ultrasound pulse [227] may artificially increase the 
population SID, and it is likely that these error sources would be greater in younger 
subjects. On examination of the young adult data for this study it would appear that 
this might be the explanation. When the young adult SID is expressed as a percentage 
of the young adult mean for BUA it is almost 20% while the corresponding value for 
BIVID is just 10%. The young adult SID for SOS measurements are also high if they are 
compared to the clinical range observed for these measurements. The Sahara device 
combines both BUA and SOS to provide an estimate of heel BIVID. If the estimated 
heel BIVID is expressed as a percentage of the young adult mean it is over one and a 
half times larger than that calculated for lumbar spine or hip BIVID (Figure 6.8). If we 
compare the young adult SID obtained for this SAH estimated heel BIVID to the young 
adult SID estimated for DXA at the calcaneus observed in a recent study, the SAH BIVID 
SID is 20% higher [280]. 
6.3.2 Prevalence of osteoporosis using the WHO criteria for QUS 
The slower rate of age-related decline in T-scores observed for QUS compared with 
DXA has implications when using the WHO criteria to diagnose osteoporosis. The 
number of subjects identified as osteoporotic will vary according to the site and 
technique used as well as the reference population. The WHO report states that 30% 
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Figure 6.8: The young adult SID for 
DXA measurements of BMD and the 
QUS SAH BMD measurement, 
expressed as a percentage of the 
young adult mean. 
of all postmenopausal Caucasian women will be identified as having osteoporosis 
based on BIVID measurements at the spine, hip and forearm [16]. This discrepancy in 
the percentage of women classified as osteoporotic is not exclusive to QUS. Even if 
the results of a single technology such as DXA are compared at different skeletal sites, 
the prevalence of osteoporosis will vary [37,411,412]. In one study 45% of 
postmenopausal women were diagnosed as having osteoporosis at the lumbar spine, 
femoral neck or forearm [79] while in another study the prevalence of osteoporosis 
ranged from 10% to 45% depending on the site measured by DXA [37]. In the present 
study, the prevalence of osteoporosis was much lower when the WHO criteria were 
applied to QUS measurements compared with BIVID. The prevalence of osteoporosis 
was approximately 3-4% for postmenopausal women aged 50 and over (Table 6.2). A 
similar prevalence rate has been reported in the literature for QUS [109]. This has 
implications when using QUS in a clinical setting, as very few women would be found 
to be osteoporotic and therefore recommended for preventative treatment if the current 
WHO definition of osteoporosis was applied uncritically to QUS. 
In the present study, T-scores were calculated using one population of young adults to 
estimate the young adult mean and SID. This consistency in using the same young 
adult population to calculate T-scores is advantageous as any differences observed 
between QUS and BIVID measurements is due to the different technologies and not 
discrepancies in manufacturer reference ranges. If manufacturer based reference data 
were used different proportions of women, as well as different individuals, might be 
identified as osteoporotic. Significant discrepancies in diagnosing osteoporosis have 
been found when using different DXA systems with incompatible reference data [161]. 
In one study, which compared the Hologic femoral neck reference values to the 
NHANES reference data for the femoral neck, the prevalence of osteoporosis fell from 
49% to 28% when the latter reference data was used [382]. This can increase the 
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apparent heterogeneity between anatomic regions and measurement techniques. 
There are now many different QUS devices in use Woddwide, all using different 
reference data to calculate T-scores, so one would expect that different populations 
would be classified depending on which ultrasound device they were measured on. 
6.3.3 Revised diagnostic for calcaneal QUS 
In the present study, four different approaches were used to derive a suitable T-score 
threshold for diagnosing osteoporosis using QUS measurements. For all four 
approaches the threshold for QUS was significantly less negative than the T-score 
threshold of -2.5 recommended for BIVID measurements at the spine, hip or forearm 
with QUS thresholds ranging from -1.05 to -2.19 (Table 6.3). The only other study to 
examine this to date revealed that a T-score of -1.5 for BUA and -2.3 for SOS 
detected 76% of hip fracture patients as well as DXA did [380]. The method used in 
the latter study by Hans et al was similar to approach 3 used in this study, although 
women with prevalent vertebral fractures were used in this case. If the T-score 
thresholds obtained in the present study were compared to those by Hans et al, the 
mean threshold for BUA and SOS was -1.9 in both this study and that by Hans et al 
[380]. Due to the diversity of QUS technology, T-score thresholds may be device 
specific with different devices having different optimum T-score thresholds. In addition 
to this, BUA measurements tend to have different T-score thresholds to velocity 
measurement variables (Table 6.3). Therefore, at present it may not be possible to 
recommend a single T-score threshold which would be appropriate for all QUS devices 
and all QUS measurement variables for identifying women at risk of osteoporosis. The 
diversity of QUS technology has been identified as a challenge for the advancement of 
QUS [228]. The International QUS Consensus Group recognises that the 
standardisation of methods of calibration and expression of measurement results would 
increase the clinical utility of QUS [228]. It was expected that the four approaches 
used in the present study would yield different T-score thresholds for QUS. The 
preferred approach used in the present study that was most similar to that used by the 
WHO Working Party to define a threshold for diagnosing osteoporosis [16] was 
approach 2 which was based on classifying a similar percentage of healthy 
postmenopausal women aged 50+ as BIVID scans. The T-score thresholds obtained 
using this approach were relatively consistent for the three QUS devices, averaging - 
1.80 and therefore this T-score threshold is probably the optimum for use in identifying 
postmenopausal women at risk of osteoporosis using the three QUS devices used in 
this study. It is important to note that, as with any measurement technique, a patients 
T-score result should be examined in conjunction with clinical risk factors such as 
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history of fracture, age etc, so an individuals risk of fracture can be fully assessed 
[413]. 
Using approach 2, based on DXA-equivalent prevalence rates, a T-score threshold for 
QUS was estimated so women could be classified as normal or osteopenic as well as 
osteoporotic (Table 6.5). This allows postmenopausal women to be placed into one of 
three diagnostic categories as is currently done using DXA. As expected due to the 
nature of the approaches used to estimate T-score thresholds for QUS, the proportion 
of women classified as normal, osteopenic or osteoporotic using QUS were similar to 
that observed for spine and hip BMD measurements (Figure 6.6). A study by Varney et 
al reported a similar finding using a similar method of estimating revised criteria for 
QUS [414]. Rather different T-score thresholds were obtained for the DTU BUA 
variable (Tables 6.3 And 6.5). On examination of the data, it appears that T-scores for 
DTU BUA do not appear to decline significantly until approximately age 65 and they 
certainly decline more slowly than UBA or SAH BUA (Figure 6.1b). Whether this is due 
to the fact that DTU BUA itself does not decline until this age, perhaps due to the 
chosen measurement ROI (area of minimum attenuation) or whether this is due to the 
relatively low number of women examined at each age-group is unclear. Longitudinal 
studies on the age-related decreases in ultrasound variables measured on the DTU are 
required to address this issue. The consequence of this somewhat slower age-related 
decline in DTU BUA T-scores is that the T-score thresholds are less negative than 
those obtained for other QUS variables. 
6.3.4 The level of diagnostic agreement between QUS and DXA 
Using a T-score threshold of :! ý-1.80 for diagnosing osteoporosis using QUS, the 
agreement between the different QUS devices in classifying individuals as osteoporotic 
was assessed, as well as the agreement between QUS and DXA measurements at the 
lumbar spine or total hip. The index of positive agreement (PPs) was consistent among 
the three QUS devices, with approximately 72% of the women classified similarly. The 
agreement between QUS and DXA was less, as expected, with approximately 45% of 
women classified similarly (Table 6.4). This value of 45% was identical to that obtained 
when comparing lumbar spine and total hip BIVID measurements. 
When the revised criteria was used for QUS to classify individuals into the three 
categones a similar percentage of women were placed into each group. 
However, a 
degree of heterogeneity remained between QUS and DXA in terms of classifying 
women into the different diagnostic categories (Figure 6.7). Approximately 
10% of 
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women classified as normal using QUS were classified as osteoporotic at either the 
lumbar spine or total hip. In a similar study by Varney et al, 6% of women were 
misclassified in this way [414]. It is not surprising that women can be classified 
differently using different techniques and/or different measurement sites. A study of 
744 postmenopausal women measured at four skeletal sites, found that 15% of these 
women were classified as 'low' at one skeletal site but had 'high' bone mass at other 
sites [415]. One of the perceived disadvantages of QUS is that, with the exception of 
the recently developed Sunlight Omnisence, measurements are taken at only one 
skeletal site. Therefore, regional bone mass at this site may not be fully representative 
of bone mass of other skeletal sites due to the only modest correlation observed 
between BIVID at different skeletal sites [157]. However, it has been suggested that the 
benefits in terms of making a more accurate diagnosis by measuring multiple 
measurement sites may not outweigh the increased financial cost associated with 
performing multiple measurements on individuals [415]. 
Approximately 10% of women classified as osteoporotic using QUS were classified as 
normal using lumbar spine and total hip BIVID (Figure 6.7). As many workers in the 
field of bone densitometry regard DXA as the 'gold standard', these women may be 
perceived to be false negatives. However, it has been shown that both low BUA and 
SOS measurements are associated with an increase in fracture risk independent of 
BIVID [341,342]. Therefore, individuals with low QUS measurements butnormal' BIVID 
measurements should not be considered misclassified but rather at increased risk of 
fracture and therefore potential candidates for therapeutic intervention. There is yet no 
diagnostic technique that can identify all women who will sustain a fracture in their 
lifetime and there will always be overlap when using different measurement techniques 
or measurements at different skeletal sites. Nevertheless, provided that different 
diagnostic techniques are shown to have predictive capabilities of similar magnitude, 
different techniques must be regarded of equal value. A similar view has been put 
forward by the International Quantitative Ultrasound Consensus Group [368]. 
6.3.5 Recommendations for the clinical use of QUS 
One of the reasons for the introduction of QUS was to increase the availability of bone 
densitometry services. It has been estimated that only 25% of Caucasian 
postmenopausal women in the US have access to bone densitometry services [376], 
while in the UK, only 35% of General Practitioners have direct access to such services 
[416]. With the introduction and acceptance of QUS and other peripheral devices, it 
has meant that more people will have the opportunity to have an assessment of their 
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skeletal status. It is important to provide clinical guidelines on how to interpret QUS 
scans, especially in view of the fact that QUS devices are more likely to be used away 
from specialist centres. Several recommendations have been published in recent 
years. Baran et al recommended that if a T-score lies between -2 to +1 for women 
under 65 or between -2 and 0 for women over 65 then further evaluation should be 
performed by DXA at the spine and hip to exclude a false negative [376]. The United 
Kingdom National Osteoporosis Society recommended that if a patient has a low QUS 
measurement then they should be referred on for axial bone density measurement 
[375]. Miller et al proposed that if an individual has a peripheral bone mass T-score of 
less than -1 they would not need additional central measurements [417]. It is clear 
from these recommendations that a large number of women will continue to be referred 
for axial measurements at specialist centres after having a low QUS or other peripheral 
measurement. This may be impractical when we consider that the main reason for the 
increasing number of peripheral devices in use in recent years has been the lack of 
availability of resources. Therefore, demand for axial measurements may still exceed 
supply if individuals with low peripheral measurements are referred on for additional 
testing. Suitable guidelines need to be provided for QUS, ideally from influential 
groups such as the Royal College of Physicians, the National Osteoporosis Foundation 
or the National Osteoporosis Society, so QUS can be used effectively in clinical 
practice without the need for referring a large proportion of women for additional 
testing. However, it must be noted that at present there is a lack of agreement on 
whether QUS can be used to monitor disease progression or treatment efficacy, and 
therefore patients may still need to be monitored using DXA or other established bone 
densitometry techniques. 
6.3.6 Study limitations 
There are several limitations to this study. There are many different commercially 
available QUS devices but only three QUS devices were assessed in this study. In 
addition, the UBA is no longer commercially available and the Sahara was developed 
to match the performance of the UBA. Other QUS devices may yield different optimum 
T-score thresholds for diagnosing osteoporosis, especially those that measure QUS 
variables at skeletal sites other than the calcaneus. The T-score thresholds have been 
derived using our own reference young adult population and therefore may not be 
applicable to the manufacturer-supplied reference data, although our reference data 
were similar to those provided by the manufacturer (Table 4.6). Although the T-scores 
were calculated using our own reference population, a large range of T-score 
thresholds for diagnosing osteoporosis were obtained using the four approaches 
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described here. Different methods of deriving equivalent thresholds for QUS may yield 
other optimum thresholds. The majority of the study population consisted of women 
who had volunteered for bone density studies and women were excluded from analysis 
if they had any risk factors associated with low BIVID, consequently there may be a 
degree of bias towards a more 'healthy' study population. Large population-based 
sampling studies do not exclude women because of specific risk factors and so these 
studies may best address the issue of how the current WHO criteria can be adapted for 
QUS and other bone densitometry technologies. 
DXA-equivalent prevalence rates of osteoporosis were used to determine suitable T- 
score thresholds for identifying high-risk individuals using QUS in the present study. In 
a talk at the 1999 ASBIVIR meeting, Black suggested that a T-score threshold should 
be estimated for QUS by using a threshold that would identify 25% of women aged 65- 
75 years as osteoporotic. Due to insufficient numbers in this age-group, this analysis 
could not be carried out for the present study. At the present time, the National 
Osteoporosis Foundation and International Society of Clinical Densitometry are 
considering 'correcting' T-score criteria obtained for different technologies in order to 
identify consistent populations based on fracture prevalence or fracture risk [418]. 
Other approaches of identifying high-risk individuals can also be used that do not rely 
on T-scores, such as annual or lifetime risk of fracture estimates [113,419-421], 
although at the present time these have only been developed for hip fracture and have 
not been widely adopted in clinical practice. Other approaches for developing 
equivalent diagnostic criteria for QUS include using prospective or cross-sectional 
fracture studies to determine appropriate thresholds. 
6.4 CONCLUSIONS AND FURTHER WORK 
In conclusion, this study indicates that the current WHO criteria for the diagnosis of 
osteoporosis in postmenopausal women using BIVID measurements cannot be applied 
to calcaneal QUS measurements. Revised diagnostic criteria have been derived for 
QUS using DXA-equivalent prevalence rates. It is possible that different QUS devices 
and possibly BUA and SOS measurements, will have different optimum T-score 
thresholds for diagnosing osteoporosis. However, the T-score thresholds obtained for 
the three QUS devices used in this study were relatively consistent. Therefore, a T- 
score threshold of -1.80 may be appropriate for identifying postmenopausal women at 
risk of osteoporosis using ultrasound attenuation and velocity measurements at the 
calcaneus. A T-score threshold of -0.50 may be appropriate for classifying women as 
normal or osteopenic using QUS. Due to the diversity of QUS technology, which is 
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expected to increase further, additional studies are required to determine suitable T- 
score thresholds for other QUS devices. 
Large population-based studies are required using QUS to further address the issue of 
how the WHO criteria can be adapted for QUS. In addition, the utility of alternative 
approaches for identifying individuals at risk of osteoporotic fracture need to be 
examined further. This will help determine whether T-scores, fracture thresholds, 
lifetime fracture risk estimates or other novel approaches are the best way forward for 
optimising the identification of high risk individuals and consequently reducing fracture 
incidence. As the number of QUS devices in use Worldwide increases and as bone 
densitometry services move away from specialist centres into primary care, it is 
important that a different clinical strategy be implemented for QUS so it can be utilised 
with confidence as an alternative diagnostic tool in the field of osteoporosis. 
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Chapter 7 
QUS AND CLINICAL RISK FACTORS 
FOR OSTEOPOROSIS 
7.1 STUDY DESIGN 
7.1.1 Aims 
The aim of this chapter is to compare calcaneal QUS and axial DXA measurements in 
women with and without clinical risk factors for osteoporosis. The objective was to 
demonstrate that, when quantified by the effect on Z-scores, QUS measurements 
respond as effectively as BIVID measurements to the presence of the risk factors 
commonly used by General Practitioners to refer patients for bone densitometry 
studies. The prevalence of osteoporosis diagnosed using BIVID and QUS 
measurements in women with and without clinical risk factors was also examined. 
7.1.2 Introduction 
Many of the risk factors associated with osteoporosis, such as oestrogen deficiency 
and glucocorticoid use, are associated with reduced BMD. At present, resources do 
not permit all women to be screened for osteoporosis and therefore clinical risk factors 
for low BIVID are used to target individuals for bone densitometry and possible 
therapeutic intervention. This 'case-finding' strategy was recommended in the recent 
Royal College of Physicians guidelines for the prevention and treatment of 
osteoporosis [422]. A recent study of 3530 women, investigating the relationship 
between spine and femur BMD results and the reason for referral for a DXA scan, 
found that certain indications such as premature menopause, secondary 
amenorrhoea and x-ray osteopenia were associated with low BIVID and an increased 
prevalence of osteoporosis [423]. A similar finding was also observed in another 
study of 929 men and women, which reported that x-ray osteopenia, glucocorticoid 
therapy and previous fractures were associated with low BIVID [424]. Several studies 
have shown that both BUA and SOS are also decreased in individuals with risk factors 
for osteoporosis, such as primary hyperparathyroidism [271,273,272,384], Crohn's 
disease [425], anorexia (426], kidney disease [427] and glucocorticoid use [274,428]. 
However, the majority of these studies have been small. In this chapter, T- and Z- 
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scores for QUS and BMD have been compared to assess whether BMD and QUS 
measurements are affected to the same extent by clinical risk factors for osteoporosis. 
7.1.3 Methods 
7.1.3.1 Subjects 
Of the 1130 pre- and postmenopausal women (Table 2.2), 1115 women were 
recruited for this part of the study. The remaining 15 women were excluded due to 
missing or incomplete questionnaires. On examination of the GP referral letter and 
self-administered questionnaire, 786 of the 1115 women were found to have one or 
more of the following clinical risk factors: (i) atraumatic fracture since the age of 25; (ii) 
report of x-ray osteopenia; (iii) predisposing medical condition or use of therapy 
known to affect bone metabolism; (iv) premature menopause before the age of 45 or 
history of amenorrhoea of longer than 6 months duration; (v) family history of 
osteoporosis; (vi) body mass index <20kg/M2; (vii) current smoking habit. Some 
women used to construct reference ranges for QUS and BIVID (Chapter 4) were found 
to have one or more of the above clinical risk factors since women with x-ray 
osteopenia, a family history of osteoporosis, low BMI, or women who currently smoked 
were not excluded from the reference population. Of the 1115 women, 329 pre- and 
postmenopausal women did not have any of the seven risk factors described above. 
Women who were past or current users of oestrogen or bisphosphonate therapy were 
not excluded from analysis. 
7.3.1.2 Data Analysis 
Data for the study population were combined as means and standard deviations. The 
pre- and postmenopausal groups with and without risk factors were compared 
statistically using the Students Mest. Women were considered "treated" if they were 
past or current users of oestrogen or bisphosphonates for longer than 12 months. 
Data for the group of 530 premenopausal and postmenopausal women used to 
construct reference ranges for BIVID and QUS measurement variables in Chapter 4 
were used to calculate T- and Z-scores. 
Multivariate regression analysis was used to calculate the Z-score decrements 
associated with each of the seven clinical risk factors using the following equation. - 
Z-score = bo + bi RF, Equation 7.1 
191 
Chapter 7- Risk Factors 
where b, is the constant and represents the mean Z-score for women with no clinical 
risk factors, the regression coefficient b, for the ith independent variable (RFj) 
represents the mean Z-score decrement associated with that risk factor, and RFj 
equals one if the risk factor is present and zero otherwise. 
The number of risk factors present for each individual was calculated. The risk factors 
used were those stated above and therefore an individual could have a maximum of 
seven possible risk factors for osteoporosis. The mean T- and Z-score for women 
with one, two, three or more than four risk factors was calculated. A two-sample 
Student Mest was used to assess whether the mean T- and Z-scores were 
significantly different from those obtained for women with no clinical risk factors. 
Using T-scores, women were classified into three groups (normal, osteopenia, 
osteoporosis) using the WHO criteria for BIVID measurements and revised criteria for 
QUS measurements (Table 6.6). The percentage of women classified as normal, 
osteopenic or osteoporotic was calculated for women with and without clinical risk 
factors. 
7.2 RESULTS 
7.2.1 Patient characteristics 
Patient characteristics for the pre- and postmenopausal women with and without 
clinical risk factors are shown in Table 7.1. Both pre- and postmenopausal women 
with clinical risk factors for osteoporosis had significantly lower BIVID and QUS 
variables compared to women without risk factors. All the BIVID and QUS 
measurement variables were significantly lower in postmenopausal women compared 
to the premenopausal women. Six percent of the premenopausal women and 36% of 
the postmenopausal women were past or current users of oestrogen or 
bisphosphonate therapy. The mean length of oestrogen and bisphosphonate use 
was 5.0 and 2.6 years respectively. 
Table 7.2 shows the patient characteristics for subjects with each of the seven clinical 
risk factors and the number of subjects measured by DXA and the three QUS devices. 
Women with a history of atraumatic fracture and x-ray osteopenia were older 
compared to women with other clinical risk factors. Women with a BMI of less than 20 
kg /M2 and women with no clinical risk factors were younger compared to women with 
other clinical risk factors. Approximately one-third of the women with a history of 
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Table 7.1: Study group characteristics. Figures show the mean and SID. 
Premenopausal Premenopausal Postmenopausal Postmenopausal 
without with without with 
risk factors risk factors risk factors risk factors 
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na, not applicable. 
aa woman was considered treated if they were currently taking or had previously taken 
oestrogen or bisphosphonates for longer than 12 months. 
b p<0.05 vs. premenopausal women without risk factors 
p <0.05 vs. postmenopausal women without risk factors 
atraurnatic fracture, x-ray osteopenia, a medical condition or use of therapy known to 
affect bone metabolism and women who had a premature menopause or prolonged 
amenorrhea were past or current users of oestrogen or bisphosphonate therapy. 
Approximately 25% of the women with a family history of osteoporosis, a BMI <20 and 
current smokers were past or current users of oestrogen or bisphosphonate therapy. 
Table 7.2: Study group characteristics and the number of subjects with each clinical risk factor. 
Risk Factor Age % Treated Total 
No. of subjects 
DXA UBA SAH DTU 
History of fracture 62.8(11.1) 34.7 236 214 226 221 178 
X-ray osteopenia 65.8(10.1) 41.5 53 53 51 52 49 
Medical or therapy 57.4(13.4) 38.2 225 183 213 190 158 
Early meno or amenorrhoea 55.3(12.2) 31.9 254 216 243 232 189 
Family History 54.0(11.9) 24.0 333 331 301 318 268 
BMI <20 49.3(14.9) 22.6 106 75 97 90 63 
Current Smoking 53.0(13.5) 22.6 146 146 124 138 113 
No clinical risk faGtors 47.9(13.8) 0 329 246 308 277 203 
193 
ChaDter 7- Risk Factors 
7.2.2 Mean T- scores 
The number of risk factors present for each individual was estimated and the mean T- 
score for women with one, two, three or more than four risk factors for osteoporosis 
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Figure 7.1: Mean T-scores for women with one, two, three or more than four clinical risk factor's 
for osteoporosis (error bars represent the SEM). 
The mean T-score for women with no risk factors was approximately -0.58 and -0-24 
for BIVID and QUS measurements respectively. All mean T-scores for women with 
clinical risk factors were significantly lower than those obtained for women with no risk 
factors and became more negative as the number of risk factors present increased. 
Mean QUS T-scores decreased from approximately -0.6 for women with one risk 
factor to approximately -1.9 for women with more than four risk factors. 
Corresponding figures for BMID were -1.1 and -2.7 respectively. In all cases QUS 
measurements yielded less negative T-scores than BMID measurements, with the 
offset between BIVID and QUS T-scores being approximately 0.5. 
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7.2.3 Mean Z-scores 
Table 7.3 shows the Z-score decrements associated with each of the different clinical 
risk factors calculated from the regression coefficients bi in equation 7.1. Also 
included in Table 7.3 are the mean Z-scores for women with no clinical risk factors 
calculated from the constant b, in equation 7.1. Women with a history of fracture, x- 
ray osteopenia, a family history of osteoporosis or a low BIVII had significantly lower Z- 
scores than women with no risk factors (with the exception of the mean Z-score for 
UBA SOS in women with x-ray osteopenia). Lumbar spine BIVID and both Sahara 
SOS and Sahara BIVID Z-scores were significantly lower in women who reported an 
early menopause or prolonged amenorrhoea. Women with predisposing medical 
conditions or use of therapy and women who currently smoked yielded essentially 
normal Z-scores for both BIVID and QUS measurement variables. The Z-scores 
decrements for each clinical risk factor were similar for BIVID and QUS measurements, 
although total hip and DTU BUA Z-scores were more negative for women with a 
history of atraumatic fracture, x-ray osteopenia or a low BIVII compared to lumbar 
spine and DTU SOS measurements respectively. 
The mean Z-scores calculated for women with one, two, three or more than four risk 
factors for osteoporosis are shown in Figure 7.2. All mean Z-scores were significantly 
lower than the mean Z-score for women with no clinical risk factors. As the number of 
risk factors present in each individual increased, the mean Z-score offset compared 
with subjects with no risk factors became more negative, increasing from 
approximately -0.3 for women with one risk factor to -1.2 for women with four or more 
risk factors. BIVID and QUS measurements yielded similar Z-scores for women with 
one, two, three or four plus risk factors. 
7.2.4 Prevalence of osteopenia and osteoporosis 
The percentage of women classified as normal, osteopenic or osteoporotic, using the 
WHO criteria for BIVID and the revised criteria for QUS, was calculated for 
postmenopausal women aged 50+ years with and without clinical risk factors (Figures 
7.3a and b). Approximately one-third of postmenopausal women with clinical risk 
factors were classified as osteoporotic using either BIVID or QUS measurements, 
compared to 12% of women with no clinical risk factors. Approximately one-half of 
women with no clinical risk factors were classified as normal while over two-thirds if 
women with clinical risk factors were classified as osteopenic or osteoporotic. 
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Figure 7.2: Mean Z-scores for women with one, two, three or more than four clinical risk factors 
for osteoporosis (error bars represent the SEM). 
the proportion of postmenopausal women classified as normal, osteopenic or 
osteoporotic was similar when using either BIVID or QUS measurements. 
7.3 DISCUSSION 
A recent survey by the United Kingdom National Osteoporosis Society revealed that 
only a third of General Practitioners had direct access to bone densitometry services 
and in addition, two-thirds of patients with osteoporosis were not diagnosed until they 
had suffered a fracture [416]. This indicates that there is a need to increase the 
availability of bone densitometry services and increase awareness of how indications 
for low BMD can be used to select individuals at risk of future fracture. The recent 
guidelines for the prevention and treatment of osteoporosis by the Royal College of 
Physicians recommended that certain clinical risk factors (identical to those examined 
here, except a BMI of less than 20 was used rather than 19 kg/M2) should be used to 
identify individuals who would benefit from a bone density examination and 
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Figure 7.3: The prevalence of osteopenia and osteoporosis in women with (a) no clinical risk 
factors and (b) one or more clinical risk factors for osteoporosis. 
possible prophylactic treatment [422]. Quantitative ultrasound has been introduced as 
a novel method of assessing skeletal status and due to the advantages of low cost 
and absence of ionising radiation it has become an alternative tool in identifying 
individuals at risk of fracture. It is clear from the evidence in the literature that DXA- 
based measurements of BIVID are significantly lower in individuals with clinical risk 
factors for osteoporosis [423,424]. The aim of this chapter was to determine whether 
calcaneal QUS variables are affected by clinical risk factors for osteoporosis to the 
same extent as axial BMID measurements obtained using DXA. This is particularly 
important if QUS is to be used alone without the need for additional densitometry 
examinations since it has been reported that this may be the most cost-effective 
approach of using QUS [368]. 
198 
LS FN THIP UBA UBA UBA SAH SAH SAH DTU DTU 
BMD BMD BMD BUA SOS BV BUA SOS BMD BUA SOS 
Chaoter 7- Risk Factors 
7.3.1 Mean T-scores for women with clinical risk factors for osteoporosis 
The mean T-scores for both BIVID and QUS measurements for women with one, two, 
three or four plus clinical risk factors were significantly lower than those obtained for 
women with no clinical risk factors (Figure 7.1). As the number of risk factors present 
in each individual increased the mean T-scores became more negative, partly due to 
older patients having more risk factors, but also the effect of the number of risk factors 
on Z-scores (Figure 7.2). A comparison of the BIVID and QUS mean T-scores for each 
group revealed that the mean T-scores for BIVID measurements were more negative 
than those obtained using QUS measurements, by approximately 0.5 T-score units. 
This is consistent with the results obtained in Chapter 6 and other studies that 
reported that the age-related decline in T-scores for QUS measurements is 
approximately half that seen for BIVID measurements performed by DXA [109]. The 
slower rate of age-related decline in T-scores observed for QUS compared with DXA 
has implications when using the current WHO criteria to diagnose osteoporosis using 
QUS as very few individuals would be classified as osteoporotic. When the revised 
diagnostic criteria were used for QUS (Chapter 6) the prevalence of women classified 
as normal, osteopenic and osteoporotic were similar for BIVID and QUS 
measurements (Figure 7.3). This indicates that the revised criteria for QUS can be 
applied to the three QUS devices used in this study with confidence, without the 
concern that a large percentage of women will be classified differently using either 
QUS or BIVID measurements. However, these criteria may be device specific, and 
therefore modified criteria may be appropriate for other QUS devices. Even though 
the revised diagnostic criteria for QUS was adequate in the present study it has been 
suggested that thresholds based on population-based sampling studies of 
osteoporosis and fracture prevalence rates would best address the issue of 
establishing appropriate diagnostic criteria for QUS [368]. 
7.3.2 Mean Z-scores for women with clinical risk factors for osteoporosis 
The use of Z-scores removes the confounding factors of chronological age and the 
influence of differences in the age-related decline of T-scores between different 
technologies. The Z-score decrements compared with women with no clinical risk 
factors were highly statistically significant for women with a history of atraumatic 
fracture, evidence of x-ray osteopenia, a family history of osteoporosis and a low BMI. 
Z-score decrements for lumbar spine BIVID and both Sahara SOS and Sahara BIVID 
were also significantly reduced in women reporting a premature menopause or 
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prolonged amenorrhoea. When expressed in Z-scores, the reduction in QUS 
measurements was similar to that observed for axial BIVID measurements (Table 7.3). 
The mean Z-score decrement obtained for women with a history of fracture or 
evidence of x-ray osteopenia for BIVID and QUS measurements combined was -0.65 
and -0.35 respectively. Many previous studies have reported that QUS 
measurements are significantly reduced in women with osteoporotic fractures 
[171,324,327], while several large prospective studies confirmed that QUS can 
identify women at risk of future fracture [336,337,339-342] and that the ability of QUS 
to estimate fracture risk was comparable to that seen for BMD measurements [340- 
342]. Therefore, women with a history of atraumatic fracture would have an increased 
risk of future fracture compared with women with no clinical risk factors, regardless of 
whether QUS or BIVID variables were assessed. As expected, the Z-score decrement 
for spine BMD was statistically significant in women with x-ray osteopenia as reported 
by Bainbridge and Eastell [424] and Ahmed et al [423]. Hip BIVID and QUS 
measurements were also significantly reduced. To date, this is the first study to report 
significantly reduced BLIA and SOS measurements in women with x-ray osteopenia, 
although this may not be surprising as it has been reported that x-ray osteopenia can 
only reliably be detected in patients with BMD less than 0.73 g/CM2 [429]. 
Women were considered to have a family history of osteoporosis if they reported that 
a sibling, parent or grandparent suffered from osteoporosis or an osteoporosis-related 
fracture (individuals whose relatives had secondary causes of osteoporosis were not 
included). Clinical studies of BIVID in families with osteoporosis have shown evidence 
of a genetic contribution to osteoporosis [25,257,430] and large prospective studies 
have shown that women who report a maternal history of hip fracture are at increased 
risk of fracture themselves [60,431]. It has also been demonstrated that calcaneal 
QUS measurements are influenced by genetic factors. A classical twin study of 500 
female twins yielded heritibility estimates of 0.53 and 0.61 for BUA and SOS 
measurements respectively [257]. A study of 207 mother-daughter pairs reported a 
heritibility estimate of 0.53 for BUA in postmenopausal daughters, which was similar in 
magnitude to that obtained for calcaneal BIVID [25]. A study of 93 mono- and 
dizygotic twins revealed that up to 80% of the variance in QUS was attributable to 
genetic factors, making QUS an equally heritable trait as IBIVID [258]. The study by 
Howard et al also revealed that only about 30% of the genetic variance of QUS was 
attributable to genetic factors specific to femoral neck BIVID, indicating that separate 
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genetic factors influence QUS [258]. In the present study, the mean Z-score 
decrement for women with a family history of osteoporosis averaged -0.24 for all the 
QUS measurements, which was similar to that found for BIVID measurements. 
Women with a BMI of less than 20 had significantly reduced BIVID and QUS Z-scores 
which were of similar magnitude to those obtained for women with a history of 
atraumatic fracture. The effect of low BMI was particularly pronounced for total hip 
BIVID (-0.92) and DTU BUA (-0.87). Body weight has been shown to be a strong 
determinant of BIVID [432,433] and risk of fracture [60] and in addition, low body 
weight has been associated with a greater rate of postmenopausal bone loss [433]. 
These facts, along with the evidence shown here, illustrate that body weight should be 
considered an important factor when evaluating a patients need for bone densitometry 
assessment. Studies are required to assess whether the age-associated decreases 
in QUS measurement variables are accelerated in women with a low BIVII. It appears 
that calcaneal BLIA measurements are affected to a greater extent by a low BIVII than 
SOS measurements (Table 7.3). 
Ahmed et al reported that mean Z-scores at the lumbar spine and femoral neck were 
significantly reduced in women who had undergone premature menopause or 
prolonged amenorrheoa [423]. Oestrogen deficiency due to menopause or 
amenorrheoa results in accelerated bone loss [434] and therefore one would expect 
the BIVID and QUS variables to be reduced in women in the present study. Only 
lumbar spine BIVID and Sahara QUS Z-score decrements were statistically different 
from zero. The reason for this finding may be explained by a combination of factors: 
women who had undergone hysterectomy without oophorectomy were included and it 
is not clear if this caused or accelerated ovarian failure; over two-thirds of women who 
had undergone both hysterectomy and oophorectomy were being treated (mean 
length of treatment 7.5 years) and finally the mean duration of amenorrheoa was only 
16 months. 
Women with a predisposing medical condition of use of therapy known to affect bone 
metabolism or women who were current smokers yielded essentially normal Z-scores. 
This was a somewhat surprising finding as these clinical risk factors have been 
associated with low BIVID in previous studies [61,423,424]. 
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Due to insufficient numbers of subjects, we were unable to subdivide women with 
medical conditions or use of therapies known to affect bone metabolism into different 
medical conditions or different therapies. Of the 225 women with a predisposing 
medical condition or use of therapy known to affect bone metabolism, 37% reported 
taking glucocorticoids, known to cause considerable decreases in bone mass 
particularly at sites rich in trabecular bone [435]. On examination of this subgroup, 
45% of the women were being treated with oestrogen or bisphosphonates and 50% 
had a BMI greater than 25 kg /M2 (and therefore classified as overweight or obese)* 
These factors may explain, at least in part, why the Z-score decrements for these 
women were not reduced to a greater extent while other studies have shown that both 
BIVID [423,424] and QUS [428] measurements are significantly lower in women on 
glucocorticoids. 
Tobacco smoking is associated with reduced BIVID [61], decreased intestinal calcium 
absorption causing a greater rate of postmenopausal bone loss [62] and an increase 
in hip fracture risk [60]. The BIVID and QUS Z-score decrements for women who were 
current smokers were not significantly different from zero (Table 7.3). On examination 
of the data, BIVID and QUS measurements showed a negative correlation with the 
number of years spent as a smoker (r- -0.10), indicating that the duration of smoking 
may be more important in terms of the effects on bone mass. Additional studies are 
needed to determine whether smoking is associated with reduced QUS variables and 
whether the rate of postmenopausal-associated decreases in BLIA and SOS are 
greater in smokers. Although the Z-scores for women with a medical condition or use 
of therapy or women who were current smokers were not significantly reduced, the 
important fact is that Z-scores for QUS measurements were almost identical to those 
obtained for BIVID measurements. This indicates that both are affected to the same 
magnitude by clinical risk factors for osteoporosis. 
Women with multiple risk factors for osteoporosis had significantly lower BIVID and 
QUS Z-score measurements than women with no or only one risk factor (Figure 7.2). 
This finding has also been observed by Cummings et al who reported that a large 
proportion of women with more than five risk factors for hip fracture had calcaneal 
BIVID in the lowest third for their age and these women also had a greater rate of hip 
fracture [60]. It would appear that these clinical risk factors have an additive effect on 
bone mass, whereby as the number of risk factors present in each individual 
increases, BIVID progressively decreases. This is consistent with the statistical model 
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(Equation 7.1) used in the present study, which assumes that the effects of risk 
factors is additive. Women with four or more clinical risk factors for reduced BMD had 
a mean Z-score for both BIVID and QUS variables of approximately -1.0 which, 
according to the evidence from prospective fracture studies, would double their risk of 
future fracture [17,60,156,159]. 
7.3.3 The use of QUS to identify women at risk of osteoporosis 
At present, there is a widely accepted convention to report BIVID results in terms of T- 
scores. The prevalence of osteoporosis in women with and without risk factors was 
similar for QUS and BMD indicating that as long as appropriately modified diagnostic 
T-score thresholds are used for QUS (Chapter 6), a similar proportion of individuals 
will be classified into the different diagnostic categories. Approximately one-third of 
postmenopausal women with clinical risk factors were classified as osteoporotic using 
either BIVID or QUS measurements, which is significantly greater than the 12% of 
women with no risk factors classified as osteoporotic (Figures 7.3a and b). Over two- 
thirds of women with clinical risk factors were classified as osteopenic or osteoporotic. 
This shows that women with the clinical risk factors for osteoporosis suggested by the 
Royal College of Physicians (422], the European Foundation of Osteoporosis and 
Bone Disease [436] and the National Osteoporosis Foundation [437] for identifying 
individuals at risk of fracture, have a higher prevalence of low bone mass and 
osteoporosis. This approach of identifying women for therapeutic intervention using 
risk factors and BIVID assessment has been shown to be more cost-effective than 
treating all women with clinical risk factors [436]. This study has shown that when 
expressed as Z-scores QUS measurements are effected to the same extent as BIVID 
measurements by clinical risk factors for osteoporosis. Therefore, QUS could provide 
an effective alternative method of assessing skeletal status to aid in a decision 
regarding treatment. However, appropriate modified criteria for QUS needs to be 
adopted in clinical practice if QUS is to be utilised effectively in this way. 
7.3.4 Study limitations 
Women who had taken oestrogen or bisphosphonates for longer than 12 months 
were not excluded from the risk factor groups. The effects of antiresorptive therapy 
on bone mass are often more pronounced at the spine [102,438] and to date, it 
appears that QUS measurements are effected to a lesser degree [254,256,439]. 
Consequently, spinal BMD may have been affected by therapeutic-use to a greater 
extent than hip or calcaneal measurements. Medical records were unavailable and 
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therefore, information regarding indications for osteoporosis was obtained using the 
General Practitioner referral letter and self-reported information from an osteoporosis 
questionnaire. This means that data such as name of medication, medication dosage 
and reasons for secondary amenorrheoa for example could not be confirmed. 
T- and Z-scores for BIVID and QUS were calculated using local reference data 
(Chapter 4) generated using the methods described by Ryan et al for the construction 
of BIVID reference ranges [343]. This may explain why the mean Z-scores for women 
with no clinical risk factors were positive for both BIVID and QUS variables (Table 7.3). 
However, the offset was small (- +0.1) and this did not affect the validity of the 
conclusions from the statistical analysis. A genuine population sample would have 
provided more reliable reference data but even that would not exclude all risk factors 
such as a low BMI, x-ray osteopenia or a current smoking habit. The aim of this part 
of the study was not to assess the appropriateness of criteria to construct reference 
ranges but rather to assess whether QUS variables respond to clinical risk factors for 
osteoporosis. Therefore, this consistency of using the same reference population to 
calculate T- and Z-scores is advantageous as any differences observed between 
BIVID and QUS measurements is due to different technologies and not discrepancies 
in reference data. 
7.4 CONCLUSIONS AND FURTHER WORK 
In conclusion, indications for osteoporosis affected calcaneal BUA and SOS 
measurements to the same extent as axial BIVID measurements. Therefore, calcaneal 
QUS could provide an alternative tool for identifying individuals with low bone mass 
who may benefit from therapeutic intervention. 
Other QUS devices, especially those that measure QUS variables at skeletal sites 
other than the calcaneus, may perform differently and therefore need to be assessed. 
Further studies are required to assess whether QUS can monitor disease progression 
in women with clinical risk factors for osteoporosis. Larger studies are needed so 
more specific groups of women can be examined, such as those with primary 
hyperparathyroidism or those on glucocorticoids for example. Revised diagnostic 
criteria for QUS need to be adopted in clinical practice so QUS can be utilised more 
effectively for identifying those women who would most benefit from therapeutic 
intervention. 
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Chapter 8 
QUS and Fracture Discrimination 
8.1 STUDY DESIGN 
8.1.1 Aims 
The aim of this chapter is to determine whether QUS can discriminate between women 
with and without fracture as well as axial DXA measurements can. A second aim is to 
assess whether the combination of QUS and DXA improves fracture discrimination. 
8.1.2 Introduction 
It is estimated that approximately 90% of all spine and hip fractures and 70% of wrist 
fractures can be attributed to osteoporosis [77] and approximately one-third of white 
women over the age of 50 will suffer a fracture at one of these skeletal sites [79]. The 
financial burden associated with osteoporotic- related fractures is immense. For 
example, approximately $14billion is spent on treating fractures per annum in the USA 
[96]. Hip fractures are associated with the most medical costs and excess mortality 
and morbidity than any of the other fractures [82]. However, all osteoporotic fractures 
may be associated with pain, disability or impaired health. 
One of the major goals of performing a bone densitometry examination is to identify 
individuals at risk of fracture before the fractures actually occur. However, a recent 
survey in the United Kingdom revealed that over two-thirds of patients were not 
identified until they had a fracture [416]. One of the reasons for this is that only about 
one-third of General Practitioners has access to bone densitometry services in the UK 
[416]. Cross-sectional and large prospective fracture studies have revealed that QUS 
can predict fracture risk as well as DXA and other established techniques, and 
therefore QUS could be used to identify those at risk of fracture and so increase the 
availability of bone densitometry services. In this study, the ability of QUS to 
discriminate between women with and without fragility fracture has been examined. 
In the field of bone densitometry, it is convention to express the discriminatory ability of 
BIVID or QUS measurements as odds ratios for cross-sectional studies. The odds 
ratios represents the increase in risk of fracture associated with a SID decrease in BIVID 
or QUS measurement variables. For example, GlCjer et al reported an odds ratio of 1.9 
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associated with hip fracture, using the data from the SOF study, indicating that for each 
SD in BUA there is a 1.9 increase in hip fracture risk [330]. 
Recently there has been interest in the possibility of combining QUS and BIVID 
measurements to improve the prediction of fracture risk [333,368]. For example, 
results from the SOF Study revealed that women with both low QUS and femoral neck 
BIVID had the highest rate of hip fracture [341] which indicates that a combination of 
QUS and BIVID may useful in identifying a particularly high risk group of women. The 
combination of QUS with either LS or THIP BIVID has been examined in this chapter to 
assess whether fracture discrimination is improved compared to using either BIVID or 
QUS measurements alone. 
8.1.3 Methods 
8.1.3.1 Subjects 
Of the 1130 study population, 217 postmenopausal women reported a history of an 
atraumatic fracture (defined as a fall from a standing height or less). These women 
reported a total of 238 atraumatic fractures which were divided into four groups: (i) 104 
vertebral fractures; (ii) 13 hip fractures; (iii) 69 wrist fractures, (iv) 52 other fractures 
(including fractures of the ankle, coccyx, elbow, face, fibula, humerus, patella, pelvis, 
ribs, skull, tibia and bones in the hands or feet). The number of women reporting a 
history of atraumatic fracture measured on the DXA and three QUS devices is shown in 
Table 8.1. Women reporting fractures of the hip or lower extremities were asked 
which side was fractured and the contralateral side scanned using DXA or QUS. DXA 
scans of the spine for women with vertebral fracture were examined and if a vertebra 
was obviously fractured it was excluded from analysis. Women with a history of 
fracture were compared to the 240 postmenopausal controls used to construct 
reference ranges in Chapter 4. 
Table 8.1: The number of subjects reporting a history of atraumatic fracture measured by DXA 
and the three OUS devices. 
QUS 
Total DXA UBA SAH DTU 
Vertebra 104 104 99 102 90 
Hip 13 12 11 13 9 
wrist 69 60 68 62 49 
Othee 52 41 50 47 33 
Any 217 196 206 201 162 
" fracture at a skeletal site o ther than the spine, hip or wrist 
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8.1.3.2 Data analysis 
The mean and SID for each measurement variable was calculated using the 240 
postmenopausal controls. The mean and SID was then used to calculate Z-scores for 
each individual in the entire study population. To examine the discriminatory ability of 
each measurement variable age-adjusted logistic regression was used to estimate 
odds ratios (for each 1 SID decrease in the measurement variable) and the 95% 
confidence intervals. The coefficient of determination (r) was also obtained from 
logistic regression analysis. ROC curve analysis was used to estimate the area under 
the curve, sensitivity, specificity and accuracy for each measurement variable. Age- 
adjusted forward stepwise logistic regression was performed to assess whether QUS 
and either LS or THIP BIVID measurements contributed independently to vertebral 
fracture discrimination. If both QUS and BIVID measurements remained significant 
when placed into the same model, the individual QUS and BIVID Z-scores were 
combined giving one Z-score for each individual (the method used to combine the QUS 
and BIVID Z-scores were combined is described in the appendix at the end of this 
chapter). 
Logistic regression and ROC analysis was performed using the combined Z-scores for 
the vertebral fracture and postmenopausal control groups. The odds ratios, coefficient 
of determination and AUC obtained using the combined QUS and BIVID Z-scores were 
compared to those obtained for the QUS and BIVID measurements individually to 
assess whether the discriminatory ability was significantly improved using BIVID and 
QUS combined Z-scores. 
The prevalence of osteopenia and osteoporosis was estimated for women with 
vertebral fracture, non-spinal fracture and postmenopausal controls using the WHO 
criteria for DXA and the revised criteria for QUS (Table 6.6). 
8.2 RESULTS 
Patient characteristics for the different study groups are shown in Table 8.2. Women 
with a history of atraumatic fracture were significantly older and had a higher 
menopausal age compared with the postmenopausal controls. Women with a history 
of vertebral fracture were significantly shorter and lighter than postmenopausal 
controls. Women reporting a history of hip fracture were significantly lighter than 
postmenopausal controls. All the BMD and QUS measurement variables were 
significantly lower in women with a history of vertebral, hip or wrist fracture. With the 
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significantly reduced in women with a history of fracture at a skeletal site other than the 
spine, hip or wrist. Over half of the women with a vertebral fracture were past or 
current users of oestrogen or bisphosphonate therapy, while between 20-40% of 
women reporting a non-spinal fracture were past or current users of oestrogen or 
bisphosphonate therapy. 
8.2.1 Quantitative Ultrasound and Vertebral Fracture 
When the group of women with one or more vertebral fractures was compared to the 
healthy postmenopausal group, age-adjusted odds ratios were significant for both BMD 
and QUS measurement variables (Table 8.3 and Figure 8.1). 
Table 8.3: Age-adjusted odds ratios for QUS and BIVID measurements associated with 
vertebral fracture 
Adjusted for age Adjusted for age, YSM, HT, WT 
Odds Ratio (95% Cl) Odds Ratio (95% Cl) 
LS BMD (g/CM2) 2.62 (1.91-3.58) 2.51 (1.74-3.64) 
FN BMD (g/CM2) 2.59 (1.82-3.68) 2.71 (1.73-4.25) 
THIP BMD (g/CM2) 3.09 (2.19-4.38) 3.42 (2.20-5.33) 
UBA BUA dB/MHz 3.11 (2.17-4.44) 2.51 (1.70-3.72) 
UBA SOS m/s 4.38 (2.83-6.76) 4.22 (2.54-7.01) 
UBA BV m/s 4.50 (2.88-7.03) 4.19 (2.52-6.95) 
SAH BUA dB/MHz 3.76 (2.61-5.41) 3.23 (2.18-4.77) 
SAH SOS m/s 5.33 (3.42-8.29) 4.93 (3.01-8.05) 
SAH BMD g/CM2 4.93 (3.25-7.49) 4.43 (2.80-7.01) 
DTU BUA dB/MHz 3.18 (2.27-4.46) 2.87 (1.96-4.20) 
DTU SOS m/s 3.37 (2.27-5.00) 3.20 (2.02-5.08) 
The odds ratios obtained for BIVID measurements ranged from 2.59 for FN BIVID to 3.09 
for total hip BMD. Age-adjusted odds ratios obtained for QUS measurements ranged 
from 3.11 for UBA BUA to 5.33 for SAH SOS. The odds ratios tended to be higher for 
QUS measurements compared to BIVID measurements and SOS measurements 
tended to yield higher odds ratios than BUA measurements, but in neither case was 
this statistically significant. When logistic regression was performed again adjusting for 
YSM, height and weight as well as age (the variables that were significantly different 
between study groups) the odds ratios decreased slightly, although not significantly 
(Table 8.3). Therefore, only age was adjusted for in subsequent logistic regression 
analysis. 
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ROC analysis gave AUC values ranging from 0.85 for LS BMD to 0.90 for SAH SOS 
and SAH BIVID, indicating that all measurement variables readily discriminated between 




Figure 8.1: Odds 




The AUC for SAH BIVID was significantly greater than that obtained for LS BMD (0.90 
vs. 0.85, respectively) and all SAH measurements and DTU BUA yielded significantly 
greater AUC value than FN BMD. The sensitivity of BIVID and QUS to discriminate 
between women with and without vertebral fracture was approximately 89% while 
specificity was approximately 62% (Table 8.4). Approximately 80% of women were 
correctly identified using BIVID or QUS measurements (Table 8.4). 
Table 8.4: ROC analysis for BMD and QUS measurements associated with vertebral 
fra ct u re. 
AUC (SE) Sensitivity Specificity Accuracy 
LS BMD g/CM2 0.85(0.03) 89.1 58.7 79.4 
FN BMD g/CM2 0.83(0.03) 89.1 55.8 78.5 
THIP BMD g/CM2 0.86(0.02) 89.1 55.8 78.5 
UBA BUA dB/MHz 0.86(0.03) 88.7 60.6 80.0 
UBA SOS m/s 0.88(0.02) 89.6 60.6 80.6 
UBA BV m/s 0.88(0.02) 86.9 61.6 79.1 
SAH BUA dB/MHz 0.89 (0.02)b 89.7 63.7 81.5 
SAH SOS m/s 0.90(0.02)b 88.3 65.7 81.2 
SAH BMD g/CM2 0.90(0.02) ab 88.8 67.7 82.2 
DTU BUA dB/MHz 0.89 (0.02)b 89.2 66.7 81.6 
DTU SOS m/s 0.87(0.03) 85.2 63.3 77.8 
a significantly greater than LS BIVID AUC, p<0.05 
bsignificantly greater than FN BIVID AUC, p<0.05 
As a further comparison between techniques, SAH Est. heel BMD for the 
postmenopausal control and vertebral fracture groups was compared at each level of 
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THIP BIVID (Figure 8.2). Estimated heel BIVID was significantly lower in women with 
vertebral fracture compared with the postmenopausal controls at each level of total hip 








THIP BMD g/CM2 
ostmenopausal controls m Fracture 
8.2.2 QUS and Non-Vertebral Fractures 
Figure 8.2: A comparison of 
SAH BMD in the 
postmenopausal control and 
the vertebral fracture groups at 
each level of THIP BMD. 
With the exception of LS and FN BMD, THIP and QUS measurement variables were 
associated with hip fracture, yielding age-adjusted odds ratios of approximately 2.8 
(Table 8.5). Due to the small number of women reporting a hip fracture (n=13), the 
95% confidence intervals were large. As seen for women with vertebral fracture, QUS 
measurements tended to give higher odds ratios than BIVID measurements and odds 
ratios for SOS were slightly higher than those obtained for BUA measurements. 
However, this did not reach statistical significance due to the large confidence intervals 
(Table 8.5). All the BIVID and QUS measurement variables yielded essentially similar 
AUC values of approximately 0.79 indicating that all measurement variables showed 
similar discrimination between groups (Table 8.5). 
Sixty-nine women reported a history of wrist fracture (Table 8.2). When these women 
were compared to the postmenopausal controls the odds ratios obtained for BIVID and 
QUS measurements were approximately 2.5 (Table 8.5), indicating that for each SID 
decrease in BIVID, BUA or SOS there is a 2.5 fold increase in the risk of wrist fracture. 
The AUC values ranged from 0.72 for LS and FN BMD to 0.80 for DTU BUA (Table 
8.5). 
BIVID and QUS measurements were also significantly reduced in women reporting a 
fracture at a skeletal site other than the spine, hip or wrist (Table 8.2). With the 
exception of the two UBA velocity measurements, age-adjusted odds ratios for BIVID 
and QUS measurement variables were significant (Table 8.5). The odds ratios 
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obtained were somewhat lower than those obtained when examining women the 
vertebral fracture group (Table 8.3) and the hip and wrist fracture groups (Table 8,5) as 
were the AUC values (Table 8.5). 
When the BIVID and QUS measurements for women with a history of any fracture 
(including those with a history of vertebral fracture) were compared to those obtained 
for the postmenopausal controls all measurements were significantly reduced (Table 
8.2). The BIVID and UBA measurement variables yielded odds ratios of approximately 
2, while the SAH and DTU measurement variables yielded odds ratios of approximately 
2.4. ROC analysis gave AUC values of approximately 0.75 for both BIVID and QUS 
measurements (Table 8.5). 
Figure 8.3 summarise the results described above, showing the odds ratios obtained 
for BIVID and QUS measurement variables for each fracture type. The odds ratios for 
BIVID measurements were relatively consistent for the discrimination of all fracture 
types, while QUS measurements yielded higher odds ratios for women with vertebral 
fracture compared to the other fracture sites (Figure 8.3). In all cases, BIVID and QUS 
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Figure 8.3: Odds ratios for BMD and QUS measurements associated with different fracture 
types. 
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8.2.3 The Combination of BMD and QUS Measurements and Vertebral 
Fracture Discrimination 
When forward stepwise logistic regression (age-adjusted) was performed, including 
each QUS measurement variable with either LS or THIP BIVID in the model until all 
possible combinations had been examined, the odds ratios for BIVID and QUS 
measurement variables remained significant in all cases (Table 8.6). This indicates 
that the QUS and BIVID contribute independently to vertebral fracture discrimination. 
When LS and THIP BIVID adjusted odds ratios were compared to those in Table 8.3, 
they were slightly lower but not significantly. When the QUS measurements were 
adjusted for THIP, the odds ratios for QUS tended to be lower than when adjusted for 
LS BMD. 
Table 8.6: Odds ratios for QUS measurements associated with vertebral fracture adjusted 
for LS or THIP BMD. 
Adjusted for age and LS BMD Adjusted for age and THIP BMD 
OR (95%Cl) OR (95%Cl) 
UBA BUA dB/MHz 2.37 (1.62-3.47) 2.17 (1.49-3.18) 
UBA SOS m/s 3.77 (2.32-6.13) 3.55 (2.07-5.14) 
UBA BV m/s 3.78 (2.31-6.18) 3.41 (2.11-5.52) 
SAH BUA dB/MHz 
SAH SOS m/s 







DTU BUA dB/MHz 2.62 (1.82-3.77) 2.45 (1.69-3.56) 
DTU SOS m/s 2.67 (1.75-4.09) 2.55 (1.67-3.90) 
The Z-scores for each of the QUS measurement variables were combined with the Z- 
scores for either LS or THIP BIVID (as described in the appendix). The regression 
coefficients obtained from forward stepwise logistic regression analysis were used to 
combine BIVID and QUS Z-scores (Table 8.7) using equation 8.3 in the appendix. As 
shown in Table 8.7, with the exception of the UBA BUA and THIP BIVID combination, 
QUS measurement variables yielded higher regression coefficients. 
Table 8.7: Regression coefficients for combined models of QUS and BIVID measurements 
used in the calculation of combined Z-scores (see appendix). 
QUS and LS BIVID QUS and THIP BIVID 
QUS BMD QUS BMD 
UBA BUA dB/MHz 0.863 0.607 0.776 0.841 
UBA SOS mIs 1.33 0.485 1.227 0.779 
UBA BV m/s 1.327 0.444 1.208 0.729 
SAH BUA dB/MHz 1.106 0.471 1.056 0.687 
SAH SOS m/s 1.458 0.484 1.399 0.711 
SAH BMD g/CM2 1.401 0.433 1.338 0.658 
DTU BUA dB/MHz 0.963 0.597 0.897 0.72 
DTU SOS m/s 0.984 0.773 0.937 0.998 
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Logistic regression and ROC analysis was performed on the combined Z-scores and 
the results were compared to those obtained for QUS alone to assess whether a 
combination of QUS and BIVID significantly improves vertebral fracture discrimination. 
When QUS Z-scores w ere combined with those for LS BMD, the odds ratios obtained 
w ere slightly higher than those obtained for QUS measurements alone, although 
these differences were not statistically significant (Table 8.8). The best improvement in 
the odds ratios were seen when the DTU BUA and DTU SOS measurements were 
combined with LS BMD, with odds ratios of 3.82 and 4.43 respectively. ROC analysis 
of the combined Z-scores improved the AUC in just 3 out of the 8 combinations, 
increasing the AUC by 1% when UBA BUA and DTU BUA were combined with LS 
BIVID and by 2% when DTU SOS was combined with LS BIVID (Table 8.8). None of the 
improvements in the AUC were statistically significant. The coefficients of 
determination increased by approximately 2%. 
When the THIP Z-scores were combined with the QUS Z-scores, logistic regression 
yielded odds ratios ranging from 3.80 for UBA BUA and THIP BIVID combined to 5.92 
for SAH SOS and THIP BIVID combined. As observed when LS BIVID and QUS Z- 
scores were combined, the odds ratios were greater than those obtained for QUS 
alone, but these differences did not reach statistical significance. ROC analysis 
increased the AUC values by 1-3%, although these improvements were not significant. 
The coefficient of determination also increased, but only by up to 7%. 
8.2.4 The Applicability of the Revised Diagnostic criteria for QUS in 
Identifying Women with Fracture 
The revised diagnostic criteria for QUS and the WHO criteria for BIVID (Chapter 6) were 
applied to the T-scores obtained for women with vertebral fracture, non-vertebral 
fractures and the postmenopausal controls (Figure 8.4). The WHO criteria was used 
for BIVID. Approximately 60% of the women with vertebral fracture were classified as 
osteoporotic using BMID and QUS T-scores, about 30% were classified as osteopenic 
and a very small percentage (approximately 5%) was classified as normal. In the case 
of SAH SOS none of the women with vertebral fracture were classified as normal. 
Approximately 75% of the women with a history of fracture other than at the spine were 
classified as osteoporotic or osteopenic, while about 20% of these women were 
classified as normal. In all cases the proportions of osteoporosis and osteopenia were 
greater than that observed for the postmenopausal controls. Approximately 50% of the 
postmenopausal controls were classified as normal and only about 12% were classified 
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as osteoporotic. The proportions of women classified as normal, osteopenic or 
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Figure 8.4: The prevalence of osteopenia and osteoporosis in women (a) with vertebral fracture, 
(b) with a non-spinal fracture and (c) postmenopausal controls. 
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8.3 DISCUSSION 
As stated in the 1994, WHO report on the assessment of fracture risk, the prospects for 
the treatment of the established disorder (osteoporosis) are significantly less than 
those for prevention [16]. Therefore, to optimise resources, individuals at risk of 
fracture should be identified before substantial bone loss has occurred and ideally 
before fractures actually occur. QUS, along with other'state of the art'techniques such 
as peripheral MRI and QCT, have the potential to be used to for this purpose, therefore 
decreasing the demand for DXA assessments and increasing the availability of bone 
densitometry services as a whole. In this chapter, the ability of calcaneal QUS, both 
alone and in combination with axial BIVID, to assess fracture risk has been examined. 
8.3.1 Quantitative Ultrasound and Vertebral Fracture 
It is estimated that the annual incidence of vertebral fracture (deformity) in women aged 
over 50 years in the UK is approximately 148,000, of which 50 000 come to medical 
attention and 12,000 require hospital admission [440]. In Western Europe between 11 
and 19% of Caucasian women aged over 50 years have vertebral fractures depending 
upon the method used for diagnosis [90]. Vertebral fractures are associated with pain 
[92,93,441], decreased functional capacity [92,442] impaired health in general [92,442] 
and psychological morbidity [93]. It has been reported that women with vertebral 
fracture have a two-fold excess mortality rate compared to women without vertebral 
fracture. However, once adjusted for other adverse health and lifestyle factors there is 
little evidence of an increased mortality rate [94]. 
Both the QUS and BIVID measurement variables were significantly lower in women with 
vertebral fracture (Table 8.2) and QUS measurements were able to discriminate 
between those with and without vertebral fracture as well as DXA (Table 8.3 and 8.4). 
These results are consistent with other cross-sectional studies reported in the literature 
that have examined QUS measurement variables in women with vertebral fracture 
[171,231,326,330,334,443]. Using the UBA575+ system, Bauer et al reported an odds 
ratio of 1.8 for BUA in women with vertebral fracture which was similar in magnitude to 
that obtained for LS and FN BIVID [231]. A study by Ross et al found that calcaneal 
BUA and calcaneal BIVID yielded similar odds ratios of approximately 1.8 for 84 women 
with vertebral fracture [171]. A recent study by Kung et al of 53 Chinese women with 
vertebral fracture reported odds ratios of 1.71 and 2.72 for BUA and SOS respectively, 
measured on the Sahara contact device [326]. However, a study by Stewart et al 
found no significant differences in BUA between women with and without vertebral 
fracture [4441. The two largest QUS prospective fracture studies to date, the EPIDOS 
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and SOF studies [341,342] did not assess vertebral fracture risk. To date, only one 
smaller prospective study has examined the ability of QUS to predict vertebral fracture 
risk [337]. Huang et al reported a relative risk of vertebral fracture of 1.50 associated 
with a1 SID decrease in BUA measured on the UBA575 [337]. A prospective study 
performed in the UK, which examined the ability of QUS to predict osteoporosis-related 
fractures (including vertebral fractures) in women followed for 3 years, found that a 
decrease of 1 SID in BUA and SOS was associated with an approximate doubling of 
fracture risk [338]. 
The odds ratios obtained in this study were somewhat higher for QUS measurements 
compared to those seen in other studies. The age-adjusted odds ratios ranged from 
3.11 for UBA BUA to 5.33 for SAH SOS (Table 8.3). This could be because the 
prevalence of actual vertebral fractures is higher in clinical practice compared to the 
general population and in addition, the average severity is often worse [445]. It has 
been reported that the mean number fractured vertebrae per subject is significantly 
greater in women referred for osteoporosis assessment compared to a population- 
based sample (3.3 vs. 2.0 per fracture case, respectively) and BIVID was also 
significantly lower in the referral sample of women [445]. The women with vertebral 
fracture in the present study were recruited from the Guy's Hospital metabolic bone 
clinic, and therefore perhaps represent the 'more severe' cases of osteoporosis. This 
may partly explain the high odds ratios for the QUS variables but does not explain why 
the odds ratios were generally higher than those seen for BIVID measurements (Table 
8.3). 
In this study, it was shown that for each level of THIP BMD, SAH BMD was significantly 
lower in the vertebral fracture group (Figure 8.2), similar findings were also observed 
for the other QUS measurement variables in the present study and in the literature for 
LS BMD [291]. Changes in the mechanical loading of the calcaneus due to the pain 
and disability associated with vertebral fracture may have an impact on bone status. 
Results from the European Vertebral Osteoporosis Study (EVOS) group revealed that 
functional capacity was reduced in women with vertebral fracture, especially in those 
with multiple vertebral fractures [92]. Immobility may lead to thinning or even loss of 
trabeculae. Only 14% of women in the vertebral fracture group participated in weight- 
bearing exercise and over half walked less than 1 mile per day and did not participate 
in any form of exercise. The calcaneus is a site of ground reaction forces due to heel- 
strike during walking and exercise, which causes strain-related remodelling. This 
osteogenic stimulus due to walking has been shown to increase BLIA in previously 
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sedentary postmenopausal women [269] and it can therefore be inferred that women 
who do not participate in activities such as walking or weight-bearing exercise might 
have lower QUS values at the calcaneus. A study of 578 women and 132 men, which 
investigated the relationship between QUS measurements and physical activity, found 
that increased physical activity was associated with increased BUA and SOS. For 
example, walking for 2.5 hours per week was associated with an increase of 4.7 
dB/MHz and 5.1 m/s, which was similar to the differences associated with 10 years 
younger age [323]. A combination of changes in bone structure due to immobility 
caused by fracture and the fact that there may have been a selection bias towards 
more healthy and active women in the postmenopausal control group could, in part, 
explain why the odds ratios were high compared to cross-sectional and prospective 
studies. 
8.3.2 QUS and Non-Vertebral Fractures 
Fractures of the hip and wrist, along with those of the spine, represent the three most 
common fracture sites associated with osteoporosis. In the present study, QUS 
measurement variables were able to discriminate between those with hip or wrist 
fracture and those without as well as BMID measurements (Table 8.5). The average 
odds ratio associated with hip and wrist fractures obtained for QUS measurements was 
3.1 and 2.5 respectively and the average AUC was 0.81 and 0.75 respectively (Table 
8.5). 
Hip fracture patients occupy one-fifth of all orthopaedic beds in England and Wales and 
it is estimated that the direct cost of hip fractures in 1988 was E160million [87]. In 
addition, they are associated with excess mortality [82,446,447] therefore it is important 
that QUS is able to identify those at risk of hip fracture. The average odds ratio 
associated with hip fracture obtained for QUS measurements was 3.1 and the average 
AUC was 0.81 (Table 8.5). The odds ratios and AUC values obtained in this cross- 
sectional study are similar to those reported in the literature [323,325,327-330,332]. 
Prospective studies using QUS have confirmed that reduced QUS measurement 
variables are associated with an increase in hip fracture risk [340-342]. The first 
prospective study by Porter et al of 1414 women aged over 69 years reported that 
baseline BLIA was significantly reduced in 73 women who subsequently suffered a hip 
fracture [340]. The SOF study of 6189 women aged over 65 years, followed up for two 
years, reported that a IISD reduction in BLIA was associated with a doubling of hip 
fracture risk [341]. Results from the EPIDOS study of 5662 women aged over 75 years 
revealed that for each 1SID reduction in BLIA and SOS the relative risk of hip fracture 
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was 2.0 and 1.7 respectively. A recent prospective study of 710 men and women using 
a calcaneal contact QUS device, reported a relative risk of hip fracture of 2.3 for BUA 
and 1.6 for SOS associated with a1 SID decrease [339]. To date, no prospective 
fracture studies have been reported for calcaneal imaging devices. However, cross- 
sectional results from this study and others [218,286] report similar results to those 
obtained on non-imaging devices. 
The odds ratios associated with hip fracture for QUS measurements were similar to 
that obtained for THIP BMD, however the odds ratios for LS and FN BMD were not 
significant, indicating that LS and FN BIVID measurements were not able to discriminate 
hip fracture patients from controls (Table 8.5). This was a surprising finding, especially 
for FN BIVID, as hip BIVID has been shown to be the best predictor of hip fracture risk 
[156]. This may have been due, in part, to the fact that hip BIVID was assessed in the 
non-fractured side. Therefore, BIVID may have been increased in the non-fractured 
side due to increasing weight-bearing demands associated with a possible decline in 
function of the fractured hip. This finding has been reported in a six-year prospective 
study that found that FN and LS BIVID was increased six years after hip fracture 
compared to 1 year after injury [448]. In addition, only 13 women reporting hip fracture 
were assessed in this study and consequently the statistical errors were relatively 
large. 
Wrist fractures are associated with 10,000 hospital admissions in the UK and are 
associated with pain and algodystrophy [449]. The 69 women reporting a fracture of 
the wrist in the present study had significantly reduced QUS and BIVID measurements 
(Table 8.2). The odds ratios for BIVID measurements ranged from 2.06 for LS BIVID to 
2.46 for THIP BIVID and those for QUS measurements averaged 2.54. The average 
AUC values for QUS measurements associated with wrist fracture was 0.75 and these 
did not significantly differ from the AUC values obtained for BIVID measurements, 
indicating that both BIVID and QUS show similar discriminatory abilities (Table 8.5). To 
date, only one study has reported QUS results in patients with wrist fracture [323]. This 
study reported odds ratios of approximately 2.5 and 2 for BUA and SOS respectively, 
when women in the lowest tertiles where compared to those the highest tertile of QUS 
values [323]. 
It is estimated that approximately half of fractures at sites other than the spine, hip or 
wrist in white women aged over 45 years can be attributed to osteoporosis [77] and are 
associated with reduced BMD [78]. Therefore, it is important that QUS can 
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discriminate between women with and without these fractures. In the present study, 52 
women reported an atraumatic fracture at skeletal sites other than the spine, hip or 
wrist. With the exception of UBA BV and UBA SOS, the BIVID and QUS measurements 
were significantly lower than those obtained for the postmenopausal controls, even 
though the women with fracture were significantly younger by 2.5 years (Table 8.2). As 
expected, the odds ratios and AUC values were lower than those associated with other 
fracture types (Table 8.5). However, odds ratios associated with these fractures were 
similar for BIVID and QUS measurement variables and averaged 1.70. AUC values 
were also similar for BIVID and QUS measurements, averaging 0.65 (Table 8.5). This is 
a promising finding and is in agreement with a study by Seeley et al, who reported that 
a 1SD decrease in BIVID of the proximal radius and calcaneus was associated with an 
approximate 1.65 increase in risk of fracture at sites other than the spine and hip [78]. 
To date, QUS prospective studies tend to report results for non-spinal fractures rather 
than separate results for fractures at sites other than the spine, hip or wrist. However, 
a small prospective study by Stewart et al of 1000 perimenopausal women, of which 18 
reported a fracture of the wrist, toes, ribs, foot, humerus and nose during the two year 
follow up, reported a relative risk of 1.43 for BUA [336]. A cross sectional study by 
GlUer et al for the SOF study group, which reported separate QUS values for women 
with a history of a non-spine, hip or wrist fracture, reported odds ratios for BUA of 
approximately 1.35 [330]. Further studies are required to determine whether QUS can 
identify women at risk of any fracture, as well as fractures of the spine, hip or forearm. 
8.3.3 The Combination of BMD and QUS Measurements and Vertebral 
Fracture Discrimination 
Several prospective and cross sectional fracture studies have shown that QUS 
measurements are associated with fracture risk even after adjustment for BMID 
[171,328,330,331,334,341,342]. This suggests that BMID and QUS measurements 
provide independent information regarding fracture risk and therefore, the combination 
of BIVID and QUS may enhance fracture prediction than either method alone. It has 
been reported that women with both a BIVID and a QUS measurement 1SID below the 
mean have an almost three fold risk of fracture compared with women with just a low 
BMID measurement [333]. This composite approach of using BIVID and QUS has been 
suggested as a possible method of how QUS could be used in clinical practice [368]. 
In the present study, the odds ratios associated with vertebral fracture remained 
significant after adjustment for either LS or THIP BIVID (Table 8.5). These results 
indicate that at similar LS or THIP values, QUS measurements can further discriminate 
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between individuals by a factor of approximately 3.2. The odds ratios for QUS 
measurements were reduced to a greater extent by the adjustment of THIP BIVID 
compared to adjustment for LS BIVID (Table 8.5). This suggests that QUS and THIP 
share more information regarding bone status than that shared by LS BMID and QUS 
measurements. However, this is not confirmed by increased correlation coefficients 
between THIP BIVID and QUS compared with LS BIVID and QUS, examined in Chapter 
5 (Table 5.3). In the SOF study, when BUA was adjusted for FN BIVID the relative risk 
of hip fracture for each IISID decrease in BLIA fell from 2.0 to 1.5 [341]. A similar 
finding was reported in the EPIDOS study for BUA and SOS adjusted for FN BIVID 
[342]. A study by Ross et al demonstrated that, even if BUA is adjusted for calcaneal 
BIVID or vice versa, both measurements independently discriminate vertebral fracture 
patients from controls [171 ]. 
In the present study, BIVID and QUS Z-scores were combined using equation 8.3. The 
use of the individual BMID and QUS regression coefficients ensures that the Z-scores 
are combined in an optimum way as the higher the regression coefficient (i. e. higher 
odds ratio) the greater the weighting given to that measurement variable when 
combining the Z-scores. In 14 out of the 16 possible combinations, greater weighting 
was given to the QUS Z-scores due to the higher odds ratios obtained for these 
variables (Table 8.6). The odds ratios and AUC values for the combined QUS and 
BIVID measurements increased slightly but in none of the combinations were increases 
statistically significantly significant compared to either method alone (Table 8.8). This 
is consistent with that reported by Peretz et al, who found that a combination of QUS 
and hip BIVID did not significantly increase fracture discrimination [325]. However, 
increases in sensitivity of 10% have been observed in another study when BUA and FN 
BIVID measurements were combined [330]. A study by Hans et al, using a QUS device 
that can measure multiple skeletal sites including axial sites, reported moderate 
improvements in discriminatory ability with AUC increases of up to 3%. However, 
these improvements were not significant [206]. 
The results from this study and others suggest that little information is gained by 
combining BIVID and QUS measurements compared to using either method alone. A 
possible reason for this is that BIVID and QUS measure similar bone properties but 
error sources associated with both techniques mean that both variables contribute 
independently to fracture risk. From a health-economic standpoint, the cost- 
effectiveness of such an approach should also be taken into consideration. The 
increased financial cost associated with performing both a BIVID and a QUS 
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measurement on an individual may outweigh any benefits associated with the modest 
improvements in the prediction of fracture risk. 
An interesting finding was that when BUA was adjusted for SOS (and vice versa) only 
one measurement variable remained significant suggesting that both BUA and SOS 
measure similar bone properties that relate to fracture discrimination (data not shown). 
8.3.4 The Applicability of the Revised Diagnostic criteria for QUS in 
Identifying Women with Fracture 
Using the revised diagnostic criteria for QUS described in Table 6.6, approximately 
90% of postmenopausal women with a vertebral fracture and 75% of women with a 
non-vertebral fracture were classified as osteopenic or osteoporotic using QUS 
measurements. Similar proportions of women were classified as osteopenic or 
osteoporotic using BIVID measurements (Figure 8.4). This shows that many of the 
women who had a history of fracture would be classified as osteopenic or osteoporotic 
and so identified as possible candidates for therapeutic intervention. However, the 
WHO criteria and the revised criteria for QUS are for diagnostic purposes, not for 
assessing fracture risk and as stated in the WHO report it is important to distinguish 
between the two [16]. Nevertheless, results from bone densitometry studies are most 
often reported in terms of T-scores and so patients are often classified into the different 
diagnostic categories. Therefore, it is important to assess whether similar proportions 
of patients with fracture (or ideally similar proportions of patients who at are risk of 
fracture in the future) are classified similarly using either BIVID or QUS measurements. 
As seen in Chapter 6 if the current WHO criteria were applied to QUS, fewer women 
would be classified as osteoporotic. However, results from Chapter 6 and Figure 8.4 
shows that similar proportions of women (with and without fracture) are classified into 
the different diagnostic categories. 
Many of the published guidelines on how to use QUS in clinical practice have 
suggested that QUS should be used as a pre-screening approach, whereby women 
with a low QUS result should be referred for additional investigation by DXA 
[375,376,417]. This may be impractical, as one of the reasons for the development of 
new techniques was to ease the demand for DXA measurements. In addition, the 
utility and cost-effectiveness of such an approach has not been fully assessed. The 
results from this study, other cross sectional studies and large prospective studies 
demonstrate that QUS has similar discriminatory and predictive capabilities as the 
established bone densitometry techniques. Therefore, QUS could be used alone as a 
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method for identifying individuals at risk of fracture, who would most benefit from 
therapeutic intervention. It has been suggested that this 'stand-alone' approach would 
be the most cost-effective method of using QUS (368]. 
8.3.5 Study Limitations 
The most important limitation is that this study was cross-sectional in design. Cross 
sectional fracture studies cannot prove that low BIVID or QUS measurements are an 
effect of fracture rather than a cause of fracture [450]. Bone loss due to disability after 
fracture may accelerate bone loss and this may bias results in favour of measurements 
at sites that are affected, to a greater degree, by decreased loading patterns. 
However, a recent study examining changes in LS and FN BIVID after hip fracture, 
reported significant decreases in BIVID 1 year after hip fracture but BIVID recovered to 
baseline values after 6 years [448]. Similar studies are required using calcaneal QUS 
to assess changes in QUS measurement variables after fracture. The recruitment of 
controls in cross sectional studies may also lead to bias as volunteers are often 
healthier and more active than women from the general population, especially for older 
age groups. 
Another limitation of the present study was that information regarding fracture was 
obtained from the self-administered questionnaire and from the General Practitioner or 
Hospital Consultant referral letter. Therefore, it is possible that women who reported a 
history of fracture may have had an injury other than a fracture or, especially in the 
case of vertebral fracture, some fractures may have been missed. However, results 
from a prospective fracture study found that all self-reported fractures were confirmed 
as fractures [451]. 
The vertebral fracture patients were recruited from the Guy's Hospital metabolic bone 
clinic and the presence of vertebral fracture was inferred from hospital notes and, in 
some cases, the General Practitioner or Hospital Consultant referral letter. The actual 
x-rays were not available and the method used to define vertebral fracture in each 
patient was unknown. However, as stated previously, these patients represent the 
'more severe' cases of osteoporosis and it is unlikely that any represent false positives. 
Women on antiresorptive therapy were not excluded and as discussed in Chapter 7, it 
is likely that the effects of antiresorptive therapy on bone mass will be more 
pronounced at the spine [102,438] and calcaneal QUS will be effected to a lesser 
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extent [254,256,439]. Therefore, higher odds ratios may have been obtained for LS 
BIVID if women on treatment were excluded. 
8.4 CONCLUSIONS AND FURTHER WORK 
Calcaneal QUS measurements were able to discdminate between patients with 
vertebral, hip, wrist and other fractures as well as axial DXA measurements. The three 
QUS devices assessed showed comparable discriminatory abilities, as did BUA and 
SOS measurements. Additional prospective fracture studies are required on contact 
and imaging devices to confirm the promising findings observed for water-based non- 
imaging devices. 
The combination of BIVID and QUS measurements did not significantly improve the 
discriminatory ability compared to either method alone. Further studies are required to 
confirm these results and to assess the cost effectiveness of such an approach, if 
adopted in clinical practice. 
Appendix: Combining QUS and BIVID Z-scores 
As stated in section 8.1.2.2, age-adjusted forward stepwise logistic regression was 
performed to assess whether QUS and BIVID measurements contribute independently 
to vertebral fracture discrimination, using the following equation: 
logit(p) =a+b Zous +C ZBMD+ d age Equation 8.1 
where logit(p) is the logit of the probability that a patient will suffer a vertebral fracture 
and represents the log odds, a is the constant, b and c are the regression coefficients, 
Zous andZBMDare the individual Z-scores for QUS and BIVID respectively and d is the 
regression coefficient for age. The odds ratios for QUS and BIVID are the exponents of 
b and c respectively i. e. eb and ec. If both QUS and BIVID measurements remain 
significant when placed into the same model, it means that both are contributing 
independently to vertebral fracture discrimination. It is then of interest to investigate 
whether the individual Z-scores for QUS and BMID can then be combined to give one 
Z-score for each individual with improved fracture discrimination. In the present 
investigation, 7-ous andZBMDwere combined as follows: 
Zcomb = (X ZOUS + O-GO ZIBMD Equation 8.2 
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where 0<a<1.0. 
In this appendix I have examined the hypothesis that the optimum value of a is b/b+c 
giving the equation: 




As the odds ratios for the individual QUS and BIVID measurements represent a one 
standard deviation decrease, the SDOf Zcomb is requiredSO Zcombgiven by Equation 8.3 
can be divided by its SID, so that logistic regression onZ-mmb iSconsistent with a one SID 
decrease. The SID Of 7--combcan be calculated as follows: we assume that Zous andZIBMD 
has a mean of zero and a SID of ±1 and have a correlation coefficient r. The 
regression equation between Zous andZBMD is: 
ZBMD =r Zous 
where the SEE is: 
SEE =±4 (1-r2 ) 
Therefore, 7--combcan be written: 
Zcomb '-- ((X + (1 _(X) r) 




The random errors in 7-comb are + (a + (1-oc) r) from the Zous term and ± (1 -cc) 
ý (1-r2) 
from the SEE. The SD Of 7-comb is obtained by combining the two sources of error: 
SDZcomb ""' ý ((a+ (1 -(x) r 
)2 + (1_()C)2 (1_r2 )) Equation 8.7 
(OC2 + 2a (1 -a) r+ (1 -a)2 r2 
+ (1 _(X)2 
((X2 + 2a r-2(X2 r+ 1 -2a+ OC2 
(2(x 2 (1-r) - 2a (1 - r) + 1) 
(1 - 2a (1 -a) (1-r)) 
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The hypothesis of Equation 8.3 was tested by combining SAH BUA and THIP BMID. In 
this case logistic regression gave b=1.056 and c=0.687. The correlation coefficient r 
betweenZSAH BUAandZTHIP BMDequals 0.38. a was varied in steps of 0.1 from 0 to 1.0 
and odds ratios calculated forZcombafter normalisation to the SID in Equation 8.7. 
The figure below shows the odds ratios obtained by combining SAH BUA and THIP 
BIVID Z-scores using equation 8.3, varying a from 0 to 1, in steps of 0.1. As can be 
seen when a equals zero or one, the odds ratios are simply the odds ratios for THIP 
BIVID and SAH BUA respectively. As a increases from zero, the odds ratios increase 
as both SAH BUA and THIP contribute independently to fracture discrimination, reach 
a peak and then decrease. The highest expected odds ratios peaks when a lies 
between approximately 0.55 and 0.65 (shaded area on figure). This is in agreement 
with a equalling 0.606 for SAH BUA in equation 8.3. Therefore, this shows that 
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Chapter 9 
Monitoring Skeletal Responses to 
Treatment Using QUS 
9.1 STUDY DESIGN 
9.1.1 Aims 
The aim of this chapter is to assess whether QUS can be used to monitor response to 
treatment in postmenopausal women on antiresorptive therapy, examined over a 
period of one year. For QUS to be used for monitoring purposes, it must show a 
response to treatment and display adequate long-term precision. Both these factors 
have been examined here to assess the potential of QUS for monitoring purposes. 
The correlation between changes in QUS measurement variables and changes in BIVID 
at the lumbar spine and hip has also been examined. 
9.1.2 Introduction 
Emerging evidence from large prospective fracture studies have indicated that QUS 
can identify individuals at risk of future fracture, who may benefit from therapeutic 
intervention. However, there is a lack of consensus on whether QUS could then be 
used to monitor response to therapy in these individuals over time and therefore axial 
DXA measurements may still be required for this purpose. 
Early cross-sectional studies revealed that QUS variables were significantly greater in 
women treated with oestrogen compared to non-users [244,249,254]. To date, there 
have been relatively few longitudinal studies assessing changes in QUS measurement 
variables in response to treatment. These longitudinal studies showed that QUS 
variables displayed significant increased in response to oestrogen [452], 
bisphosphonates [453], calcitonin [256], calcium [454] and combinations of 
antiresorptive therapy [439]. In contrast, several investigators have reported no 
significant treatment effects on calcaneal QUS measurement variables [410,455,456]. 
It is thought that bone densitometry assessment a within one or two years of starting 
treatment improves compliance and also identifies possible non-responders. 
Therefore, if QUS is to be used alone in clinical practice, without the need for additional 
assessment by DXA, it is important to determine whether QUS can monitor skeletal 
changes over a relatively short time. In this chapter, changes in QUS in response to 
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therapy have been examined over one year. These changes have been compared to 
the long-term precision of QUS to assess the longitudinal sensitivity of calcaneal QUS 




Questionnaires were sent to postmenopausal women one year after their first DXA and 
QUS scans, to determine whether they had commenced treatment and whether they 
would volunteer for follow-up assessment by DXA and QUS. Women who had 
diseases that affected bone metabolism or those on thyroid or corticosteroid therapy at 
baseline were not sent a questionnaire. Women who had started thyroid or 
corticosteroid therapy, or had any periods of immobilisation in the preceding 12 months 
were subsequently excluded and not offered follow-up scans. Two hundred 
postmenopausal women were suitable and had repeat BIVID and QUS measurements 
12 months after the initial baseline visit. These women were placed into one of three 
groups; (i) 128 women who had not taken oestrogen, bisphosphonate or calcium 
therapy in the preceding 12 months (controls); (ii) 41 women treated with oestrogen 
(n=28), bisphosphonates (n=10), high dose calcium (n=2) or combinations thereof 
(n=l), who were already on treatment at baseline (treated); (iii) 31 women treated with 
oestrogen (n=16), bisphosphonates (n=12), high dose calcium (n=2) or combinations 
thereof (n=l), who had commenced therapy shortly after the baseline visit (baseline 
treated). Of the treated women, 11 women had been on treatment less than two 
years, 7 women had been on treatment between two and four years, 11 women 
between four and six years, and 10 women had been on treatment more than 6 years. 
One woman could not recall when she had commenced treatment. All treated women 
were questioned regarding the degree of medication compliance over the preceding 12 
months but actual compliance was not assessed. Included in the control group were 
43 women enrolled in the seasonal study (Section 2.2, Chapter 2). The number of 
women in each group measured by DXA and the three QUS devices is shown in Table 
9.1. 
Table 9.1: Number of subjects measured by DXA and QUS. 
QUS 
Total DXA UBA SAH DTU 
Controls 128 117 110 116 87 
Treated 41 35 38 36 31 
Baseline Treated 31 31 26 30 17 
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9.1.3.2 Data analysis 
The baseline study group characterisfics were compared using Student's Mest. 
Changes in BIVID and QUS measurements from baseline to year one were expressed 
as percentage changes from baseline. The mean percentage change and its SEM 
were calculated for BIVID and QUS measurement variables for women in the control, 
treated and baseline treated groups. The distribution of absolute values at baseline 
and 1 year and the percentage changes were tested for normality and nonparametric 
statistics were subsequently applied to non-gaussian data. A two-tailed paired 
Student's Mest or Wilcoxon ranked-signed test were used to compare changes at year 
1 with the baseline values. Differences in the percentage changes in the control and 
treated groups at 1 year were assessed using ANOVA. The overall treatment effect for 
each BIVID and QUS measurement variable was defined as the difference in the 
percentage change in the baseline treated and control groups. The overall treatment 
effect was also expressed in T-score units so each measurement variable could be 
better compared, by dividing the difference in the changes at year 1 (in absolute units) 
by the young adult SD. 
To assess the ability of each measurement variable for measuring response to 
treatment the overall treatment effect (for the baseline treated group) was divided by 
the long-term precision. Long-term precision was estimated using the postmenopausal 
women enrolled on the seasonal study (section 2.2). These women were measured 
every 3 months over 24 months (BMD and UBA), 21 months (SAH) or 18 months 
(DTU). These results were normalised to that obtained for LS BMD. 
Linear regression and Spearman rank correlation analysis were used to examine the 
correlation, in the two treated groups combined and control group, between: (i) 
changes in BUA and SOS measured on the same device; (ii) changes in both BUA and 
SOS on the different QUS devices; (iii) changes in QUS and BIVID measurement 
variables; (iv) changes in the LS and hip BIVID measurements. 
9.2 RESULTS 
9.2.1 Patient characteristics 
Table 9.2 shows the baseline characteristics of the control and treated groups of 
women. Women in the control, treated and baseline treated groups were of similar age 
but the baseline treated women were significantly shorter and lighter than women in the 
control group. Women in the treated group had a significantly higher menopausal age 
compared to the control women. All the BIVID and QUS measurement variables were 
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significantly lower in the baseline treated group, and all but LS BIVID and UBA BUA 
were significantly lower in the treated group, compared to controls. The mean length of 
time the treated group had been on treatment at baseline was 3.8 years. 
Table 9.2: Baseline study group characteristics. Figures show the mean and SID 
Controls Treated Baseline Treated 
n 128 41 31 
Age (Yrs) 59.3(8.0) 58.3(8.4) 59.5(8.5) 
YSM (Yrs) 11.4(8.0) 14.8 (10.1)* 12.6(6.5) 
Height (cm) 161.4(5.6) 160.8(6.5) 158.9 (7.2)* 
Weight (kg) 65.2(11.3) 63.7(11.2) 60.9 (6.8)* 
BMI (kg /M2) 25.0(4.2) 24.6(4.1) 24.2(2.8) 
LS BMD g/CM2 0.943 (0.138) 0.910 (0.173) 0.806 (0.100)** 
FN BMD g/CM2 0.773 (0.111) 0.723 (0.146)* 0.662 (0.094)' 
THIP BMD g/CM2 0.896 (0.121) 0.830 (0.164)* 0.782 (0.107)' 
UBA BUA dB/MHz 69.7(14.4) 65.8(14.9) 58.8 (11.7)' 
UBA SOS m/s 1502.9 (7.2) 1500.1 (9.0)* 1497.5 (5.8)' 
UBA BV m/s 1608.6 (47.7) 1589.9 (54.2)* 1574.8 (35.8)' 
SAH BUA dB/MHz 71.9(14.9) 66.5 (15.2)* 61.5 (12.4)' 
SAH SOS m/s 1548.3 (30.7) 1537.9 (30.6)* 1527.1 (25.0)' 
SAHBMD g/CM2 0.513 (0.114) 0.466 (0.119)* 0.432 (0.093)** 
DTU BUA dB/MHz 52.4(6.2) 48.9 (8.8)* 46.5 (7.1)** 
DTU SOS m/s 1549.2 (10.6) 1542.9 (12.2)' 1541.7 (8.8)* 
Length of treatment (Yrs) na 3.8(2.4) na 
na, not applicable. 
P<0.05 vs. controls 
** P<0.001 vs. controls 
9.2.2 Changes in BMD and QUS measurements with treatment 
Figure la-k shows the percentage changes in BMD and QUS measurements from 
baseline to 1 year for the baseline treated and control groups. These data are 
summarised in column 1 and 3 of Table 9.3. After 1 year, only DTU BUA showed a 
significant decreases in the control group, although the decrease in THIP BMD 
(p=0.07) and increase in SAH BUA (p=0.07) approached significance. A significant 
increase in all BIVID and SAH measurements was observed as well as UBA BV in the 
baseline-treated group (Figure 9.1 and Table 9.3). After one year, BIVID had increased 
by 4.32%, 2.25% and 1.46% at the LS, FN and THIP. Sahara BUA, SOS and BIVID 
had increased by 8.82%, 0.45% and 7.78% respectively after 1 year and UBA BV 
increased by 0.46%. The increase in UBA BUA (p=0.07) and UBA SOS (p=0.06) 
approached significance when compared to baseline values. The increases from 
baseline to year 1 observed for the baseline treated group were greater than those 
observed for the treated group. With the exception of UBA SOS, UBA BV and DTU 
SOS, a significant difference was found for changes in all measurements between the 
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p <0.05 vs. controls. *p <0.05 vs baseline. ** p <0.001 vs baseline. 
Figure 9.1: Mean percentage change from baseline in the control and baseline treated groups 
for (a) LS BMD, (b) FN BMD, (c) THIP BMD, (d) UBA BUA, (e) UBA SOS, (f) UBA BV, (g) SAH 
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Figure 9.1 cont. : (i) SAH BMD, 0) 
DTU BUA, (k) DTU SOS. 
#p <0.05 vs. controls. *p <0.05 vs baseline. ** p <0.001 vs bas 
When the treated group were examined, which included the women who were already 
on treatment at baseline, BIVID at the LS, FN and THIP increased significantly in the 
treated group by 2.65%, 2.01% and 1.45% respectively (Table 9.3). Only SAH BUA 
increased significantly from baseline in the treated group, while none of the other QUS 
variables increased significantly. The difference in the percentage changes between 
the control and treated groups was significant for LS, FN and THIP BIVID. In contrast, 
the percentage change in QUS variables between the control and treated groups were 
not significant, although the difference for SAH BUA approached significance (p=0.08). 
Table 9.3: Mean percentage change (SEM) from baseline after 1 year in the control, treated and 
baseline treated groups. 
Controls Treated Baseline Treated 
LS BMD g/CM2 -0.11 (0.26) +1.23 
(0.49)ab +4.32 (0.47)ab 
FN BMD g/CM2 -0.28 (0.29) +1.69 (0.57)ab +2.25 (0.64)ab 
THIP BMD g/CM2 -0.46 (0.24) +1.40 (0.30)ab +1.46 (0.57)ab 
UBA BUA dB/MHz -0.72 (0.64) -0.05 (0.1.43) +3.53 (1.73) 
b 
UBA SOS m/s +0.04 (0.02) +0.03 (0.05) +0.08 (0.04) 
UBA BV m/s +0.14 (0.13) +0.20 (0.27) 0.46 (0.22)a 
SAH BUA dB/MHz +2.02 (0.82) +4.99 (1.08)a +8.82(2 o5)ab 
SAH SOS m/s -0.07 (0.07) +0.09 (0.13) +0.45 (0.14) 
ab 
SAHBMD g/CM2 +0.28 (0.72) +2.74 (1.63) +7.78 (1.93)ab 
DTU BUA dB/MHz -1.57 (0.45)a -0.42 (0.71) +0.82 (1.06)b 
DTU SOS m/s +0-01 (0.05) +0.09 (0.08) +0.15 (0.08) 
a p<0.05 vs baseline 









Chapter 9- Monitohnq 
The overall treatment effect for each measurement variable, defined as the difference 
in the mean percentage changes between the baseline treated and control groups, is 
shown in Table 9.4 and Figure 9.2. 
Table 9.4: Overall treatment effect expressed as a percentage and in T-score units for the 
baseline treated group. 
Overall Treatment Effecta 
% T-score units b 
LS BIVID g/CM2 4.43 0.31 
FN BIVID g/CM2 2.53 0.16 
THIP BIVID g/CM2 1.92 0.14 
UBA BUA dB/MHz 4.25 0.16 
UBA SOS m/s 0.03 ns 0.08 ns 
UBA BV m/s 0.32 ns 0.11ns 
SAH BUA dB/MHz 6.80 0.28 
SAH SOS m/s 0.52 0.32 
SAH BMD g/CM2 7.50 0.32 
DTU BUA dB/MHz 2.38 0.19 
DTU SOS m/s 0.14 ns 0.25 ns 
a the overall treatment effect is defined as the difference between the 
control and baseline treated group. 
b the overall treatment effect in absolute units divided by the young 
adult SID (data from Table 4.6). 
ns no significant treatment effect (no significant difference between 
treated and control groups). 
The overall treatment effect was greatest for SAH BMD, SAH BUA, LS BIVID and UBA 
BUA with values of 7.50%, 6.80%, 4.43% and 4.00% respectively. SAH SOS 
measurements displayed a small overall treatment effect of 0.52% but this was 
statistically significant. The overall treatment effect for UBA SOS, UBA BV and DTU 
SOS was considered insignificant as there was no significant difference in % changes 
between the baseline treated and control groups for these measurement variables 
(Table 9.3). When the overall treatment effect was expressed in T-score units, which 
takes into account the different sized denominators and clinical ranges, the overall 
treatment effect was largest for LS BIVID and the SAH QUS measurements, being 
approximately 0.30 T-score units (Table 9.4). The remaining variables that displayed a 
significant treatment effect yielded values of approximately 0.16 T-score units for the 
overall treatment effect. 
The overall treatment effect, expressed as a percentage, was divided by the long-term 
precision for each measurement variable (Table 9.5, column 3). This provides an 
indication of the ability of each variable to measure statistically significant longitudinal 
changes, with higher values representing better ability to detect changes. The LS 
BIVID 
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Figure 9.2: Overall treatment effect defined as the difference between changes measured in the 
baseline treated and control groups, expressed in T-score units by dividing the difference in 
absolute units by the young adult population SID. ns, no significant treatment effect observed. 
yielded the highest ratio of 2.89 and all measurement variables were subsequently 
normalised to the ratio for LS BIVID (Table 9.5, column 4). When normallsed to LS 
BMD, the ratio of the treatment effect over precision was 0.39 and 0.54 for FN and 
THIP BMD. The results for the QUS measurements were lower still, with values 
ranging from 0.17 to 0.36 for those variables showing a significant treatment effect 
(Figure 9.3). 
Table 9.5: The ratio of the treatment effect over long-term precision and the ratio normalised 
to LS BMD. 
LT Precision Treatment effect/ 
(CV%) precision Ratio to LS BMD 
LS BMD g/CM2 1.53 2.89 1.00 
FN BMD g/CM2 2.22 1.14 0.39 
THIP BMD g/CM 2 1.23 1.56 0.54 
UBA BUA dB/MHz 8.42 0.50 0.17 
UBA SOS m/s 0.20 0.17ns 0.06 ns 
UBA BV m/s 1.11 0.29ns 0. , ons 
SAH BUA dB/MHz 6.56 1.04 0.36 
SAH SOS m/s 0.84 0.62 0.2 
SAH BMD g/CM2 7.95 0.94 0.31 
DTU BUA dB/MHz 3.43 0.69 0.24 
DTU SOS m/s 0.45 0.3 , ns 0. ,, ns 
ns no signficant treatment effect. 
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Figure 9.3: The ability of BIVID and QUS measurements to measure longitudinal changes 
calculated by dividing the overall treatment effect by long-term precision. These results are 
normalised to that for LS BMD. ns, no significant treatment effect observed. 
9.2.3 Correlation between changes in QUS and BIVID measurements 
The correlation between the changes in QUS measurements after 1 year in the control 
and baseline treated groups with the changes in BIVID at the spine and hip are shown 
in Table 9.6. For the majority of comparisons in the control group, the correlations did 
not reach significance and, for the eight comparisons that did reach statistical 
significance, the correlation coefficients were low ranging from 0.19 to 0.29. This 
indicates that only approximately 5% of the changes in QUS measurements could be 
explained by changes in axial BIVID. With the exception of the UBA BV and FN BIVID 
comparison in the baseline treated group, none of the changes observed for QUS 
measurement variables were correlated with the changes observed for BIVID 
measurements. In addition, changes in UBA BV were negatively associated with 
changes in FN BIVID. 
Table 9.6: The correlation (r) between changes in BIVID and QUS measurement variables in the 
baseline treated and control groups. 
Controls Basel i ne-treated 
LS BMD FN BMD THIP BMD LS BMD FN BMD THIP BMD 
UBA BUA dB/MHz 0.03 -0.12 0.1 0.05 -0.17 0.05 
UBA SOS m/s 0.19* 0.20* 0.19* 0.01 -0.23 0.04 
UBA BV m/s 0.16 0.19* 0.29* 0.01 -0.25* 0.09 
SAH BUA dB/MHz 0.09 0.22* 0.15 0.13 0.12 0.14 
SAH SOS M/s 0.03 0.19 -0.02 0.15 -0.07 0.14 
SAH BMD g/Crn2 0.08 0.24* 0.07 0.13 0.00 0.11 
DTU BUA dB/MHz 0.26* -0.05 0.06 0.04 0.19 0.11 
DTU SOS M/S 0.06 
_O. 
25* 0.17 0.03 -0.23 0.00 
* P<0.05 
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When the changes in BUA were compared to the changes in SOS measured on the 
same device, only the changes in SAH BLIA and SAH SOS were correlated in the 
baseline treated and control groups (Table 9.7). The changes in BUA and SOS on the 
UBA and DTU were not significantly correlated. When the changes in the different 
BIVID measurements were compared, changes in LS were correlated with changes in 
FN BIVID in the baseline treated group only, while the changes in FN BIVID was 
significantly correlated with changes in THIP BIVID as expected yielding correlation 
coefficients of approximately 0.41 (Table 9.7). 
Table 9.7: The correlation (r) between changes in BUA and SOS measurements measured on 
the same device and between changes in LS and hip BIVID measurements in the baseline- 
treated and control groups. 
Controls Treated 
Qus 
UBA BUA vs SOS 0.03 0.16 
SAH BUA vs SOS 0.31 ** 0.58** 
DTU BUA vs SOS -0.16 0.06 
BMD 
LS vs FN BMD 0.05 0.11 
LS vs THIP BMD 0.41 ** 0.13 
FN vs THIP BMD 0.40** 0.42** 
** 
P<0.001 
Table 9.8 shows the correlation between the different BUA and SOS measurements 
measured on the three QUS devices. None of the changes in BUA on one device 
correlated with the changes in BLIA observed on the other devices. In contrast, 
changes in SOS measured on one device correlated significantly with changes 
observed on the other devices, with all comparisons yielding correlation coefficients 
above 0.50 in both the treated and control groups. 
Table 9.8: The correlation (r) between changes in BUA and SOS measured on the different 
QUS devices in the baseline treated and control groups. 
BUA SOS 
Controls Treated Controls Treated 
UBA vs SAH 0.20 0.01 0.63** 0.51 ** 
UBA vs DTU 0.09 0.22 0.67** 0.70** 




There are two important factors that determine a measurement techniques ability to 
monitor skeletal changes: the response of the bone being measured to treatment and 
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the sensitivity of the technique to detect changes. In terms of calcaneal QUS, it is 
important that the calcaneus responds to treatment and that the precision of QUS 
should be small compared to the expected changes. The International QUS 
Consensus Group report of 1997 suggested that the issue of the use of QUS to monitor 
disease progression or response to treatment needed to be addressed [228]. The 
United Kingdom National Osteoporosis Society recommends that DXA should be used, 
rather than QUS, to assess treatment efficacy in an individual [375]. The aim of this 
part of the study was to assess whether QUS can be used to monitor skeletal changes 
over one year. 
9.3.1 Changes in BMD and QUS measurements with treatment 
After one year of treatment in women who were already on treatment at baseline 
(treated group), only the BIVID measurements displayed a significant increase 
compared to baseline values, while the QUS measurements did not increase 
significantly (Table 9.3). The increases in BIVID were comparable to those reported in 
the literature for axial BIVID measurements [125,359]. However, the increases in BIVID 
observed with antiresorptive therapy occur in the first few years after initiation of 
treatment, after which time BIVID changes very little [102]. The mean length of time the 
women had been on treatment at baseline in the treated group was 3.8 years (Table 
9.2) and therefore, much of the increases expected with treatment would have taken 
place. Nevertheless, BIVID measurements did display a significant increase (Figure 
9.1) after 1 year in the treated group, which is consistent with a study that found 
oestrogen therapy exerted continuous effects on BIVID when taken for 10 years [103]. 
The group of women who commenced treatment shortly after the baseline visit 
(baseline treated) more closely represent the groups of women assessed in 
longitudinal studies who commence treatment at baseline. Therefore, results for the 
baseline treated women will be discussed here. 
For the group of women who commenced treatment at baseline, all BIVID and SAH 
measurements and UBA BV increased significantly after one year of treatment 
compared to baseline values (Figure 9.1 and Table 9.3). The increases in UBA BUA 
and UBA SOS approached significance with p values of 0.07 and 0.06 respectively. 
BIVID at the LS, FN and THIP increased by 4.32%, 2.25% and 1.46% respectively. The 
increase in LS BIVID was similar to that reported by Gonelli et al for women treated with 
alendronate for one year [453]. 
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BUA measured on the SAH displayed the largest increase of 8.8% after one year 
(Table 9.3), which was greater than that reported in the literature for BUA increases 
after two years of salmon calcitonin therapy [256] or alendronate therapy [453]. The 
increase in SAH BUA was also greater than that found on the UBA and DTU (Table 
9.3). A possible reason for this is a possible small shift in calibration for SAH BUA 
measurements that was not detected by QC measurements. Women in the control 
group displayed an unexpected increase in SAH BUA of 2.02% which approached 
significance (p=0.07). This may indicate that SAH showed a small upward drift during 
the study period. However, neither the daily QC measurements nor the weekly in vivo 
measurements seemed to confirm this (Figures 3.1 and 3.3). 
Of the SOS variables only that measured on the SAH displayed a significant increase 
compared to baseline values of 0.45% which is similar magnitude to that found for 
women on salmon calcitonin [256] or alendronate therapy [453]. SOS measured on 
the UBA or DTU did not increase significantly after one year and was not significantly 
different to the changes observed for women in the control group (Table 9.3), a finding 
reported in other longitudinal studies. A study of 248 institutional ised women aged 62 
years and over found that SOS decreased in women on calcium and vitamin D therapy 
by the same amount as women on no treatment [454]. A study by Rosenthall et al of 
673 women on antiresorptive therapy reported that SOS decreased significantly after 
one year of treatment and decreased further still up to four years after baseline [439]. 
A possible reason for the lack of response for SOS measurements is the adverse affect 
of temperature on the precision of QUS results. The SEM for the SOS measurements 
in all three groups was large compared to the percentage changes observed (Table 
9.3). As shown in Chapter 3, SOS measurements are affected by the temperature of 
the water bath and ambient temperature. When the expected variation in SOS over the 
range 20-250C was expressed in relation to the young adult SID the size of the 
temperature effect was large, especially for SOS measured on the UBA and DTU 
(Figure 3.4). This may explain why no significant treatment effects were observed for 
the UBA or IDTU SOS measurement variables. It has been suggested that combined 
parameters such as estimated heel BIVID provided by the SAH or stiffness provided by 
the Lunar Achilles device may increase precision as BUA and SOS have opposite 
temperature coefficients. This increase in precision may allow changes in QUS 
variables to be measured more accurately. The SAH BIVID did display a significant 
increase after one year for the baseline treated group, however, this was largely due to 
the large increase observed for SAH BUA (Table 9.3). Further longitudinal studies on 
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combined parameters such as SAH BIVID are required, as well as the adverse effects 
of temperature on the accuracy of serial QUS measurements. 
Only the DTU BUA displayed a significant decrease after one year in the control group 
while the other BIVID and QUS measurement variables did not change significantly from 
baseline (Table 9.3). These changes for control women can be compared to two 
longitudinal studies on changes in calcaneal QUS in untreated women [250,251]. The 
study by van Daele et al, which examined the changes in BUA and SOS in 543 men 
and women over a median follow-up of 1.4 years, reported that SOS decreased by - 
0.8% per year [251]. However, BUA did not decrease significantly in this study [251]. 
A two-year longitudinal study by Schott et al reported significant decreases in SOS but 
not BLIA or FN BIVID for untreated postmenopausal women [250]. However, it must be 
noted that the decreases in SOS reported in both these longitudinal studies were large 
compared to those observed in cross-sectional studies. Therefore, the decreases in 
SOS may reflect machine drift rather than disease progression. The changes in BIVID 
associated with disease progression are smaller than those associated with treatment 
and therefore one may not expect significant changes in either BIVID or QUS variables 
measured over a time of just one year. 
The overall treatment effect, defined as the difference in the mean percentage change 
in the control and baseline treated groups, ranged from approximately 7.50% for SAH 
BIVID to 0.52% for SAH SOS (Table 9.4). The overall treatment effect for UBA SOS, 
UBA BV and DTU SOS was considered not significant as no significant differences 
were observed between the control and baseline treated groups for these variables 
(Table 9.3). The overall treatment effect for BIVID measurements was greatest for LS 
BIVID and was almost twice as large as that observed at the femoral neck. This is 
consistent with other studies examining differential rates of increase in BIVID at different 
skeletal sites that concluded that the LS was the optimal site for measuring longitudinal 
changes in BIVID [438,457]. The overall treatment effect for UBA BUA, SAH BUA and 
DTU BUA were 4.0%, 6.8% and 2.4% respectively (Table 9.4) and 0.52% for SAH 
SOS. These values for BUA and SAH SOS were similar to those reported for BUA 
measured on the Lunar Achilles when the overall treatment effect was assessed in 
women treated with oestrogen [460], alendronate [453], salmon calcitonin [256] and 
calcium [454]. 
When the overall treatment effect was expressed in T-score units to take into account 
the different sized mean values and clinical ranges, the treatment effect was similar for 
LS BMD and BUA, SOS and BMD measured on the SAH, averaging 0.31 T-score units 
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(Table 9.4). The overall treatment effect for hip BIVID and the other significant QUS 
variables averaged 0.16 and therefore was half that observed for LS BIVID and SAH 
QUS measurement variables. 
9.3.2 The responsiveness of BIVID and QUS measurements in relation to 
long term precision 
To fully assess the sensitivity of QUS to monitor skeletal changes, the ratio of precision 
and responsiveness is important [458]. For example, a study by Blake et al reported 
that lateral spine BIVID showed a larger response to two years of bisphosphonate 
therapy than PA LS BMD. However, once the long-term precision was taken into 
account, lateral spine BIVID performed slightly worse than LS BIVID for measuring 
skeletal changes [457]. Any change observed in BIVID or QUS measurements must 
exceed the variability inherent in the measurement process so that changes can be 
considered statistically significant [459]. The overall treatment effect was divided by 
the long-term precision (Table 3.6) and the larger the ratio the higher the statistical 
significance of the measured response to treatment. Long term precision values were 
used as they reflect additional error sources not observed in the short term such as 
machine drift, recalibration effects, changes in patient weight and temperature 
variations. Other factors that may influence the long-term precision of calcaneal QUS 
measurements include the influence of changes in weight-bearing activity [268,269], 
changes in the surrounding soft-tissue composition and thickness [282,283] and 
changes in marrow composition. 
The ratio of treatment effect over precision was largest for LS BMD and so the ratios 
for the other measurements were normalised to that for LS BMD (Table 9.5 and Figure 
9.3) so the comparison was easier to make. The ratios for FN and THIP BMD were 
half that observed for LS BMD and the ratios for QUS measurements were smaller still. 
The ratios for the significant QUS measurement variables ranged from 0.36 for SAH 
BUA (versus one for LS BMD) to 0.17 for UBA BUA (Table 9.5). Many of the 
longitudinal studies on changes in QUS with treatment have not reported the changes 
in relation to the long term precision. However, a study by Herd et al of 152 women in 
a double-blind placebo-controlled study of cyclical etidronate found that QUS 
measurements did not increase significantly with treatment and once divided by long 
term precision, the ratio was not statistically significant from zero [456]. 
It was difficult to compare the effectiveness of BUA and SOS measurements to monitor 
response to treatment as UBA and DTU SOS did not display significant increases with 
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treatment over the relatively short time pedod of one year. However, the overall 
treatment effect for SAH BUA and SAH SOS was similar when expressed in T-score 
units (Table 9.5). However, when long-term precision was taken into account, the ratio 
was almost twice as large for SAH BUA compared to SAH SOS. Further studies are 
required over longer periods to assess whether BUA and SOS are comparable in their 
ability to monitor skeletal changes. 
QUS imaging at the calcaneus allows for the more accurate placement of a 
measurement ROI and so reduces a large error source caused by the heterogeneous 
nature of the calcaneus. Several investigators have reported an improvement in the 
short-term precision of QUS measurements using imaging technology 
[216,218,286,377] leading to speculation that this would improve the ability of QUS to 
assess longitudinal changes. To date, there have been no long term precision studies 
or longitudinal studies for QUS imaging. However, in the present study the 
improvement in precision observed for the IDTU device in the short term was not seen 
in the long term (Table 3.6). The IDTU displayed a comparable monitoring ability to the 
UBA but was worse than that observed with the SAH device. However, the IDTU was 
in the early stages of commercial development and may not represent the full potential 
of QUS imaging technology. In particular, the lack of a temperature controlled water 
bath may be a significant limitation. Additional studies are required, both on the DTU 
and other commercial imaging devices, to assess whether improvements in precision 
lead to improvements in longitudinal sensitivity. 
9.3.3 Correlation between changes in QUS and BIVID measurements 
When the changes observed for QUS variables in untreated women were compared to 
those observed for axial BIVID measurements, the correlations were either low or not 
statistically significant (Table 9.6). Only nine comparisons out of 24 reached statistical 
significance in untreated women and five of these were obtained when QUS changes 
were compared to FN BIVID changes (Table 9.6). Only about 5% of the variance in the 
changes in QUS measurements could be explained by changes in axial BIVID in 
untreated women. In the case of the treated women, only changes in UBA BV were 
correlated with changes in FN BIVID, but even this result was unexpected as the 
changes UBA BV were negatively associated with changes in FN BIVID (Table 9.6). 
These findings are similar to those reported by Rosenthall et al [439]. They compared 
changes in calcaneal QUS with changes in axial BIVID in 673 women on antiresorptive 
therapy and found either non-significant or weak correlations between changes in QUS 
and BIVID measurements [439]. In contrast, higher correlations have been observed 
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when changes in LS BIVID were compared to changes in calcaneal QUS in a study of 
women treated with salmon calcitonin [256] and alendronate [460]. It would appear 
that changes in QUS and BIVID variables were independent of one another in the 
present study. This may have been due to the fact that QUS variables respond 
differently to axial BIVID in response to ageing or treatment or that the study time period 
was insufficient to show meaningful changes in QUS due to the relatively poor long 
term precision of QUS, with changes in QUS variables being dominated by random 
errors rather than true changes in skeletal status 
When the changes in BLIA and SOS measured on the same device were compared, 
only measurements on the SAH were significantly correlated with one another (Table 
9.7). The results for the other two devices are difficult to interpret as neither UBA SOS 
nor DTU SOS displayed significant changes in the control or treated groups. Changes 
in SAH BUA explained 10% and 34% of the changes in SAH SOS in the control and 
treated groups respectively. 
When changes in BUA or SOS on each device were compared, only changes in SOS 
on the different devices were correlated. These correlations were high relative to those 
obtained between BIVID and QUS measurements and even LS and hip BIVID 
measurements, which was rather surprising considering the non-response of SOS on 
the UBA and DTU. This may have been a spurious result as one could speculate that 
the reason for the high correlation is that changes in SOS reflect changes in the 
ambient or water bath temperature: all three SOS measurements display a negative 
relationship with temperature and therefore an increase or decrease in temperature 
would produce similar changes in SOS on each device. 
Correlations of similar magnitudes to that observed for BUA and SOS comparisons 
were observed between changes in FN and THIP BIVID measurements (Table 9.7). 
The correlation between the changes in LS BIVID and hip BIVID measurements were not 
significant in the treated group of women. Therefore, BIVID at one site cannot predict 
changes that occur at other skeletal sites with any accuracy even when measured 
using the same measurement technique. 
Studies over longer time periods may show higher correlations between changes in 
spine and hip BMD measurements, BUA and SOS measurements or QUS 
measurements on different devices as the changes expected in BMD and QUS 
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measurements in response to treatment would be larger with respect to long term 
precision. 
9.3.4 Study Limitations 
One limitation of this study was the relatively short time over which the study was 
performed. Changes in QUS measurements variables expected after one year are 
small relative to the precision error and even for DXA of the spine, longer time periods 
are recommended to assess an individuals response to treatment. However, skeletal 
responses to treatment are greater in the first few years of therapy [102]. This part of 
the study is ongoing and to date over half of the study population have returned for a 
two year visit and it is hoped that these women will be followed up for an extended time 
period. The changes expected after several years of treatment will be larger with 
respect to long-term precision than those expected after one year. Therefore, a more 
detailed analysis of changes in QUS response to treatment and parallel changes in 
axial BIVID can be made. 
Another limitation was that only about half of the women commenced treatment at the 
baseline visit (baseline treated group) with the remaining treated women having been 
on treatment for, on average, 3.8 years (treated group). It is known that increases in 
BMID associated with antiresorptive therapy occur in the first few years of treatment 
with a plateau effect thereafter [102]. Incorporation of QUS measurements into 
controlled clinical trials better addresses the issue of how QUS responds to treatment, 
with parallel assessment of BIVID by established techniques as recommended by the 
International QUS Consensus Group [228]. A useful study would assess changes in 
calcaneal QUS with changes in calcaneal BMID and structural and architectural 
parameters, perhaps using high resolution MRI, to examine whether the calcaneus is 
responsive to treatment and if changes in QUS reflect changes in BIVID or other bone 
properties. 
There may have been a selection bias towards more healthy individuals in the control 
group as these women are more likely to return for follow up assessment. In addition, 
it has been shown that participants in such trials may change their behaviour in 
response to being studied [461]. A study of premenopausal women found that BIVID 
testing and osteoporosis education led to individuals being more likely to improve 
lifestyle behaviour such as stopping smoking or increasing calcium intake [461]. A 
study by Rubin et al found that 94% of women with low BIVID results and 56% with 
normal results, took measures to improve bone mass and decrease the risk of fracture, 
such as increase calcium intake and exercise [462]. When interviewing the study 
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participants at the follow-up visit it was noted that a large percentage reported a 
change in lifestyle in response to their DXA result and this was not restricted to those 
with low BIVID results. 
9.4 Conclusions 
With the exception of UBA velocity measurements and DTU SOS, all the BIVID and 
QUS showed a significant response to treatment after one year in the baseline treated 
group. However, once long term precision was taken into account, DXA BMD 
measurements of the lumbar spine was the optimum measurement site for monitoring 
response to treatment. Changes in QUS measurements did not reflect changes that 
occurred in axial BIVID and therefore direct assessment of the axial skeleton is required 
for this purpose. At present, the time required to assess significant changes in an 
individual would most likely exceed that needed for clinical decision making regarding 
response to treatment. Advances in QUS technology and quality control procedures 
may increase the utility of QUS to monitor skeletal changes in the future. 
Further carefully controlled clinical trials are needed, over longer time periods, to fully 
assess the sensitivity of QUS to monitor skeletal changes, both in response to 
treatment and disease progression. More importantly, but more difficult to assess, it is 
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Chapter 10 
QUS and the Assessment of 
Skeletal Status during Adolescence 
10.1 STUDY DESIGN 
10.1.1 Aims 
There are two main objectives to this part of the study, to further assess whether QUS 
can be used in longitudinal studies and whether QUS can be used to assess skeletal 
development during adolescence. The aim was to examine: (i) the effect of ballet 
dance training during adolescence on BIVID and QUS measurement variables; (11) 
changes in QUS variables during adolescence with respect to the event of menarche; 
(111) whether changes in QUS during adolescence reflect changes in BMD. 
10.1.2 Introduction 
One of the most important determinants of BIVID during adult life is bone mineral 
acquisition during adolescence and early adult life [463]. Skeletal mass doubles 
between the onset of puberty and young adulthood [464] and therefore it is important 
that peak bone mass is optimised to decrease the risk of osteoporosis in later life. It is 
estimated that approximately 80% of the total variance in BIVID can be attributed to 
genetic factors, but modifiable environmental factors such as exercise and calcium 
intake can determine whether an individual reaches their genetic potential in terms of 
bone mass [465]. 
Weight-bearing activity during childhood and adolescence has been shown to be a 
determinant of bone mineral accrual, with more active individuals having higher bone 
mass than more inactive individuals [32,466-469]. However, excessive exercise during 
the critical years of adolescence can lead to delayed menarche [27,470,471] and 
amenorrhoea or oligomenorrhoea [26,27,57,470,471]. This hypo-oestrogenic state 
may partially or entirely override the beneficial effects of exercise and lead to lower 
than average BIVID [27,29,56-58], which may be irreversible once normal menses 
return [28]. 
The training demands on ballet dancers have increased over the years, subsequently 
potential dancers begin training at an earlier age, and these girls will strive to stay slim 
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in what is a competitive discipline [472]. Ballet training during adolescence can delay 
menarche [28,471] and lead to menstrual disturbances [28,46,471], that can adversely 
effect BIVID [26,28,56]. The aim of this part of the study is to determine whether QUS 
can detect the effects of intensive ballet dance training during adolescence on skeletal 
status. 
To date there have been few studies examining the use of QUS in children and 
adolescents [473-478]. These studies have shown that QUS measurement variables 
increase with age during childhood and adolescence (473,474,476,478] and are 
correlated with BIVID at axial and appendicular skeletal sites [473,474]. In the present 
chapter, the effect of the event of menarche on QUS measurements is examined. The 
correlation between changes in QUS observed during the three-year study period and 
changes in BMID are also examined to determine whether changes in QUS reflect 
changes in BIVID. 
10.1.3 Methods 
10.1.3.1 Subjects 
A total of 87 girls aged 11-17 years were recruited from a secondary school and two 
performing arts schools (see Chapter 2). These girls were recruited in a three-year 
longitudinal study to examine the effects of ballet dance training on development and 
BIVID (Study investigator Dr Nicola Keay). A total of 61 girls completed the study at 
three years. BMD measurements of the spine (PA and lateral) hip and total body, body 
composition by DXA and calcaneal QUS assessment were performed annually. The 
DTU QUS device was not available at the beginning of this study (September 1996) 
and therefore QUS measurements on the DTU began one year after the initial baseline 
visit. Due to a technical problem with the DTU, SOS measurements were not available 
for six girls measured two years from baseline. Evaluations were made of growth, 
body proportions, pubertal development and menstrual history at six-month intervals 
but only the annual data are examined here. Only some of these data are presented in 
this chapter. 
For the first part of the study, the effect of dance training on QUS measurements was 
assessed. At the performing arts schools, all girls follow the same dance programme 
of approximately 11 hours of training per week for the first two years of schooling (i. e. 
aged 11-13 years), subsequently girls choose either the ballet or the musical theatre 
course that involves approximately 11 or 18 hours of dance training per week 
respectively. The 87 girls were placed into one of five groups according to their age, 
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which school they attended and the amount of dance training they did per week: (i) 14 
girls from the performing arts school aged 11-13 years (Young Dancers); (ii) 20 girls 
from the normal secondary school aged 11-13 years (Young Controls); (iii) 19 girls from 
the performing arts school who specialised in ballet aged 14-16 years (Older Dancers), 
(iv) 17 girls from the normal secondary school aged 15-16 years (Older Controls); (v) 
17 girls from the performing arts school who specialised in musical theatre (Theatre). 
The second part of the study the 87 girls were treated as one group and changes in 
QUS during adolescence were assessed in relation to menarche. 
10.1.3.2 Data analysis 
10.1.3.2.1 The effect of dance training on BMD, QUS and development 
The mean (and SEM) of BIVID, QUS and anthropometric measurement variables was 
calculated at baseline, year 1, year 2 and year 3. To take into account girls that 
dropped out during the study, the difference in each variable between visits was 
calculated and this was added on to the mean of the previous visit. The baseline and 
follow-up study group characteristics were compared using Student's Mest. The young 
dancers were compared to the young controls, the older dancers were compared to the 
older controls and theatre group, and the theatre group was compared to the older 
controls. Changes in measurement variables from baseline to year 3 were expressed 
in absolute units and averaged for each study group and the mean total change for 
each study group were compared using a two-tailed Student's Mest. The mean total 
change over three years for each measurement variable in each study group was also 
expressed in T-score units so each measurement variable could be better compared, 
by dividing the mean change by the young adult SID (Table 4-6). 
10.1.3.2.2 Changes in QUS during adolescence 
The longitudinal data taken from four time points (three for the DTU) were used to 
examine changes in QUS during adolescence in relation to the event of menarche. 
The correlation between changes in BIVID and QUS measurements with time since 
menarche was examined using regression analysis. 
Linear regression analysis was used to examine the correlation between (i) changes in 
QUS and BIVID measurements; (ii) changes in BUA and SOS measured in the same 
device; (iii) changes in both BUA and SOS measured on the different devices; (iv) 
changes in LS and THIP BMD. 
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10.2 RESULTS 
10.2.1 The effect of dance training on BMD, QUS and development 
10.2.1.1 Baseline Characteristics 
Table 10.1 shows the baseline characteristics of the different study groups. The two 
younger and the three older study groups were matched for age. The young dancers 
had a mean age of menarche of 14.3 years which almost reached statistical 
significance (p=0.06) when compared to the mean menarchal age of 13.3 years for the 
young controls. The mean age of menarche for the older controls was 12.5 years, 
which was significantly younger than that of 14.2 and 13.5 years observed for the older 
dancers and theatre groups respectively. With the exception of UBA SOS and DTU 
SOS, none of the measurement variables were significantly different when the young 
dancers were compared to the young controls. In contrast, when the older dancers 
were compared to the older controls and theatre students, the BIVID measurements 
were significantly lower. Of the QUS measurement variables, only DTLI SOS was 
significantly lower in the older dancers and theatre students compared to controls. The 
theatre students had significantly less fat mass and % body fat compared to the older 
controls. 
10.2.1.2 Changes in measurement variables over three years 
Figure 10.1 displays the changes in the BIVID, height and QUS measurements over the 
three-year study period. BIVID measurements increased significantly in both the young 
controls and young dancers over the three years and at each time point there was no 
significant difference in mean BIVID at the spine or hip. Both the young dancers and 
young controls displayed large increases in height over the three years but from year 1 
onwards, the young dancers were significantly shorter than the young controls. 
When the changes in QUS measurements were compared in the young study groups, 
BUA increased in both young dancers and young controls although the increases 
observed for young dancers tended to be larger. At no time point did BLIA on any of 
the devices differ significantly between the young dancers and controls. SOS 
measurements followed a less consistent pattern. UBA SOS increased in both the 
young dancers and young controls but at a greater rate in the young dancers so that 
after one year, UBA SOS was no longer significantly lower in the young dancers. SOS 
measured on the SAH increased slightly in the young dancers but actually decreased 
by approximately 10 mls over the three years in the young control group. However, 
there were no significant differences in SAH SOS at any time point between the young 
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Figure 10.1: Changes in measurement variables over the three-year study period for the 
different study groups for (a) LS BMD (young groups), (b) LS BIVID (older groups), (c) THIP 
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Figure 10.1 cont.: (g) UBA BUA (young groups), (h) UBA BUA (older groups), (i) UBA SOS 
(young groups), 0) UBA SOS (older groups), (k) UBA BV (young groups), (1) UBA BV (older 
groups). 
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Figure 10.1 cont.: (s) DTU BUA (young groups), (t) DTU BUA (older groups), (u) DTU SOS 
(young groups) and (v) DTU SOS (older groups). 
DTU SOS followed a similar pattern to that of SAH SOS, with the young controls 
showing a decrease of 7 m/s over the two years and the young dancers showed a 
small increase which meant, that by year 3, the young dancers did not have 
significantly lower DTU SOS than the young controls. The UBA BV measurement 
increased in the young dancers but remained stable in the young controls but due to 
the large SEM, UBA BV was not statistically different between the two groups. 
The increases observed in spine and hip BIVID measurements in the older groups were 
smaller than that observed for the younger groups. However, BMU measurements 
increased in all three older groups. The older dancers and theatre students tended to 
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the older dancers compared with the older controls after one year but by year 2 the two 
groups had similar LS BIVID values. The theatre students had significantly greater LS 
BIVID at all time points compared to the older dancers. A similar pattern to that 
observed for LS BIVID was observed for THIP BMD, where the older dancers had 
similar THIP BIVID to that of the older controls by year 2 but the theatre students faired 
best with significantly greater BIVID than the older dancers at all time points. The older 
dancers and theatre students increased in height over the three years by approximately 
2.5 cm, whereas the older controls gained very little in height. The older dancers were 
significantly shorter than the older controls at baseline and year 1 but by year 2, they 
had caught up and the difference between the two groups was no longer significant. 
As seen for the younger groups, the changes in QUS over the three years did not 
appear to follow a simple expected increase as observed for BIVID measurements. The 
older controls showed a significant decrease in UBA BUA, UBA BV, SAH SOS and 
DTU SOS while the other QUS measurements variables changed very little in this 
group. The older dancers showed large increases in UBA BV, SAH BUA and a smaller 
but significant increase in DTU BUA and UBA SOS and by year three UBA BUA and 
UBA BV were significantly greater than that observed for the older controls. The 
theatre students showed increases in UBA BV, SAH BUA and DTU SOS but a 
decrease in UBA BUA over the three years and tended to yield intermediate or similar 
values to the other two groups. With the exception of UBA BUA and UBA BV, the older 
groups yielded similar QUS values by the end of the study period. 
Table 10.2 shows the total absolute gain in the measurement variables over the three- 
year study period for the different study groups. When the two younger groups were 
compared, the increases in BIVID observed for the young dancers were similar to those 
observed for the young controls. In contrast, the young dancers showed significantly 
greater increases in QUS measurement variables compared to the young controls. 
When the older groups were compared, the increases in BIVID measurements in the 
older dancers were significantly greater than those seen in the older controls and in 
several cases were significantly greater than the increases seen in the theatre 
students. As for BIVID, the older dancers displayed significantly greater increases in 
QUS measurements over the three years than the older controls. The difference in the 
rate of increases between these two groups was quite large in several comparisons 
due to the fact that the older controls displayed significant decreases in four of the QUS 
measurement variables. The theatre students tended to show intermediate increases 
in both BIVID and QUS increases compared to the older controls and dancers. 
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To better compare the gains in BIVID and QUS observed in the study groups over the 
three years, the total gain in absolute units was divided by the young adult mean (Table 
4.6). Figure 10.2 shows the gain observed for each study group in T-score units. As 
expected the largest increases were observed in the younger groups. Increases in 
BIVID at the LS and THIP were greater than the increases observed for QUS 
measurements with BIVID increasing by approximately 1.75 T-scores in the younger 
groups, compared to approximately 0.75 for BUA. The significant decreases observed 
in UBA BUA, SAH SOS, and DTU SOS of approximately 0.5 T-scores were seen in the 
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Figure 10.2: Total gain in BMD and QUS measurements over the three year study period 
expressed in T-score units. 
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10.2.2 Changes in QUS during adolescence 
To examine the evolution of BIVID and QUS measurements during adolescence, the 87 
girls were treated as one study group. It was hypothesised that the difference in 
skeletal status observed in dancers and controls was related to delayed menarche and 
therefore data for these groups could be pooled to assess changes in BIVID and QUS in 
relation to menarche. 
Figure 10.3 displays the rate of annual increase associated with years since menarche 
for BIVID and QUS measurements. Both LS and THIP BIVID accrual was greatest 
between 12 months prior to and at the time of menarche in the adolescent girls. From 
the time of menarche onwards, the rate of increase in BIVID decreased and by 
approximately 40 months after menarche, the rate of BIVID accrual was small. Just 
over 50% of the variance in the increases in LS and THIP BIVID were explained by the 
event of menarche. The rate of change in QUS measurements with months since 
menarche did not show a similar pattern to that observed for axial BIVID. In fact, with 
the exception of DTU BUA and to a lesser extent SAH BUA, the time of menarche did 
not appear to influence changes in QUS variables and only a maximum of 2% of the 
vadance in the rate of change in QUS was explained by time since menarche. The 
rate of increase in DTU BUA did appear to peak at menarche and decrease steadily 
until approximately 60 months since menarche when no further increases were 
observed. A total of 17% of the variance in changes in DTU BUA was explained by 
time since menarche. 
10.2.3 Correlation between changes in QUS and BMD measurements 
during adolescence 
Changes in BIVID and QUS measurements over the three-year study period for the 
entire study population were correlated to assess whether changes in QUS reflect 
changes in BIVID of the LS or THIP (Table 10.3). Changes in BUA on all three devices 
were highly correlated with changes in BIVID of the LS and THIP with approximately 
33% of the variance in changes in QUS explained by changes in axial BMD. Changes 
in UBA SOS and UBA BV were also significantly correlated with changes in BMD. The 
changes in SOS measurements on the SAH and DTU were not correlated with the 
changes observed for BMD at either the LS or THIP 
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When changes in BUA were compared to the changes in SOS measured on the same 
device, only those measured on the UBA and SAH were correlated while changes in 
DTU BUA and SOS were not correlated. BIVID increments at the spine over three 
years were highly significantly correlated with changes in BIVID at the hip and this 
correlation was greater than those observed when BUA and SOS (measured at the 
same site) were compared (Table 10.4). 
LS BIVID THIP BIVID 
UBA BUA dB/MHz 0.68** 0.59' Table 10.3: The correlation (r) between UBA SOS m/s 0.49** 0.54** changes in BIVID and QUS UBA BV m/s 0.35* 0.40* measurements. 
SAH BUA dB/MHz 0.46** 0.48** 
SAH SOS m/s 0.07 0.10 
SAH BIVID g/CM2 0.25 0.28 
DTU BUA dB/MHz 0.59** 0.67** 
DTU SOS m/s 0.01 0.02 
*p <0.05. ** p<0.001 
Changes between both BUA and SOS measured on the different devices were 
correlated, with approximately 16% of the variance in changes in either BUA or SOS 
explained by changes in either BUA or SOS on the different devices (Table 10.5). 
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Table 10.4: The correlation between changes in BUA and SOS measured on the same QUS 
device and between changes in spine and hip BMD. 
r 
Qus 
UBA BUA vs SOS 0.51 
SAH BUA vs SOS 0.48** 
DTU BUA vs SOS 0.01 
BMD 
LS vs THIP BMD 0.93** 
** <0.001 
Table 10.5: The correlation between changes in BUA (top half of table) and changes in SOS 
(bottom half of table) measured on the different QUS devices. 
UBA SAH DTU 
UBA 0.65** 0d30* 
SAH 0.30* 0.30* 
DTU 0.45 0.42* 
p <0.05 
** p <0.001 
10.3 DISCUSSION 
Due to the absence of ionising radiation, portability and relatively low cost, QUS could 
become a useful tool for the assessment of skeletal development in children. However, 
before QUS can be used it is important to determine how calcaneal QUS measurement 
variables change during childhood and adolescence and whether it reflects changes 
that are occurring in BIVID at other parts of the skeleton. The use of QUS in the 
assessment of skeletal status in adolescence has been examined here and some of 
the issues surrounding the use of QUS in paediatric populations addressed. 
10.3.1 The effect of dance training on BMD 
The event of menarche was delayed by at least twelve months in the ballet dancers 
(Table 10.1), a finding also reported in the literature for both ballet dancers [27,471] 
and intensively trained athletes [58,470]. The pubertal growth period between the 
onset of puberty and menarche is critical as increases in both bone length and bone 
mineral accrual are at a maximum and by menarche, bone lengths are within 3% of 
their adult peak and the rate of increase in BIVID begins to fall [463,479-482]. It has 
been shown that approximately 50% of bone mineral is acquired during the four years 
surrounding menarche and by two years after menarche, BIVIC is 85% of the peak adult 
value [481]. Therefore, a delay in puberty observed in ballet dancers, associated with 
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low levels of oestrogen, may lead to sub-optimal bone mineral accretion and lower than 
average peak bone mass. 
The young dancers displayed similar values for BIVID at baseline and similar rates of 
bone mineral accrual to the young controls, and BMID at the LS and THIP did not differ 
significantly between these two younger groups over the three year study period 
(Figure 10.1). In contrast, the older dancers had significantly lower BMID at all 
measured sites at baseline compared to +he both the older controls and musical theatre 
students (Figure 10.1). However, due to larger annual increments in BMID over the 
three year study period observed for the older dancers (Table 10.2), BIVID of the older 
dancers was similar to that observed for the older controls by the end of the study 
period. This seems to indicate that, even though the event of menarche was delayed 
in the ballet dancers, the large increases in bone mineral accrual associated with the 
perimenarchal period do occur in girls with delayed menarche, albeit at a later 
chronological age. This is in accordance with other studies that found that BIVID of 
ballet dancers is not significantly different from controls, even though ballet dancers 
have a later age of menarche and a higher prevalence of menstrual disturbances and 
low body fat [56,471 ]. 
At the end of the study period, the theatre students had significantly greater BIVID at the 
spine and hip compared to the older dancers (Figure 10.1). The theatre students 
trained on average 11 hours per week, compared to 18 hours of training in the older 
dance group (Table 10.1). The 11 hours of weight bearing activity per week observed 
in the theatre students exceeded the average time spent in weight bearing activity by 
the girls in the older control group. The higher BIVID observed in the theatre students 
seem to indicate an optimal level of exercise, where normal fat mass and oestrogen 
levels are maintained and so exercise has a positive osteogenic effect on BIVID, 
particularly at weight bearing skeletal sites. A study by Keay et al of 57 
premenopausal, previously professional ballet dancers, reported that weight bearing 
activity can attenuate the effects of low oestrogen on BIVID at the spine and hip [27]. 
This has also been observed in a study of adolescent rowers, which found that 
mechanical loading by rowing had a positive effect on LS BIVID but these benefits were 
less when associated with low oestrogen levels [58]. 
10.3.2 The effect of dance training on QUS 
With the exception of UBA SOS and DTU SOS, there was no significant difference in 
QUS variables between the young dancers and controls at baseline (Table 10.1). This 
is in agreement with that observed for BMD between the two younger groups. 
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However, only DTU SOS was significantly lower in the older dance group compared to 
the older controls, while all the BIVID measurements were all significantly reduced at 
baseline in the older dancers (Table 10.1). A possible reason for this finding is that 
dancers have greater increments in QUS during adolescence due to high impact 
loading in the previous three years of ballet dance training. The total change in QUS 
measurement variables over the three-year study period were greater in both the 
young and older dancers compared to the corresponding changes observed for 
controls (Table 10.2 and Figure 10.2). This seems to indicate that calcaneal BUA and 
SOS are positively influenced by the weight-bearing activity during adolescence and 
this is supported by other studies that found that high impact loading is associated with 
greater QUS measurements in children [477]. This is further supported by studies in 
adults that have found that exercise positively influences calcaneal QUS 
measurements [268,269]. 
At the end of the study period, only UBA BUA and UBA BV were significantly greater in 
the older dancers compared to controls although the older dancers displayed greater 
increases over the study period (Figure 10.1). An interesting finding was that SOS 
measured on the SAH and DTU decreased in the younger and older control groups, 
while SOS in the dancers and theatre students increased or remained relatively stable 
over the three years (Table 10.2). UBA BUA also decreased in the older control group. 
When these decreases were expressed in T-score units, a decrease of approximately 
0.5 T-score units was observed, which are approximately of the same order of 
magnitude as some of the increases seen for the other study groups (Figure 10.2). 
This was a somewhat surprising finding, as others have found SOS increases during 
adolescence [476]. The reasons for such a finding are speculative and further 
research is required to fully understand the evolution of calcaneal SOS during 
adolescence. 
These results suggest that QUS measurement variables are effected by dance training 
during adolescence, however, not necessarily in the same manner that BIVID is. For 
example, although BIVID in the older dancers was significantly reduced at baseline, 
QUS measurements in this group were not. This indicates that, due to the nature of 
ballet training, that makes the heel a site of high mechanical loading, calcaneal QUS 
may not necessarily reflect the changes occurring in the axial skeleton. 
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10.3.3 Changes in QUS during adolescence 
There have been relatively few studies of changes in QUS variables during childhood, 
partly because no manufacturer has designed a QUS device specifically for use in 
paediatric populations. However, studies that are available have reported that both 
BUA and SOS increase with advancing age during childhood and adolescence and 
high correlations have been observed between QUS measurements and age 
[473,474,476,478]. A study by Sundberg et al of 280 healthy Swedish children, 
reported increases of approximately 8 dB/MHz and 35 m/s between ages 12-15 years 
for BUA and SOS respectively [474]. An increase of 10 dB/MHz was observed for girls 
aged between 11-15 years measured on the CUBA QUS device [478]. It is difficult to 
directly compare these results in the literature with those obtained here as they were 
obtained on different QUS devices. However, the increases in BUA observed here are 
similar to those reported in the literature. 
The time around menarche has been shown to be a period when a bone mineral 
accrual is at its maximum [463,479-483]. In the present study, mineral accretion at the 
LS and THIP peaked just before and at the time of menarche and the rate of increase 
decreased thereafter. Approximately 52% of the variance in changes in BIVID were 
explained by the event of menarche (Figure 10.3). In contrast, changes in QUS 
measurement variables were not influenced by menarche and did not peak during 
puberty or after menarche (Figure 10.3). Only DTU BUA appeared to peak at the time 
of menarche but only 17% of the variance in the rate of change of IDTU BUA was 
explained by menarche. A study by Lappe et al of 568 children aged 8-18 years, 
reported that SOS increased with pubertal stage, although they also reported that a 
greater amount of the variance in BIVID was explained by Tanner stage than the 
variance in SOS [476]. One possible reason for this may have been that the positive 
influence of ballet training on BUA and SOS may have masked the effects of 
menarche, however, when the dancers were excluded from analysis, a similar pattern 
emerged. 
Changes in BUA over the entire study period were significantly correlated with changes 
in BIVID of the LS and THIP (Table 10.3). Only changes in SOS measured on the UBA 
correlated with changes in BIVID, while changes in SAH SOS and DTU SOS did not 
reflect changes in BIVID (Table 10.3). In addition, changes in BIVID at different skeletal 
sites were highly correlated, while BUA and SOS measured at the same skeletal site 
displayed poorer correlations (Table 10.4). To date, this is the first study to examine 
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both changes QUS and BMD in a longitudinal study of adolescents and so it is not 
possible to compare these findings with others. 
10.3.4 Factors influencing QUS measurements during adolescence 
There may be several reasons why QUS measurements did not appear to respond to 
the event of menarche or that changes in SOS did not reflect changes in axial BMD. 
One possible reason is that QUS measurements were performed at the calcaneus. 
Calcaneal BIVID was not measured in this study but it may not be surprising that 
changes at one skeletal site may not reflect changes at other sites. In addition, the 
number of trabeculae in bone is determined at the growth plate and the epiphysis of the 
calcaneus fuses at approximately 7.5 years of age. Therefore, trabecular number 
would remain constant but thickening of the trabeculae would occur in a process 
termed bone consolidation. It has been suggested that scattering rather than 
absorption is the predominant mode of ultrasound attenuation at the calcaneus and 
scattering would depend on trabecular pattern rather than trabecular thickness [231]. 
Therefore, BUA measured in adolescents may reflect trabecular pattern rather than 
trabecular thickness and one may not expect BUA to increase at menarche in a similar 
fashion to BIVID. 
Possible sources of precision and accuracy errors are important factors to consider 
when measuring calcaneal QUS in adolescents. As the QUS devices used in this 
study were not specially adapted for use in adolescents, a different area of the 
calcaneus may have been measured than that measured in adults, due to smaller bone 
and smaller amounts of surrounding soft tissue. The UBA and SAH are both fixed 
point devices and therefore, smaller amounts of soft tissue surrounding the calcaneus, 
would mean that the measurement ROI would be located in a more antero-superior 
location of the calcaneus. It has been shown that this area of the calcaneus has higher 
bone mass and BUA than the posterior tuberosity [193,213] and is more 
heterogeneous, which may lead to waveform distortion and refraction [361]. This 
would adversely effect the precision of QUS, especially in longitudinal studies. Only 
short-term precision was assessed in the present study (Table 3.5) but this was not 
greater than that observed in adult populations. QUS imaging overcomes this 
positioning problem and therefore may be a more accurate method of measuring QUS 
in younger children. 
It has been demonstrated that SOS is negatively associated with both bone and heel 
width [229,282]. Cortical bone width increases during adolescence 
[479], 
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therefore increasing overall bone width. This may partly explain why SOS did not 
change during significantly adolescence and may explain the apparent decrease in 
SOS observed in the younger and older controls (Table 10.2). Changes in marrow fat 
can also effect QUS measurements [282] and this would increase during adolescence. 
10.3.4 Study Limitations 
The most important study limitation is that the QUS devices were not adapted for use in 
children. This may not be too important in the older study groups but may be a 
problem in the younger age groups. The CUBA and ACHILLES QUS devices have 
been adapted in other studies by the use of shims and beam collimation [473,478]. 
However, the imaging device used here overcomes this problem and did not behave 
differently to the other fixed point devices and therefore it is unlikely that the adaptation 
of the QUS for use in younger populations would change the study conclusions. 
Due to the competitive nature of ballet dance training, there was a trend for dancers to 
change to musical theatre training and subsequently reduce the number of hours 
training they participated in. Therefore, the results for the dance groups may not fully 
represent the changes occurring in the girls that did remain in ballet training. 
10.4 CONCLUSIONS AND FURTHER WORK 
Although puberty was delayed in intensively trained ballet dancers, by the end of the 
study period, BIVID and QUS measurements were not significantly different between 
dancers and controls. Dancers tended to show larger increases in QUS measurement 
variables than controls, presumably due to higher loading patterns, and therefore 
calcaneal QUS may not fully reflect the changes occurring at the axial skeleton. 
The event of menarche was associated with accelerated rates of bone mineral accrual, 
while changes in BUA and SOS appeared unaffected by the events of puberty and 
menarche. 
Further work is required to ascertain whether QUS assessment during childhood and 
adolescence reflects changes in skeletal status and fracture risk, in both healthy 
children and those with diseases that affect bone metabolism. QUS 
devices 
specifically designed for use in paediatrics would enhance precision and increase 
the 
potential of using it effectively in such populations. 
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Over the past decade there has been intensive research directed at QUS and an 
abundance of studies examining the utility of QUS and its potential use in clinical 
practice. Findings from several large prospective fracture studies have confirmed that 
calcaneal QUS can be used to identify individuals at risk of fracture [338,341,342], the 
main objective of bone densitometry assessment. The number of QUS devices in use 
Worldwide is increasing and it is almost inevitable that QUS will become an integral 
part of osteoporosis assessment in the future. This thesis has attempted to address 
some of the current obstacles to the wider application of calcaneal QUS in clinical 
practice and show that for many important applications QUS measurements provide 
equivalent information. 
11.1 Conclusions 
11.1.1 The long-term stability and precision of QUS 
To date, there have been few studies examining the stability of QUS devices. The 
long-term stability of QUS was found to be poor, with all three devices showing drifts or 
abrupt calibration changes. The SAH device underwent a period of significant drift due 
to a change in composition of the rubber transducer pads. However, it is now routine 
to change these rubber pads annually and therefore it is unlikely that this problem 
would occur again. The DTU device was subject to several recalibrations due to 
system upgrades or technical problems, which adversely affected the long-term 
stability of this device. The DTU was in the early stages of commercial development 
and further development is still ongoing that may lead to a more stable device in the 
future. Temperature changes affected both the phantom and in vivo measurements 
and consequently QUS devices using water or a coupling medium should be 
temperature controlled. 
Visual inspection of the phantom data allowed small shifts in calibration to be detected, 
and if necessary corrected for. Quality assurance procedures, such as those seen for 
DXA, should be performed daily by trained operators and results regularly inspected to 
assess machine performance and stability. However, changes in phantom data did not 
always reflect changes in vivo and therefore there is a need for phantoms that mimic 
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the acoustic properties of the calcaneus and show a similar range of values to that 
encountered in vivo. 
The precision errors for QUS measurements were standardised and expressed in T- 
score units so different QUS devices and different techniques could be better 
compared. In addition, the use of T-scores allows precision errors to be readily 
interpreted as they directly relate to the accuracy of diagnosing osteoporosis using T- 
scores. The SP for QUS was around twice that of DXA. Although QUS imaging 
improved the short-term SID of QUS, with SID errors that approached that seen for DXA, 
mid- and long-term precision errors were greater than that observed in the short-term 
and between two and seven times greater than that observed for LS BMID assessed 
over the same time period. Although QUS imaging improved the long-term precision of 
QUS for BUA measurements, the SID of SOS measurements was not improved and in 
fact showed signficantly poorer SID than the two non-imaging devices. Temperature 
changes significantly affected the long-term precision of QUS measurements, 
particularly for the two devices using water as the coupling medium. QUS 
measurements should be performed in te m perature-control led waterbaths and in the 
case of contact devices, the skin temperature should be taken and measurements 
corrected accordingly. 
11.1.2 Determination of QUS reference data 
It was important for the purpose of this study to determine normal values for QUS and 
DXA using a single study population so any differences between QUS devices or 
techniques was due to differences in technology rather than discrepancies in 
manufacturer reference data. A group of 530 women was used to construct reference 
ranges for the three QUS devices and DXA. These data allowed T- and Z-scores to be 
calculated for each individual and so allowed a direct comparison of different devices 
and techniques. These data also provide local reference values for QUS if it is 
implemented into clinical practice. 
Annual decreases in BUA and SOS measurements, standardised and expressed in T- 
score units, decreased with age and years since menopause at a similar rate to that 
observed for LS BMD. THIP BIVID appeared to be affected by age- and menopause- 
related factors to a greater extent than the QUS measurements. 
Measurements of BUA or SOS on the three devices were significantly correlated with 
one another. However, there were large variations in both mean values and clinical 
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ranges for the different devices and therefore results from one device can not be 
directly compared to that obtained on another device. 
QUS measurements were significantly correlated with BMD at both axial and peripheral 
skeletal sites. However, these correlations were modest and a large proportion of the 
variation in QUS was left unexplained by BMD. The SEE between QUS and BIVID 
measurements, expressed in T-score units, was approximately ±1 and therefore QUS 
cannot be used to predict BMD. However, QUS should not be viewed as a means of 
predicting BMD but rather a means of assessing fracture risk. 
11.1.3 The clinical application of QUS 
Revised diagnostic criteria were derived for QUS as the currently accepted WHO 
criteria for diagnosing osteopenia and osteoporosis were shown not to be applicable to 
QUS. A T-score threshold of -1.80 was proposed to identify postmenopausal women 
at risk of osteoporosis using the three devices in the present study. A T-score 
threshold of -0.50 may be used to classify women as normal or osteopenic. It is 
important that revised criteria are applied to QUS results so similar proportions of 
women with clinical risk factors are diagnosed with osteopenia and osteoporosis as 
DXA measurements of BIVID. The revised criteria derived in this study classified the 
same proportions of women with clinical risk factors into the three diagnostic categories 
using QUS measurements compared to axial BIVID measurements, using the WHO 
criteria. 
The clinical risk factors such as previous fracture or early menopause, suggested by 
the Royal College of Physicians and commonly used by General Practitioners to 
identify women who would most benefit from bone densitometry assessment and 
possible prophylactic treatment, affected QUS Z-scores to the same extent as those for 
axial BMD. Clinical risk factors had an additive effect on QUS Z-scores, whereby as 
the number of risk factors present in an individual increased, QUS measurements 
progressively decreased. 
QUS measurements were able to discriminate between women with a history of fragility 
fracture at the spine, hip or forearm and those without as well as DXA measurements 
of the spine and hip. The three QUS devices displayed comparable discriminatory 
abilities, as did BUA and SOS. Odds ratios obtained for QUS ranged from 2.1 to 5.3, 
indicating that for each standard deviation decrease in QUS measurement variables, 
there is at least a doubling of fracture risk. In addition, the majority of the QUS 
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measurement variables were able to discriminate between those individuals with and 
without fractures at non-spine, hip or forearm sites such as the humerus and ribs. The 
three QUS devices displayed comparable discriminatory abilities, as did BUA and SOS. 
The combination of QUS and DXA did not enhance the spinal fracture discriminatory 
ability compared to either method alone. In addition, the cost-effective of such an 
approach would probably limit the use of this method in clinical practice. 
With the exception of the UBA velocity measurements and DTU SOS, QUS 
measurements displayed a significant response to treatment after one year of 
antiresorptive therapy, indicating that QUS has the potential to monitor skeletal 
responses to treatment. However, the relatively poor long-term precision of QUS 
compared with DXA meant that DXA assessment of the lumbar spine remained the 
optimum measurement site for monitoring response to treatment. Changes that 
occurred in QUS measurements did not reflect changes occurring at the spine or hip 
and therefore direct measurements at these sites are required for this purpose. Due to 
the current precision of QUS technology, the time required to measure significant 
changes in skeletal status of individuals on treatment would most likely exceed that 
required for clinical decision making. However, it was encouraging that calcaneal 
measurements responded positively to treatment and advances in precision and quality 
control procedures may allow QUS to be used for this purpose in the future. 
As a further assessment of the utility of QUS in longitudinal studies, along with the 
additional examination of the use of QUS in the assessment of skeletal status in girls 
aged 11-18 years, the effect of intensive dance training on QUS measured over three 
years was examined. Due to higher loading patterns, the effects of delayed puberty on 
axial BIVID observed in ballet dancers was not reflected in QUS measurements, and 
therefore calcaneal QUS may not fully reflect levels of BIVID in the axial skeleton or the 
changes occurring there. The events of puberty and menarche did not affect QUS 
measurements to the same extent as axial BIVID measurements. The precision of QUS 
measurements on this population was similar to that observed in adults. 
11.2 Further Work 
11.2.1 The long-term stability and precision of QUS 
Due to the poor long-term stability of QUS, there is a need to develop improved quality 
control procedures, which are easy to implement by non-technical staff such as 
practice nurses. The long-term stability of QUS will continue to 
be monitored, to fully 
address this issue and to assess whether changes in phantom 
data represent changes 
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occurring in vivo. In the future, with further developments in QUS technology that may 
enhance the precision of QUS, quality control procedures such as Cusum charts may 
become a useful adjunct to QUS quality assurance procedures. 
Devices that are temperature controlled such as the Lunar Achilles or the DIVIS UBIS 
5000, need to be examined to assess whether short- and long-term precision is 
significantly improved. If this were indeed the case, it would be interesting to determine 
whether this improves the monitoring ability of calcaneal QUS. 
11.2.2 Determination of QUS reference data 
To fully address the issue of how QUS measurements change during an individuals 
lifetime, longitudinal studies, performed over a sufficiently long time period, need to be 
performed on large populations, including men and non-Caucasian populations. 
The diversity of QUS technology has been recognised as a challenge for the 
advancement of QUS by the International QUS Consensus Group [228]. It is important 
to cross-compare more devices and assess how QUS results can be standardised, 
perhaps using T-scores, which would aid in the clinical introduction of QUS and assist 
physicians in interpreting QUS findings. 
11.2.3 The clinical application of QUS 
DXA-equivalent prevalence rates of osteoporosis were used to derive T-score 
thresholds for the three QUS devices. It is important that guidelines on how QUS can 
be used in clinical practice are established and then to assess the impact of such 
guidelines on patient management. Diagnostic criteria need to be developed for other 
calcaneal devices to investigate whether one diagnostic criterion is adequate for all 
QUS devices. Alternative approaches such as lifetime fracture risk or other novel 
approaches of classifying high-risk individuals should be examined using QUS to 
determine the best way forward for optimising the identification of high risk individuals 
and consequently reducing fracture incidence. The triage approach of using QUS 
needs to be examined to assess whether a combination of DXA, QUS and biochemical 
markers optimises the identification of individuals most at risk of osteoporotic fracture. 
The cost-effectiveness of such an approach would also need to be considered. 
It was encouraging that calcaneal QUS measurements were sensitive to those clinical 
risk factors suggested by the Royal College of Physicians for identifying individuals 
who would benefit from bone densitometry assessment. It would be interesting to 
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examine whether a combination of risk factors along with QUS assessment would 
enhance the identification of high-risk individuals. Additional studies on specific groups 
of women with risk factors, such as those on glucocorticoids or those with 
hyperparathyroidism, need to be carried out with further evaluation of whether QUS 
could monitor such individuals. 
BMD at the lumbar spine remains the optimum measurement site for monitoring 
response to treatment. Clinical trials performed over longer time periods are required 
for QUS, with parallel assessment of BMD, so the sensitivity of QUS to monitor skeletal 
changes, due to both disease progression or response to treatment, can be fully 
addressed. More significantly, it is important to determine that changes in QUS reflect 
changes in fracture risk, although this is more difficult to assess. Further studies are 
required to examine the evolution of QUS measurements during adolescence and 
possible variables that influence changes in QUS at this age. An assessment of QUS 
devices specifically designed for use in paediatrics would determine whether this 
enhanced precision and increased the potential of using QUS effectively in such 
populations. 
11.3 ACHIEVEMENT OF STUDY OBJECTIVES 
In this study a wide cross-section of patients referred by hospital consultants and 
general practitioners for skeletal assessment by DXA and volunteers were also 
investigated on three calcaneal QUS devices representative of the current state of 
QUS technology. This allowed QUS measurements and DXA BIVID measurements to 
be directly compared in the same group of subjects and an examination made of the 
hypothesis stated at the beginning of Chapter 2 that QUS technology has now reached 
a point where for many clinical purposes it could replace DXA. 
The compadson of QUS and DXA measurements showed that for many important 
applications of bone densitometry such as the diagnosis of osteoporosis, the 
investigation of patients with clinical dsk factors for osteoporosis, and the identification 
of patients at risk of fracture, the QUS measurements gave equivalent clinical 
information to DXA provided that appropriate reference ranges are used and an 
adjustment made to the T-score threshold used for the interpretation of scan 
findings. 
The principal limitations to the wider use of QUS measurements that remain are- 
(1) 
the long-term stability was unsatisfactory, at least for the devices studied in this thesis, 
and there was significant temperature dependence of the 
SOS measurements. Closer 
attention to QC procedures and phantoms more representative of 
in vivo 
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measurements are required if QUS equipment is to be used in an environment with 
limited scientific support; (2) the poor precision of QUS measurements compared with 
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Contact Quantitative Ultrasound: An Evaluation of Precision, Fracture 
Discrimination, Age-Related Bone Loss and Applicability of the WHO 
Criteria 
A L. Frost, G. A Blake and 1. Fogelman 
Osteoporosis Unit, Guy's Hospital, London, UK 
Abstract. The aim of this study was to assess a dry 
calcaneal quantitative ultrasound (QUS) device by 
examining: (i) short- and long-term precision; (ii) the 
ability of the ultrasound parameters to identify women 
with vertebral fractures; (iii) age- and menopause-related 
bone loss; (iv) applicability of the WHO criteria in scan 
interpretation. The study group consisted of 422 healthy 
women with no risk factors associated with osteoporosis 
(227 premenopausal and 195 postmenopausal) and 93 
women with one or more vertebral fractures. All women 
had calcaneal QUS and bone mineral density (BMD) 
measurements of the lumbar spine and hip performed. 
Broadband ultrasound attenuation (BUA) and speed of 
sound (SOS) measurements in the heel were combined 
and expressed as estimated heel BMD. Short-term 
precision studies yielded coefficient of variations of 
0.3% for SOS, 4% for BUA and 3.3% for estimated heel 
BMD. Standardized short-term precision values were 
approximately 0.2 SID. Long-term standardized precision 
errors ranged from 0.17 to 0.38 SD. All the QUS and 
BMD measurement parameters showed significant 
negative relationships with age in the postmenopausal 
group. Annual losses were 0.35 dB/MHz per year for 
BUA, 0.56 m/s per year for SOS and 0.002 g/cm 2 per 
year for estimated heel BMD. All the QUS and BMD 
parameters were able to discriminate between healthy 
postmenopausal women and women with vertebral 
fracture. Age-adjusted odds ratios for each SD decliný 
in QUS measurements were 3.63,5.25 and 4.79 for 
BUA, SOS and estimated heel BMD respectively. 
Corresponding odds ratios for BMD at the lumbar 
Correspondence and offprint requests to: M. L. Frost, Osteoporosis 
Unit, Guy's Hospital, St Thomas Street, London SEI 9RT, UK. Fax: 
+44 (0)171 955 8883. e-mail michelle. frost@kci. ac. uk 
spine, femoral neck and total hip were 2.39,2.51 and 
2.95 respectively. When the QUS and BMD parameters 
were expressed as T-scores, estimated heel BMD showed 
the least age-related decline, while femoral neck BMD 
displayed the greatest decrease with age. The mean T- 
score and prevalence of osteoporosis (T< -2.5) for a 
Caucasian woman aged 60-65 years were - 1.35 and 
21% respectively for the lumbar spine compared with 
-0.59 and 2% for estimated heel BMD. In conclusion, 
this study revealed that contact ultrasound can detect 
age- and menopause-related influences on bone status 
and was able to discriminate between healthy individuals 
and women with vertebral fracture. However, the widely 
accepted threshold of a T-score of less than - 2.5 for the 
definition of osteoporosis may need modifying for the 
interpretation of QUS scans. 
Keywords: Fracture; Osteoporosis; Precision; Quantita- 
tive ultrasound 
Introduction 
Osteoporosis is the most common generalized disease of 
the skeleton and, due to the progressive aging of the 
world's population, fracture incidence and the financial 
costs of osteoporosis continue to rise. Therefore, the 
early detection of bone fragility is of the utmost 
importance. At present, the most commonly used 
technique for the assessment of skeletal status is dual- 
energy X-ray absorptiometry (DXA). Quantitative 
ultrasound (QUS) has been under investigation during 
the past decade as an alternative method for assessing 





patient or operator exposure to ionizing radiation, low 
cost and portability. QUS has emerged as a promising 
tool in identifying individuals at risk of sustaining a 
fragility fracture [1-9]. These findings have been 
confirmed by several large prospective studies of 
fracture incidence [10-12]. 
At present, osteoporosis is defined in terms of BMD T- 
scores as recommended by a World Health Organization 
(WHO) Working Party [131. The WHO definition of 
osteoporosis of a T-score value less than -2.5 was developed for bone mineral density (BMD) measure- 
inents at the forearm, hip and lumbar spine. However, it 
has been reported that a T-score cut-off of - 2.5 may not 
appropriate at other skeletal sites or for different 
measurement techniques such as QUS [14,15]. 
The aim of this study was to assess a dry calcaneal 
QUS systern in a clinical setting. We have measured in 
vivo short- and long-term precision, age- and meno- 
pause-related bone loss and assessed the ability of the 
ultrasound measurement parameters to discriminate 
between women with vertebral fracture and healthy 
postmenopausal controls. In addition, we have examined 
the age-dependence of T-scores for QUS at the heel and 
compared these with the T-scores obtained for BMD 
measurements performed at the spine and hip, with a 
view to assessing the applicability of the WHO criteria 
to the interpretation of QUS scan findings. 
SI ubjects and Methods 
M. L. Frost 
consists of two unfocused transducers mounted coaxially on a motorized calliper. One transducer acts as the transmitter and the other as a receiver. The transducers 
are acoustically coupled to the heel using soft rubber pads and an oil-based coupling gel. The Sahara device 
measures both broadband ultrasound attenuation (BUA) 
and speed of sound (SOS) at a fixed region of interest in the mid-calcaneus and the BUA and SOS results are 
combined to provide an estimate of heel BMD (Est. heel BMD) with units of grams per square centimeter using the following equation: 
Est. heel BMD = 0.002592 x (BUA + SOS) - 3.687 g/CM2 
It is important to note that the estimated heel BMD is inferred from a linear combination of BUA and SOS and is not an actual measurement of calcaneal BMD. The 
BMD measurements of the lumbar spine (LI-4), femoral 
neck and total hip were performed using a Hologic QDR4500 (Hologic, Bedford, MA). 
Instrumental Quality Control 
Quality control checks of the QUS scanner were 
performed daily by scanning manufacturer-provided 
phantoms prior to patient scanning. Two phantoms 
were used: (i) a urethane phantom; (ii) a temperature- 
independent phantom filled with a mixture of water and 
alcohol. As an additional check two volunteers had QUS 
measurements performed weekly during the 2-year study 
period. 
Suýjects 
'rhe study population consisted of three groups: (i) 
healthy premenopausal women (n = 227); (ii) healthy 
postmenopausal women (n = 195); (iii) women with one 
or more vertebral fractures (n = 93). Women were 
excluded from the premenopausal and postmenopausal 
groups if they had a history of low-trauma fracture, a 
menopause before the age of 40 years, a history of 
amenorrhea or any treatments or diseases known to 
affect bone metabolism. These women were recruited 
from three sources: (i) patients referred by their general 
practitioner for routine bone density screening by DXA; 
(ii) young hospital personnel; (iii) women from the 
general population who volunteered to participate in 
clinical research. A group of patients with known 
vertebral fractures were recruited from the Guy's 
Hospital metabolic bone clinic. Written informed 
consent was obtained from all study participants and 
the study was approved by the Guy's Hospital Research 
Ethics Committee. 
Measurements 
All subjects had calcaneal QUS measurements and DXA 
measurements of the lumbar spine and hip. QUS 
measurements were performed using the Sahara Clinical 
Bone Sonometer (Hologic, Bedford, MA). The system 
Precision 
A group of 260 women (128 premenopausal, III 
postmenopausal and 21 women with vertebral fracture) 
had duplicate scans performed on the QUS device to 
estimate short-term precision. To obtain more detailed 
infon-nation on precision a group of 10 young healthy 
volunteers from the premenopausal group took part in an 
extended study of short- and long-term. precision. To 
examine short-term precision the 10 volunteers had 10 
repeated measurements performed on the same day with 
repositioning of the heel between each scan. These 
subjects also had monthly QUS scans over a period of 10 
months to examine long-term precision. 
Data Analysis 
Data for the three groups of subjects were combined as 
means and standard deviations. The pre- and postmeno- 
pausal and the postmenopausal and fracture groups were 
compared statistically with Student's Mest; p-values 
<0.05 were considered to be significant. 
Short-term precision estimated by performing dupli- 
cate scans was expressed as the coefficient of variation 
(CV%) defined as the root mean square standard 
deviation (RMS SD) divided by the mean. Short-term 
)19 
`x 
Contact Quantitative Ultrasound 
precision as estimated by performing 10 scans on 10 
individuals on the same day was defined as the RMS SD 
divided by the mean. Long-term precision was expressed 
in the same way. Standardized precision (SP) was also 
calculated so the precision of the different measurement 
parameters could be better compared in relation to their 
clinical range. SP was defined as the RMS SD divided by 
the young adult population SD and was expressed in 
T-score units. The young adult population SD was 
calculated for each measurement parameter from a 
subgroup of 102 healthy premenopausal women aged 
20-40 years. 
Linear regression analysis was used to determine the 
relationship between each measurement parameter and 
both age and years since menopause. Annual changes 
were expressed as absolute values and as fractional 
standard deviations relative to the SD of the young adult 
group so a direct comparison between techniques could 
be made. 
To examine the discriminative ability of each 
measurement parameter age-adjusted logistic regression 
was used to estimate odds ratios (for aI SD decrease in 
the measurement parameter) and the 95% confidence 
intervals. Receiver operating characteristics (ROC) 
curve analysis was used to estimate the area under the 
curve. 
To compare the applicability of the WHO definition of 
osteoporosis for DXA and QUS measurements the 
healthy pre- and postmenopausal subjects were divided 
into 5-year age groups and mean T-scores calculated 
based on the mean and SD for the young adult women 
aged 20-40 years. 
Results 
Patient characteristics for the three groups are shown in 
Table 1. Also included in Table I are data for the young 
adult group consisting of healthy women aged 20-40 
Table 1. Patient characteristics 
443 
years used for the calculation of T-scores. The group of 
subjects with vertebral fracture was significantly older 
and had a higher menopausal age compared with the 
postmenopausal group. The fracture group was also 
shorter and lighter than the postmenopausal group. Significant differences were observed between the 
premenopausal, postmenopausal and fracture groups for all measurement parameters. The most significant differences were observed between the postmenopausal 
and fracture groups. 
Instrumental Quality Control 
Results of the daily quality control scans of the 
manufacturer-provided phantoms showed evidence of a 
small downward drift in both BUA and SOS halfway 
through the study. The fault was corrected by replacing 
the rubber pads which acoustically couple the trans- 
ducers to the patient's heel and recalibrating using the 
phantoms. The in vivo data collected during this period 
of instrumental drift were corrected using a time- 
dependent correction factor obtained from the slope of 
the regression line. After replacement of the pads there 
was no subsequent drift in either BUA or SOS. Figure I 
shows the results obtained on the two volunteers who 
underwent weekly scans after the correction described 
above. The date of replacement of the pads is marked 
and the calibration correction did not have any effect on 
the QUS results for either subject. The SD of the Est. heel 
BMD measurements obtained during the study period 
were 0.017 and 0.017 g/cm 2 for the two volunteers. 
Precision 
Both short- and long-term precision were examined and 
the results are shown in Table 2. The short-term 
precision study based on 10 repeated scans in 10 
individuals gave CV values ranging from 0.3% for 
Young adult' Premenopausal 
group 
11 102 227 
Age (years) 32.0(5.5) 40.4(8.9) 
Height (cm) 165 (5.8) 164(10.5) 
Weight (% 65.9(11.4) 65.0(10.5) 
BMI (kg/m 24.2(4.2) 24.1 (3.7) 
YSM (years) N/A N/A 
BUA (dB/MHz) 77.6(13.5) 76.7(14.4) 
SOS (M/s) 1560.7 (25.0) 1558.6 (29.3) 
Est. heel BMD (g/cm 2 0.560 (0.096) 0.553 (0.139) 2) 
Lumbar spine BMD (g/cm 1.065 (0.118) 1.054 
(0.122) 
2 
Femoral neck BMD cm 0.892 (0.104) 0.857 
(0.117) 
Total hip BMD (g/cM 0.988 (0.098) 0.957 (0.110) 


























Values are expressed as mean (SD)- 
BMI, body mass index; YSM, years since menopause; BUA, broadband ultrasound attenuation; 
SOS, speed of sound. 
*/)<0.01 versus premenopausal group. 
**I)<O. ol versus postmenopausal group. 
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Fig. L In vivo instrument quality control based on measurements of Est. heel BMD for two healthy premenopausal women measured weekly for a 
period of 22 months. There was significant instrumental drift in both BUA and SOS which began in April 1997. The arrow represents the date at 
which the transducers were replaced. In vivo data collected in the 5 months prior to the changing of the pads were corrected for this drift in BUA 
and SOS by adding the changes observed in daily measurements of the manufacturer-provided phantoms. Refer to Table 2 for definitions. 
SOS to 3.6% for BUA. Short-term precision values as 
estimated by performing duplicate scans showed some- 
what poorer reproducibility. The CV values obtained 
were 4.4%, 0.4% and 4.1 % for BUA, SOS and Est. heel 
BMD respectively. The short-term standardized preci- 
sion for estimated heel BMD expresses in T-score units 
was 0.22 for the duplicate scan measurements and 0.15 
for the short-term precision study. Long-term reprodu- 
cibility as estimated over 10 months for 10 individuals 
was inferior to short-term reproducibility. CV values 
were 6.9% for BUA, 0.7% for SOS and 6.3% for Est. heel 
BMD. The long-term standardized precision values were 
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Table 2. Short-term and long-term precision 
BUA (dB[MHz) SOS (M/S) Est. heel BMD (g/cm 2 
RMS SID CV% SP RMS SID CV% SP RMS SD CV% SP 
Short-term Precision 
Duplicate scans 3.1 4.4 0.23 5.8 0.4 0.23 0.021 4.1 0.22 
10 individuals x 10 scans 2.7 3.6 0.20 3.9 0.3 0.16 0.014 2.5 OIS 
Long-ferm precision 
10 individuals x 10 months 5.1 6.9 0.38 10.4 0.7 0.41 0.035 6.3 0.30 
RMS SD, root mean square standard deviation; CV, coefficient of variation; SP, standardized precision (T-score units). 
approximately twice those seen for the short-term 
precision estimates, with values of 0.38,0.41 and 0.36 
for BUA, SOS and Est. heel BMD respectively. 
Age- and Menopause-Related Bone Loss 
Scatter plots showing the age-associated decline in 
ultrasound measurement parameters are given in Fig. 2. 
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both the premenopausal and postmenopausal groups. 
Linear regression analysis revealed that only the femoral 
neck and total hip BMD measurements showed a 
significant decline with age during the premenopausal 
period, displaying annual decreases of 0.0035 g/CM2 
(p<0.001) and 0.0029 g/cm 2 (p<0.01) respectively. A 
significant decline in all measurements was observed in 
the postmenopausal period (Table 3). When the annual 
loss was standardized by estimating bone 13ss in T-score 
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Table 3. Age- and menopause-related bone loss in postmenopausal women for QUS and BMD measurements 
Age Years since menopause 
Annual Annual Correlation Annual Annual Correlation 
loss loss/SD coefficient loss loss/SD coefficient 
BUA (dB/MHz) -0.35 -0.026 0.21 * -0.45 -0.033 0 27** SOS (rn/s) 
/ 2 D -0.56 -0.023 
0.17* -0.72 -0.029 
. 0.21 * (g CM ) Est. hecl BM -0.0022 -0.023 0.19* -0.0030 -0 031 0 24* 2 Lumbar spine BMD (g/cm ) -0.0033 -0.028 0.20* -0-0034 
. 029 -0 




Total hip BMD (g/cm -0.0050 -0.051 0.35** -0-0054 -0.055 0.36** 
SD, population SID for young adults. 
*P<0.05; **P<0.001. 
approximately twice the rate of the ultrasound measure- 
ments. Correlations with age were also greater for the 
BMD measurements. Years since menopause showed a 
significant relationship with all measurement parameters 
and figures for annual loss and the coffelation coefficient 
were somewhat larger than for chronological age. 
Fracture Discrimination 
When the group of women with one or more vertebral 
fractures was compared with the healthy postmenopausal 
group, age-adjusted odds ratios were significant for both 
the ultrasound and BMD parameters (Table 4). The odds 
ratios obtained for the BMD measurements ranged from 
2.4 at the lumbar spine to 3.0 at the total hip region. 
Higher odds ratios were obtained for the ultrasound 
measurements, with the SOS measurement displaying 
the best discrimination between groups with an odds 
ratio of 5.3. ROC analysis gave figures for the area under 
the curve that ranged from 0.82 at the femoral neck to 
0.89 for Est. heel BMD (Table 4). 
As a further comparison between the techniques we 
examined the ultrasound measurement of Est. heel BMD 
at each stratum of total hip BMD for the postmenopausal 
and fracture group (Table 5). Est. heel BMD was 
significantly lower in the fracture group compared with 
the healthy postmenopausal group at each level of total 
hip BMD. 
WHO Criteria: Comparison Between DXA and QUS 
Table 4. Age-adjusted odds ratios and ROC analysis for the QUS and 
BMD measurements 
Odds ratio (95%Cl) ROC-AUC 
BUA (dB/MHz) 3.6 (2.5 -5.3) 0.87 
SOS (avs) 5.3 (3.3 -8.3) 0.89 2) Est. heel BMD (g/cm 4.8 (3.1 -7.4) 0.89 2 Lumbar spine BMD (g/cm ) 2.4 (1.8 -3.3) 0.83 2 Femoral neck BMD (qcm ) 2.5 (1.8 -3.6) 0.82 
Total hip BMD (g/cm 3.0 (2.1-4.2) 0.85 
Cl, confidence interval; ROC, receiver operating characteristics curve 
analysis; AUC, area under the curve. 
Table 5. A comparison of estimated heel BMD in the postmenopausal 
group and vertebral fracture group for each level of total hip BMD 
Total hip Est. heel BMD p value 
BMD (g/CM2) 
postmenopasual Fracture group 
group (n = 195) (n = 93) 
<0.7 0.367 0.291 0.002 
0.7-0.8 0.444 0.350 0.001 
0.8-0.9 0.478 0.379 0.0001 
0.9-1.0 0.524 0.377 0.0001 
> 1.0 0.544 0.411 0.001 
The age-dependence ' of mean 
T-scores for both Est. hcel 
BMD and BMD measurements is shown in Fig. 3 for the 
healthy pre- and postmenopausal subjects grouped into 
5-year age bands. For subjects aged 50 years and above, 
mean T-scores for Est. heel BMD were approximately 
half those measured in the axial skeleton. The Est. heel 
BMD measurement showed the least decline in age- 
related T-score while the femoral neck BMD showed the 
greatest decrease in T-scores with age. The mean T- 
scores for the lumbar spine displayed an apparent 
increase from age 70 years that probably reflects 
degenerative changes in the spine - which is a problem 
when measuring the spine in more elderly subjects. The 
prevalence of osteoporosis based on the WHO definition 
and the average T-score for a Caucasian woman aged 
between 60 and 65 years for QUS and BMD 
measurements are shown in Table 6. The mean T-score 
for the BMD measurements ranged from - 1.03 at the 
total hip site to - 1.39 at the femoral neck. In 
comparison the T-score for estimated heel BMD was 
lower at -0.59. The prevalence of osteoporosis as 
defined by the WHO criteria of a T-score less than - 2.5 
was also considerably different depending on the site and 
technique used, ranging from 2% for QUS to 21% for a 
BMD measurement at the lurnbar spine. 
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Fig. 3. The age-dependence of T-scores for BMD and QUS measurements. 
Table 6. The average T-score and prevalence of osteoporosis (as 
defined by the WHO criteria) for women aged 60-65 years 
Site Method Mean WHO Osteoporosis 
T-score classification prevalence 
Est. heel BMD QUS -0.59 Normal 2% 
Lumbar spine DXA -1.35 Osteopenia 21% Femoral neck DXA -1.39 Osteopenia 14% Total hip DXA -1.03 Osteopenia 12% 
Discussion 
This study has assessed a contact QUS device in a 
clinical environment by examining precision, the 
detection of age- and menopause-related changes in 
bone, fracture discriminative ability and the applicability 
of the WHO criteria. All four of these factors are 
important in determining the utility of a particular QUS 
device. 
The precision values reported for QUS systems vary 
according to the instrument used and the site measured. 
The precision values we obtained for this contact system 
are comparable to those obtained on water-based 
systems utilizing unfocused transducers [16-19]. The' 
use of a standardized precision estimate eliminates the 
favorable bias for measurement parameters that have a 
relatively narrow clinical range. The standardized 
precision for QUS has been shown to be approximately 
double that observed for DXA techniques [20]. Our 
precision estimates of approximately 0.20 seem to 
confirm this if we assume a standardized precision of 
0.10 for DXA (0.01g/cm 2/0.1 g/C M 2). When comparing 
short- and long-term precision we found that long-term 
precision measured over a period of 10 months was 
twice that seen in the short term. However, the long-term 
precision values we obtained for the two volunteers who 
underwent weekly scans over a period of 22 months 
were comparable to those obtained in the short term (Fig. 
1). 
Both ultrasound attenuation and velocity measure- 
ments readily differentiated between the healthy pre- 
menopausal and postmenopausal groups. An inverse 
relationship between QUS and BMD measurements and 
age was observed. When the annual loss was expressed 
in terms of the young adult group SD, annual changes in 
QUS measurements were similar to lumbar spine BMD 
measurements, although the hip DXA measurement 
seemed to display a greater annual loss. The annual 
loss in BUA and SOS was comparable to the annual 
losses seen in other cross-sectional studies using water- 
based devices [4,19,20]. During the postmenopausal 
period Est. heel BMD declined by 0.0022 g/CM2 per 
annum. This rate of decline is in accordance with the 
age-related decline observed at the calcaneus using DXA 
measurements of bone [211. Both BUA and SOS were 
significantly correlated with years since menopause. An 
increase in bone turnover at the time of menopause is 
associated with an accelerated rate of postmenopausal 
bone loss. The decrease in ultrasound parameters with 
years since menopause was greater than the decrease 
observed with chronological age, although this differ- 
ence did not reach statistical significance. The decrease 




0.34 dB/MHz per annum for BUA and 0.65 m/s per 
annum for SOS in a study of 134 healthy Italian women 
[221. 
Two important points should be taken into account 
when interpreting the present data. The majority of the 
healthy postmenopausal women over the age of 70 years 
were volunteers who had contacted the hospital to offer 
to participate in clinical research. This may lead to 
selection bias toward more healthy individuals and may 
exclude women who are too frail or ill to attend the 
hospital, and therefore one might expect the volunteers 
to have higher than average bone mass. The effect of 
self-selection was also seen in a study which reported 
normative data for UK women [23] and such bias may 
result in the true annual rate of loss in ultrasound 
parameters being underestimated. The present study 
examined age- and menopause-related changes in 
ultrasound parameters using cross-sectional data. 
One of the most important reasons for examining 
skeletal status is to identify individuals at risk of 
sustaining a fragility fracture. This study has examined 
the ability of ultrasound measurements to discriminate 
between healthy women and those with prevalent 
vertebral deformity. Vertebral fractures are an important 
consequence of osteoporosis. It has been estimated that 
the incidence of vertebral fractures in the UK could be as 
high as I 10 000 per annum [24]. Both the QUS and 
BMD measurement parameters were significantly lower 
in individuals with vertebral fractures. Several cross- 
sectional studies have demonstrated that QUS can 
discriminate between healthy individuals and those 
with osteoporotic fracture [5-9,25,26]. 
The odds ratios obtained in this study for the QUS 
measurements are somewhat higher than those seen in 
other studies. This could be due to the fact that the 
prevalence of actual vertebral fractures is higher in 
clinical studies compared with the general population 
and, in addition, the average severity is often worse [27]. 
This may partly explain the high odds ratios observed in 
this study for QUS. However, it would not explain why 
the odds ratios for the ultrasound parameters were almost 
double those seen for BMD measurements. 
In this study we showed that, for each level of total hip 
BMD, calcaneal Est. heel BMD was significantly lower 
in the fracture group (Table 5). A similar finding has 
been reported in the literature for the lumbar spine [28]. 
Changes in the mechanical loading of the calcaneus due 
to the pain and disability associated with vertebral 
fractures may have an impact on bone status. Results 
from the European Vertebral Osteoporosis Study 
(EVOS) group revealed that functional capacity was 
reduced in women with vertebral deformity, especially 
in those with multiple severe deformities [29]. Im- 
mobility may lead to thinning or even loss of trabeculae. 
Only 14% of women in the vertebral fracture group in 
the present study participated in weight-bearing exercise 
and over half the fracture group walked less than I mile 
(1.6 krn) a day and did ni ot participate 
in any form of 
exercise. The calcaneus is a site of ground reaction 
forces due to heel-strike during walking and exercise 
L. Frost 
which causes strain-related remodeling. This osteogenic 
stimulus due to walking has been shown to increase BUA at the calcaneus in previously sedentary post- 
menopausal women [30] and it can therefore be inferred that women who do not participate in activities such a. s, walking or weight-bearing exercise might have lower QUS values at the calcaneus. A combination of changes in bone structure due to immobility caused by fracture 
and the fact that there was a degree of selection bias 
toward more healthy and active women in the healthy 
postmenopausal controls could, in part, explain why the 
odds ratios obtained in this study are high compared with 
the prospective QUS studies. 
The changes in T-scores with age were different for 
QUS measurements at the heel compared with the BMD 
measurements performed at the axial skeletal sites. QUS 
measurements at the heel displayed the least age-related 
decrease and even for the oldest group of women aged 
75-80 years, the mean T-score for Est-heel BMD was 
only - 1.20. The age-related decreases in T-scores were 
similar for BUA and SOS measurements. The mean T- 
scores for women aged 60-65 years for BUA, SOS and 
Est. heel BMD were -0.53, -0.58 and -0.59, 
respectively. There could be two explanations for this: 
(i) the calcaneus displays a slower rate of age-related 
bone loss, or (ii) QUS measurements have a higher 
population SID compared with DXA. The first explana- 
tion seems unlikely as studies have revealed that the 
calcaneus displays similar rates of bone loss to the spine 
and hip [31,32]. The second explanation appears more 
plausible. The data in Table I shows that the young adult 
SD for QUS measurements is high compared with the 
young adult mean and larger than that seen for axial 
BMD measurements. The Sahara QUS device uses fixed 
transducers and therefore takes measurements at a fixed 
location at the calcaneus. Imaging devices take 
measurements at a standardized location of the calcaneus 
so the same area of bone is measured in different 
individuals regardless of overall bone size and soft tissue 
thickness. This may actually reduce the interindividual 
variability and therefore lower the population SD. 
Similar studies are required for imaging QUS devices 
to see whether this is indeed the case and to examine the 
effect this would have on the age-related decrease in T- 
scores. The slow rate of decline in T-scores observed for 
QUS measurements has implications when using the 
WHO criteria to diagnose osteoporosis, as very few 
individuals would be found to be at risk. We found that 
the expected prevalence of osteoporosis for women aged 
60-65 years was just 2% for heel ultrasound measure- 
ments compared with 21% for spine BMD and 12% for 
total hip BMD. Few data are presently available on this 
effect, but one study found that the estimated prevalence 
of osteoporosis for a Caucasian woman aged 60 years 
was 3% at the heel compared with 14% for DXA at the 
lumbar spine [14]. Therefore, the use of the current 
WHO criterion for diagnosing osteoporosis using spine, 
hip or forearm BMD may not be appropriate for QUS at 
the heel. The number of QUS devices in use world-wide 
is increasing, so it is important that a different clinical 
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